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1. Management and
Organisation
1.1 Organisational Issues
P-001
A STUDY OF RELATIONSHIP AMONG INTERNAL MARKETING,
ORGANIZATIONAL IDENTIFICATION AND ORGANIZATIONAL
CITIZENSHIP BEHAVIORS IN NON-PROFIT
ORGANIZATIONS-THE STAFFS OF TAINAN BLOOD CENTER
AS AN EXAMPLE
Chu YM, Chen CT, Chang KS, Huang YH
Tainan Blood Center of TBSF, Tainan, Taiwan
Background: TheNon-Profit Organization can provide entirely flawless service through
employees supporting each other. Therefore, the implementation of internal marketing is
important for relying on the cohesion of the mission-oriented Non-Profit Organization.
Aims: The purpose of this study was to explore the effect of internal marketing on the
organizational identification and organizational citizenship behavior of employees in a
nonprofit organization.
Methods: This study used a questionnaire to survey 170 employees in the Tainan
Blood Center. One hundred and fifty-two (89%) questionnaires were returned. All the
data were analyzed by SPSS 14.0. This study used descriptive statistics analysis, cor-
relation analysis and multiple regression analysis to test all the hypotheses.
Results: The result showed the internal marketing, organizational identification and the
average value of equity in organizational citizenship behavior were above the middle
level. The internal market had a positive impact on organizational identification and
organizational citizenship behavior. There was a positive and indirect effect of internal
marketing on organizational citizenship behavior through organizational identification.
Conclusion: Internal marketing was found to have a positive impact on improving
employees’ organizational identification and organizational citizenship behavior. It is
helpful to enforce internal marketing by motivation management, training and com-
municating in the NPO.
1.3 Cost ⁄Effectiveness
P-002
This abstract has been withdrawn.
P-003
THE ADVANTAGES OF BLOOD DONATION PROGRAM IN DR
HASAN SADIKIN HOSPITAL BANDUNG INDONESIA
Lismayanti L, Dalimoenthe NZ, Yulianti N
Hasan Sadikin Hospital, Bandung, Indonesia
Introduction: Until 2009, blood transfused in Dr Hasan Sadikin Hospital (RSHS) was
only provided by Bandung Blood Transfusion Service of Indonesian Red Cross (UTDC-
PMI Kodya Bandung). By the end of 2009 UTDC-PMI Kodya Bandung has increased the
cost of blood per unit, from IDR 130,000 to IDR 200,000. This condition urged RSHS to
find another source of blood, by performing blood donation program in RSHS. This
decision was supported by RSHS’s capability to perform screening test for infectious
diseases (HIV, Hepatitis, Syphillis) with ELISA Method, and the availability of potential
donor in RSHS such as doctors, nurses, medical students, residences and other hospital
staff. Thus, since the beginning of 2010, RSHShas conducted its blood donation program.
Aims: The purpose of this study was to find out how much RSHS’s blood donation
program contributes to blood availability in RSHS, and how much money can be saved.
Methods: In this retrospective study,we reviewed the amount of blood in theRSHSblood
bankwhich came fromUTDC-PMI Kodya Bandung and fromRSHS’s own blood donation
program, and we calculated the amount of money which could be saved, during 2010.
Results: The amount of blood derived from UTDC-PMI Kodya Bandung during 2010
was 50,745 units, while from RSHS’s blood donation program was 705 units, which
contributed for about 1.4% of all blood available in RSHS. The cost for one unit of WB
and PRC production in RSHS is IDR 161,419. Thus, during 2010 RSHS can saved 705 X
IDR (200,000–161,419) = IDR 27,199,605.
Conclusion and suggestion: RSHS’s blood donation program contributes only a small
portion to the availability of blood in RSHS, but at least some savings can be made. We
suggest RSHS to increase the frequency of its blood donation program to reduce the
dependency to UTDC-PMI Kodya Bandung.
P-004
EFFECTIVENESS OF PCR MULTIPLEX TESTING OF BLOOD
DONORS
Kuznetsov O1, Matveev A1, Konovalov A2, Dashkova N1, Ragimov A1
1Russian Scientific Center of Surgery Named. Acad. B. V. Petrovsky, RAMS, Moscow,
Moscow, Russian Federation 2Central Research Institute of Epidemiology, Moscow,
Russian Federation
Background: At present, Russia adopted Government Decree 1230 from 31 December
2010, for the first time regulate the use of molecular-biological methods of testing for
blood donor screening, including a multiplex testing. The use of closed commercial
systems of expensive equipment and reagents significantly reduces the economic
efficiency of the organization of the PCR laboratories and leads to the impossibility of
widespread implementation of nucleic acid testing (NAT).
Aim: Current practice is to use local multiplex open test systems and evaluate their
effectiveness in the blood service.
Methods: Total 180,297 donors tested in three regions of Russia: Saratov blood
transfusion station has tested 157,220 donors, Pyatigorsk blood transfusion station
10,937 donors, the Department of Blood Transfusion Russian Scientific Center of Sur-
gery 12,140 donors. For the analysis, the test system Central Research Institute of
Epidemiology of the Russian Federation: ‘AmpliSens HCV/HBV/HIV-FL’ AmpliSens
HCV-FRT (HCV-FL), AmpliSens HIV RNA-FRT. All samples were examined by PCR in
real time amplifier DT-96 by ‘DNA technology’ (Russia) and Rotor Gene RG-6000
‘Gorbett research’ (Australia) in the format minipool (5–10 samples in the pool). To assess
the cost-effectiveness of testing is necessary to calculate the costs of NAT-tested 180,297
samples of plasma (A) A = A1 + A2 + A3 + A4 + A5 + A6. A1 – the sum of direct costs
associated with implementation of laboratory tests: the cost of reagents and other
consumables. A2 – wage fund for the period of research laboratory staff. A3 – total
overhead costs – maintenance costs laboratories, utilities, etc. A4 – repair fund instru-
ment. A5 – depreciation of laboratory equipment. A6 – cost quality control laboratory.
Results: Of the 180,297 surveyed donors in seronegative window period identified: 10
samples of HCV RNA and a DNA sample HBV. Total cost to identify one HCV RNA
positive donor (ELISA negative) accounted for 19,500$. From one dose of whole blood
obtained from the donor was possible to prepare three hemocomponents that can be
transfused to three potential recipients. The costs of treating hepatitis in three recipi-
ents are on average 35,000$.
Conclusions: Improvement of the effectiveness of PCR testing in Russia is achieved
through the use of local development of laboratory equipment and test kits
for multiplex analysis format minipool. It is important to maintain a balance between
the economic component of testing in general and sensitive detection of pathogens.
1.4 Training and Education
P-005
DEVELOPING STAFF CAPABILITY THROUGH EXPERIENTIAL
LEARNING IN THE BLOOD BANK, SINGAPORE
Leou KK, Teo D
Health Sciences Authority, Singapore, Singapore
Background: While organizational performance depends on both the professional
skills and the personal attitude of staff, training is an influential tool that can improve
both performance and morale. As the national blood service, the Blood Services Group
(BSG) of the Health Sciences Authority is committed to maintain a high standard of
safety and quality in our national blood supply. Training is required for staff to deliver
better work performance and keeping abreast of the latest knowledge and skills.
Currently, workplace training on Process Excellence Skills is conducted in-house, to
strengthen the capabilities of BSG’s staff.
Aim: To develop staff capability in process management and improvement skills
amongst BSG members
Methodology: Lean Six Sigma Green Belt training with certification with project
consulting services was introduced for training. An awareness workshop on an
‘Overview of Process Excellence’ was also conducted for section leaders and staff. The
objective was to provide an overview of the DMAIC (Define, Measure, Analyse,
Improve and Control) Methodology through Lean Six Sigma Simulation where par-
ticipants learned how to identify inefficiencies, eliminate waste and errors and improve
quality and productivity. After the awareness workshop, a small team of seven staff
from three different sections were selected for training which includes working on
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three improvement projects proposed by Management. Staff underwent intensive
training and the duration of training is from July to November 2010. Total training
period is 19 days, in which 12 days are for classroom training, 5 days coaching and
2 days of workshop. The training included both, DMAIC and Lean methodologies. The
process steps of DMAIC ensure that the process analyses are consistent and lean
methodology to eliminate waste. Statistical and graphical analysis of data is by using
the SigmaXL Statistical software. A high emphasis is placed on Trainee’s Project. About
35% of times are set aside for the actual application of learnt tools to be applied to the
trainee’s project. Training followed a Learn-Apply format. Training includes a very
strong project coaching component. Trainees experience not only the lessons from
their project but also those of their colleagues as well which is an additional benefit.
Finally, a Practical Examination is conducted to find out whether trainees understand
how to use the Methodology and Tools.
Results: Staff is able to identify factors that affect processes within the blood bank
(section). Training has produced significant results; improving the turn-a-round time
for donor donation, sustained a significant rejection rate for platelet clumping from
10% to 3.5% and improving the quality of services provided.
Conclusion: In order for a Lean Six Sigma implementation to be successful, man-
agement must fully embrace the Lean Six Sigma philosophy. Training has enabled staff
to apply a simple structured approach to problem solving. Towards the end of the
project, all teams are motivated to come up with more creative ideas. Through Lean Six
Sigma projects, staff has generated a pipeline of supplementary and subsequent pro-
jects. Thus, a culture of continuous improvement is instilled over time.
P-006
ENHANCEMENT OF EXECUTIVE ADMINISTRATION ON THE
APPROPRIATENESS OF BLOOD FOR CLINICAL USE IN
SHENZHEN
Yang BCh
Shen-Zhen Blood Centre, Shenzhen, China
Objective: To improve the optimal use of blood across-the board in Shenzhen.
Methods: On the basis of reviewing medical records of transfusion and of under-
standing the current situation, a systemic administration in transfusion medicine has
been established and a comprehensive plan of training and education on transfusion
medicine has been made and implemented. This includes the Shenzhen Committee of
Blood Transfusion Administration, a handbook and manuals of basic knowledge of
blood transfusion training clinicians on how to appropriately use blood, and quality
control by reviewing transfusion record.
Results: The percentages in review of medical records accordance with appropriateness
use of RBC and plasma have a raise from 65.26% and 22.94% in 2006 to 86.79% and
33.2% in 2010 respectively. Meanwhile, the requirements for blood components have
increased. For instance, the platelet concentrates and the cryoprecipitate rose from8.19%
and 4.56% to 33.2% and 23.3% of the total blood components during the same period.
Conclusion: There appears a rational trend in clinical use of blood components and
improvement of clinical knowledge in transfusion medicine.
P-007
ONE WEEK EDUCATION IN APHERESIS AT DHARMAIS
NATIONAL CANCER HOSPITAL
Eka B1, Vrielink H2, Hukom R1, Lubis Y1
1Apheresis Unit, Dharmais Hospital (National Cancer Center), West Jakarta, Indonesia
2Sanguin Blood Foundation, Amsterdam, The Netherlands
Introduction: In Indonesia, an increasing number of apheresis procedures are per-
formed. Single donor platelets are collected in six Blood Transfusion Services and five
hospitals. Also therapeutic apheresis procedures are performed in all of these hospitals
also perform therapeutic apheresis procedures. In the last 3 years, in Indonesia in total
448 therapeutic apheresis procedures (TPE, leuco- and platelet reduction, and PBSC
collection) were performed of which 146 (32.5%) in the Dharmais Cancer Hospital. More
hospitals in East Java planned to start a therapeutic apheresis service and asked for
education of physicians and nurses. Therefore, a 1 week educational program to increase
the knowledge, skills and capability of apheresis nurses for therapeutic apheresis was
developed and performed (August 2010) at the Dharmais Hospital in Jakarta.
Program of the training:
The educational program was build-up of a curriculum including:
1. Basic hematology, including the characteristics, kinetics, physiology and function
of blood cells, and blood circulation.
2. Basic apheresis physiology, including calculation of total blood volume, maximal
extra corporal blood volume, fluid balance etc.
3. Indications for apheresis procedures, including the aim, advantages/disadven-
tages of apheresis in specific diseases, the method of apheresis, start/stop
sequences, volume to be processed, volume to be removed/replaced, choice of
replacement fluids.
4. Criteria for donors and patients for apheresis, including the obstacle and the risk
of procedures as well as the actions to be taken in case of side effects, volume to
be taken.
5. Introduction to the apheresis machine available (MCS+, Haemonetics) including
mechanism of the machine, availability of disposables, how to operate, as well as
trouble shooting.
6. Documentation (such as SOPs, working instructions, worksheets).
7. Performance of a donor and patient procedure using the MCS+.
Method: In the first 2 days of the training, four speakers discussed the theoretical
topics mentioned above, while on the 3rd day, machine knowledge and machine
operating was trained by Haemonetics. The last 2 days, the participants practiced
installation of various disposables and participated in donor procedures. At the end of
every session, the training was ended with a discussion the daily subjects. To evaluate
the success of the complete educational course, a pre- and post-training test was
performed by all participants.
Results: In total four nurses and one medical specialist (internal medicine) of a hospital
located in East Java participated in our course. Based on the pre- and post-training test,
the knowledge of the five participants increasing by 74%, 36%, 61%, 97% and 173%.
Conclusion: We conclude that our 1 week educational program in apheresis is suc-
cessfull in upgrading the knowledge and the skill of participants in apheresis procedures.
P-008
DONOR MEDICINE, ESTABLISHING A MEDICAL PROFESSION
van den Burg PJM, Koopman MMW, Lijten R, de Kort WLAM, van der Poel CL
Sanquin Blood Supply, Amsterdam, The Netherlands
Background: Although many physicians are involved in Donor Medicine, the area is
not recognized as a separate medical (sub)speciality. Despite many believe that
transfusion medicine includes the whole transfusion chain from donors to recipients
(vein to vein), there are good arguments to distinguish Donor Medicine as a separate
entity. In fact donors rely on the idea that they trust their bodies to entities (blood
banks) where a medical responsibility lies for donation and selection procedures,
including apheresis, stimulation, immunisation and proper counselling for aberrant
test results. The needs and arguments in favour for Donor Medicine are promotion of
quality of donations and safety and security of donors and prevent conflicts of interest
with physicians involved in the care of recipients.
Aims: The aim of our project is to build and imply a curriculum for Donor Medicine
that meets criteria of medical education and competencies (CANMEDS) and indepen-
dent assessments and qualification.
Methods: The project is divided in several parts:
1. Defining the learning objectives
2. Creating a modular programme
3. Organise and define internships and training on the job
4. Setting up terms for assessment and certification
5. Assuring the quality
6. Defining guidelines for reregistration
Results: Based on defined learning objectives a formal curriculum for donor medicine
was created and all physicians involved in donor care were invited to participate in the
program. The programme consists of a 2 year period with theoretical modules,
internships and training on the job. Several modules were developed such as donor
selection and assessment, bleeding procedures and apheresis, blood born diseases,
quality control and systems, immunohematology, blood processing, stem cells/tissues
and organs, donor counselling en epidemiology. An independent medical certification
committee was installed to approve the programme and to assess the individual cur-
ricula vitae and requests for qualification and/or exemption of some modules. From
January 2005 until January 2010, 48 physicians enrolled in the programme; of these at
present 36 have been qualified, four have dropped out for personal reasons and eight
are presently in training. Qualified physicians should be requalified every 5 year and
should meet the demands of 16 h practice a week and a total of 200 accreditation
points. An average of six physicians is starting each year with the programme. The
national medical association recognized the programme as a training for a new medical
subspeciality Donor Medicine, part of Public Health.
Summary: A competency-based modular professional medical curriculum for Donor
Medicine has been build to meet the needs for improvement of quality of medical
donor care and prevent conflict of interest with patient care. The programme is rec-
ognized as a new subspeciality within Public Health. This development will further
stimulate medical care for donors who are health in principle and should remain
healthy with respect to medical and social-ethical aspects.
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P-009
CONTINUING MEDICAL EDUCATION AT NATIONAL INSTITUTE
OF TRANSFUSION MEDICINE-CURRENT EXPERIENCES AND
FUTURE EXPECTATIONS
Blagoevska M, Mitevska L, Dukovski R, Makarovska Bojadzieva T, Todorovska O
National Institute of Transfusion Medicine, Skopje, Macedonia
Introduction: Continuing medical education (CME) is a key factor in a contemporary
medicine. The models of CME are different and depend of the practical and theoretical
needs of the medical institutions.
Aim: To evaluate current experiences in a process of CME that was organized after the
process of reorganization and integration of Blood Transfusion Services (BTSs) into a
National Institute of Transfusion Medicine (NITM).
Material and method: The 120 employees divided in three groups were included in
CME. The participants were with different educational status and working positions
(medical doctors, specialists in Transfusion Medicine (TM), laboratory technicians,
biologists and nurses). After the CME, the participants were interviewed to express their
opinion and attitudes about the CME. The education was provided by eight educators
from NITM (professors, associate professors in TM, quality managers, MD specialist in
TM and pharmacist). The program had 13 topics in four modules: blood donation
process, control of blood and blood products, storage and distribution of blood as well
as quality assurance and quality control. Each module lasted 8 h. There were presen-
tations, group work, discussions and elaboration of personal experiences as case
studies. The written evaluation was part of the official rapport together with sugges-
tions, propositions and questions from the participants.
Results and discussion: Beside other forms of education, CME was accepted with
positive attitudes from all participants. Specially was positively evaluated the team
work, multi professional approach and involvement of all employees to discuss about
the different phases in the work. Participants have pointed out some weak points on
which should work in a future.
Conclusion: There is a real need of CME at TM. The current experiences showed that
CME had positive impact in everyday work at BTSs, especially after the reorganization
and transformation of BTSs.
1.5 Risk Models, Standards
and Regulation
P-010
EARTHQUAKES AND AFTER EFFECTS
van Essen J
New Zealand Blood Service, Christchurch, New Zealand
On February 22nd a 6.3 magnitude earthquake struck the Canterbury region. The
earthquake caused widespread damage and multiple fatalities in Christchurch City.
Services in the city were severely disrupted.
The purpose of this poster is to describe the impact of the earthquake on the New
Zealand Blood Service in Christchurch and to examine the response of NZBS to the
disaster. It deals with the events on the day and also in the days of recovery which
followed, with the emphasis being on the Donor Centre.
The Donor Centre in Christchurch is in the Suburb of Riccarton which is about a 15 min
drive from the Blood Bank in town. With telephone and internet being down directly
after the earthquake, communication between the centres was initially impossible.
A meeting of team leaders was immediately called. The Coordinated Incident
Management System (CIMS) was called into place to manage the disaster. A timeline
illustrates the events and actions taken on a day by day basis. These included the
management of staff, delegation of duties post earthquake, checks on the building to
ensure structural safety and working facilities. Equipment had to be checked, repaired
and calibrated. Contingency plans had to be made to ensure that blood products were
available to treat patients at Christchurch hospital. NZBS centres throughout the
country were feeling the strain as they had to take on extra work to support and supply
Christchurch. The effects of the earthquake on the wellbeing of staff also affected the
timeline and the decision to reopen the laboratory.
The disaster has highlighted the need for laboratory emergency protocol to be updated
and the need to have ongoing training and drills for staff. Improved emergency plans
are in draft and work on these is ongoing. So far, earthquake drills are being planned.
The possibility of training in basic disaster management for all staff is being examined,
with in depth training for staff in roles of responsibility. Also alternative communi-
cation systems (satellite phones) are being considered in case of future telephone and
internet failures.
New Zealand is a very seismically active country, and earthquakes can strike any time
and in any place. The importance of having disaster management plans in any
laboratory is made plain by the experiences of Christchurch. Earthquakes are common
throughout the whole of the Pacific Circle. Therefore it would be advisable for all
laboratories to have plans in place to deal with natural disasters such as earthquakes.
Hopefully, Christchurch’s experiences will be useful as a model for future disaster
management planning.
P-011
EFFECTS OF A SIMPLE CLEANSING PROTOCOL ON BACTERIAL
GROWTH IN PLASMA THAWING WATER-BATH
Lin YS, Chu FY
Far Eastern Memorial Hospital, New Taipei City, Taiwan
Background: Though commercial plasma thawing device was adopted by more and
more blood banks in Taiwan, the traditional water-bath was still in use in most blood
bank due to its higher speed to thaw frozen plasma component and much lower price to
purchase. Unfortunately, documented cases of transfusion-related bacterial infection
resulting from contamination in water-bath have been reported in the literature.
However, there are no defined criteria for the acceptable colony count in water used in
water-bath container. The criteria of <2000 CFU/ml for R.O. water, which has been
revised to <200 CFU/ml later, used in hemodialysis might be a more or less similar
counterpart. Furthermore, protocol for cleansing water-bath is not yet established.
Aim: This study aims to evaluate the effect of a simple cleansing protocol upon the
time-dependent bacteria growth in the water-bath.
Method: The water-bath container was cleaned using R.O. water and kept in use for
24 h. Then the container was filled with 11 l of R.O. water and 1 l of 6% bleach
solution with a final concentration of 0.5% per liter. After 15 min, the container is
rinsed with clean R.O. water three times and then the water-bath container was filled
with R.O. water and kept running for 24 h. The colonies in the water were counted in
accordance with the guideline published in ‘General Rule for Environmental
Microbiology-Bacteria, Environmental Analysis Laboratory EPA, Executive Yuan,
ROC. Briefly, 100 ml of R.O. water was collected for culture before use. After the R.O.
water is poured into the water bath container, aliquot of 100 ml of R.O. water was
collected in duplicate at 5 min (0 h), 4, 8, 12, and 24 h. Each sample was cultured
and counted in Mueller-Hinton media. The procedure was repeated in triplicate.
Result: The initial colony count at 0 h was up to 3318 CFU/ml. After cleansing and
soaking with 0.5% bleach solution, no colony growth was detected for samples col-
lected at 0 and 4 h. The colony count averaged 11.7 (range: 9–17) CFU/ml, 1058.3
(1045–1065) CFU/ml, and 360,757.6 (27,831–49,091) CFU/ml for samples collected at
8, 12, and 24 h, respectively.
Conclusion: The present research showed that a simple cleansing process using diluted
bleach solution effectively decrease the bacteria colony growth in water-bath container
for up to 12 h if we used <2000 CFU/ml as acceptance criteria.
P-012
This abstract has been withdrawn.
1.6 Blood Supply
Management and
Utilization
P-013
This abstract has been withdrawn.
P-014
RETROSPECTIVE INVESTIGATION AND ANALYSIS OF CLINICAL
BLOOD TRANSFUSION DURING EMERGENCY
Zhang R1, Peng T2, Lin J3, Li ZJ4, Xiao J2, He Y3, Ye XD4, Deng E1, Li CQ1
1IBT Chinese Academy of Medical Sciences Peking Union Medical College,
Chengdu, China 2General Hospital of Chengdu Military Region of PLA, Chengdu,
China 3Sichuan Academy of Medical Sciences and Sichuan Provincial People’s
Hospital, Chengdu, China 4Xinqiao Hospital, Third Military Medical University,
Chongqing, China
Objective: To estimate the appropriateness of emergency transfusions of plasma by
using technical specifications of clinical transfusion.
Methods: Two separate retrospective surveys of medical records from 12 May 2008 to
12 July 2008 (151 transfused patients) and from 6 June 2009 to 18 August 2009 (17
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transfused patients) from three hospitals selected from all hospitals that are involved in
emergency rescue were investigated and analyzed.
Results: In total of 538,080 ml of plasma that was transfused in 956 cases, 88% was
fresh frozen plasma (FFP) and 12% was frozen plasma (FP). 33.4% (319/956) of plasma
transfusions were assessed as inappropriate.
Conclusion: In terms of the technical specifications of clinical transfusion guidelines
on component transfusion, there is considerable inappropriate transfusion of FFP and
FP during emergency.
P-015
AN APPROACH TO SHORTEN RED BLOOD CELLS SHELF LIFE
Zhiburt E, Shestakov E, Karavaev A
Pirogov Russian National Medical Surgical Center, Moscow, Russian Federation
Background: Changing the maximum shelf lives for RBC units would require novel
approaches to RBC inventory management. E.g. in Stanford University RBC units spent
on average 8.6 days on the shelf with a mean age of 10.2 days at delivery and
18.8 days at issue for transfusion1.
Aims: To evaluate RBC shelf lives in Pirogov Center and our approaches to shorten red
blood cells shelf life.
Methods: There were evaluated ages of RBC before delivery and before transfusion in
2009.
Results: Ages of RBC in Pirogov Center are at 25% less than Stanford University
(Tables 1 and 2). With the exception of days on shelf of O negative cells which in USA
are transfused more often in emergencies without crossmatch. We have four blood
suppliers and try to have hospital blood supply for 1 week. RBC consumption in
previous years and current clinical situation are taking into account for blood order.
One procurement consisted from 1 to 77 units. Amount of monthly delivered RBC
correlates with the amount of transfused RBC (Table 3).
Table 1: Mean age at delivery and at issue and mean number of days spent on shelf
based on ABO/Rh type in Pirogov Centre
Table 2: Mean age at delivery and at issue and mean number of days spent on shelf
based on ABO/Rh type in Stanford University
Table 3: Correlation between monthly quantities of delivered and transfused RBCs in
Pirogov Centre
Conclusion: Diversification of suppliers and maintain the stock of RBC in the volume
of weekly clinical needs can reduce the shelf life of RBC before transfusion. The
criterion for the effectiveness of logistics RBC is a correlation number of doses of RBC
transfused and delivered monthly.
Reference:
1. Fontaine MJ, Chung YT, Erhun F, Goodnough LT: Age of blood as a limitation for
transfusion: potential impact on blood inventory and availability. Transfusion 2010;
50: 2233–2239
E-mail: www.transfusion.ru (ezhiburt@yandex.ru)
P-016
CONSUMPTION TREND OF BLOOD AND BLOOD COMPONENTS
IN AMIR ALLMOMNIN HOSPITAL IN AHWAZ
Bharami H, Bani R, Kalantar Hormozi M
Amir Allmomnin hospital, Ahwaz, Iran
Background and objectives: Order for a large number of blood and blood component
is a very common practice that leads to great reduction in blood supplies, lower blood
unit quality, increase the number of expired units, and imposes heavy cost on blood
transfusion centers. To evolution the most common indication for blood order and
blood use, we studied Amir Allmomnin hospital to seek a standard pattern for blood
transfusion in Ahwaz.
Materials and methods: This is a cross sectional study on 2300 blood order form in
blood bank department of Amir Allmomnin hospital in Ahwaz. The data were collected
with a questionnaire in all blood order forms from March to May 2011. Data were
analyzed in SPSS 16 with the use of chi square and T test. To calculate C/T ratio, the
number of cross matched units was divided by the number of transfused units.
Results: In this study, 2300 blood order forms were evaluated. Out of the patients,
44.8% were male with the age average of 54. The average number of products ordered
for every patient was 2.36 ± 1.70 units and the average number of transfusion unite
was 1.97 ± 1.50. From all blood order forms, 54.5% (CI: 95% = 52.1–56.9) were not
transfused. The highest rate of blood orders pertained to gynecology (19%), ICU (14%),
general surgery (5.8%), orthopedics (7%). Packed cell was the product with the highest
order rate of 79.6%.
Conclusion: The result of this study show that the rate of non-transfused ordered
blood components in Amir Allmomnin hospital is so high. Thus, we need a regional
guideline for blood orders so that we would be able to reduce this rate. We should also
reconsider the blood order processing and the blood utilization strategy.
P-017
A STUDY OF BLOOD USAGE IN A TERTIARY CARE HOSPITAL IN
SRI LANKA
Aarewatte PAPM
National Blood Transfusion Service, Colombo, Sri Lanka
Background: In Sri Lanka, blood and blood product usage has been increased sig-
nificantly during past 5 years due to epidemics of dengue hemorrhagic fever and
increasing number of cardiac and transplantation surgeries. Sri Lanka has a nationally
coordinated blood transfusion service (NBTS), where 85 hospital based blood banks are
managed by National Blood Center (NBC) which is the headquarters in Colombo. This
study was done in Sri Jayawardanapura General Hospital which gets all the blood and
blood component support from NBC. It has a total bed strength of 1065 which includes
transplantation and cardiac surgery units.
Aim: In order to minimize the wastage of Red Cell Concentrates (RCC) and optimize
blood usage, retrospective analysis of cross matches and cross match to transfusion
ratio (C:T) was obtained with the aim of preparing a Maximum Surgical Blood Ordering
Schedule (MSBOS) for the hospital.
Method: Data of number of cross matches and RCC issues for each specialty were
collected from the cross match request register and RCC and blood component issue
register and analyzed accordingly.
Results: C:T ratio was highest in the gynaecology and obstetrics units, where as is up
to the recommended ratio in medical and paediatric units. The overall C:T ratio for the
hospital was 4:1 which is showed in detail in Table 1. Total RCC discards are shown in
Table 2.
Table 1: Cross match: transfusion ratio
Table 2: Blood discard rates for 6 months
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Conclusions: Inappropriate reservation of RCC for surgeries which hardly needs blood
transfusions results in greater wastage of RCC. Implementation of MSBOS and group,
screen and serum saving method should be implemented without any delay in order to
assure appropriate clinical use of blood and blood products.
P-018
A SURVEY OF HOSPITAL BLOOD BANK PRACTICE AND
INVENTORY MANAGEMENT IN HONG KONG: INSIGHTS INTO
BETTER OUTCOME
Tsoi WC, Chan CMY, Ng JTK, Chua EKM, Lin CK
Hong Kong Red Cross Blood Transfusion Service, Hong Kong, China
Background: Blood stocks are kept in hospitals to ensure adequate and timely supply
of blood components for effective and efficient therapeutic use, including unexpected
massive transfusions. On the other hand, hospital blood banks (HBB) have the
responsibility to minimize blood wastage and outdating.
Aims: To assess HBB inventory management practice and performance based on the
data collected in a survey conducted in May 2011.
Methods: Questionnaires were sent to 28 local hospitals including 16 public hospitals
managed by Hong Kong Hospital Authority (HA hospitals) and 12 private hospitals
(non-HA hospitals). Questions asked included blood stock holding, methods of pre-
transfusion testing, application of maximal surgical blood ordering schedule (MSBOS),
durations of crossmatch reservation and crossmatching in advance, stock sharing
relationship with other hospitals, application of ‘First-in-first-out’ (FIFO) principles in
blood distribution, use of standard operating procedures (SOP) and method for cal-
culating blood order. Two parameters were computed: (i) Issuable Stock Index (ISI):
estimation of the number of days of unreserved red cell stock of all blood groups held
in the inventory; (ii) Wastage as a Percentage of Issues (WAPI). Hospital ISI, WAPI and
other variables asked in the questionnaire were compared. Mann-Whitney test was
used to test for differences when applicable.
Results: Response rate to the questionnaire was 100%. During May 2010–April 2011,
217,101 units of red cells were distributed to all hospitals (HA hospital: 89.7%; non-HA
hospitals: 10.3%). Nominal stock value or average red cell distribution per day was
594.8 units. Overall ISI and WAPI for all hospitals was 7.27 days and 1.02% (2211
units) respectively. For hospital ISI, the medians and ranges for all (n = 28), HA
(n = 16) and non-HA hospitals (n = 12) were 8.21 (3.88–25.72), 7.02 (4.72–13.87) and
12.40 (3.88–25.72) days respectively. For hospital WAPI, the medians and ranges for
all, HA and non-HA hospitals were 0.65% (0.00–44.86%), 0.25% (0.00–1.30%) and
12.04% (0.54–44.86%) respectively. Majority of the responses showed the following
local blood bank practice: (i) use of type and screen with abbreviated/computer
crossmatch method for pre-transfusion testing (n = 21/28, 75.00%); (ii) not using
MSBOS (n = 23/28, 82.14%); (iii) crossmatch reservation of 72 h (n = 15/28, 53.57%);
crossmatch in advance <24 h (n = 22/28, 78.57%); (iv) not sharing stocks (n = 24/28,
85.71%); (v) FIFO (n = 26/28, 92.86%); (vi) SOP for placing order (n = 26/28, 92.86%);
(vii) use both computer and visual count in estimating blood order (n = 17/28,
60.71%). Non-HA hospitals were associated with higher ISI (median: 12.40 days vs
7.02 days; P = 0.0154) and WAPI (median: 12.04% vs 0.26%; P < 0.0001). ISI
>7.5 days was associated with higher WAPI (median: 2.47% vs 0.42%; P = 0.0269).
Comparison with other variables was not possible due to small sample size of some
question responses.
Conclusions: It is advisable to hold a blood stock to an ISI of <7.5 days in order to
minimize blood wastage. The application of MSBOS to reserve the optimal quantity
of red cell units, shortening crossmatch reservation to 24 h and crossmatching
<24 h in advance, sharing stock with clustered hospitals and using FIFO principle
for blood distribution may help reduce WAPI and improve performance at hospital
blood banks.
P-019
DISTRIBUTION AND UTILIZATION RATE OF WHOLE BLOOD
AND BLOOD COMPONENT IN DR HASAN SADIKIN GENERAL
HOSPITAL: 6 YEARS REVIEW (2004–2010)
Sugianli AK
Universitas Padjadjaran, Bandung, Indonesia
Background: The purpose of a blood transfusion is to replace lost blood, to increase
the flow rate of cardiac output, to increase blood elements, to replace the missing
clotting factors and immune system elements. Whole blood and blood component
transfusion is a serious event. Therefore, blood or components transfusion must be
made within the appropriate indication after careful evaluation of clinical status. It
is important that distribution and utilization rates of whole blood and blood com-
ponent use have to sufficient extent regarding to rational transfusion in daily
practice.
Aims: The aim of this study is to determine and evaluate the distribution and utili-
zation rate of whole blood and blood component in Dr Hasan Sadikin General Hospital
as the main hospital of West Java province in Indonesia.
Methods: The data collected from January, 2004 to December, 2010 (6 years) in Blood
Bank Service Dr Hasan Sadikin General Hospital, which consist of: ABO type of whole
blood and blood component, the amount and type of blood component, transfusion
rate and the clinic where transfusion have done. Utilization rate is determined as blood
to patient ratio and whole blood to blood component ratio.
Results: The amount of whole blood and blood component transfused was 324.539
units for 114.232 patients with ratio blood unit to patient = 3:1. Percentage ABO
type of transfused products was as follows: O type (35%), A type (29%), B type
(28%), and AB type (8%). Percentage of transfused products was as follows: packed
red cell (60.8%), platelet suspension (18.5%), whole blood (9.8%), fresh frozen
plasma (5.7%), washed red cell (3.5%), cryoprecipitate (1.4%), and buffy coat (0.4%).
Transfusion rate of whole blood and blood components by clinic service type as
follows: 12.6% in internal medicine, 15.1% in general surgery, 7.8% in obstetric and
gynecology, 13.2% in department of child health and disease, and 51.2% in other
service.
Table 1: Distribution of whole blood and the components
Table 2: Transfusion rate by clinic service type
Conclusions: Utilization rates of whole blood and blood components are effective,
proved by decreasing whole blood utilization rates and increasing the use of blood
component. Information work always should be increased and the clinicians always
should keep in mind that transfusion can lead to serious complication and benefit/risk
assessment must take into account each transfusion.
P-020
PACKED RED CELL TRANSFUSION REQUEST PATTERNS IN A
TERTIARY CARE WOMEN’S HOSPITAL IN SRI LANKA
Bandara MCPK, Yapa DAN, Munasinghe SR, Liyanapatabandi D
National Blood Transfusion Service, Homagama, Sri Lanka
Background: De Soysa Maternity Hospital for Women (DMH), Colombo, is one main
hospitals totally dedicated for women’s health in Sri Lanka. Thus, it becomes a main
centre for referral of patients from all parts of the country needing specialised tertiary
care in the fields of Obstetrics and Gynaecology. Therefore the blood bank of DMH gets
many requests for transfusions.
Aims: To analyse the patterns of requests for packed red cell transfusions in relation to
the clinical indications, to recognise unnecessary blood reservations, and to improve
blood bank services to give the patient best possible care with available resources.
Methods: A descriptive retrospective study was carried out by analysing all request
forms (excluding neonatal transfusions) for packed red cells, over a period of 6 months
from 1 January 2010 to 30 June 2010. A detailed collection of data was gathered and
analysed using SPSS data analysis tool.
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Results: There were 2388 request forms evaluated during the study, out of which only 91
patients (3.8%) needed transfusions. Seventy-two per cent (1721) of the requests fell in to
the ‘Obstetric’ category. More than 2/3 of all the requests were marked as ‘Urgent’ cases.
Considering the indication for the request, 50.3% were for ‘Emergency Caesarean Sec-
tions’, 21.5% for ‘Elective Caesarean Sections’, 9.7% for ‘Abdominal Hysterectomy’, 5.7%
for ‘Laparotomy’, 5.4% for ‘Laparoscopy’, 4.4% for ‘Vaginal Hysterectomy and Repair’.
With comparison to other indications, those who underwent myomectomy had the
highest probability of needing transfusions (29.7%), followed by ‘Dilatation and
Curettage’ (11.1%) and ‘Laparotomy’ (9.6%). Although the highest number of red cell
reservation requests were for Caesarean Sections, only 2.6% of them needed a
transfusion later. None of the Laparoscopic surgeries (128) carried out in DMH needed
blood transfusions during the study period.
Summary/conclusions: This study clearly shows that there is a marked discrepancy
between packed red cell requests and actual instances of transfusions. Unnecessary
cross-match requests overburden the staff of the blood bank. Some minimal risk
surgeries such as laparoscopic procedures didn’t need a single blood transfusion even
though the practise was to routinely cross match and reserve blood. Therefore an
evidence based discussion should take place between the ward staff and the blood
bank, to revisit and renew blood ordering schedules to reduce wastage of manpower
and resources.
P-021
ANALYSIS THE DEMOGRAPHIC CHANGES OF THE BLOOD
DONORS IN KAOHSIUNG BLOOD CENTER
Lin I1, Chen M1, Wang Y1, Hung C1, Lin K2
1Kaohsiung Blood Center, Kaohsiung, Taiwan 2Head Office Taiwan Blood Services
Foundation, Taipei, Taiwan
Background: Blood Services Organization should monitor the demographic structure
of the donor population and decide the strategy for recruiting donors. Kaohsiung Blood
Center (KBC) database provides a unique opportunity for analyzing the demographic
changes of the blood donors.
Methods: This study started with data in 2000 to have equal distance between each
year. The numbers of donors and donations by sex, age group and donation patterns
(first-time (FT) donors or repeat (RP) donors) for 2000, 2002, 2004, 2006, 2008, 2010
were generated from the database. Data on the general population were obtained from
the Department of Household Registration.
Results: Over 180,000 volunteer blood donors donated over 400,000 bags of blood in
KBC. During the 11-year period, the donor population reduced with an average
percentage of 0.15 every year but the general population of age group between 17
and 65 years increased by 0.5% per year. Study results also revealed that 62.5% of
the donors were male, and 79.5% were RP donors. Donors of age 20–24 years
(35.51%) predominated over the blood donation in 2000, however, donors of 30–
39 years (22.31%) predominated in 2010. The proportion of 17–24 years decreased in
both FT and RP donors. Male RP donors of age 20–24 years decreased significantly
from 15.49% in 2002 to 8.47% in 2010, indicating that it was hard to recruit and
maintain the donors with this age stratification. RP donors of 50 years or older
increasingly contributed to a larger proportion of the donor pool (3.82% in 2000 to
14.92% in 2010) and made the highest donation frequency. People of these age
groups limited by the donor selection criteria will affect donor population within
15 years.
Conclusion: The population structure in KBC is shifting from younger to older age
groups. The ageing situation is more severe than the general population trends.
Strategies should be focused on the younger age group recruitment and increasing
their donation frequency. Therefore we can maintain a stable blood supply.
P-022
THE ANALYSIS OF BLOOD NEEDS IN CHINESE NEW YEAR
HOLIDAY
Wu WCW1, Lin KTL1, Hung CMH1, Lin KS2
1Kaohsiung Blood Center, Kaohsiung City, Taiwan 2Head Office Taiwan Blood Services
Foundation, Taipei City, Taiwan
Background: People travel domestically or overseas during Chinese New Year Holi-
days. In the holidays, blood donation decreases tremendously, medical need for blood
is also uncertain and adequate supply of blood preparations becomes the greatest
challenge to the Blood Center.
Aim: This is a retrospective review of the supplies of blood components from Ka-
ohsiung Blood Center database to assess the need for blood and trend for usage, and to
suggest adequate management for blood inventory.
Methods: Kaohsiung Blood Center database was queried to analyze the supplies of
blood components including RBCs, platelet concentrate, apheresis platelets and plasma
between 2005 and 2009. Supply was compared between three intervals: I: Chinese New
Year’s Eve to the beginning of sixth, II: the week before the Chinese New Year, III:
2 weeks before the Chinese New Year.
Result: A total of 250,175 units were supplied to hospitals by Kaohsiung Blood Center
between 2005 and 2009.
Table 1: Supply of blood components between 2005 and 2009 (unit: unit)
RBCs Platelet
concentrate
Apheresis
platelets
Plasma
Interval I 1570 ± 542 1941 ± 752 227 ± 97 1124 ± 625
Interval II 10,019 ± 770 3279 ± 565 389 ± 85 11,318 ± 1213
Interval III 7870 ± 256 3606 ± 992 386 ± 101 8307 ± 777
Conclusion: The need for both RBCs and Plasma in interval II were highest probably
because hospitals began to increase the inventory of blood preparations 1 week before
Chinese New Year. Accordingly, Kaohsiung Blood Center must be prepared to urge
volunteers to give blood prior the peak of need, and increase RBSs and plasma
inventory in before the Chinese New Year.
P-023
REQUESTS FROM MEDICAL INSTITUTES UNDER UPCOMING
BROAD AREA BLOOD SERVICES IN JAPAN
Okada H, Naoki K, Ikeda K
Okayama Red Cross Blood Center, Okayama, Japan
Background: Japanese Red Cross Society (JRCS) has been pushing ahead the reor-
ganization of blood service in Japan to accomplish the supply of safety and even blood
products in just proportion. This may be called Broad Area Blood Services (BABS). By
around FY 2012, Blood Centers (BCs), originally several BCs including Okayama Red
Cross Blood Center (ORCBC) had their own laboratories, will be basically reconstructed
to seven-Block Area Centers (BACs) having manufacturing facilities and the other
regional BCs only having promoting, collection and distribution sections. ORCBC be-
longs to ‘Tyu-Shikou Area (consists of adjacent nine prefectures)’ will change to one of
regional BCs.
Aims: We aim to find out the needs of medical facilities for regional BCs under BABS
by carrying out a questionnaire survey to get the whole picture of local medical
institutions.
Methods: In December 2009, we conducted a questionnaire to ask transfusion services
of regional medical institutions in the name of Prefectural Government Joint Trans-
fusion Therapy Committee with their agreement. Institutions surveyed (248) were
chosen by the usage record of transfusion even a single unit in 2008. The survey items
were 114 as following: scale of a facility, amount of blood products used, management
system, protocol of transfusion, transfusion-related blood tests, autologous blood
transfusion, peripheral blood stem cell transplantation, etc. The item: the effects of
BABS were collected as inquiries and requests.
Results: The collection rate was 52.8% (131/248 facilities). The analyzed data indi-
cated that facilities whose beds are <49 require a quick delivery of blood products in
acute situations and technical supports of blood type testing when strike on prob-
lematic patients. We received 97 matters as inquiries and requests about the effects of
BABS. Among them, obtaining compatible blood type and constructing emergent
blood distribution systems were most frequent matters, similarly.
Summary/conclusions: We have carried out several approaches to our district medical
institutions to achieve the advancement of transfusion therapy and promote the proper
use of blood products in collaboration with prefectural government, medical associ-
ation, hospital association and association of medical technologists. Upcoming BABS,
we did a wide questionnaire survey of transfusion therapy to our regional medical
institutions. This survey showed us the needs of rapid supply of blood in emergency
and technical support of laboratory blood type tests in times of trouble. By these needs,
we have started planning a new blood supply station in remote location and presenting
some workshops of blood type testing according to their technical levels.
P-024
IMPLEMENTING ARIMA MODEL IN FORECASTING BLOOD
DEMAND IN SARDJITO GENERAL HOSPITAL BLOOD BANK,
YOGYAKARTA, INDONESIA
Rizki M
Faculty of Medicine, University of Mataram, Mataram, Indonesia
Background: Blood demand in a hospital is dynamic in nature. This requires blood
bank manager to manage blood supply and blood bank resource carefully, especially in
a relatively young blood bank like Sardjito General Hospital Blood Bank. Blood col-
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lection effort and blood bank resource management will gain benefit from an adequate
forecast of blood demand.
Aims: This study aims to examine ARIMA model performance in forecasting blood
demand.
Methods: The time series consisted of the monthly blood units issued by Sardjito
General Hospital Blood Bank from January 2008 to December 2010. Using statistical
package Stata 10.1, an ARIMA model was created and subsequently monthly blood
demand for the first quarter of 2011 was forecasted. Performance was indicated by the
coverage rate of blood demand by the predicted value.
Results: ARIMA model performs accurately to forecast monthly blood demand in the
first quarter of 2011 with the median coverage rate of 98.29%, minimum of 95.24%,
and maximum of 107.42%.
Conclusion: Over the first quarter of 2011, prediction of monthly blood demand
generated by ARIMA model are accurate enough to be of help in the planning of blood
collection efforts and blood bank resource management.
P-025
This abstract has been withdrawn.
P-026
IMPROVEMENT OF BLOOD COMPONENT TRANSFUSION
APPROPRIATENESS WITH A PROSPECTIVE AUDIT PROGRAM
AT A MEDICAL CENTER: A 2-YEAR EXPERIENCE
Kuo SF, Lin JS, Young LH, Wu CW
Changhua Christian Hospital, Changhua, Taiwan
Background: Inappropriate transfusion practice can be identified and corrective ac-
tions can be taken by monitoring blood component utilization upon request. Useful
tools like predetermined transfusion guidelines, pretransfusion approval, and trans-
fusion audits are useful tools in the education of those requesting blood components.
The experience of a blood utilization auditing program and its outcome at a tertiary
care medical center (1600 beds) in Central Taiwan was here presented.
Aims: A continuous improvement of blood transfusion practice was achieved by
reduction of inappropriate use of blood component through blood utilization
auditing.
Methods: With the support from the transfusion committee, a prospective audit pro-
gram had been started since February 2009. A revised indication for blood component
transfusion was announced about 1 week before initiation of the blood auditing. With
assistance of the hospital information system upon request for blood components, the
ordering physicians must indicate the reason for transfusion, related clinical infor-
mation and any corresponding laboratory results. All above information were first
reviewed by specialists of blood bank upon receipt of the request. If there was any
doubt or deviation from the transfusion indications, the ordering physicians would be
first notified by specialists to check any error in order entry. Otherwise, a second
opinion from a transfusion or the third opinion from the chairperson of the Transfusion
Committee should be consulted if the ordering physicians insisted that transfusion was
necessary. The blood components were issued only when such requests were approved
by any supervisor. Blood component utilization was monitored monthly and reported
to the Transfusion Committee quarterly.
Results: From February 2009 to April 2011, a total of 2845 requests (4.85%) were
subject to notification: 2707 requests (95.15%) granted after enquiring complete
information as required for review, 117 requests (31.99%) cancelled after communi-
cation, 26 requests (0.91%) modified in amount or type of components and 21 requests
(0.74%) subject to consultation. The average decrease of blood utilization per month
from February 2009 to April 2011 as compared with the baseline amount calculated
from January 2008 to January 2009 was as follows: 40% for whole blood, 6% for
packed red cell, 2% for cryoprecipitate, 26% for fresh frozen plasma and 95% for
frozen plasma.
Summary and discussion: Effective improvement of inappropriate use of blood
components could be achieved by a prospective blood auditing program. Most requests
notified because of lacking complete information as required for review. The infor-
mation system may be improved and helps in reduction of notification and play as an
important role in alerting and autoverifying related information upon request.
P-027
REVIEW OF BLOOD AND COMPONENT TRANSFUSION
PRACTICE IN A TEACHING HOSPITAL OF NORTH INDIA – A
RETROSPECTIVE STUDY
Chaudhary J1, Misra R1, Upreti S1, Chaudhary K2
1Subharti Medical College, Meerut, India 2Dr. R.M.L. Hospital, New Delhi, India
Background: Availability of component therapy, has transformed transfusion practice
in recent years. However, pattern of utilisation differs from one institution to another.
Several studies demonstrate wide variations in clinical transfusion practice between
institutions. Evaluation of blood and component utilisation patterns defines practice in
an institution and permits comparison with other institutions. It also helps in proper
inventory management, better planning of resources to reduce wastage and cost.
Further, problem areas in transfusion practice that require improvement can be
identified. Hence this study was undertaken to assess the blood utilisation pattern in a
teaching hospital of a developing country.
Aims: 1. To study prevailing transfusion practices.
2. To analyse component utilization patterns.
3. To identify gaps in prescription.
Methods: The study was conducted in a 300 bedded, teaching hospital of India
with newly established component separation unit. Request forms for a period of 3
consecutive months in the year 2011, were analysed retrospectively. A total number
of 868 request forms were included. Data related to patient demographics,
specialty, diagnosis, emergency or routine transfusion, type and quantity of
components ordered, were extracted from the request forms. The data was coded
and a database was created in MS Excel. SPSS VER.16 was used for analysis.
Transfusions were analysed to determine, proportion of component use by
speciality, indication, type and volume of component requests, patient demo-
graphics, proportion of single unit transfusions, and quantity of component demand
per episode of transfusion.
Results: Sex distribution of transfusion requests showed that 70% were males and 30%
were females. Breakup of requests by age showed that most heavily transfused age
category was, 16–30 years, followed by 31–40 years, together accounting for 50% of
all. Most requests came from the department of surgery – 29%, followed by medicine at
22%. The department of Paediatrics utilised 10% of all transfusions. Demands from
Orthopaedics and Obstetrics were similar at 6%. Emergency ward utilised 6% of
transfusions. 15.36% requests were from other hospitals. Analysis of component de-
mands showed that most were for PRBC – 61%, followed by demand for whole blood –
24%. FFP was at 10% and Platelets at 5%. Out of all PRBC requests, 46% were for single
units, followed by two unit demands at 39%. Similarly within Whole Blood, 52% was
for single units. Most requests for Platelets too were for single units – 39%. However
for FFP proportion of one and two unit requests were same at 32%. Platelets were
ordered mostly by departments of medicine and paediatrics for indications like leu-
kemia, hemetemesis, clotting disorder, hepatosleenomegaly, acute liver disease. FFP
was used mostly by departments of surgery and paediatrics for ascites, intestinal
obstruction, liver disease, TB and hematemesis.
Most prevalent blood group was B Positive followed by O, A and AB. Negative groups
were approximately 9% of all.
Summary/conclusions: Surgical specialities constituted the bulk of all transfusion
requests. Some inadequacies in transfusion practice like improper dose and indication
of Platelets and FFP could be addressed by dissemination of guidelines among clini-
cians. Continuous monitoring and review of requests by hospital transfusion com-
mittee is necessary.
P-028
AN ANALYSIS OF BLOOD USAGE IN SURGICAL UNITS OF
GENERAL HOSPITAL, AMPARA
Puthra S1, Rambukwella RWU2
1National Blood Transfusion Center, Colombo, Sri Lanka 2Blood Bank, General Hospital
Ampara, Ampara, Sri Lanka
Introduction: Human blood is an invaluable limited resource that needs to be use
appropriately with minimizing the wastage. The preoperative cross-matching of blood
units for surgical patients is performed in anticipation of a potential need. The lack of
proper guideline for blood ordering leads to requesting unnecessary cross-matches.
Consequently, it consumes blood bank resources unnecessarily, increases the blood
stocks that must be maintained, and increases the number of units that become out-
dated.
Objectives: To analyze pre-operative blood ordering practices in the surgical units of
General Hospital Ampara and to propose suitable strategies for appropriate blood usage.
Material and methods: General Hospital Ampara has one general surgical unit and
one obstetrics and gynecology unit. This was a retrospective analysis of cross-match
requests and operation theatre records. The blood ordering and usage data was ana-
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lyzed over a 9 month period from 1 January 2009 to 30 September 2009. The cross-
match to transfusion ratio (C: T), transfusion index (TI) and range of units transfused
are calculated for each procedure as they can be used as indicators of blood require-
ment and potential severity of bleeding.
Results: Data was analyzed for 27 surgical procedures in 1598 patients. One thousand
eight hundred and thirty-one units cross-matched for these patients and only 232
(12.6%) units were transfused. Overall C: T was 7.9; 23.8% cases were from general
surgical unit and C: T was 6.9; 76.2% were from obstetrics and gynecology unit and C:
T was 8.1; 26 (96.3%) procedures had C: T > 2.5; 23 (85.2%) procedures had TI < 0.5
only four procedures had C: T £ 2.5 or TI ‡ 0.5.
Conclusions: For majority of surgical procedures, the ‘group and saving’ method can
be applied instead of routine cross-matching. The results of this study can be used for
drafting Maximum Surgical Blood Order Schedule (MSBOS), and the hospital trans-
fusion committee should review schedule and adjustments should be made according
to blood usage data.
P-029
This abstract has been withdrawn.
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P-030
COACHING AND AUTOMATION RESULT IN SIGNIFICANT
PROCESS IMPROVEMENTS IN ONE TRANSFUSION SERVICE
South SF1, Dikeman J2, Leonard K2
1Ortho Clinical Diagnostics, Scottsdale, AZ, United States of America 2Mount Sinai
Medical Center, New York, NY, United States of America
Background: Our facility provides full-service support to a large, metropolitan area
and includes 1300 inpatient beds. We deliver multi-dimensional care and related
services and dispense approximately 53,000 blood products yearly. Our organization is
not unlike most others in that we have tried various methods for process improvement
and multiple ways to engage personnel and make changes. We have achieved some
success with process changes but faced ever increasing complexity of care and pro-
cesses, difficulties with timely communication, and work processes and automation
that didn’t support the workload.
Study: In November of 2010, we implemented new automation for pretransfusion
testing. In addition to training all personnel in the use of the new instruments and
manual gel methods, personnel were introduced to lean thinking concepts and the
principles of flow and creating value for the end customers of the process, our patients.
Rather than using strictly didactic learning and mandating process changes, we chose to
set up focused coaching sessions for not only the personnel learning the new technol-
ogies but also for the middle managers who would be monitoring the new processes and
encouraging adoption of new ways of thinking about the work. Key personnel were
engaged to help design and implement standardized work areas for specimen receipt and
processing, automated and manual testing, and specimen storage. One-on-one training
and coaching sessions were set up with each technologist, to make sure they were
comfortable with the new testing methods and analyzers. Daily huddles were introduced
to enhance communication and foster teamwork, and daily assignments were rotated
among technical leaders to monitor and support flow of specimens and personnel.
Results: Because personnel were involved with every level of the changes, they felt
that their ideas and concerns were being heard and respected. The coaching approach
we took ensured involvement and engagement at all levels of our transfusion services.
Some of the results we achieved through coaching for process improvement are in the
table and include >95% reduction in pretransfusion testing clerical errors and customer
complaints, 20% savings in physical space, 79% reduction in routine T&S TATs, 68%
reduction in labor needed for pretransfusion testing, 77% reduction in RBC waste, and
>$39,000 reduction in special unit charges due to personnel suggesting and imple-
menting Rh phenotyping on analyzer.
Table 1: Summary of results from coaching and automation
Conclusion: The coaching approach moved our employees from a less engaged group
to a fully engaged team, focused on serving our patients more effectively and
optimizing resources.
P-031
OPERATIONS, QUALITY MANAGEMENT AND RISK MANAGE-
MENT IN THE TRANSFUSION SERVICE
Goodnough LT
Stanford University School of Medicine, Stanford, CA, United States of America
Background: For general healthcare, the difference between quality and safety has
been unclear for measurable patient outcomes. In contrast, in the Transfusion Service
(TS) the relationship between quality and safety has been direct and demonstrable.
Methods: Case studies are described to illustrate the relationship between operations,
quality management and risk management in the TS.
Results: Blood availability for elective surgery:
Over three audited intervals, the incidence of patients undergoing elective surgery
without available crossmatched blood that had been requested was 1:333, 1:328, and
1:225 for pre-QI, post-QI, and subsequent post-intervention audit assessment,
respectively.
Event discovery reports (EDRs):
Over 2 years, incidence of Biologic Product Deviation Reports (BPDRs, FDA-reportable)
was successfully reduced from 60 BPDRs (12%) of 507 EDRs in 2009 to 42 (12%) of 336
EDRs in 2010.
Wrong blood in tube (WBIT):
One hundred and two WBIT specimens were identified (by a change in patient’s ABO/
Rh) from 176,711 type and screen/crossmatch specimens received over a 5 year
interval, detected either by previous patient record of ABO/Rh, or by a second specimen
for blood type confirmation requirement, since implemented in our TS for the last
3 years. No known cases of ‘mismatched’ RBC transfusion have occurred during this
interval.
Conclusion: There is an inverse relationship between resources/time expended on
quality and risk management relative to volumes of operations in the TS. Laboratory-
based initiatives that improve patient safety and clinical outcomes, need to have re-
sources aligned with the personnel and time required for quality management and risk
management.
E-mail: ltgoodno@stanford.edu
P-032
PROCESS IMPROVEMENT IDENTIFIED IN HKRCBTS QUALITY
CONTROL LABORATORY WITH QUALITY TOOLS FROM LEAN
MANUFACTURING
Wong A, Chan B, Yuen M, Liu G, Lin CK, Cheng S
Hong Kong Red Cross Blood Transfusion Service, Hong Kong, China
Background: Q.C. testing of blood and blood components ensures consistent product
quality and efficacy. The frequency of quality control adopted is 1% of all units with a
minimum of 4 units per month, and if less, each unit. In 2010, all Q.C. parameters tested
were 16,740 for 604,750 units of blood products manufactured. The Q.C. specimen
sampling time in pre-examination phase was 357 h per annum. The need to identify and
eliminate waste (non-value-added activities), led the BTS to seek for improvement
opportunities that could be identified using quality tools from LEAN manufacturing.
Aims: To apply LEAN tools to uncover areas of process waste in blood product Q.C.
pre-examination phase such as unnecessary conveyance, inventory, waiting/idle time,
inspection and rework, and to produce exponential results aiming at 30% reduction of
current processing time.
Methods: Adopting DMAIC model in five stages: (i) Define problems of Q.C. specimen
sampling process, (ii) Measure and quantify the capability of the existing process, (iii)
Analyze data, (iv) determine and implement Improvement, and (v) establish Control to
ensure improvement continuity. SIPOC identification (the acronym stands for supplier,
input, process, output and customer) was the first LEAN tool applied to define the
boundaries of current process. Flow of materials and movement of operators between
sub-processes were tracked in a Spaghetti Chart to reveal inter-laboratory layout
problems, crossing over, bottlenecks, redundant moves and other inefficiencies. The
major causes of these problems were further identified and verified by Cause and Effect
Diagram. Proceeded with Value Stream Mapping (VSM), improvement opportunities
were identified across the entire pre-examination phase. Current state value stream
map (cVSM) was created to determine the total value-added time (VAT) and total non-
value-added time (NVAT). Every sampling step was scrutinized to reduce/eliminate the
NVAT. In Improve Phase, ‘Pull-system’ was applied to ensure immediate availability of
required Q.C. products on site during sampling; ‘Cell-line’ to ensure readily accessi-
bility of necessary equipment. Finally, future state value stream map (fVSM) was
constructed to evaluate and monitor process improvement.
Results: The results of cVSM and fVSM were tabulated and analyzed as follows. Re--
designed work flow, work areas and improved equipment accessibility contributed 11%
sampling time reduction, 100% reduction in waiting/idle time, and 25% reduction in
transportation time. The total VAT was 11% reduced; total NVAT was significantly 71%
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reduced, resulting annually 99 h saving in pre-examination phase, i.e. overall 27% time
saving was achieved through this LEAN manufacturing operation. See Table 1.
Table 1: Comparison of process times and distances
Conclusions: The LEAN quality tools were effective in identifying opportunities for
improving work processes and the flow of Q.C. specimens and reduction in valuable
operator process time in pre-examination phase. The Q.C. specimen sampling time was
reduced by 27%, i.e. 3% less than the 30% reduction target. Further improvement
opportunities would be identified using the LEAN quality tools. We consider this LEAN
manufacturing operation a valuable experience in BTS’s sustainable development; will
extend LEAN application scopes in future planning of work area and work flow designs
prior to moving into our new blood centre.
P-033
REDUCING ERROR POTENTIAL IN UNEXPECTED ANTIBODY
DETECTION TESTING WITH AUTOVUE INNOVA
South SF1, Chow E2, Mallion R1, Hegarty J1
1Ortho Clinical Diagnostics, Scottsdale, AZ, United States of America 2United Christian
Hospital, Hong Kong, China
Background: Automation can greatly reduce the need for human intervention and
overall error potential in pretransfusion testing. The right automation coupled with
lean thinking can ensure optimization our most scarce resource – human experience
and intellect.
Aims: United Christian Hospital in Hong Kong wanted to use lean tool applications to
evaluate pretransfusion testing processes post-implementation of the ORTHO Auto-
Vue Innova (AVI) analyzer and evaluate the error potential reduction with AVI for
antibody screening. The overarching business goals of our facility continue to be to
decrease error potential and simplify current work processes, enhance services while
absorbing increased workload, and decrease employee stress levels. The aim of this case
study was to use lean thinking applications to identify continued improvement
opportunities and evaluate the effectiveness of the AVI integration for antibody
screening only, to impact our business goals.
Method: Lean principles and tools were used to assess work practices and identify
improvement opportunities to optimize personnel, the physical space and the invest-
ment in the AVI instrumentation. The main tools used were product and operator value
flow analyses and defect and error potential analysis. Work practice assessment in-
cluded the people, processes, equipment, physical plant, and reagents and disposables
required. The testing operations associated with manual test tube and grouping plate
methods, manual column agglutination technology, and AVI for antibody screening
were analyzed. Also analyzed were specimen receipt and processing and donor unit
confirmatory grouping.
Results: Lean application of value analysis and error potential analysis revealed
multiple areas for continued improvement, which could be achieved by a simple layout
redesign and additional consolidation of testing platforms. Results and projected re-
sults are shown in Table 1. Projected improvements with testing consolidation included
a 40% reduction in group and screen (G&S) cycle time from specimen receipt to
released results by automation the ABD testing as well as the antibody screen. Also
projected were a 58.1% reduction in operator time for G&S testing and an 83%
reduction in operator time for overall testing and 88% reduction in hands-on time.
Other benefits included 98% reduction in error potential for G&S testing and improved
flow of specimens and operators with re-location of AVI analyzer.
Table 1: Summary of projected results from lean and AVI
Summary: The application of lean tools provided an effective way to uncover ongoing
opportunities for process improvement and AVI optimization in order to accomplish
our business goals.
P-034
APPLICATION OF LEAN SIX SIGMA TO STREAMLINE
WORKFLOW OF TRANSPORTATION, RECONCILIATION AND
SORTING OF PRE-PROCESSED WHOLE BLOOD UNITS IN A
BLOOD TRANSFUSION SERVICE
Chan GM, Lu KKW, Chan CMY, Lau TKC, Chua EKM, Tsoi WC, Lin CK
Hong Kong Red Cross Blood Transfusion Service, Hong Kong, China
Background: Due to space constraint, bins containing pre-processed blood units are
stored in a cool room on the second floor (2/F) of the building. After overnight-hold of
whole blood units, moving carts located on the ground floor (G/F) are brought to 2/F to
transport blood bins to the processing laboratory on G/F. Upon reconciliation of blood
units, empty bins are returned to another room on 2/F for cleaning but the moving carts
must be returned to G/F for storage and other usage. Blood components have to be pro-
cessed within 24 h of blood collection. Time spent on transportation, reconciliation and
sorting of pre-processed blood determines time-line of workflow in component prepa-
ration. Any delay in an element of this process will affect overall component preparation.
The effect will be remarkable when total quantity of blood units collected is high.
Aims: The aim of this study is to identify process improvement opportunities through
Lean Six Sigma tools so as to decrease total time for transportation, reconciliation and
sorting of pre-processed whole blood: targeted at a 10% total time reduction. Expected
benefits obtained from this improvement are smoothening of production workflow,
release the time strain for component preparation within 24 h and decrease in staff
overtime work.
Methods: Lean Six Sigma tools were applied to analyze various work tasks and
identify process improvement opportunities. The main tools used were process map-
ping (SIPOC: Supplier, Input, Process, Output and Customer), Flow Process Chart, Is-
hikawa Diagram and Pareto Chart. Variation was assessed in five aspects: operator,
method, environment, material and machine. Lean concept on reduction in various
forms of waste was used to cut excess motion, waiting time, transportation time and
distance travelled. A pilot study was conducted to eliminate doubts that skipping an
apparent non-value-added step might affect quality of blood units.
Results: Ishikawa Diagram, Pareto Chart and Variation Analysis revealed multiple
possible root causes and multiple areas for improvement that could be achieved by
purchasing sufficient utensils, re-locate storage area for moving carts. Non-value-
added procedure was reduced by a pilot study to ensure good quality of packaging by
eliminating plastic bag wrapping coolants and work instruction was updated accord-
ingly. Total process steps were reduced by 19.4%, total distance travelled was reduced
by 37.1% and total travel/waiting time was reduced by 41.7%. The time for the whole
process (workflow of transportation, reconciliation and sorting of unprocessed whole
blood units) was successfully reduced by 12.1%. Moreover, the more the units col-
lected, the more the time would be saved as the time reduction was calculated in terms
of minutes per blood unit.
Conclusions: Through application of Lean Six Sigma tools, tasks were analyzed in
details and process improvement opportunities were identified to aid speeding up the
processes of reconciliation of pre-processed whole blood units. In the end, not only such
processes have been streamlined to achieve a target of decreasing the whole process
time by 12.1%. Additional benefits which included addressing the OHS (occupational
health and safety) issues and enhancement of environmental green were also obtained.
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P-035
THE POWER OF LEAN PLUS AUTOMATION TO INCREASE
OPERATIONAL PRODUCTIVITY AND SAFETY IN
PRETRANSFUSION TESTING
South SF1, Leung Y2, Mallion R1, Hegarty J1
1Ortho Clinical Diagnostics, Scottsdale, AZ, United States of America 2Prince of Wales
Hospital, Hong Kong, China
Background: Business needs at our transfusion service included optimizing the
investment in automation, enhancing process effectiveness, capacity and overall
quality of services, and optimal placement of new instrumentation for pretransfusion
testing.
Aims: Our transfusion service, Prince of Wales Hospital in Hong Kong, set about
applying lean principles and tools to the main operations in the transfusion services
related to pretransfusion testing: specimen receipt and processing, blood grouping and
screening, donor unit confirmatory testing, and compatibility testing. The case study aim
was to use lean applications to identify improvement opportunities in all areas and to
identify and make improvements in the specimen receipt and testing areas quickly and
integrate pretransfusion testing automation with optimal placement of the instrument.
Method: Lean principles and tools were used to assess work practices and identify
improvement opportunities with and without ORTHO AutoVue Innova automation
(AVI). The main tools used were product and operator value flow analyses and
defect and error potential analysis. Work practice assessment included the people,
processes, equipment, physical space, and reagents and disposables required. The
testing operations associated with manual test tube methods, manual column
agglutination technology, and AVI were analyzed. Also captured and analyzed were
specimen receipt and processing, compatibility testing, and donor unit confirmatory
grouping.
Results: Lean application of value analysis and error potential analysis revealed
multiple areas for improvement that could be achieved by a simple layout redesign and
consolidation of testing platforms. Projected improvements with testing consolidation
are shown in the table below as related to Group and Screen testing (G&S) and included
an 18% reduction in test result cycle times without automation and a 52% reduction
with the AVI. Reductions in the overall labor required to support testing was projected
to be 84.9% with integration of the AVI to support >90% of routine pretransfusion
testing. Other benefits of the lean analysis and AVI integration included 83.3%
reduction in process steps and a 98% reduction in error potential along with a layout
that minimized congestion and maximized specimen and operator flow.
Table 1: Summary of projected results with lean and AVI
Summary: The application of lean tools provided an effective way to uncover sig-
nificant opportunities for process improvement. When coupled with the use of the AVI
instrumentation, exponential improvements were identified.
P-036
AUTOMATED PRETRANSFUSION TESTING ENHANCED BY
LEAN THINKING TO DRIVE OPERATIONAL EFFICIENCIES
South SF1, Cameron J2, Marsay Y1
1Ortho Clinical Diagnostics, Scottsdale, AZ, United States of America 2ACT Pathology –
Canberra Hospital, Canberra, Australia
Background: Business needs in transfusion services include optimization of personnel,
increased service capability, enhanced process effectiveness and overall quality of
services, and optimal placement of equipment. The specific needs in one site were to
decrease the stress on personnel, optimize the investment in automation and other
resources, and continue to provide good service to clinicians.
Aims: This transfusion service is located in Canberra, Australia, and serves a wide
geographical area. We wanted to apply lean principles and tools to the main operations
of specimen receipt and processing, pretransfusion testing, and donor unit confirma-
tory grouping tests. The case study aim was to use the lean applications to identify
improvement opportunities and recommend optimal usage and placement of ORTHO
AutoVue Innova (AVI) analyzers for pretransfusion testing.
Method: Lean principles and tools were used to assess work practices and identify
improvement opportunities with AVI and instrument placement. The main tools used
were product and operator value flow analyses and defect and error potential analysis.
Work practice assessment included the people, processes, products, equipment, phys-
ical space, and reagents and disposables required. The testing operations associated
with manual test tube and column agglutination technology methods and the AVI were
analyzed. Process focus was on group and screens (G&S) and donor unit confirmatory
grouping tests. Point-to-point diagrams were constructed to follow the flow of both
specimens and personnel.
Results: Multiple areas for improvement were identified with value-added lean
analysis and error potential analysis. These improvements could be achieved by a
simple layout redesign and consolidation of testing platforms. Table 1 shows a
summary of the results of the lean application and integration of AVI. These results
included a 98% reduction in error potential, 32% reduction in G&S cycle time from
specimen receipt to released results and a 35% reduction in donor unit confirmatory
grouping. A 72% reduction in operator time was projected with the inclusion of
donor unit confirmatory grouping on the AVI. Other benefits included reorganization
of supplies in testing areas, decreased visual noise, consolidation of functional
activities to eliminate congestion of walk patterns, and optimal location of AVI
analyzers.
Summary: Lean tools provided an effective way to uncover significant opportunities
for process improvement. When coupled with the use of the AVI instrumentation,
exponential improvements were identified. In addition, the lean tools drove best
placements for the two AVI analyzers by identifying current and optimal flow of the
patient and donor unit specimens as well as the people.
Table 1: Results from lean and AVI optimization
P-037
ASSESSTMENT OF ERROR REPORTS AT SHEBIN EL KOM RBTC
DURING 2010
El Batta M1, Moftah F2, El kareh S1
1Shebin El Kom RBTC – NBTS, Shebin el Kom, Egypt 2National Blood Transfusion
Center, Cairo, Egypt
Background: Shebin El Kom RBTC is situated at Menoufia Governorate and it’s about
60 km far from Cairo.
Shebin El Kom RBTC is a large Regional Blood Transfusion center which is renovated
and reconstructed through the Egyptian – Swiss project for developing Blood
Transfusion Services.
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Table 1
Some new activities and services was offered at our center after new opening at
January 2008.
These activities include the establishment of Quality Department, Training and
Research Department and Information Technology Department. Since then we started
to ensure applying national blood transfusion standards and recording error reports.
Aim: Categorization and evaluation of errors happened at Shebin El Kom RBTC during
2010 started from 1 January 2010 to 31 December 2010.
Materials and methods: 1. Documents of recorded error reports (From 1 January 2010
to 31 December 2010).
2. Data analysis.
3. Statistics and charts.
Results: Analysis of recorded error reports during 2010 showed the following results:
1. Total No of error reports was: 28 errors.
2. Categorization of errors based on types of errors and Departments committed for
these errors was illustrated in the following tables.
Conclusion: We conclude from this study that the highest % of errors according to
types was recorded to be laboratory errors (39.3%) and according to the committed
department was the patient care Dep. (35.7%) followed by Donor care Dep. (28.6%).
Recommendations: 1. All staff must follow safety measures and SOPs.
2. All Documents must be used.
3. Retraining and Refreshment for staff members especially PCD and DCD.
4. Revision and Follow up held by Head of Departments and physicians.
E-mail: Communication Doc_somiahamdy@hotmail.com
P-038
APPLYING QUALITY ASSURANCE TO CLINICAL INTERFACE OF
BLOOD TRANSFUSION THROUGH ESTABLISHMENT OF
HOSPITAL TRANSFUSION COMMITTEES IN SRI LANKA
Gunasekera DAK
National Blood Center, Narahenpita, Sri Lanka
Background: Sri Lanka has a centrally co-ordinated National Blood Transfusion Service
(NBTS), where 85 hospital based blood banks are managed and monitored through 16
cluster centers by theNational BloodCenter (NBC) inColombo.Whenachieving the target
of good transfusion practices, it is necessary to establish hospital transfusion committees
(HTC) in all the hospitals covering the entire country. HTCs act through a peer-reviewed
process aimed at improving safety, enhancing education, developing policies and
monitoring appropriateness of blood component use.
NBTS of Sri Lanka initiated action to implement HTCs in the year 2005. The success of
this programme until the year 2010 is debatable as the number of hospitals where HTCs
were established from 2005 to 2009 was <10 where active participation took place only
in one or two.
Objective: NBTS has decided to achieve its aim of 100% functioning HTCs in the
country by strengthening already established HTCs and taking steps to establish new
HTCs in all hospitals island wide.
Method: A focal point was established In NBC to coordinate this project with the
Administration. Following areas were taken in to primary consideration. When
establishing HTCs in a resource poor country like Sri Lanka strategies adapted by the
NBTC were
1. Changing the context of the existing programme.
2. Getting an authorization from ministry of health.
3. Training medical officers in charge (MOIC) on management in organizing and
conducting meetings.
4. Establishment of a direct link with the CEO of the NBTS on the project.
5. A simple, effective and attractive agenda to support the clinical and adminis-
trative staff of the hospitals to address issues promptly.
6. Acquisition of funds for a sustainable programme.
7. Recommendations to upgrade the blood bank performance and transfusion
practices were sent to relevant authorities after each committee meeting by the
National Blood Centre.
8. Guidance and resource persons were provided for all awareness programmes
required by the end users of blood and blood components.
Review of statistics for previous 6 months was presented in each Hospital Transfusion
Committee meeting that lead to interactive and informative discussions at the
meetings. This served as a very good platform to review of performance of each
hospital blood bank and blood usage of clinicians. A model for this review was
provided by the NBTS, which includes following critical poits
1. Analysis of blood collection.
2. Analysis of blood and blood component production and usage.
3. Cross match transfusion ratio for each speciality.
4. Data of Heamovigilance and necessary corrective actions.
5. Monitoring of wastage rates.
The results of the review were used by the transfusion committee to recommend
changes in practice by the hospital staff to improve patient care.
Results: The objective of implementation of HTCs in all hospitals with all clinical
specialities throughout the country was achieved. The table below shows the
achievement results.
Table 1: Achievements gained through implementation of HTCs
Table 2: Number of HTC Held
P-039
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P-041
STRINGENT SPECIMEN-LABELING REQUIREMENTS AND
DISPOSAL DECREASE THE RATE OF ‘WRONG BLOOD IN
TUBE’ IN TRANSFUSION PRACTICE
Lee T1, Chu F2, Ho Y3
1Far-Eastern Memorial Hospital, New Taipei City, Taiwan 2Department of Clinical
Pathology, Far-Easter Memorial Hospital, New Taipei City, Taiwan 3School of
Laboratory Science and Biotechnology, Taipei Medical University, Taipei city, Taiwan
Background: Wrong blood in tube (WBIT) was one of the important causes of trans-
fusion errors. Since the implementation of quality management system, such as ISO
15189, CAP Laboratory Accreditation Program or COLA Laboratory Accreditation,
much progress has been made to the accuracy of specimen identification in Taiwan.
Though the American Association of Blood Bank’s guideline suggest that in case of
discrepancy or doubt, another sample shall be obtained, but the criteria of specimen
rejection and the following disposal of the rejected specimen are essentially different
among hospitals. For example, some will return the specimen to the person who col-
lected the specimen, and others will retain the rejected ones and ask a newly collected
specimen for testing. These different levels of operative specification might have
undesirable effect on transfusion safety, or more specifically wrong specimen for
compatibility testing before transfusion.
Aim: A prospective observational study was conducted to evaluate the effect of a
stringent labeling requirement upon the rate of wrong blood in tube in real transfusion
practice.
Method: From 1 January 2008 to 31 May 2011, each specimen that did not fulfill
the requirement of acceptance for pre-transfusion testing (rejected specimens) was
retained, and a new legible specimen was requested and used for compatibility
testing according to routine procedures. The retained specimen was tested for ABO
and Rh typing, and was recording on a special sheet not for routine use. The results
of the rejected specimens and the newly collected accepted specimens were com-
pared. Incident reports of wrong blood in tube were also collected. Rates of wrong
blood in tube among accepted specimen and rejected specimen were calculated, and
were compared by Fisher’s exact test. A P value of <0.05 was considered statistically
significant.
Result: A total of 57,181 consecutive specimens were received for compatibility
testing. Among them, 1151 (2%) failed to meet the defined criteria of acceptance in the
laboratory. The reasons for rejection included wrong name or hospital patient iden-
tification number (i.e., did not match requisition form), lack of at least one signature of
phlebotomist on the specimen tube, etc. Overall, the rate of WBIT was 0.61% (7/1151)
and 0.004% (2/56,030) for rejected and accepted specimens, respectively. Compared to
the rate of WBIT in accepted specimen, the rate in rejected specimens was 170-folds
higher. (P < 0.05)
Table 1: Frequency of ABO and/or Rh discrepancies
Conclusion: A stringent policy for labeling requirement including retained the re-
jected specimen would significantly decrease the rate of wrong specimen for pre-
transfusion testing (i.e., WBIT).
P-042
IMPROVEMENT OF TRANSFUSION ACQUISITION ACCURACY
USING PROSPECTIVE BARRIER ANALYSIS
Lin H1, Chu FY2
1Far Eastern Memorial Hospital, New Taipei City, Taiwan 2Department of Clinical
Pathology, Far Eastern Hospital, New Taipei City, Taiwan
Background: Transfusion acquisition errors would not only waste the time of the
blood bank technologist to resolve it, but also potentially lead to the delay of issue the
delivery of life saving blood product to the critical patient. Barrier analysis was first
developed by Trost and Nertney and was introduced into healthcare organization with
root cause analysis in recent decade. A barrier is a control measure designed to prevent
harm to vulnerable or valuable objects. The prospective barrier analysis has been
applied to improve the safety of drugs usage, and is demonstrated an easy, simple and
rapid assessment tool to detect safety barrier defects and switch on the fail-safe
mechanism.
Aim: This study is to use the prospective barrier analysis to detect and modify the
defense barrier defect, and to evaluate its effect on transfusion acquisition accuracy.
Method: Transfusion acquisition errors were retrieved from rejection records of
specimen and transfusion request form. All errors were categorized according to the
transfusion acquisition process. Corresponding current barrier/control/defense mech-
anism was recorded and its importance to safe practice and power of failsafe was
analyzed by consensus of blood bank technologist, nursing practitioner and quality
management staff. Then possible new B/C/D mechanism was proposed to counteract
each of the hazards, and the potential importance to safe practice and power of failsafe.
The implementation cost and responsible department or person was also defined. After
the implementation of the new mechanism, the numbers of transfusion errors was
compared to those before.
Result: Before this project, a total of 1641 transfusion acquisition errors were
recorded. The rejection of transfusion acquisition includes patient’s blood type was not
written, lack of patient’s information, the time of transfusion and blood product counts
that were not written, etc. Seventeen hazards were identified and six of them (84% of
all errors) were selected for barrier analysis, and six additional barriers were proposed
and implemented. The transfusion acquisition errors reduce 74.7%.
Conclusion: Prospective barrier analysis is simple and easy to use and is effective in
reducing transfusion acquisition errors. Successful application to other area of trans-
fusion process would be expected.
P-043
COMPARISON OF QUALITY PARAMETERS OF PLATELET
CONCENTRATES PREPARED BY DIFFERENT METHODS
Adikarama BMGMP
National Blood Transfusion Service, Colombo, Sri Lanka
Background: There are two types of platelet concentrates namely Recovered or Random
Donor Platelets (RDP) and Single Donor Platelets (SDP) or Aphaeresis Platelets (AP-PC).
There are twobasicmethods of producingRecovered/RandomDonor Platelets (RDP) from
whole blood donations, one is the Platelet Rich Plasma-Platelet Concentrate (PRP-PC)
method and the other is the Buffy Coat Derived Platelet Concentrate (BCD-PC) method.
Single Donor Platelets (SDP) or Aphaeresis Platelets (AP-PC) collected from voluntary
thrombocytaphaeresis donors with the help of an automated cell separator.
Aim: Study is designed to compare different types of platelet concentrates prepared at
National Blood Centre, Sri Lanka based on standard Quality monitoring parameters.
Method: Study was based on an analysis of platelet preparations performed and tested
from 1 January 2008 to 31 March 2009. A set of 323 data were available for PRP-PC,
428 for BCD-PC and 691 for AP-PC.
Results: In the present study the mean volume of PRP-PC, BCD-PC and aphaeresis-PC
was 62.87 + 12.63, 62.17 + 10.97 and 191.72 + 52.46 ml and ranged from 20–104 and
28–114 and 96–448 ml respectively. Out of these units, 315 are for PRP-PC, 417 for
BCD-PC and 679 units are for AP-PC. Their mean pH was 7.25 + 0.57 (mean + SD),
7.15 + 0.44 (mean + SD), 6.66 + 0.57 (mean + SD) and ranged from 5.74–8.82, 5.66–
9.16, 5.11–8.10 respectively. The mean platelet count of PRP-PC, BCD-PC and AP-PC
was, 39.38 + 25.41, 59.89 + 28.99 and 253.62 + 89.33 · 109/unit and ranged from
10–134, 11–159 and 22.9–601 · 109/unit respectively. The mean WBC count in PRP-
PC, BCD-PC and AP-PC units was 0.0467 + 0.342, 0.0435 + 0.054, and
0.0625 + 0.012 · 109/unit and ranged from 0–6, 0–0.55 and 0–6 · 109/unit respec-
tively. There is no significant difference between three types (P > 0.05). The mean RCC
count in PRP-PC (n = 321), BCD-PC (n = 427) and AP-PC (n = 690) units was
0.0467 + 0.342, 0.435 + 0.054 and 0.0625 + 0.262 · 109/unit and ranged from 0.00–
0.03, 0.001–0.082 and 0.00–3.00 · 109/unit respectively.
Conclusion: There is no significant difference between PRP-PC and BCD-PC in terms
of the mean values of volume, platelet count per unit, pH, WBC count per unit and RBC
count. All three types of platelet products have required pass rate in relation to NBTS
standards with regard to pH and RBC count per unit. This study also highlights the
importance of the routine quality monitoring, in order to minimize the variation in end
products produced and reduce the likelihood of releasing the low quality products,
which can occur due to variation in blood donors, collection and component pro-
duction processes.
P-044
‘INTERNAL AUDITS’ – ARE WE DOING IT PROPERLY?
Adikarama BMGMP
National Blood Transfusion Service, Colombo, Sri Lanka
‘Internal Audit’ (IA) is an independent examination of a quality system which measures
the effectiveness of an organisation’s quality management system. In ISO 15189
accreditation program, it is required to audit all 15 management and eight technical
elements internally during a calendar year. It is a documented and systematic tool and
should be done periodically by independent and qualified people. IA allows an
organization to find and resolve non-compliances before the certification body/
customer finds them.
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‘Auditor’ is a person with the demonstrated personal attributes and competence to
conduct an audit. The auditor should never be aggressive no matter what happens.
Audit process consists of five stages namely, preparation and planning, performance of
the audit, closing meeting, submitting an audit report and the follow up. It is very
important to remember that, ‘Proper Planing and Preperation Prevent Poor Perfor-
mance’. Firstly, the annual Audit schedule is given to respective Laboratory Manage-
ment. Then appoint trained personnel to perform the internal audits. Audit team should
consist of following four categories, and they should not attach to the laboratory being
audited. The categories are, Lead Auditor, two or three Audit team members, technical
experts and observers. Auditee should be notified at least 1 week in advance.
Development of a audit checklist by obtaining and reviewing all relevant documen-
tation such as previous audit reports, quality manual, relevant SOP and working
instruction is a very important step, as it controls the continuity and act as a memory
aid, guide and a controller to the depth of the audit. It can either be high level (Generic
or specific) or low level (detailed) one. Checklists have lots of advantages, if developed
for a specific audit and used correctly. They promote planning, ensure a consistent
approach, and act as a sampling plan and time manager an easy way to take notes
during the audit process, and ensure that the adequate evidence is obtained. Auditors
need to be trained to use it to obtain maximum information. It also helps to ensure
systematic and comprehensive audit.
Usually audit should be started with a brief opening meeting in which lead auditor do
the introduction, explain the objectives and scope of the audit, give the timetable and
discuss the general administrative arrangements and limitations. During the perfor-
mance objective evidence are gathered to verify compliance or non-compliance. This is
done by inspecting documents, asking questions or by observing procedures
performed. Following completion audit team will evaluate the evidence and agree
on non-conformances found in order to make a list of non compliances.
The lead auditor explain the outcome of the audit and ensure the auditee understands
and accepts the findings, which can be categorise as major/minor non-conformities or
as an observations in closing meeting. Then agree for the final release of the audit
report and dates for correct of non-conformities. After submitting an audit report
follow up should be done with regard to see a satisfactory response from auditee and
their commitment to correct for any deficiency.
P-045
IMPROVEMENT IN LABORATORY SERVICES AND BETTER
UTILIZATION OF LIMITED RESOURCES THROUGH
APPLICATION OF BASIC LEAN PRINCIPLES
Permpikul P1, Outrakoolpoonsuk K1, Jaiyen B1, Mallion R2
1Faculty of Medicine Siriraj Hospital Mahidol University, Bangkok, Thailand 2Ortho
Clinical Diagnostics, a Johnson and Johnson Company, Singapore, Singapore
Background: The lack of adequate laboratory space is a concern facing transfusion
services. Congested physical space for performing key functions can lead to increased
stress levels and higher error potential.
Aim: To make better use of limited space and resources, our transfusion service
wanted to use some basic lean concepts and tools to try and reduce our turnaround
times and identify alternative layouts to create better workflow in the laboratory.
Methods: We applied lean principles and tools on two separate occasions to identify
improvement opportunities, first in our Type and Screen (T&S) and, second, in our
Crossmatch (XM) testing processes. We followed the path of the personnel as well as
the blood samples, established a baseline measurement, and identified key points where
we could make changes.
After identifying areas for improvements in our processes on our first assessment, we
then set about changing our floor plan to improve workflow. After a period to allow
staff to acclimatize with the new lay out and processes, we applied the lean tools a
second time. We measured our processes to calculate the improvements, and these new
measurements now serve as our new baseline when we need to re-evaluate our status
in the future.
Results: Our baseline data showed the distance travelled by our technicians, who
operate the ORTHO AutoVue Innova (AVI), was significant. With process redesign and
the implementation of a new LIS system, it was projected that we could reduce the
distance travelled by the technician by up to 97% and reduce the operator hands on
time by 81%.
Historical data shows our average turnaround for T&S plus XM testing was 180 min.
Post lean implementation, our data indicates that our current turnaround time is
120 min, a reduction of 33%.
In March 2011, we then looked to further reducing our turnaround times by applying
the tools on our current XM method (manual gel card). Through operator analysis, we
calculated that by automating our XM tests on the AVI, and further layout
reconfigurations, we could project a 24% reduction in operator hands on time and a
23% reduction in process steps.
Summary: Lean thinking and tools provided unbiased, data-driven evidence to sup-
port change within our laboratory and enhance services. We were able to reduce
operator hands-on time, which has led to reduced turnaround times and decreases error
potentials. The new laboratory layout has led to a better working environment with less
stress. Lean, along with automation, has given our laboratory increased capacity with
the same amount of resources.
P-046
SATISFACTION SURVEY OF BLOOD DONORS IN NATIONAL
CENTER FOR BLOOD IN ABIDJAN, COTE D’IVOIRE
Sekongo YM, Yao D, Konate S, Kabore S, Dembele B, Kouamenan G, Siransy B, Abisse
A, Toure P, Konan K, Hyda J, Tchimou J
Centre National de Transfusion Sanguine (CNTS), Abidjan, Cote d’Ivoire
The National Blood Transfusion Center (CNTS) is responsible for the execution of the
blood policy in Coˆte d’Ivoire. Make quality, is simply to do what you planned to do, to
measure the effectiveness of our action, to make the necessary corrections or in the
execution, or in the forecast. Now all quality system shall satisfy the customer.
Therefore, any quality system require to measure the degree of customer satisfaction.
The purpose of this survey report focuses on measuring the satisfaction of the blood
donor at the fixed site of the CNTS in Cote d’Ivoire.
Methodology: Our study was conducted on the CNTS site fixed of Treichville in
Abidjan, Coˆte d’Ivoire. This is a prospective study of systematic random type which
took place from 2 February to 1 March 2010. The study population consisted of vol-
unteer blood donors aged 18–65 of both sexes and of any origin.
With the help of a questionnaire completed by the donors we evaluate all the services
offered to the blood donor reception, consultation, collection, collation. Nine hundred
and one blood donors have been interviewed.
Results: Donors are mainly young with a median age of 32. Eighty-five per cent of
respondents are regular donors. Seventy-seven per cent of donors were satisfied with
opening hours of the site which is at 7:30 min. Text messaging reminder of the date of
donation is appreciated by our donors (over 90% in favor). Our donors have acclaimed
the comfort of the reception room in 98%. Our host is rather popular (81% favorable).
The cleanliness of our premises is advocated by the donors. About 20% of donors are
not satisfied with the information we give them during and after the donation. The
satisfaction rate is modest (77%) for the waiting time for a blood donation. The
reception staff fixed site is satisfactory at all levels of the process (91%). Doctors
consultation are very close to the plebiscite. Collection staff is deemed competent by
88% of donors interviewed and deemed insufficient by 35% of donors. The donors
have acclaimed the comfort of the room collection. Thirty-one per cent of donors are
not satisfied with the post donation snacks we provide. The arrangements for
reporting the results of biological gift are considered satisfactory by 79% of donors.
Eighty-eight per cent of blood donors say they talk about blood donation in their
communities.
Conclusion: Satisfaction rate exceeds the lowest 60%. Points satisfactions existed, and
they are many.
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P-047
THE IMPACT OF IMPLEMENTATION OF THE H1N1-RELATED
DEFERRAL CRITERIA ON BLOOD DONORS IN SINGAPORE
Nwe N, Tan H
Health Sciences Authority, Singapore, Singapore, Singapore
Background: Study on blood donors who came to donate blood in Blood Bank at HSA,
Singapore during H1N1 epidemic period.
Aim: To analyze the total number of donors deferred due to the implementation of
H1N1 related deferral criteria and to look into the return rate of deferred donors within
a 6-month period from their date of deferral.
Method: This is a retrospective analysis of all the donors deferred due to the newly
implemented H1N1 related deferral criteria. The period of study was from 29th April till
14th July 2009. The donors who have traveled to H1N1 affected countries were de-
ferred for 2 weeks. The deferral was lifted on 7 July 2009 after many countries were
affected including that of Singapore. The donors who were symptomatic for influenza,
or diagnosed to have H1N1, or asymptomatic with close contact with H1N1 patients
were deferred for 3 weeks.
Result: Total 206 donors were deferred. Seventy-seven (37.4%) of them were new
donors and 129 (62.6%) were repeat donors. Only 7 (9.1%) of new donors returned for a
donation and 70 (90.9%) did not. For repeat donors, 70 (54.3%) returned for a donation
and 59 (45.7%) did not.
Conclusion: The repeat donors were generally more committed to the blood donation
program while the new donors tended to drop off from our donor pool if they were
deferred on their first attempt.
P-048
This abstract has been withdrawn.
P-049
TYPES OF DONOR SOLICITATION AND THEIR EFFECTIVENESS
ON BLOOD DONATION RATES IN EASTERN TAIWAN
Tsai HJ, Yu CM, Wang YL
Hualien Blood Center, Hualien, Taiwan
Background: The decreasing eligible age-group blood donors in the widely dispersed
population in eastern Taiwan demanded the Blood Center to increase individual
donations as its top priority goal.
Aims: It is the purpose of this study to find out the most effective method of blood
solicitation among different age-group donors.
Methods: The survey was conducted on whole blood donors at four fixed blood
donation stations, six randomly selected blood drive event, and seven mobile stations,
which were chosen based on the blood donation rate of each station from June to
September 2010. A total of 1400 questionnaires were handed out and all data were
analyzed by SPSS.18.
Results: The three major source information for blood donation was postcard notifi-
cation (35.0%), passing through the event (17.2%), encouraged by family and friends
(15.6%). The top three most effective method of solicitation regarded by the donors are
postcard notification (41.9%), e-mail notification (19.1%), and text message notifica-
tion (12.5%). The fact that only 1.7% of donors participated in the event through
website notification was relatively low, methods to enhance promotion through
website is worthy of further study. It was also noted that 67.7% repeat-blood donors
needed to be reminded of the blood donation event.
Conclusions: A cross analysis of the donors’ basic information showed that the most
suitable and effective method for solicitation varies among donors with different attri-
butes. The best way for donors with high numbers of donation and over 40 years old can
be solicited more effectively through postcards and those who are younger with higher
education and lower frequency of donation can be more effectively reached through e-
mail or textmessaging.However, to confirm if an effective donation solicitationwill yield
a higher rate of return requires further extensive research in the future.
P-050
THE EFFECT OF MAJOR DISASTERS ON NEW DONORS – A CASE
STUDY ON 921 EARTHQUAKE AND TYPHOON MORAKOT
Yang ZS1, Tsung P2, Lin Tsai SJ2, Lin KS2
1Head Office Taiwan Blood Services Foundation, Taipei, Taiwan 2Taiwan Blood
Services Foundation, Taipei, Taiwan
Background: Blood drives in Taiwan are now entering their 37th year. According to
the statistics published by the Taiwan Blood Services Foundation, over the years, the
‘Annual Blood Collection’, ‘Donation Rate’, and ‘Donation Frequency’ have been on a
steady rise. This shows that citizens of Taiwan have developed the concept of regular
blood donation.
However, there is one phenomenon worth close scrutiny. A gradual decline in new
donor rate appeared in recent years, which was unprecedented in the recent decade
(please see Table 1). People in Taiwan are often motivated with enthusiasm to donate
blood when a major disaster hits Taiwan. To further explore whether a major disaster
acts as a catalyst to New Donors, this research sets its objective to study the connection
between ‘New Donors’ and the two factors.
Methodology: Based on the statistics published by the Taiwan Blood Services Foun-
dation, this research made a comparison on the New Donors rate in the respective
month of the 921 Earthquake 1 and Typhoon Morakot 2 to the rates recorded in the
month before and after the disasters.
Results: 1. The 921 Earthquake hit Taiwan on September 21st 1999. The New Donor
rate during that month was10.11%, which registered a 3.17% of increase
compared to the previous month (August, 6.94%) and a 0.42% increase com-
pared to the following month (October, 9.69%). The statistics revealed that the
New Donors rate of the month of the disaster is significantly higher than the
rate recorded in the month prior and after to the disaster, which indicates that
the disaster effectively encouraged New Donors.
2. Typhoon Morakot hit Taiwan on August 8th 2009. The New Donors rate was 8.51,
which registered a 2.83% of increase compared to the previous month (July, 5.68%)
and a 1.62% increase compared to the following month (September 6.89%).
Table 1: TBSF recent decade New Donor rate Unit: %
Year 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
New
Donor
rate (%)
29.16 24.28 21.71 20.25 17.81 17.40 17.45 16.65 15.80 15.26
Conclusion: When these two disasters hit Taiwan, the New Donors rate saw a signif-
icant surge, compared to the month before and after the events. Both disasters, the 921
Earthquake and Typhoon Morakot, caused high casualties, and the continuous in-depth
media coverage motivated many people to join in a blood drive.
Since blood has a relatively short preservation period, the risk of having to abandon
excess blood is an issue demanding close attention. Another issue arising from a
sudden surge in blood donation is the problem of blood testing. Therefore, the best
strategy lies in health education. Encouraging people to stay healthy and donate blood
regularly would be the best strategy.
Notes: 1. 921 Earthquake (21 September 1999): 2415 deaths, 29 missing persons, and
11,305 injured persons.
2. Typhoon Morakot (8 August 2009): 673 deaths, 26 missing persons, and 34 injured
persons were recorded.
P-051
THE STRATEGY TO INCREASE THE RATE OF FIRST TIME
DONORS RETURN
Hung YS1, Liu JH1, Wang YM1, Hung CS1, Lin L2
1Taipei Blood Center, Taiwan Blood Services Foundation, Taipei, Taiwan 2Taiwan
Blood Services Foundation, Taipei, Taiwan
Background: According to Taipei Blood Center 2003–2004 statistics, the first time
donors showed no significant gender differences, their ages concentrated in 17–
20 years, while the type of career were chiefly students, about 50%. The percentage of
first time donors was account to 12.3% of total blood donors and about 60,000 persons
per year. More complex and advanced therapeutic treatments have led to increasing
blood utilization. Blood centers are challenged to maintain a safe and adequate blood
in the face of increasing blood demand. Donation at first time donors is critical to
building a cadre of committed repeat donors. First time donors are of great importance
because they represent the continuity of the blood supply.
Aim: The aims of this study are to interview first time donors with telephone ques-
tionnaire to understand the motives of their donation, the reasons why they do not
continue to give blood and the adverse reactions after blood donation.
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Methods: Between 1 April 2006 and 31 May 2007, a total of 840 blood donors who
only donated blood once in 2005 were interviewed. Another 840 donors, matched in
donation time, age and sex with study group were selected as control, there was no
telephone questionnaire were given to them.
Results: The motives for the first time donors were as follows, convenient place to
donate (39.6%), requests by organizations (22.9%), responsibility to help others
(19.1%), and recruited by relatives or friends (11.8%). The reasons why they did not
continue to give blood were busy (42.1%), do not know where to donate blood (30.3%),
and health problem (16.5%). As for the adverse reactions, the most was bruise (2.2%),
followed by feeling of fatigue after blood donation (1.6%) and arm sore (0.2%). The
total donor reaction rate was 6.9%. Finally the rate of return in the study group was
14.0% and that of control group was 17.7%.
Conclusions: Convenient place to donate, requests by organizations, responsibility to
help others, and recruited by relatives or friends appear to influence first time donors
return. The return rate of study group is 14.0%, compared to 17.7% in control group.
There are no statistically significant differences between the study group and control
group. Further long-term follow-up and evaluation are necessary to assess the effec-
tiveness. Our findings may assist blood centers in optimizing their efforts in recruiting
and retention of first time donors.
P-052
THE INFLUENCE OF HIGH-PRICE SOUVENIR ON THE BLOOD
DONATION RESULTS IN NORTH TAIWAN
Chen SL1, Huang KY1, Hung CS1, Lin KS2
1Taipei Blood Center, Taipei, Taiwan 2Taiwan Blood Services Foundation, Taipei,
Taiwan
Background: The blood donors get used to receive various souvenirs after donations.
These souvenirs usually affect the achievements of blood drives a lot according to their
designs and values especially during the economic depression era. Sometimes they may
also influence the first time donor rate and laboratory exam results.
Aims: To understand the changes and influences of blood drive achievements,
unqualified donation ratio and anti-HIV EIA positive ratio by the high-price souvenirs.
Methods: We gave every donor who successfully donated blood a voucher for
exchanging a free beefsteak set (value: 500NTD/set) contributed and sponsored by local
chain restaurant during the Chinese Lunar new year which brought the most blood
shortage period in Taiwan each year. There were total 1500 free vouchers which were
sent in 17 different blood donation sites in this study on 2 February 2010 near the
Chinese Lunar New Year.
Results: There were 3339 persons successfully donating their blood while the
achievement rate was 185% higher than usual. Among the 3339 donors (include 1500
voucher winners), the first time donor rate was 24.1% (annual = 7.6%). The age portion
rate of 17–24 years old was 43.7% (annual = 15%). The total unqualified donation rate
in laboratory was 3.11% (annual = 1.56%) which was approximately near two times
than annual. The anti-HIV 1 + 2 EIA positive rate was 0.24% (annual = 0.10%) which
was approximately near 2.4 times than annual. Among the 1500 persons who got the
beefsteak vouchers successfully, the first time donor rate was 32%, the age portion rate
of 17–24 years old was 28.4%, the total unqualified donation rate in laboratory was
2.66%, the anti-HIV 1 + 2 EIA positive rate was 0.4% (six persons) which was four
times higher than annual.
Conclusions: The high-price souvenirs actually not only influenced the donation
achievement remarkably but also affected the donors’ motive especially the young
group of 17–24 years old and the unqualified donation ratio in the laboratory exam.
We are now facing the impacts of both decreasing birth rate and aging of population,
therefore, we still have lots of efforts to promote, inspire, recruit, educate and even
attract the young generation to donate their blood with correct knowledge of HIV
prevention and protection in the near future.
E-mail: beard.tp@blood.org.tw
P-053
IMPACT OF PROMOTION TO THE MOTIVATION OF THE DONORS
IN A LARGE BLOOD DONATION EVENT
Wang YC1, Wang HM1, Chung HL1, Yeh CH1, Wang YF1, Hung CM1, Lin KM2
1Kaohsiung Blood Center, Kaohsiung, Taiwan 2Head Office Taiwan Blood Services
Foundation, Taipei, Taiwan
Background: Kaohsiung Blood Center is responsible for the blood supply for the
areas of Kaohsiung, Pingtung, and Penghu. More than 2000 events annually, blood
donation provides as much as 57.7% of the blood the center offers the hospitals in
the areas. It attracted our attention that 4415 bags of blood were given by the donors
in a town with 850,000 populations in an 10-h donation event. The aim of the study
was to define the motivation of the donors participating in a large blood donation
event.
Methods: A total of 2993 volunteers took part in the Blood Donation sponsored by a
local company (Kuo-Hsing Poultry & Livestock Feeds Co., Ltd) in 2 January 2011.
Among them, 2245 volunteers were studied to evaluate their motivation for blood
donation. With dimensions of Motivation and Behavior to examine the impact of
promotion, a questionnaire was developed including basic demographic, experience of
blood donation, and reasons for donating. Descriptive analyses and Student t-tests
were used to test the differences.
Results: Among the 2245 volunteers who were studied, 1316 were male (58.6%), 929
were female (41.1%). Most of them were local residents (83.2%). Blood were given most
frequently at the blood donation vehicle (37.4%), and followed by Pingtung Blood Center
(31.7%). 660 volunteers (29.8%) were motivated by the company image of Kuo-Hsing
Co., Ltd, and 594 (26.8%) were urged by the family and friends. Direct-mail promotional
cards were ranked most efficient material to attract people to give blood, whereas
broadcasting via promotion car was ranked least. However, the differences (3.61–3.95)
were not significant. Female donors demonstrated significantly higher degree of
acceptance toward promotional cards direct mailed (P = 0.022) and promotion text
paged to them (P = 0.047). When compared with donors in Kaohsiung city, donors in
Pingtung area preferred significantly the promotion banner (P = 0.032). On the attitude
to routine donation, there was no difference between male and female donors, never-
theless, female donors were inclined to give blood in a particular activity (P = 0.004).
Study results also revealed that 23.5% of the regular donors only took part in the
activities sponsored by Guo-Hsing. In addition, only 7.3% of the donors gave their blood
for the first time, yet the average percentage of first-time donors was 15% in those areas.
Conclusion: Especially female, donors in the Pingtung area are willing to participate
and are satisfied with the blood donation activities sponsored by specific company (i.e.
Kuo-Hsing Poultry & Livestock Feeds Co., Ltd). With or without remuneration or
gimmick, company image reinforces the motivation of volunteers to give blood.
P-054
DETECTION OF HEMOGLOBIN CONCENTRATION FOR
ANALYZING BLOOD LOSS AND RECOVERY IN TAIWAN
Wang HH1, Yen LL1, Lin CC1, Lin SJ2, Lin KS2
1Taichung Blood Center, Taichung, Taiwan 2Head Office Taiwan Blood Services
Foundation, Taipei, Taiwan
Background: Blood donation plays an important role in each health care system. Hb
concentration is estimated, taking gender, weight and height into account. Therefore,
the purpose was to investigate the recovery of Hb after standard blood donation.
Aims: Hb serves as a mere indicator of iron status in this study. The research analyzed
Hb concentration before and after blood donation.
Methods: The study was approved by Ethics Committee of TBSF, with two groups to be
tested in this research: one group donating 250 cm3 and a second group donating
500 cm3 The Hb concentrations of 42 blood donors were analyzed before and up to 3,
6, 8, 14 and 30 days after blood donation. Body weight and height of each donor was
measured immediately before donating blood. For each donor, the decrease in Hb
concentration on various days was estimated by fully automated system. The data are
presented as the means and standard deviations for continuous variables. For differ-
ences between values of baseline and days 3, 6, 8, 14 and 30, mixed models with fixed
effect of time and BMI and random effect of subject were used to analyze the data. The
test revealed two-tailed P values and a P value <0.05 was considered statistically
significant. All analyses were performed with the statistical package SAS for Windows
(Version 9.2; SAS, Cary, NC, USA).
Results: Hb concentration decreased until day 6 for donors donating 250 cm3 blood,
prior to starting to increase slowly. For blood donors donating 500 cm3 blood, Hb
concentration decreased until day 3 before showing slow recovery. All test subjects
remained healthy during the observation period.
Conclusion: The main finding of this study is that Hb as a direct measure of the blood
system is restored in about 30 days after 250 and 500 cm3 whole-blood donation. The
results of this study confirm the minimal, recommended donation intervals (60 days
for 250 cm3 donation, 90 days for 500 cm3 donation) as adequate when, for the first-
time, being judged upon by Hb as a direct marker of hematologic recovery in Taiwan.
P-055
GIFT: THE INFLUENCE ON BLOOD DONOR’S CHARACTERISTICS
IN TAIWAN
Wang HH1, Lin CC1, Lin SJ2, Lin KS2
1Taichung Blood Center, Taichung, Taiwan 2Head Office Taiwan Blood Services
Foundation, Taipei, Taiwan
Background: The weather is changeable, freezing and cold weather attacks continu-
ously during winter season, while heavy rain and hot, humid weather hits in summer.
The preceding causes leading to the public’s less willingness to donate blood had
resulted in lower level of blood donation behavior during the year. Therefore, the
scheduled quantity of blood supply usually can hardly be achieved. Some business
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corporations will sponsor certain valuable and attractive gifts (i.e. discount coupons of
famous restaurant) to draw donors’ attention and willingness during this period.
Aims: The purpose of this study was to determine whether the incentives for blood
donation have impacts on the donors’ characteristics.
Methods: The implementation of an incentive-based blood donor recruitment program
on 2 February 2010 drew participation from 1081 blood donors. The incentive for blood
donation was to provide donors with discount restaurant coupons. Goodness of fit test
was used to examine whether the distributions of donor characteristics for this incen-
tive-based recruitment program were different from those of donor population in 2010.
The donors’ characteristics applied in this study include gender, age group, employment
status, blood groups, volume of donation and donor status. All analyses were performed
with the statistical package SAS for Windows (Version 9.2; SAS, Cary, NC, USA).
Results: Our research findings revealed that the distributions of age group, donation
volume, donor status and employment status between donors recruited from the incen-
tive-based donation program were statistically different from those of donor population
in 2010 (all P < 0.05). The donors recruited from the incentive-based donation program
had higher proportions of 21–30 year age group, blood volume of 250 cm3, first-time
donor and students from gift-providing donors than donor population in 2010 (59.9% vs
30.2%, 89.3% vs 66.1%, 24.0% vs 11.8% and 73.9% vs 22.6%, respectively).
Conclusion: Business corporations can provide better, valuable gifts to draw blood
donors of different characteristics, as well as increase first-time donor rates. However,
the public still needs to be informed and instilled the importance of blood donating
behavior in long term, making sufficient blood supply match the needs from hospitals.
P-056
DONATION FOLLOW UP STUDY OF FIRST TIME DONOR IN
TAINAN
Chao CT, Tsai KC, Lin HC, Lee PH
Tainan Blood Center, TBSF, Tainan, Taiwan
Background: According to TBSF statistics in 2003, 43.5% of new donors did not
donate again. Why did they not keep donating? That issue had influenced the pro-
motion of blood donation remarkably, so we want to investigate the reasons.
Aims: To identify factors that influence the first time donors returning.
Methods: One thousand five hundred and twenty-one persons are selected randomly
from 3282 first-time donors in Tainan area during March 2007. We designed a semi-
structure questionnaire and mailed to the objects. The data are analyzed by using SPSS
ver 17.0. They are grouped by gender, occupation, education, religion, marital status
and so on. Analysis of variance is used to compare the intention by first-time donors
who return to donate or not. We compared them via chi-squares and t-test method.
Results: Among 1521 mailed persons, 120 persons were withdrawn due to incomplete
address, 350 persons replied validly. The reply rate is 25.5%. By the result of correlation
matrix of continuous variables, we found the satisfied donation experience and the
attitude in blood donation shows a significant positive correlation (r = 0.403); the
attitude in blood donation and the knowledge of blood donation shows positive cor-
relation (r = 0.132), age and the attitude in blood donation has negative correlation
between (r = )0.149). Other variables showed no significant differences, but there are
significant differences between the two variables, namely the shortage of blood supply
and the age of the first-time donor. Comparing the person who think the supply of blood
is not enough and return to donate after August 2008, has 4.388 times than those think
the supply of blood is enough. About age, the odds ratio was 1.100, it meaned that each
additional 1 year of age may increase the probability of repeat donation by 10.0%.
Conclusion: 1. Perception of insufficient blood storage will motivate donors to donate.
Adequate message release is important to attract donors to give blood.
2. The first-time donors do not donate again after August, 2008 are caused by several
factors. The first factor is ‘do not find appropriate blood donation sites’ (41.6%). It
indicates the promotion for blood donation sites must be convenient to the first donors.
P-057
DONORS CHARACTERISTIC ANALYSIS OF MASS BLOOD DRIVE
IN TAINAN
Chen YC, Lee CL, Tsai MC, Cho CT, Tsai KC
Tainan Blood Center, Tainan, Taiwan
Background: It is an important goal to balance the blood donation and supply for each
blood center. Tainan blood center demands 900–1000 U (250 cm3) of bloods for
medical transfusion every day. Initiation mass blood drive on weekend is the major
blood donation recruitment
Aims: The purpose of this study was to analyze the donors’ personality character,
response to service, satisfaction and the subsequent donation at mass blood drive.
Methods: We designed a questionnaire that questions included the service quality
assessment, the donors’ satisfaction with services, personality characters and the ten-
dency of subsequent donation. The questionnaires were collected at two mass blood
drives, sponsored by ‘Huwei Lions Club’ and ‘Yi Cheng Charity Organization’. There
were 2035 donors and 1205 donors individually. One thousand one hundred fifty-six
donors at HLC and 745 donors at YCCO filled the questionnaire respectively. The rate of
participation is 58.67%. We used SPSS14.0 software to analyze the data which were
showed with descriptive statistics, frequency distribution, correlation analysis, multiple
regression analysis.
Results: Among these 1901 donors, male/female ratio is 69%/31%. 35.1% of donors
aged 21–30 years in HLC, by contrast, 31.5% of donors aged 31–40 years in YCCO. In
occupation, most donors are students (27.4%) in HLC and most donors are labors (31%)
in YCCO. The major cause of this time donation is friend’s invitation (19.1%) in HLC,
however the major cause of this time donation is regular donation (31.3%) in YCCO.
Small size donation (250 cm3) is higher in HLC than YCCO.
In the service quality assessment the highest score is empathy in HLC (88.87) and YCCO
(90.47). In satisfaction, donors expressed 83.11 score in HLC, and 87.79 score in YCCO.
In personal characteristics, the highest score is agreeableness (81.04) in HLC, and it is
conscientiousness (81.57) in YCCO. The willingness of subsequent blood donation is
78.04 in HLC and 78.25 in YCCO.
Among the factor analysis, we analyse the factor by Standardized coefficients. In the
mass blood drive of ‘HLC’, (i) ‘conscientiousness personality character’ got the highest
b value (b = 0.214, P < 0.0005) and it means that it is the greatest influence on
subsequent blood donation. The following factors were (ii) ‘extraversion personality
character’ (b = 0.137, P < 0.0005), In the mass blood drive of ‘YCCO’, (i) ‘blood donor
satisfaction’ got the highest b value (b = 0.268, P < 0.0005) and represents that it is the
greatest influence on subsequent blood donation. The following factors were (ii)
‘extraversion personality character’ (b = 0.191, P < 0.0005).
Conclusion: At the two mass blood drives, results of regression analysis indicated that
the positive factors for blood donors’ subsequent donation are service quality at the
donation, donors’ satisfaction and their personality characters. Adjusted by the
regression model, their explanatory power (Adjusted R2) are 0.287 and 0.324, respec-
tively. There are significant but the explanatory power is not high enough. This findings
show that there are other factors to affect blood donors and further research is needed to
understand whether other intervening variables affect subsequent donation behavior.
P-058
WAITING TIME IN THE PROCESS OF BLOOD DONATION ON
CAMPUS
Chang HC1, Cheng YL2, Yang B2
1Hsinchu Blood Center, Taiwan Blood Services Foundation, Hsinchu County, Taiwan,
China 2Hsinchu Blood Center, Jhubei, Taiwan
Background: School is one of the important blood donation sites for each blood
center. In 2007, Hsinchu Blood Center has conducted a survey of how the campus
donors feel about the procedure of blood donation. It was found that people com-
plained about the waste of time when they were standing in line waiting too long
before blood donation. Those who have experienced a sense of emptiness, anxiety, and
dissatisfaction become less willing to donate again. Researchers have found that the
cost to business organizations is unexpectedly high when customers give up because
the waiting line is too long. To improve the situation of standing in line for blood
donation on campus, this study has performed a time-and-action analysis of the ser-
vice procedure. Using the waiting line theory, this study seeks to discover the statistical
distribution of the donor’s waiting time during the service hours.
Method: 1. The analysis is based a sample of 1994 donors.
2. The concept of six-sigma management is used to define blood donation procedure,
to observe the actual donation process as it took place on site, and to establish the
core procedure and to identify key donors.
3. To construct a chart for the service procedure, the study divides the procedure into
six steps: (i) entrance; (ii) filling out the forms; (iii) waiting for donation; (iv)
interview and screening; (v) blood collection; and (vi) exit. For each step, those who
stayed and those who left were separately recorded.
4. SPSS software is used to understand the distribution of the amount of time the
donor spent in each step.
5. Situational simulation is used to produce a chart in which the percentage of donors
in each half-hour is shown.
Results: 1. About 10% donors who left without donating blood. Of them, 48% donors
left immediately because they had no strong intention in donating blood, moreover,
too many people had been queuing up. There were 10% of them who liked to donate
but 10 min waiting was the limit they could endure.
2. The donors spent most of their time waiting outside the bloodmobile. There is much
variation, however, in the amount of time each step took. What caused the
prolonged waiting was Step 2 (the time spent in filling out the forms) and Step 4 (the
time needed for interview and screening). Thus, to shorten the waiting period for
donors, the donation service should simplify the forms they are to fill out and add
more staff members during the peak hours for interview.
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P-059
A STUDY TO EVALUATE THE EXPERIENCES OF REGULAR
VOLUNTEER BLOOD DONORS IN ORDER TO ELIMINATE THE
MYTHS ABOUT BLOOD DONATION
Bandara N, Perera P
National Blood Transfusion Service, Colombo, Sri Lanka
Background: National Blood Transfusion Service (NBTS) of Sri Lanka, adhering to the
recommendations of World Health Organization encourages the voluntary non
remunerated regular blood donors. Many programs are conducted for the motivation
recruitment and retention of volunteer non-remunerated donors. Celebration of World
Blood Donor Day is one of the main attractions where felicitation of regular blood
donors is done annually at selected cluster center blood banks all over the country.
There are many myths regarding blood donations established in the society. In spite of
these common myths blood donors attended to the felicitation programs has been
regularly donating blood.
Aims: To evaluate the attitude of voluntary regular blood donors towards the common
myths about blood donation.
To utilize the experiences of regular blood donors to eliminate the myths on blood
donation.
Method: A questionnaire was developed taking in to account the most common myths
regarding blood donation. Donors were requested to mark one of the three responses
according to their experience.
Age, Sex and number of blood donation also were included in the questionnaire and no
questions were made to reveal the personal identification details of the donor.
Along with the World Blood Donor Day Calibrations; Blood donors who have donated
more than twenty times (20) were invited for the felicitation ceremony organized at the
National Blood Center Sri Lanka. While the donors were attending for the calibration
this questionnaire was offered to them and the responded papers were evaluated.
Results: A total of 60 (sixty) donors had responded to the questionnaire. Out of the
responders 25 donors had donated blood for 20–40 times. Eighteen donors had donated
blood for 41–60 times. Fifteen donors had donated blood more than 61 times. Responses
of these regular blood donors for the above questions are summarized in the given table.
Evaluation reveals that out of the responded blood donors 80% considers blood
donation has no effect on alteration of body weight, 88% consider blood donation has
no effect on alteration of physical fitness, 95% consider blood donation has no effect
on alteration of sexual performances and 82% consider blood donation has no effect
on alteration of the exposure to diseases.
Table 1
Summary/conclusions: In this study regular blood donors have demonstrated that the
act of regular blood donation has no significant effect on alteration of their body
weight, physical fitness, sexual performances or the exposure to diseases. National
Blood Transfusion Service can use the results of this study for the awareness programs
on donor motivation and retention eliminating the myths on blood donation.
P-060
USE OF DONOR DEFERRAL EVALUATION FOR OPTIMIZING
RECRUITMENT OF BLOOD DONORS
Munasinghe SR1, Senaviratne PAUK2, Liyanapatabandi D1, Bandara MCPK1, Yapa
DAN1
1National Blood Transfusion Service, Nittambuwa, Sri Lanka 2Post Graduate Institute
of Medicine, Colombo, Sri Lanka
Introduction: A healthy donor population is the greatest asset of any blood transfu-
sion service. The Sri Lankan National Blood Transfusion Service is heavily dependent
on voluntary non remunerated blood donors and blood donors undergo basic screening
tests of weighing and hemoglobin measurement and are counseled and examined by
trained medical officers to check the suitability to donate. Donors not suitable for
donation are deferred temporarily or permanently. Deferral of a large number of do-
nors who present voluntarily to donate blood can adversely affect the donor popula-
tion and blood collection. Therefore every effort should be made to minimize the donor
deferral due to preventable causes.
Aims: To evaluate the donor deferral patterns in donor population of blood bank, Base
Hospital, Wathupitiwala and identify the factors which could help to improve the
donor recruitment in future and minimize the preventable deferrals.
Methodology: A retrospective study was done by retrieving data from donor deferral
registers and donor declaration forms of blood bank, base hospital, Wathupitiwala, Sri
Lanka from2008 to 2010. Donorswere categorized as permanent and temporary based on
the time period of deferral and reasons for deferral and donation history were analyzed.
Results: A total of 7609 donors were recruited during the 3 years from 2008 and 887
were deferred with a deferral rate of 11.65%. Out of the deferred donors 57% (n = 506)
were between 18 and 30 years of age and 568 (64%) were males. Low hemoglobin level
was the commonest reason for deferral (n = 242, 27.3%) followedby chronic disease such
as hypertension, diabetes mellitus and ischemic heart disease (n = 81, 9.1%), high blood
pressure at the time of examination (n = 72, 8.1%) and infected wounds (n = 60, 6.8%).
There were 563 (63.5%) first time donors among the deferred population and the
commonest reasons for deferral among them were low hemoglobin level (n = 195,
34.6%) followed by chronic disease such as hypertension, diabetes mellitus and ischemic
heart disease (n = 38, 6.7%), taking antibiotics for upper respiratory tract infection
(n = 38, 6.7%), and inadequate overnight sleep (n = 32, 5.6%). Out of the 324 deferred
donors who had donated blood at least once before 41 (12.6%) were deferred as they have
not completed the minimal interval of 4 months before the next donation.
There were 111 (12.5%) permanent deferrals and 776 (87.5%) were deferred temporarily.
Commonest reasons for permanent deferral were chronic disease such as hypertension,
diabetesmellitusand ischemicheart disease (n = 81,72.9%), epilepsy (n = 19, 17.1%)and
valvular heart disease (n = 7, 6.3%). A significant number of females (n = 191, 78.9%)
compared tomales (n = 51, 21.1%) were deferred due to low hemoglobin level (P < 0.05)
Conclusion: Large number of deferrals due to low hemoglobin levels in both first time
and repeat donors has a significant effect on donor pool and blood collection. Edu-
cation of donors on simple dietary modifications should be done during counseling
and supplementary iron therapy should be considered. Large number of repeat donors
getting differed due to non-completion of 4 months after the last donation should be
addressed by educating the donors with appropriate post donation information.
P-061
THE CHARACTERIZATION ANALYSIS OF BLOOD DONORS IN
BLOOD DRIVE BY TASTY RESTAURANTS: A CASE STUDY OF
TAINAN BLOOD CENTER
Yu PY, Tsai T
Tainan Blood Center of TBSF, Tainan City, Taiwan
Background: In order to maintain sufficient blood in the blood bank, Tasty restau-
rants, it is popular for youth, held massive blood drive to attract more blood donors.
Aims: Blood center is responsible for meeting the blood demand in a region. The blood
drives sponsored by Tasty restaurants usually attracted passive blood donors. This
research seek to understand the features of these donors and find ways to recruit them
as regular donors.
Methods: This research incorporates data analysis towards the differences between the
blood drive sponsored by Tasty restaurants on January 20th to 21st (study group) and
other seven drives in the same month and region (control group). The variables include
their ages, genders, occupations, volume, frequencies, and the qualified rate of their
blood screen. This research uses the statistics software, SPSS ver 17.0, to conduct a t-
test and a chi-square test for difference analysis (q < 0.05).
Results: The statistical analysis shows: For the study group, the average age of the
donors is 27.5 ± 9.0 years, M: F = 55.5%: 44.5%, while control group has a mean age
of 34.7 ± 11.7 years, M: F = 63.0%: 37%.
1. There is a significance difference between two groups regarding ages, genders,
occupations, volume, and first-time donor. The donors in the study group are
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(i) younger, (ii) more female population, (iii) more students, (iv) more 250 cm3
donation, and (v) more first-time donors.
2. There is no significant difference in their blood screen results.
3. There is a significant amount of students in the study group than control group
(49.4% vs 21.8%), but not much difference in other occupations.
Conclusion: This research shows that blood donors in the study group are mainly stu-
dents compared to the control group, yet there is no significant difference between two
groups regarding other occupations. Special marketing approaches would attract dif-
ferent blood donors. However, the clustering effects and the instability features of student
donors are the challenges towards recruiting these donors and become regular donors.
P-062
THE CHARACTERISTIC ANALYSIS OF BLOOD DONORS IN
BLOOD DRIVE IN TEMPLES
Chang C, Yu Y, Tsai T
Tainan Blood Center of TBSF, Tainan City, Taiwan
Background: Taiwanese people have the tradition to visit temples during the Chinese
New Year, praying for a peaceful and harmonious year. Some people believe the
superstition that donating their blood can avoid potential accidents on themselves. The
Tainan Blood Center held blood drives in three temples during the Chinese New Year,
contributing to the blood supply.
Aim: The study seeks to understand the features of blood donors in the temples, and
attracting them to become regular donors.
Methods: This study adopts data analysis to distinguish the differences between (i) the
study group: the blood donors in three temples, the South Kunshen Dai Tianfu Temple,
the Orthodox Luerhmen Matsu Temple, and the Dongshigan Temple, during the 2011
Chinese New Year (February Fourth to Seventh) and (ii) the control group: the other
donors in Tainan within the same time period. This research uses the statistics software,
SPSS ver 17.0, to conduct a t-test and a chi-square test in the difference analysis
(q < 0.05).
Results: 1. The statistical analysis shows: For the study group, the average age of
donors is 36.0 ± 10.5 years,M:F = 64.4%: 35.6%,while control group has amean age
of 35.1 ± 11.6 years, M:F = 64.3%:35.7%. The result reveals there are significant
differences in ages (t = 2.39), occupations (v2 = 99.47), andblood screen (v2 = 17.18).
2. No significant difference between two groups in genders (v2 = 0.005), donation
volume (v2 = 2.09), and first time donors (v2 = 0.41).
3. The donors in the study group are (i) elder, (ii) identifying as labors in occupations,
(iii) higher qualified rate in the blood screening.
Conclusion: Taiwanese people practice the tradition to visit temples during the Chi-
nese New Year, and the blood drives in the temple can help to meet the blood demand.
This research reveals that the ages and occupancies are significantly different in the
study group. However, the blood tests in the study group have significantly lower
qualified. This study assumes the irregular lifestyle during the long vacation period
contributing to the result, yet this assumption needs further study.
This study suggests that the blood drives during the Chinese New Year can supply the
usual blood shortage over the same time period. Different marketing strategies should
be practiced to attract these donors.
P-063
NEW ATTEMPTS TO DEVELOP BETTER SURROUNDINGS OF
BLOOD DONATION IN JAPAN RED CROSS TOKYO
METROPOLITAN BLOOD CENTER
Itsuki K, Nakajima K, Matsuzaki M, Kanematsu F
Japanese Red Cross Society Tokyo Metropolitan Blood Center, Tokyo, Japan
Background: Our blood business is supported by volunteer civilian as blood donor. So
we have to treat them with great gratitude. From such standpoint, our hearty hospi-
tality is getting more and more important.
Aims: For aims of stable blood supply, we give donors high satisfaction for contri-
bution and secure them as unshakable supporter.
Method: At first, we established some new donation rooms which suit the town and
people who live in or visit there as the place where donors share moments of donating
contribution. In these new rooms, we entrust promotion of blood donation, which have
been under the leadership of us, to the partners (which means cooperating companies,
schools, and ordinary donors as volunteer in ‘industrial-academic cooperation’. The
partners circulate information about new room’s comfort and interest, donation’s
easiness and helpfulness. That gives more people opportunity to join the donation
volunteer. In addition, from the standpoint that ‘The leader in blood donation sur-
roundings is a donor’, we have been pursuing hearty hospitality. Our hospitality aim to
encourage the donor’s feeling that ‘Blood donation enrich my heart’ or ‘Blood donation
makes me a tender-hearted’. Moreover, we are exploring the new way to promote blood
donation utilizing the power of design and art. Under the theme ‘Design, Art and
humanitarian assistance’, we built an interactive relationship with Art University and
confer with its professors and students about what should be a place to share moments
of donating contribution and what should be a space design.
Results: The attempt above attracted many attentions of Media all over the world. It
highlighted blood donation especially in young people. As one of the result of that
effect, donors increased by about 23,000 person from 2008 to 2010 in Akihabara area.
And ‘akiba: F’, which is one of the new room, were awarded ‘2010 Good Design Award’
(in the category of Society/Public, Cultural, and Educational Facilities). It’s a proof that
our idea and method were recognized as supporting the future of transfusion medicine.
Conclusion: Under our motto of ‘feeling better for donor’, ‘warmth in heart for donor’
and ‘more timely for donor’, we keep improving the surroundings of blood donation.
Then our first mission is to give more people opportunity to participate in donation
volunteer. And the second mission is to provide the satisfaction for their contribution by
our hearty hospitality. Then the final mission is to make donors become aware that they
are not just ‘participants’, but ‘the supporters to save the patients’. We have to encourage
our partners who kindly understand our blood business. And we have to co-work with
them to secure stable blood supply. We and partners also have to be conscious strongly
that, the most important thing, all the blood donation is for patients.
P-064
INFECTIOUS MARKERS AMONG BLOOD DONORS IN A
PROVINCIAL HOSPITAL OF THAILAND: ANALYSIS FOR
SURVEILLANCE AND IMPROVEMENT OF BLOOD
RECRUITMENT
Urwijitaroon Y
Faculty of Associated Medical Sciences, Khon Kaen, Thailand
Background: Procurement of blood for safety transfusion includes recruitment and
retention of low risk donor selection and proper screening for infectious markers in
donated blood.
Figure 1: The entrance of ‘Yurakucho donation room’
Figure 2: ‘akiba: F donation room’ themed ‘near future’
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Aims: This retrospective study was carried out for surveillance and improvement of
blood recruitment by analysis for infectious markers among blood donors at Kamp-
hangphet Hospital, Kamphangphet province, situated in the central part of Thailand.
Methods: Retrospective study for prevalence of HIV, HBV, HCV and syphilis infections
detected in donated blood during 2005–2008 was performed. The prevalence of
infectious markers in accordance to sex, age and frequency of donation (first time and
repeated) were analyzed.
Results: There were 28,373 units of blood collected from 24,040 blood donors
consisting of 59% (14,219) male, 41% (9821) female, 39% (9437) first time and 61%
(14,603) repeated donors. The total prevalence of blood transmitted in the 3 year
period including HIV, HBV, HCV and syphilis as screened by ELISA for anti-HIV/
HIVAg, HBsAg, anti-HCV and syphilis by RPR testing were 0.26%, 2.36%, 0.71%,
and 0.44%, respectively. None of the HIV infected donor positive for HIVAg only
was found. The highest prevalence of anti-HIV (0.39%), HBsAg (3.05%) and an-
ti-HCV (1.12%) were demonstrated in 2008 with statistically significant differ-
ence (P < 0.05). Male donors had higher prevalence than female in all of four
infectious markers. The prevalence of HCV infection in male donors was increased
by age. We also confirmed the higher prevalence of HIV, HBV and HCV infectious
markers in first time donors compared to repeated donors. In addition, collected
blood from previous positive infected donors was found increasingly, mostly at
mobile units.
Conclusion: This study reveals that HIV, HBV and HCV infections remain health
problems in Thailand, which need education for prevention of blood and sexual
transmitting pathogens for general population at all age group including school
children. Pre donation counseling including donor informed consent should be
intensively implemented in all of first time and repeated donors. Post donation
counseling for infected blood donors is also necessary for care and monitoring of their
health status especially prevention of transmission and stop blood donation. For
improving safe blood recruitment and cost effectiveness, the active data system with
efficient process management is important to exclude repeated donation from previous
positive infected donors. The effort to recruit and retain female donors which is lower
risk should be encouraged.
P-065
A STUDY OF DONOR DEFERRAL PATTERNS IN SOUTHERN
REGIONAL BLOOD CENTER – KAMBURUGAMUWA,
SRI LANKA
Withanage VH
Southern Regional Blood Center, Matara, Sri Lanka
Background: Sri Lanka has a cluster based Blood Transfusion Service which is cen-
trally co-ordinated by the National Blood Center. In the Southern Region of the
country, our blood center is the main Blood collector with a contribution of 17,495
units in 2010. The ultimate goal of a blood transfusion service is to provide blood from
100% voluntary, non-remunerated donors. The deferral pattern of the voluntary do-
nors has a major impact in achieving the above targets.
Aim: To study the donor deferral patterns according to age, gender and to locate the
group of donors who should be address and educate. This will support in policy for-
mulations to promote voluntary blood donors and to develop strategies to call up
deferred donors as soon they become eligible to donate blood.
Methods: The data was collected from in-house and mobile donor deferral registers
maintained at Southern Regional Blood Center – Kamburugamuwa. The time period
considered was from 1 January 2010 to 31 December 2010. Relevant donor declaration
forms were traced and data was verified. The information abstracted includes age,
gender and reasons for deferral. Further, reasons for deferral have divided mainly as
temporary and permanent.
Results: Total blood collection for year 2010 was 17,459 units and out of which 1279
(7.3%) were deferrals. Out of the total deferrals, 864 (67.6%) were males and the
balance 415 (32.4%) were females. A total of 744 (58.2%) were temporary deferrals and
534 (41.8%) were permanent deferrals. Of the temporary deferrals most of the donors
had brief medical illness which totals to 199 (20.7%) and other reasons like alcohol
ingestion, lack of sleep amounts to 197 (20.5%). Among other temporary reasons
anaemia 29 (3.9%), use of antibiotics 150 (20.2%), surgical procedures 32 (4.3%), last
donation <4/12 78 (10.5%) were categorized.
With the analysis of permanent reasons the majority fall in to chronic medical illness
463 (86.7%) as other reasons were history of hepatitis 87 (16.3%), high risk behavior 67
(12.5%) and age >60 years 17 (3.2%).
Age distribution of donors is shown in the table below.
Table 1
Age Number Percentage (%)
Temporary Permanent Temporary Permanent
<24 303 77 79.7 20.3
25–34 300 132 69.4 30.6
35–44 151 154 49.5 50.5
45–54 82 129 38.9 61.1
>55 7 36 16.3 83.7
Summary: Main concerned should be on temporary deferral group as most had brief
medical illness or had taken antibiotics recently. They should be educated regarding
these issues and make strategies to call them back when they become eligible for
donations. Regular donors should be addressed effectively on the time period between
two donations.
Anaemia in females has shown to be significant compared to males. They should be
referred to medical clinics and encourage seeking treatment with haematanics.
Also temporary deferrals are more in young donor population and permanent deferrals
are more in ageing population. So the main concentration should be to address the
young population in order to increase the blood donor numbers.
P-066
This abstract has been withdrawn.
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A STUDY ON COMPARISON OF SERVICE QUALITY PERCEPTION
BETWEEN SERVICE PROVIDERS AND BLOOD DONORS
Huang YT
Taichung Blood Center, Taiwan Blood Services Foundation, Taichung, Taiwan
Background: In Taiwan, blood collection centers operate as non-profit and private
organizations to collect blood from volunteers to be supplied to regional hospitals.
With the decline of birth rates, the donation rates of new donors drop year by year.
Moreover, as the age increasing or health problems the repeat donors gradually cannot
to donate blood. It’s important to boost the motivations of donating blood and to
recruit new blood donors continuously. Taichuang blood collection center have already
made much effort, including good personnel training, well-appointed blood collection
room, delicious biscuit and practical gifts, to facilitate the regular recruitment of blood
donors to meet the demand of hospital patients.
Aims: The purposes of this study are: (i) To evaluate the donors’ satisfaction of service
quality with Taichung blood donation center; (ii) To evaluate the service providers’
satisfaction perception of service quality; (iii) To understand the service quality gap
between service providers and blood donors; and (iv) To develop a high reliability and
validity scale of service quality as an evaluation instrument of service quality in our
blood collection center.
Methods: We conducted a cross-sectional study, and a questionnaire was designed
according to SERVPERF (Q = P) model modified to the specific service quality
requirements of the blood collection center. The survey instrument consisted of 31
items grouped according to five dimensions of quality service: tangible, reliability,
convenience, responsiveness and benefit, on a 5-point Likert scale ranging from very
dissatisfactory (score = 1) to very satisfactory (score = 5). The participants were blood
donors donating blood in 1 year and the service provider that are blood collection
staffs to which the participants were expected to respond anonymously. The inter-
reliability Cronbach’s a used in this research indicated good inter item reliability and
the test–retest reliability that showed a good consistency obtained in blood donors and
service provider.
Results: A total of 407 blood donors and 99 of service providers were tested in this
research, and the data showed both groups are close to the degree of satisfaction in the
dimensions of tangible, convenience and benefit. It means the blood donation service
quality of the three dimensions had a satisfied level to blood donor. In the dimensions
of reliability and responsiveness, the blood donors had a lower score of service sat-
isfaction than that of the service provider that means there is a service quality gap
between blood donor and service provider.
Conclusions: Related policies should be enacted in response to catch up on what blood
donors have expected. In addition, this study established a high reliability and validity
scale of service quality to as an evaluation instrument of service quality.
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P-068
A STUDY OF ASSESSING THE ATTITUDES OF MOBILE
ORGANIZERS TOWARDS THE MOBILE TEAM OF NATIONAL
BLOOD CENTRE SRI LANKA
Seneviratne C
National Blood Centre, Colombo, Sri Lanka
Background: National Blood Centre (NBC) Sri Lanka (SL) is the headquarters of the
blood transfusion service of the nation which coordinates 85 hospital blood banks.
Annual blood collection of NBC mainly depends on the mobile drives. The mobile
organizers are a very important category for the better provision of blood service as
they are the stakeholders for donor motivation and retention. Mobile organizers’
attitudes towards the blood service are of paramount importance to any blood trans-
fusion service.
Aim: To assess the attitudes of mobile organizers towards the mobile blood collection
team of NBC.
Method: A cross sectional study was done by sending a questioner by post to all mobile
organizers of the NBC SL in 2009. It was filled by the organizers and posted back to the
centre anonymously. Questioner contained the attitudes regarding, (i) Punctuality and
initiation of mobile, (ii) Team friendliness towards the donors and team discipline, (iii)
Ending of mobile, (iv) Any delay in procedures (registration, counseling and donor
bleeding) and (v) Team adequacy. Attitudes were analyzed under each category.
Results: Total of 166 mobile organizers had responded within the period of 3 months.
Sixty per cent of the organizers were satisfied about the punctuality and initiation of
the mobile while 36% were unsatisfied and 4% had not responded. Ninety-five per cent
of organizers were satisfied about the team friendliness towards the donors and team
discipline while 5% were unsatisfied. Satisfactory attitude of organizers on ending of
mobile was 92% while 8% was unsatisfied. Seventy-six per cent of the organizers said
that there was no delay in registration while 19% were unsatisfied and 5% had not
responded. Eighty-four per cent of organizers were satisfied about the counseling while
8% said counseling was delayed and 8% of organizers did not respond to the question.
Eighty per cent of organizers said there was no delay in donor bleeding while 5% said it
was delayed and 15% did not respond. Eighty per cent of the organizers were satisfied
about the team adequacy and 18% were unsatisfied while 2% were not responding.
Out of them overall satisfactory rate was 81% where as 14.14% results were
unsatisfactory. On the other hand 4.86% were non responders.
Conclusion: Overall satisfaction of organizers towards the mobile team is good, but
the punctuality and the initiation of mobile is a little less than other factors considered.
This must be due to the fact that the location of the mobile is far away from the center,
it takes a lot of time to travel from NBC to an out of city mobile due to the distance and
also due to the heavy traffic with in Colombo limits. To solve this problem the orga-
nizers can get the help of the closest peripheral blood bank. All other factors considered
in the questioner have got satisfactory levels reflecting the efficient professional
attitude of the staff of the NBC SL.
P-069
WHY WE DEFER OUR VALUABLE DONORS
Wijesiri RD
National Blood Centre, Colombo, Sri Lanka
Background: Annual blood collection of Sri Lanka is around 300,000. National Blood
Center of Sri Lanka contributes around 20% of annual blood collection by mobile and
in house blood collection. It is important to study causes for donor deferral and donor
deferral patterns as it has a significant impact on blood collection.
Aim: 1. To study donor deferral patterns.
2. To identify preventable causes of donor deferral.
Material and method: A retrospective study was done in a period of 6 months from 1
April 2010 to 31 September 2010. The data collected from the donor deferral registers
of four mobile blood collecting teams at National Blood Center, Sri Lanka.
Results: From 1 April 2010 to 31 September 2010 total mobile blood collection at
National Blood Center was 25,948. There were total 2037 donor deferrals, of which
1484 (73%) were temporary deferred while 553 (27%) were permanently deferred.
Analysis of donor deferral criteria shows that, unfulfilled basic requirements (age,
weight, Hb, adequate sleep,4 months from previous donation) consisted 256 (13%),
acute infections 433 (22%), past infections 204 (10.2%), on treatment for a systemic
illness 317 (15.5%), undiagnosed systemic diseases 31 (1.5%), blood pressure
abnormalities 329 (16%), past history of surgery 69 (3.3%), high risk behaviors 31
(1.5%), tattooing, ear piercing, acupuncture treatments 64 (3%), recent foreign travel
63 (3%), and others 226 (11%).
Of those due to unfulfilled basic requirements, 41% were deferred due to low
hemoglobin levels.
Of the total number of deferral, 997 (49%) donors were first time donors and 1040
(51%) donors had donated more than once.
Conclusions: Acute infections were the leading cause for donor deferral in our donor
population. A significant percentage of our donor population was deferred due to low
hemoglobin. Public education about blood donation and causes of donor deferral may
lower the donor deferral rates since significant percentage of donors were deferred due
to unfulfilled basic requirements and tattooing, ear piercing and acupuncture treatment.
As most of the donors were temporary deferred and nearly half of deferred donors were
first time donors, counseling after deferral and provision of next date for blood donation
is important to maintain adequate amount of blood collection in the country.
P-070
SEASONAL FLUCTUATIONS OF VITAMIN D3 IN A COHORT OF
BLOOD DONORS IN UPPER AUSTRIA
Gabriel C, Falkinger A, Su¨ssner S, Ecklbauer D, Fru¨hwirth K, Schreiberhuber S
Red Cross Transfusion Service of Upper Austria, Linz, Austria
Problem: Vitamin D3 (calcidiol, 25-OH-vitamin D3) is generated by UV-irradiation
and stored in the human body, in summer more than in winter. Reduced sun exposure
in winter can result in a decrease of vitamin D3. We decided to detect seasonal vari-
ations of vitamin D3 in voluntary blood donors to evaluate the impact of this
parameter for our donors.
Patients and methods: Samples were taken from 105 blood donors (18–65 years)
before and after winter and stored immediately without light exposure. After centri-
fugation, freezing and thawing the vitamin D content was tested with the testing kit
‘25-OH-Vitamin D3/D2’ (Chromsystems, Germany) according to manufacturer’s
instructions on a HPLC instrument (LC20; Shimadzu, Japan). The results of vitamin D3
were categorized in normal range (20–70 lg/l), undersupply (10–20 lg/l) and defi-
ciency (<10 lg/l). Vitamin D2 was not interpreted because the tested cohort did not
supplement vitamin D in this period.
Results: The difference of vitamin D3 concentration before and after winter was sig-
nificant. The mean reduction was above 40% and does not depend on gender. Vitamin
D3 deficiency was present in 1.9% of the samples before winter and in 21.9% after-
wards. 17.1% of the cohort had an undersupply at the first point of testing. This group
increased to 50.5% after the winter. Only 27.6% of the donors were in the normal range
at the first as well as at the second sampling.
Conclusions: The prevalence of an undersupply/deficiency of vitamin D3 of 0.190
before winter and 0.724 afterwards implicate that reservoirs of vitamin D3 are emptied
in winter due to reduced solar irradiation. Our results suggest that the parameter vitamin
D3 could be a gratification for our voluntary blood donors in or after wintertime. In case
of undersupply/deficiency a supplement therapy could be recommended.
2.2 Blood Collection including
Apheresis
P-071
EVALUATION OF BLOOD DONOR DEFFERAL
Palle Mulle Gamlath Ralalage C
National Blood Center, Colombo, Sri Lanka
Background: The goal of selection of blood donors is to ensure safety of blood donor
as well as the recipients. To accomplish this donor deferral criteria must be precise and
uniformly used by the blood transfusion service of the country.
Aim: To evaluate the reasons for blood donor deferral during mobile blood collection
programs organized by National Blood Transfusion Service, NBC, Colombo, Sri Lanka.
Material and method: Retrospective analysis of whole blood donor deferral registers
at the NBC – Sri Lanka during August 2010 to December 2010. Prior to evaluation,
potential blood donors are screened using haemoglobin level, blood pressure, pulse rate
and medical examination according to the Stranded Operative Procedures (SOP) pre-
pared by quality management section of NBC.
Results: The total number of prospective blood donors was 25,564 for the study
period. 19,429 (76.0%) were male donors and 6135 (23.99%) were females. One
thousand three hundred eighty-four prospective donors were differed. Out of this 955
(69.0%) were male donors and 429 (30.99%) were female donors.
While analyzing the age of female differed donors’ majority 181 (42.19%) were in 31–
45 years age group and among male donors major contribution 487 (50.99%) was from
18 to 30 age group.
The total number of deferred donors, volunteered for the first time for blood donation
was 751 (54.26%) [300 female (69.9%) and 451 (47.22%) male].
The deferral was temporary in 1097 (79.26%) cases [female 348 (81.1%) and 806
(84.39%) male].
The most frequent causes for temporary deferral was high blood pressure, donation
interval between last donation is <4 month, inadequate sleep and infected wounds.
 2011 The Authors
Vox Sanguinis  2011 International Society of Blood Transfusion Vox Sanguinis (2011) 101 (Suppl. 2), 39–134
58 Posters
The leading causes of permanent deferral were unsatisfactory medical conditions,
chronic illnesses and infectious diseases.
Conclusion: The donor deferral is a complex process. According to this study 54.26%
of donors were first time donors and 79.26% were differed temporary. So it is man-
datory to provide clear explanation about the cause of the deferral to increase return
rate for future donations.
P-072
OPTIMIZATION OF THE TIME FROM ARRIVAL AT WORKPLACE
TO 1ST VENEPUNCTURE IN MOBILE BLOOD COLLECTION UNIT
BY USING LEAN SIX SIGMA METHODOLOGY
Lee YM, Kwok I, Kung S, Leung C
Hong Kong Red Cross Blood Transfusion Service, Hong Kong SAR
Background: Lean Six Sigma is a methodology to improve the performance excellence
for the organization. It uses a systematic approach to identify defects and eliminate the
waste by using data-driven structured strategy and root causes analysis. The mobile
blood collection unit in Hong Kong Blood Transfusion Service usually takes about
60 min to start the 1st venepuncture for blood donation after arrival at workplace. The
project adopted the core value of Lean Six Sigma for the continued quality
improvement to optimize the time of starting the first venepuncture in the mobile
blood collection team.
Aims: The goal statement is to reduce the time span from the arrival of mobile unit at
the workplaces to the start of the 1st venepuncture by 15%.
Methodology: The approach includes the various phases of Define, Measure, Analysis,
Improve and Control (DMAIC).
Y = f (X) Y is the output measure of the time to start the 1st venepuncture where as the
X(s) are all the variables from the high level process flow (Supplier, Input, Process,
Output and Customer) that possibly contributed to the output Y. The data collection
included the workflow study, the audit plan and the time study.
Result: The time study showed the mean of time spent from the arrival of mobile team
at the donation site to the time of starting the 1st venepuncture was 56.49 min. Three
variables from the workflow study were identified to show their associations with the
time span to start the 1st venepuncture time. They are pre-donation preparation of
donation group (P = 0.0066), the set-up sequence (P = 0.0013) and the time to start 1st
health screening (P = 0.03).
An improvement plan based on the findings was then initiated. The result showed that
the time to start the 1st venepuncture after arrival of the donation site was reduced by
14.57%. The compliance of the most interventions was from 73% to 100%
Conclusion: In general, the compliance rates of most interventions were satisfactory.
The evaluation revealed that mobile jobs without sign-up were the major obstacle for
compliance of the interventions. If the data was analyzed by deleting those MU drives
without sign-up, the result showed that the time span from MU arrival to 1st vene-
puncture would further be reduced by 17% which could achieve more than the goal
statement set in the project. The improvement plan showed its effectiveness to optimize
the time to start the 1st venepuncture to donor. However, pre-arrangement of sign up is
highly recommended for the collection drives.
P-073
PLASMAPHERESIS AND CLOTTING ACTIVATION
Vrielink H, Karssing W, de Korte D, Koopman MMW
Sanquin Blood Foundation, Amsterdam, The Netherlands
Introduction: Recently, flocculation and/or clots have been observed in a substantial
percentage of defrosted FFP delivered by the Dutch blood transfusion organisation.
Activation of platelets can initiate activation of the clotting cascade. Therefore, it has
been suggested that the root cause of the flocculation/clots is activation of the clotting
system by activated platelets due to the apheresis equipment used. In the Netherlands,
all FFP is collected by apheresis applying Fenwal and Haemonetics equipment.
Aim of the study: To study activation of the clotting system in donors and in
apheresis derived plasma using Fenwal’s Autopheresis C and Haemonetics’ PCS2.
Materials and methods: After informed consent, six repeat plasmapheresis donors
were asked to donate two times a unit of 650 ml of plasma with an interval of 4 weeks.
Three donors donated at day 1 with the Autopheresis C (Fenwal) and 4 weeks later with
the PCS2 (Haemonetics) and vice versa. Prior to, and directly after the plasmapheresis
procedure, an EDTA sample was drawn from the donor for whole blood cell counts,
measurement of thrombo-elastography (TEG), CD62P, annexine-V, PAC-1, thrombin-
antithrombin complex (TAT-complex), prothrombin fragment 1 + 2, D-dimers, FVIII-
antigen, FVIII-activity and total protein. Since one donor refused the 2nd donation,
results from five donors were analysed. Prior to the freezing of the apheresis plasma,
and after thawing (after 12 days), thrombin-antithrombin complex (TAT-complex),
prothrombin fragment 1 + 2, D-dimers, FVIII-antigen, FVIII-activity and total protein
were measured.
Statistics: To compare the laboratory results in the donors, a paired t-test was used; A
P-value of <0.05 was considered to be significant.
Results: In 11 plasmapheresis procedures, no statistical differences in tests results
performed with donor blood drawn prior to, and after the apheresis procedure were
observed. No differences were observed between the collected plasma parameters in the
paired study in five donors donating with Autopheresis C or with PCS2. In none of the
11 plasma units, activation of the clotting system was observed.
Conclusion: In 11 plasmapheresis procedures with six donors, no activation of the
clotting system in donors and derived products was observed. No changes caused by
the apheresis procedure were seen. A root cause for the flocculation/clot formation in
the plasma could not be resolved. Additional research is needed.
P-074
EXAMINATION OF BLOOD FERRITIN IN LONG TERM, REGULAR
PLATELETPHERESIS DONORS
Lu HJ, Wang CH, Lin KH
Taipei Blood Center, Taiwan Blood Services Foundation, Taipei, Taiwan
Background: The major side effect of whole blood donation is iron depletion. For
regular plateletpheresis (PH) donors, less was discussed. It is worthwhile to study the
blood ferritin level as well as iron deficiency rate (ID rate) in apheresis donors.
Methods and results: This study was conducted from January to December 2007.
Venous blood was collected for ferritin examination from long-term, regular, repeat PH
donors. These were donors who donated platelet by apheresis 20–24 times per year.
First-time PH donors were also selected simultaneously as a control group. A total of
325 cases were collected, of which 125 were first-time donors and 200 were repeat
donors. Of the 200 repeat PH donors, group (A) were 50 cases who had a history of 20–
50 donations, (B) 50 cases of 51–100 donations, (C) another 50 cases of 101–150
donations, (D) 25 cases of 150–175 donations and (E) 25 cases of 176–200 donations.
Amongst the first-time donors, there were 75 men and 50 women, and 40% were
21–30 years old. This gender and age distribution were similar to that of whole blood
donors. For the 200 repeat PH donors, however, there was male predominance of more
than 90%, and the peak age group was 51–60 years (34.5%). The average ferritin level
amongst male donors was 67.8 ng/ml for first-time donors. For repeat male donors, the
ferritin levels were 47.3 ng/ml in A, 48.5 ng/ml in B, 38.8 ng/ml in C and 43.2 ng/ml
in D for the different groups. The proportion of cases whose ferritin levels dropped
below 20 ng/ml was 6.7% amongst first-time donors. For repeat male donors, low
ferritin levels occurred in 9.1% of the cases with 20–50 PH donations, 13.6% of the
cases with 51–100 donations, 19.6% of the cases with 101–150 donations and 26.0% in
the cases with 151–175 donations. Apparently, the occurrence of iron deficiency in-
creased with an increased number of donations. Comparison of female donors were not
done, because of limited cases.
Conclusion: Repeat, long-term, regular plateletpheresis could cause iron depletion.
Iron deficiency increases with the years of donation and the number of apheresis. Two
Hematonic tablets, with elementary iron 100 mg on the day of apheresis, is effective in
preventing iron depletion as well as the decrease of hemoglobin. Regular iron study,
such as ferritin examination, is necessary for repeat donors, especially those with a
history of apheresis of more than 100 times within 5 years.
P-075
CORRELATION OF DONATION FREQUENCY WITH CAPILLARY
AND VENOUS BLOOD HEMOGLOBIN
Kung HC
Kaohsiung Blood Center, Kaohsiung, Taiwan
Background: To avoid inadequate blood obtained from donation, it is essential to
know whether there are differences among the results analyzed by different
methods to quantify hemoglobin (Hb) and ferritin, and if donation frequency affects
donors.
Aims: This study attempts to compare the results gained from three methods (CuSO4
gravimetric method, HemoCue system, and CBC test) frequently used to test for Hb
level, to examine the level differences between Hb and Ferritin on target variables, and
to understand if donation frequency affects Hb level and Ferritin level.
Methods: Blood samples were obtained from 1512 volunteers to test for Hb; capillary
fingerprick sample analyzed by both the CuSO4 gravimetric method and the HemoCue
system, venous sample analyzed by the CBC test. The Hb level obtained from CBC test is
defined as ‘true’ value. Additional 5989 volunteers entered the study during 6 July and
16 October 2009, and were further grouped based on gender, age, first-time donors,
and regular donors. Data were recorded and analyzed with SPSS 18.0.
Results: When comparing the Hb level analyzed by the CuSO4 gravimetric method
with that analyzed by the CBS test, the ‘true’ rate was 63.5% and 85.8% for female and
male, respectively. The Hb level analyzed by the HemoCue system was consistent with
that analyzed by the CuSO4 gravimetric method. Age impacts upon Hb level but not
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Ferritin. Aged male donors had significantly lower Hb level than younger donors
(P = 0.001). Instead, elder female donors had higher levels of both Hb and ferritin
(P < 0.001). First-time donors had higher ferritin level than regular ones (P < 0.05). For
both female and male donors, donation frequency influenced on the ferritin level
significantly (P < 0.001).
Conclusions: The ‘true’ rate of the Hb level analyzed by CuSO4 gravimetric method is
low. Donation frequency has less impact on Hb level but more on ferritin level. That
ferritin levels of the older female donors are higher than younger ones might be
attributed to menopause.
P-076
CHANGES IN SERUM FERRITIN LEVEL IN APHERESIS DONORS
Lin L, Lee PH, Lu SC, Tsai KC
Taiwan Blood Services Foundation/Division of Medical Affairs, Tainan, Taiwan
Background: In order to understand the changes of serum ferritin in apheresis donors,
blood center started the detection of serum ferritin for the repeated apheresis donors
every 6 months since July 2008.
Aims: In this study, retrospective analysis of serum ferritin changes in apheresis do-
nors will be performed, so that we can provide sustainable health care for blood donors.
Methods: This study was a retrospective study, to analyze 212 (male) repeated
apheresis donors who received serum ferritin examination in 2010 May–June were
selected as the study sample and all of them had been done five times ferritin detection.
According to the frequency, blood donors were divided into four groups: (Group A)
First time of apheresis donors, (Group B) <100 times, (Group C) 101–200 times, (Group
D) more than 201 times. We used SPSS ver 18.0 software to analyse the association
between ferritin, blood donation interval and frequency (significant difference as
P < 0.1).
Results: 1. Average age of 212 apheresis donors was 44.1 ± 9.6 years, average serum
ferritin was 50.3 ± 39.9 lg/l. The statistical results of four groups: Group A (n = 11)
mean age was 41.3 ± 9.7 years, mean serum ferritin was 45.9 ± 55.7 lg/l, previous
donation interval was 114.4 ± 23.1 days, Group B (n = 109) mean age was
40.9 ± 9.3 years, mean serum ferritin was 56.0 ± 44.5 lg/l, previous donation interval
was 36.4 ± 30.8 days. Group C (n = 49) mean age was 46.2 ± 7.9 years, mean serum
ferritin was 46.3 ± 33.2 lg/l, previous donation interval 31.6 ± 22.9 days. Group D
(n = 43) mean age was 50.3 ± 8.7 years, mean serum ferritin was 41.6 ± 27.5 lg/l,
previous donation interval was 37.3 ± 38.1 days.
2. 15.92% of repeated apheresis donors were low serum ferritin (<20 lg/l).
3. The frequency of repeated apheresis donors was negatively affected to serum ferritin
(b = )0.168, P = 0.017), it showed long-term sustainability of the platelet donation has
a downward trend of serum ferritin. The interval between blood donation and serum
ferritin was positively (b = 0.117, P = 0.065), that means the longer the interval
between blood donation, blood ferritin values would be higher.
4. IngroupDof repeatedapheresis donors the serumferritinwas lower thanpreviousother
groups, but statistical analysis among the three groups was no significant difference.
Conclusion: The study found the serum ferritin was significantly related to the interval
between blood donation and the frequency, Page, E. A. (Transfusion Medicine 20,
February 2010) presented the same results. The results show consistent positive cor-
relation for the iron content decrease and interval between blood donation. Care for
blood donors’ health, some countries have continued to supplement oral iron, the
results of this study also provide a reference for oral iron supplementary.
E-mail: hsiuhsiu.tn@blood.org.tw
P-077
THE EFFECT OF TRIMA ACCEL SYSTEM ENABLING
PLASMA-ASSISTED RINSEBACK FEATURE ON REPEATED
PLATELET-APHERESIS DONORS
Lin KH, Wang CH, Wang CF, Chiao CC, Huang S, Horng CS
Taipei Blood Center, Keelung, Taiwan
Background: Three cell separators, MCS, Trima, and Fenwal, were compared in 2007.
It is found that Trima Accel system without plasma-assisted rinseback left the most
residual blood volume. We requested the agent to enable the function of plasma-
assisted rinseback in Trima Accel system to improve the performance. In this study, the
effect of plasma-assisted rinseback was evaluated.
Aims: We recruited the donors harvesting platelets by Trima Accel system for
investigation the changes of residual blood volume in Trima kits and serum ferritin
level of donors after enabling plasma-assisted rinseback feature.
Methods: In the first stage, 31 platelet-pheresis donors (all male) were recruited, and
we evaluated the changes of residual blood volume, HCT, packed RBC in kits and their
experiences after enabling plasma-assisted rinseback feature. In the second stage, 48
platelet-pheresis donors who the sequences of donation were more than 15 times
1 year were traced, and we evaluated the changes of serum ferritin level after enabling
plasma-assisted rinseback feature.
Results 1. The results of ‘process time’ and ‘actual ACD volume’ weren’t significantly
different.
2. The experiences of the donors after enabling the feature were the same as before.
3. The results of ‘residual blood volume’, ‘HCT’ and ‘packed RBC’ in kits were
significantly lower. The decrease of ‘residual blood volume’ was 13.8%. The
decrease of ‘HCT’ was 51.3%. The decrease of ‘packed RBC’ was 59%, the reducing
volume was to a certain degree of 36 ml whole blood.
4. Before enabling plasma-assisted rinseback feature, the mean of serum ferritin level
was 28.06 ± 20.26 (SD) ng/ml, and the frequency of Iron deficiency (serum ferritin
<20 ng/ml) was 39.6%. After enabling plasma-assisted rinseback feature, the mean
of serum ferritin level was 52.77 ± 25.07 (SD) ng/ml, and the frequency of Iron
deficiency (serum ferritin <20 ng/ml) was 6.3%.
Conclusions: After enabling plasma-assisted rinseback feature in Trima Accel system,
the blood loss of donors was reduced, and the serum ferritin level of donors was
increasing significantly. The plasma-assisted rinseback feature was beneficial for re-
peated platelet-apheresis donors.
P-078
ADEQUATE LENGTH OF THE NEEDLE FOR WHOLE BLOOD
DONATION
Matsuzaki K, Kato N, Sasaki SH, Shuto SK, Ono OY, Nakajima K
Japanese Red Cross Tokyo Blood Center, Tokyo, Japan
Background: In the whole blood donation, a blood collection needle of 36 mm in
length is generally used. The needle makes not only the blood donor but also nurses
scary. Aims:
The aim of this study is to examine the adequate length of the whole blood collection
needle.
Methods: Whole blood collection bags Kawasumi ABQ-200M7NF, ABQ-400M7NF and
Terumo BB-ZQM207J, BB-ZQM407J were used for this study. Each of the bags has a
same 17G needle of 36 mm in total length. Ninety-six of Sumo wrestlers who are
thought representative of the good physique in Japan and 1032 of usual voluntary
donors were examined and donated whole blood as an ordinary manner. The needle
length inserted in the skin (inserted needle length) was calculated by measuring the
needle length out of the skin (outer needle length) during blood donation.
Result: The body weight of the groups of Sumo wrestlers vs usual voluntary donors
were 119 ± 28 kg (range 60–200 kg) and 65 ± 11 kg (40–120 kg), respectively. The
height of those were 178 ± 7 cm (range 153–192 cm) and 168 ± 8 cm (147–188 cm).
Then the inserted needle length of Sumo wrestlers was 15.3 ± 4.1 mm (range
6–27 mm). On the other hand that of usual voluntary donors was 15.2 ± 2.9 mm
(5.6–26.5 mm). There is no significant difference between the two groups on the
inserted needle length.
Summary: It was clarified in this study. First, the length of the needle necessary for
whole blood donation was not different in the body weight and height. Second, the
average length of the needle inserted at the blood donation was around 15 mm. Third,
the length of the needle does not need over 27 mm. Based on these findings, needles
for whole blood donation can be shortened. According to the Poiseuille equation, the
fourth power of the radius of the needle is in inverse proportion to the length. So a
smaller needle will become acceptable for whole blood donation.
E-mail: ko-mastuzaki@tokyo.bc.jrc.or.jp
P-079
STUDY ON NUMBER OF CYCLES AND YIELD PERFORMANCE
AMONG DONORS WITH HISTORY OF FAILURE TO MEET
PLATELET YIELD PERFORMANCE
Jamil NF, Poo LH, Pennefather DJ
Health Sciences Authority, Singapore, Singapore
Background: Platelet demand is high and recruitment of apheresis donors in order to
meet daily usage is our primary goal. There is a small group of apheresis donors who
have 150,000–190,000 · 109/l platelet count which in turn results in low platelet yield
performance.
Aims: The aim of this study was to obtain a 3.0 · 1011 platelet dose from these donors
paying particular attention to the duration of the process, post platelet count, platelet
depreciation and acceptance by donors.
Methods: The study was conducted for a period of 6 months from the month of June
to December 2009. All donors met the apheresis criteria and given written informed
consent. Eighty apheresis donors with an average pre-platelet count of 150,000–
190,000 · 109/l and with history of failure to obtain the desirable platelet yield were
recruited into the study. The procedures were carried out on the Haemonetics MCS+
cell separator machine using the SDP protocol.
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In this study, donors donated platelets consistently for 6 months instead of doing
alternate donation between plasmapheresis and plateletpheresis with an interval of 2–
3 months. The target yield was decreased from 3.6 to 3.0 · 1011 which corresponds to
the decrease on the number of cycles in the procedure. The post platelet count was also
monitored to assess platelet depreciation.
We started our recruitment in June and used the results collected in that month as a
baseline data. We only adjusted the target platelet yield from 3.6 to 3.0 · 1011 from
July onwards (3.6 · 1011 is our centre set target). Within the duration of the study, pre
platelet count was taken and the collection of their platelet was based accordingly to
donor’s exact platelet count instead of taking the average three previous consecutive
donations to obtain estimated platelet count.
Results: The average platelet depreciation during the study was 17,000 · 109/l as
compared to 44,000 · 109/l before the study. This was demonstrated on 53 (92%) of the
donors but for the four (8%) of the donors there seem to show a fluctuation in their
platelet depreciation. We noticed a gradual increase in the donors’ platelet count after
4 months onwards among all the different age group. Through the immediate avail-
ability of pre-platelet count, we are able to set the precise process volume and cycles
needed to obtain the target yield of 3.0 · 1011. (As opposed to setting a higher pro-
cessed volume based on previous average counts.)
Summary/conclusion: This small study suggests that by decreasing the platelet yield
target from donors with these pre platelet counts is possible without compromising
donor safety and efficacy of the platelet concentrates. The platelet concentrates ob-
tained satisfy the international guidelines. With close monitoring of these donors we
are able to increase our apheresis pool of donors and meet daily targets.
P-080
PREOPERATIVE AUTOLOGOUS BLOOD DONATION USING A
DOUBLE-UNIT RBC COLLECTION SYSTEM IN ORAL AND
MAXILLOFACIAL SURGERY
Han KS1, Kim H1, Park H1, Choi JS2, Hwang SJ3, Yang HJ3, Kim MJ3, Lee JH3, Choi JY3
1Seoul National University Hospital, Seoul, South-Korea 2Korea University Hospital,
Seoul, South-Korea 3Seoul National University Dental Hospital, Seoul, South-Korea
Background: As the life expectancy increases, blood shortage is becoming a matter of
great concern worldwide. Recently, double RBC collection system is adopted in many
countries to procure more blood from healthy blood donors. Pre-operative autologous
blood donation (PABD) aims to meet future blood transfusion requirements and has the
advantage of safety because it is free from transfusion transmitted infection and
alloimmunization.
Aim: We conducted double-unit PABD for patients who underwent scheduled elective
oral and maxillofacial surgery to find out if the procedure is safe and effective.
Methods: We compared laboratory and clinical parameters of patients who underwent
double-unit RBC collection using ALYX system (n = 117) with 82 patients who do-
nated one unit of blood every week for 3 weeks before surgery.
Results: No significant adverse reaction was found in the double-unit PABD group.
The hemoglobin (Hb) and hematocrit (Hct) before autologous blood deposit, the pre-
operative Hb, and 24-h postoperative Hb and Hct didn’t show significant differences
between two groups. Double-unit PABD group showed higher preoperative Hct level
(ALYX, 39.7 ± 3.2%; control, 38.6 ± 2.7%; P = 0.024) and less decrease in Hct
(12.3 ± 5.9%) when compared to control group (14.8 ± 5.6%) (P = 0.008). Duration of
hospitalization showed no significant differences between two groups, however,
double-unit PABD group showed a shorter interval from the first day of collection to
the time of admission (ALYX, 14.4 ± 4.7 days; control 20.8 ± 3.8 days; P < 0.001).
The percentage of patients requiring additional allogeneic blood transfusion was not
significantly different between two groups.
Conclusions: PABD using double-unit RBC collection system was convenient since the
patients visited our blood bank only once for pre-operative deposit. Clinical and
laboratory parameters were comparable to the conventional one-unit PABD. In con-
clusion, double-unit PABD is considered as a safe and efficient method for patients
undergoing autologous transfusion for scheduled elective surgery.
P-081
PREVALENCE OF HIGH TITRE IGM ANTI A/B AMONG
VOLUNTARY BLOOD DONORS IN SRI LANKA
Kuruppu KADDP
National Blood Transfusion Service, Colombo, Sri Lanka
Background: The National Blood Centre (NBC) is the headquarters of the National
Blood Transfusion Service and it contributes to 21% of total annual whole blood
collection. One hundred per cent of the whole blood collection is processed into blood
components. Platelet concentrate is prepared either from Buffy coat derived or PRP
method from 81% of the whole blood collected by the NBC.
Providing ABO compatible platelets may, at times become a difficult task because of
the increasing demand for platelets and its limited shelf life. ABO incompatible platelet
transfusion is shown to have a varied outcome.
A major mismatch platelet transfusion may show a reduction in platelet increment
whereas a minor mismatch transfusion may show a severe haemolytic transfusion reac-
tion due to presence of high titre IgM Anti A or Anti B in the donor plasma.
In Sri Lanka practice of transfusing minor incompatible platelet is not a standard
practice. The advantage of using minor incompatible platelet is to minimize the
wastage of platelets that expires 5 days after collection.
Aim: The purpose of this study is to determine the titre of IgM Anti A and Anti B
among group A, group B and group O voluntary blood donors at the National Blood
Centre – Sri Lanka.
Method: A descriptive study conducted at National Blood Centre – Sri Lanka in
2 months from April 2011 to May 2011. One hundred and fifty donor samples selected
by stratified sampling method.
The anti A titre of group B, anti B titre of group A and anti A and anti B titre of group O
donors were tested. Serial twofold dilutions of plasma were prepared in PBS. Samples
were tested in parallel, for anti A and Anti B by direct agglutination using 3% pooled
freshly prepared A1 and B cells. O cells were used as a negative control. The titre was
recorded as reciprocal of the highest dilution giving 1 + clumping. The cut off value to
determine the donor as high titre is taken as a positive result at 128 or more in saline
agglutination.
Results: Out of 150 donor samples 50% of the donors were group O, and 82% of them
weremale. Forty-four per cent of thedonorswere between the age28–37and34%of them
were between the age18–27. Thirty-eight per cent of the donors were high titre positive
and 62 of them were high titre negative. Sixty-three per cent of the high titre positive
donors were group O. Forty-four per cent of female donors were high titre positive.
Conclusion: This study shows that the prevalence of high titre donors among Sri
Lankan voluntary blood donor population was 38% and it is highest among group O
donors. There was no significant rise in high titre positive donors among females.
It is recommended that it is important to consider the risk and the benefit before
deciding out of group platelet transfusion.
P-082
USAGE OF THROMBOCYTAPHERESIS (SINGLE DONOR
PLATELET) IN BANDUNG BLOOD DONATION SERVICE,
INDONESIAN RED CROSS
Djoechro Y, Suryawidjaja W, Nuraini Y, Djuhjar U
Indonesian Red Cross, Bandung, Indonesia
Background: Thrombocytapheresis is the separation and collected the platelet com-
ponents and the remainder blood component are returned to the donor automatically
using a special machine. Can be conducted continuously or intermittently.
Single Donor Platelet is more benefit than Multi Donor Platelet but due to the price is
more expensive therefore still limited usage.
In Bandung Blood Donation Service, Single Donor Platelet has been done since 2003,
using MS 3000 machine which is continuously flow with two access.
Since 2006, Bandung Blood Donation Service use Haemonetics machine MCS 3p and
MCS+ with intermittent flow using one access.
Until now the usage of plateletpheresis (SDP) still on request from the physician
clinicians.
The participation of the government with more affordable prices is highly expected.
Aims: (i) Increase the usage of plateletpheresis (SDP) by socialization to hospitals, (ii)
To gain attention from government to give participation with affordable prices.
Situation analysis: 1. The number of doctors who have been trained are four people
2. Trained operators are six people
3. Number of Haemonetics machine available are: 1 unit MCS 3p and 2 unit MCS+
Methods: (i) Interviews with operators and technicians, (ii) Data collection.
Result: In 2003: 2 SDP, 2004: 3 SDP, 2005: 6 SDP, 2006: 10 SDP, 2007: 14 SDP, 2008:
23 SDP, 2009: 54 SDP, 2010: 211 SDP and from January to May 2011: 177 SDP.
Conclusion: There was an increase in usage, especially since 2010, the average de-
mand for 13 SDP/month and from January to May 2011 average request are 35/month.
P-083
PLASMA PRODUCTION BY A NEW CELLULAR SEPARATOR: A
GENERAL ASSESSMENT OF NIGALE NGL XJC 2000
D’Onofrio M1, Paesano L1, Leonardi GM1, Vaccaro G1, Lubrano G1, Pecora R1, Misso S2,
Nocera C1
1ASL Napoli 1 Centro, Naples, Italy 2ASL Caserta, Aversa, Italy
Background: The Nigale NGL XJC 2000, distributed by Hemotrans (Pomezia, Italy), is
a new cellular separator exclusively dedicated to plasma production by apheresis. This
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instrument, characterized by a discontinuous blood flow with a single venous access,
adopts the technology developed by Latham, namely the separation of blood compo-
nents according to their density gradient by applying an appropriate centrifugal force.
In the Nigale’s kit, a blow moldeld bowl is included: Thanks to the structure of this kind
of bowl the coming in blood does not go through stratified hemocomponents, more-
over the greater rotation speed respect to Latham bowl (7.000 vs 4.800 r.p.m.) permits
to obtain a plasma with a lower cellular contamination. Moreover, compared to the
previous version, a needle-fistula for collection, a satellite bag for donor’s sampling, a
spike for clinical use of plasma collected and a device for quality controls on product
have been included in new kit.
Aims: We evaluated, in terms of effectiveness and efficiency, the qualitative and
quantitative performances of this equipment.
Methods: Between November 2010 and May 2011, 200 plasmapheresis were per-
formed with this new instrument, of course after informed consent, on 150 periodic
blood donors with at least one previous experience in apheresis donation. In order to
evaluate the operability and manageability of this cellular separator, the quality of its
kits and the compliance of donors, we have recorded all adverse reactions to donation,
any interruptions in the procedure due to malfunctions of instrument or abnormalities
of kits.
Results: We did not detect any serious accident, only in 20 out of 200 plasmapheresis
(10%) were recorded minor inconveniences. We have observed 18 mild adverse reac-
tions due to citrate toxicity (9%), resolved by changing the pump speed or with a little
break, but completing the procedure in all cases; in one case the donation was inter-
rupted by a fainting (0.5%), an adverse reaction of moderate grade; while in the last
case the apheresis failed for a prolonged low-pressure in the collection (0.5%) due to
difficulties in venipuncture, but without consequences for the donor. Serious reactions
were not observed, thus no one procedure has been interrupted for malfunctions of
instrument or for defects or disruptions of the kits.
Conclusions: Italy is still far away to obtain the self-sufficiency in plasma-derivates,
for this reason the collection of plasma by apheresis must be implemented. Nigale NGL
XJC 2000, in our experience, is characterized by an intuitive management software and
by simplicity in the mounting kit. The donation can be customized according to the
parameters of the donor and the amount of plasma to produce. The safety in the
process is guaranteed thanks to the various sensors connected to alarms, moreover it is
possible to re-infuse saline solution at will to achieve an optimal hemodynamic
compensation. Also considering the low costs of kits and the few mild observed adverse
reactions, in our experience, the benefits of this new cell separator are related to safety,
reliability and efficiency.
P-084
USING LEAN TOOLS TO IMPROVE DONOR TURN AROUND TIME
Pyone P, Rahamat N, Pennefather DJ, Tan HH
Health Sciences Authority, Singapore, Singapore
Background: The need to optimise scarce resources and reduce waste, without sac-
rificing quality and patient safety led our facility to apply lean tools to look for
improvement opportunities. Being the only blood bank in Singapore a high volume
of donors come each day to donate and time is the motivating factor that propel
donors coming forward. We recognised that time wasted with a poor process was
time. Tools from lean six sigma were introduced in our work area from registration to
donor room and the main goal of these tools is to identify activities in our workflow
which will help improve donor turn-around time which in turn affects service
delivery.
Aims: The aim of this study was to identify ways to enhance efficiencies in our
workflow using lean six sigma tools to improve donor turn-around time.
Methods: With the help from a business partner, routine work processes from donor
registration to donor room were analysed. The lean six sigma tools were applied to
evaluate every second of a process and how long and how fast the donor goes from one
station to another station of the whole donation process. The analysis also seek to
determine how much of any donor’s time is spent adding value to the donor vs how
much time is spent performing registration, medical screening, haemoglobin testing
and donation.
Results: Analysis showed that process timing for each station was consistent regard-
less of day of week. Average turn-around time was around 45 min on a non busy day..
From the study we noticed if there was a centre booking it effects the turn-around time.
Relationship between waiting time and staff ratio at screening and donation showed
the higher the ratio, the longer the wait. Waiting time at all stations affected the overall
turn-around time of up to 90%. Based on the analysis, we incorporated haemoglobin
testing together with medical screening which demonstrated a drop in the turn-around
time.
Summary/conclusion: The lean quality tools were effective in identifying opportu-
nities for minimizing or eliminating waste while conserving scarce resources. The tools
pointed to more efficient design for work areas and reduction of donor traffic in
already congested area.
P-085
HEMOGLOBIN PRE-DONATION SCREENING USING A NOVEL
NON INVASIVE METHOD
Etlin S, Troyanovsky N, Shinar E
MDA Blood Services Center, Ramat Gan, Israel
Background: Current Standard Operation Procedures worldwide require performance
of Hemoglobin (Hb) levels measuring as a prerequisite for blood donation. At present,
tests are performed using different invasive techniques, which have a number of dis-
advantages including donor’s discomfort and pain, risk of infectious disease trans-
mission, significant quantities of bio-hazardous waste and the need for very well-
trained personnel. An innovative, non-invasive method was employed, which is based
on Occlusion Spectroscopy technology in the red/near-infrared range, where a new
bio-physical signal is generated following an over-systolic pressure which is produced
at the finger base.
Aims: To evaluate the feasibility and validate the performance of a novel non-inva-
sive method for Hemoglobin detection (NBM-200 device; OrSense Ltd. Israel) on a
volunteer blood donors population in a national blood services set-up.
Methods: A total of 120 healthy volunteer blood donors (75 male, 45 female) in the
age range 18–66 years participated in the study, which was conducted at the Blood
Services Center fix-site donor’s room. Upon receipt of informed consent from the
donors, measurements were performed by placing an annular, multi-wavelength probe
with pneumatically operated cuffs on the volunteer’s thumb. Venous samples were
taken from the same donors, before donation, and evaluated on a Cell-Dyn Ruby
(Abbott) blood analyzer (‘Reference values’). Results were compared by using Means,
Standard Deviations (SD) and t-test.
Results: Hemoglobin levels measured on the NBM-200 device ranged from 10.6 to
16.4 g/dl, with an average of 14.1 ± 1.4 g/dl. These values were in accordance with the
‘reference values’, which ranged from 10.0 to 17.1 g/dl, with an average of
14.2 ± 1.4 g/dl. The difference between the Hb readings on the NBM-200 and the
venous references samples is statistically insignificant (P = 0.65). The mean difference
calculated as an absolute value, was 0.8 ± 0.6 g/dl. About 67% of the differences
between the two sets of data were <1 g/dl, and 97% of the differences were <2 g/dl.
The device did not cause any discomfort to the study participants, was safe and well
tolerated.
Conclusions: The Hb measurements obtained by the NBM-200 (OrSense) new method
were in relatively good agreement with venous blood reference values. The operating
staff found the NBM-200 easy to use, reliable and appreciated by the donors. The
technique reduces the need for invasive finger prick or venous blood sampling, thereby
enhancing safety, and improving the overall experience of blood donation.
2.3 Donor Adverse Events
P-086
MILD ANEMIA CORRECTION IN REGULAR APHERESIS DONORS
AS A SHORTEST WAY BACK TO DONOR’S ACTIVITY
Appalup M, Maiorova O, Momotjuk K, Averina E, Volodyaeva E
Moscow Blood Bank, Moscow, Russian
Depletion of iron stores is a frequent side effect not only for blood donors, but also for
regular plasma donors (RPDs), donating plasma by apheresis up to 20 times per year.
Mild anemia is common reason for temporary deferral and in most cases, nutritional
recommendations directed on increase of hemoglobin and completion of iron stores
don’t lead to their normalization and deferred donors leave blood bank for a long time.
Aim: To develop effective scheme for anemia correction for regular plasma donors.
Methods: Within 6 months at Moscow Blood Bank (MBB) to all RPDs deferred due to
decrease of hemoglobin (Hb), red blood cells (RBCs) and haematocrite (Ht) follow
therapy was administered for 30 days: complex iron medication (in one capsule – iron
sulfatis 150 mg, ascorbic acid 50 mg, riboflavinum 2 mg, tiamin mononitrate 2 mg,
nicotinamid 15 mg, pyridoxine hydrochloride 1 mg, pantotenic acid 2.5 mg) – one
capsule daily, and additionally – Ascorbic acid 100 mg three times daily and Folic acid
100 mkg three times daily. Upon 30 days of therapy, the control blood examination
was performed in all cases.
Obtained results were evaluated by Biostatistica (version 4.03) and statistically
significant differences were observed for P < 0.05 (Mann–Whitney test).
Results: Total number of RPDs, donated plasma during research period was 2613, in
which 671 (25.7%) women and 1942 (74.3%) men. Totally 76 (2.9%) persons were
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deferred due to mild anemia – 46 women and 30 men. Thus, frequency of this com-
plication at female donors was 6.9%, at male – 1.5%.
Initial Hb level at the moment of deferral in female group was 115.0 ± 2.8 g/l, RBCs
count 3.83 ± 0.21 · 1012/l, Ht – 34.28 ± 2.8%, in male group – 123.3 ± 4.5 g/l,
4.27 ± 0.49 · 1012/l and 37.2 ± 2.29%, respectively. After 30 days of therapy, it has
appeared that 10 women and nine men have ignored received recommendations. Thus,
they composed comparative group of study, whereas donors, who received the therapy
– main group. In main female group, Hb concentration has increased to 124.6 ± 4.0 g/
l, RBCs up to 4.2 ± 0.27 · 1012/l, Ht up to 37.4 ± 1.21%; in main male group Hb
raised up to 136.7 ± 5.4 g/l, RBCs up to 4.9 ± 0.44 · 1012/l, Ht up to 41.3 ± 2.28%
(P < 0.05 in comparison with initial value in all cases).
In comparative groups upon 30 days significant increase of analysed parameters
wasn’t noted: in female group Hb level was 114.2 ± 8.6 g/l, RBCs 4.03 ± 0.14 · 1012/
l, Ht – 34.1 ± 2.43%, in male – 127.7 ± 2.3 g/l, 4.67 ± 0.46 · 1012/l and
37.8 ± 1.03%, respectively (P > 0.05 in comparison with initial value in all cases).
Conclusion: It is obvious that proposed therapy is highly effective for RPDs deferred
for mild anemia and allows them to return to donation in shortest terms. It is necessary
to consider, that MBB donors, being inhabitants of a huge megacity, are chronically
stressed, in most cases can’t keep healthy diet and suffer from hypovitaminosis.
Therefore, despite presence at a complex preparation both iron and vitamins, ascorbic
and folic acids which deficiency is most often observed at Moscow inhabitants, were
additionally administered. Taking responsibility in maintaining of donor health, spe-
cialists of blood bank should work out effective schemes for anemia prophylaxis and
criteria for it’s administration.
P-087
HB A2 LEVELS AMONG INDIVIDUALS WITH
BETA-THALASSEMIA TRAIT
Yakout N
NBTS at RBTC (Alex.), Alexandria, Egypt
Background: Level of HbA2 is a well established screening test for beta-thalassemia
trait (BTT). Some reports suggested that iron deficiency in BTT patients causes HbA2 to
be lower than expected. However, conflicting reports have led to confusion amongst
clinicians as to the reliability of HbA2 measurement when screening for BTT in iron
deficient individuals.
Methods: Out of 3000 blood donors at Regional blood transfusion center, Alexandria,
Egypt, accidently discovered patients with hypochromic microcytic anemia where
screened for presence of BTT, and confirmed by molecular testing, variability in HbA2
was assessed. Thirty eight cases were found and classified as ‘iron deficient’ or ‘non-
iron deficient’ based on their serum ferritin, (serum ferritin < 15 lg/l) and data was
analyzed independently. The association of HbA2 levels with gender, iron deficiency or
beta-thalassemia mutation type was evaluated using a two-sample T-test. The rela-
tionship of HbA2 with gender, hemoglobin level, Hb F percentage, reticulocyte per-
centage and/or the natural logarithm of serum ferritin was evaluated using single and
multiple linear regression analysis.
Results: HbA2 ranged from 1.8% to 7.8%, with a mean of 5.2%. Mean HbA2 in females
(4.9%, SD 0.7%) was lower than that in males (5.5%, SD 0.8%) (P = 0.002). Ten cases
had a HbA2 level below 3% (range 2.0–3%), all of whom had serum ferritin 15 lg/l.
The 10 cases with serum ferritin <15 lg/l had evidence of iron-deficient hematopoiesis.
However, HbA2 was lower (5.3%) vs HbA2 in non-iron deficient individuals (5.5%;
P = 0.04). A significant association of low HbA2 with low ferritin (P = 0.04) and
beta+-thalassemia mutation type (P < 0.001). There was no significant association with
gender (P = 0.1), hemoglobin (P = 0.2), reticulocyte count (P = 0.08) or hemoglobin F
level (P = 1.0).
Conclusions: Serum ferritin <15 lg/l was associated with a small but significant de-
crease inHbA2 (meanHbA2of 5.3%, vs 5.5% innon-irondeficient individuals; P = 0.04).
Although ferritin under 15 lg/l was associated with lower HbA2 levels, beta+-thalas-
semia mutation type explained more of the variability than did iron status in individuals
with lower HbA2 values. HbA2 remains a reliable test for BTT screening, even in the
presence of iron deficiency. In patients known or suspected to have BTT, but in whom
HbA2 is found to be <3.5%, testing for delta-globin abnormalities should be pursued.
P-088
A RETROSPECTIVE STUDY OF VASOVAGAL REACTION IN
BLOOD DONORS: CONTRIBUTORY ROLE OF GENDER, AGE,
WEIGHT, DONATION STATUS AND BLOOD PRESSURE
Myint K, Tan H, Toh L
Health Science Authority, Singapore, Singapore
Background: Vasovagal reactions are renowned adverse events related to blood
donation. Although vasovagal reactions occur in small number of donors, these
reactions may have negative effect on return donation and disrupt blood collection
activities.
Aim: The objective of this study was to determine the input of age, weight, mean
Arterial Blood Pressure, gender and donation status in vasovagal reaction in blood
donors.
Study design and method: A retrospective study involved 11,314 blood donors from
center and 11,361 blood donors from mobile sessions during June 2009 to December
2009 in Singapore. One-way ANOVA was used to study the significance of each
variable contributed to vasovagal reaction in blood donors.
Results: It was occurred in 60 out of 11,314 (0.5%) donors had vasovagal reaction
after blood donation in center and 555 out of 11,361 (4.9%) donors in mobile sessions
respectively. First time donor status had a greater influence on developing vasovagal
reaction compare to repeated donors, 3% vs 0.3% in center and 7.8% vs 3.36% in
mobile sessions respectively. In the same time, age under 30 years had a higher chance
of getting vasovagal reaction compare to those of 30 years and above, 1.2% vs 0.18%
in center and 7% vs 2% in mobile accordingly. After analyzing with one-way ANOVA,
age, donation status (first time donor), weight, gender, meanABP (except in center)
were observed to have significant effect (P < 0.001). The most important variables in
center, in descending order, were donation status (first time donor), age, weight, and
gender. On the other hand, age, donation status (first time donor), weight, gender and
meanABP were graded in descending order at mobile sessions.
Conclusion: Donation-related vasovagal syncope reactions are a multifactorial process
largely influenced by age, donation status (first time donor) and weight.
P-089
SERUM FERRITIN MONITORING IN PLATELETPHERESIS
DONORS WITH UNEXPECTED PROCEDURE TERMINATION
Hsieh H, Hong CS
Taiwan Blood Services Foundation, Taipei, Taiwan
Background: Serum ferritin is a good lab. test revealing iron storage in bone marrow.
It had also been used in nutrition and health survey in Taiwan (1993–96) and in
Jiangsu, China (2002). Ferritin together with hemoglobin and/or transferrin saturation
were used to evaluate anemic status in these two surveys. In blood donors, ferritin has
been used to evaluate the iron status of repeated apheresis blood donors in large scale.
However, it has been found difficult to apply ferritin data in blood donors, due to wide
normal range from 20 to 300 lg/l. We evaluated a group of blood donors who inad-
vertently lost hundreds c.c. blood due to unexpected procedure termination upon
plateletpheresis. The series ferritin follow-up every 6 months as schedured, allowed us
look into ferritin change longitudinally in individual donors.
Methods and results: Thirty-eight plateletpheresis donor’s records from 2009 July to
2010 June, were reviewed. Of whom 34 were male and four female. Serum ferritin data
were retrospectively found 42–68 days prior to the unexpected procedure termination,
and 100–150 days post the event, upon regular plateletpheresis . Expect two of these
38 donors who were found no change of ferritin level before and after the event, 25
donors (21 males and 4 females) had ferritin level decreased from 36 to 25 (100 days)
and 27 lg/l (150 days). Interestingly, 11 males had ferritin level increased from 46
(42 days before) to 76 lg/l (126 days after). Four hundred and sixty-two plateletph-
eresis donor’s ferritin data were reviewed from October 2009 to April 2010. Half of
these donors had elevated ferritin level, instead. Blood loss ranged from 100 to 474 c.c.
(mean 230 and median 287 c.c.), estimated in the discarded collecting device. Half of
the donors used MCS apheresis machine and half used Trima machine. Hematocrit (Hct)
in the bowel of MCS collecting device was about 1.4 times of donors Hct, and 1.2 times
in the cassette of Trima collecting device. The reason of ferritin increment post blood
loss was not clear. Unfortunately, the diet habit and/or iron supplement taken were not
clear in these donors.
Conclusion: From this retrospective study, we can approximately estimate ferritin
decrement of 14.08 lg/l in male and 8.21 lg/l in female upon 100 c.c. blood loss in the
discarded collecting device of 25 donors. The ferritin change following blood loss or
donation need further prospective, detailed study of these group donors, which is
underway.
P-090
DETECTION OF STREPTOCOCCUS BOVIS IN AN APHRESIS
DONOR DIAGNOSED AS HAVING COLON CANCER
Wang YM, Hsieh HH, Hung CS
Taipei Blood Center, Taiwan Blood Services Foundation, Taipei, Taiwan
Background: Back to 1950–1970, clinical researchers spent time and effort trying to
understand the etiology of septisemia in patients. The colon bacterias were found
adhere to the colon tumor and spread into blood circulation by enriched lymphatics
and neovasculized vessels. Strptococcus bovis was found adherent to the receptor of
tumor and suspected the most probable bacteria to cause bacteremia.
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Methods and results: All plateletpheresis blood products were routinely cultured by
aerobic BactT/ALERT method. A long term plateletpheresis donor was found repeated
positive cultures in 1 and half years. The bacteria was Bacillus Sp. for the first time
(October 2007) and Gr. D Enterococcus at the second and third times, Streptococcus
bovis for the fourth time. The doctor interviewed the donor upon the third positive
culture reported. The donor claimed living well without bloody stool noticed. Skin
sterile technique performed on this donor 12 times, without positive reports. Gauzes
and cotton swarbs were sent for culture without positive reports, neither. Colonoscopy
and endoscopy were suggested by the doctor, however, refused by the donor. Three
months after the fourth positive culture, the donor called and stated colon cancer
diagnosed post bloody stool. Pathological report and operation report were refused
hand in by the donor. The donor had blood cultures 2 weeks after each plateletpheresis
positive cultures and revealed negative at all.
Conclusion: The bacteria adhered to colon tumor can spread into blood circulation
upon pressure change in the colon, such as constipation. The same mechanism might
play a role upon the donors blood inflow and outflow during apheresis. Streptococcus
could spread into blood circulation passively during the procedure. This also explained
the negative blood culture 2 weeks post apheresis.
P-091
INTRAVENOUS FLUID CHALLENGE FOR BLOOD DONORS WITH
SEVERE DONOR REACTIONS
Tsai ML, Hsieh H, Hung CS
Taipei Blood Center, Taiwan Blood Services Foundation, Taipei, Taiwan
Background: The blood donors with severe complications post whole blood or aphr-
resis donation, such as nausea, vomiting, dizziness, cold sweeting, lethargy, rigidity,
convulsion and transient conscious loss, used to be sent to emergency room nearby, if
they were unable to leave the donation site. Since May 2010, the intravenous solution
Dextrose 2.5%/Saline 0.45%, 500 cm3, was added into first-aid box. The doctor started
giving verbal order from central office as full-run of such IV solution at donation site
for these donors with severe complications. Comparison of these two groups was
carried out retrospectively.
Methods and results: From March 2008 to April 2011, 11 such severe complications
donors were sent to emergency room accompanied by nurse. Laboratory tests and IV
solution at regular rate were given by doctor. Eight of these 11 donors stayed at
emergency room from 1 h 20 min to 7 h 45 min, average 3 h 28 min, until the donors
were able to walk with assistance and sent home. From May 2010 to May 2011, nine
such donors received IV Dextrose 2.5%/ Saline 0.45% full-run at donation site and
finished 250–500 cm3 in 1–1.5 h. They were able to leave donation site after rested for
20–30 min.
Conclusion: By giving IV at donation site for those severe complications post donation
is as effective as emergency room management. In addition, the donor and nurse can
be benefit from time and stress relief.
P-092
FREQUENCY OF ADVERSE EVENTS IN PLATELETPHERESIS
DONORS IN REGIONAL TRANSFUSION CENTRE IN NORTH
INDIA
Gopal G, Ratti ram R, Neelam N
PGIMER, Chandigarh, Chandigarh, India
Background: Although automated cell separators have undergone a lot of technical
refinements, attention has been focused on the quality of platelet concentrates than on
donor safety. We planned this prospective study to look into donor safety aspect by
studying adverse events in normal healthy plateletpheresis donors.
Study design and methods: The study included 500 healthy, first-time (n = 301) and
repeat (n = 199) plateletpheresis donors after informed consent. The plateletpheresis
procedures were performed on Trima Accel (5.1 version, GAMBRO BCT) and Amicus
(3.2 version, FENWAL) cell separators. The adverse events during procedure were
recorded and classified according to their nature. The pre and post procedure hema-
tological and biochemical profiles of these donors were also assessed with the help of
automated cell counter and analyser respectively.
Results: A total of 18% (n = 90) adverse events were recorded in 500 plateletpheresis
donors, of which 9% of were hypocalcaemia in nature followed by hematoma (7.4%),
vasovagal reaction (0.8%) and kit related adverse events in (0.8%). There was signif-
icant post procedure drop in Hb, Hct, platelet count of the donors (P < 0.0001) whereas
WBC count showed a statistically significant rise (P < 0.0001). Divalent cations (iCa+,
TCa+, TMg+) also showed a statistically significant decline after donation (P < 0.0001).
However there were no statistically significance difference between adverse events in
Trima Accel (5.1 version, GAMBRO BCT) and Amicus (3.2 version FENWAL) cell
separators.
Conclusion: Donor reactions can adversely affect the voluntary donor recruitment
strategies to increase the public awareness regarding constant need for blood and
blood products. Commonly observed adverse events in plateletpheresis donors were
hypocalcemia, hematoma formation and vasovagal reactions which can be
prevented by pre-donation education of the donors and change of machine con-
figuration. Nevertheless, more prospective studies on this aspect are required in
order to establish guidelines for donor safety in apheresis and also to help in
assessing donor suitability, especially given the present trend of double product
apheresis collections.
P-093
COMPARE DETECTION OF SYPHILIS IN DONOR POPULATION
AT SOUTHERN REGIONAL BLOOD CENTER – KAM-
BURUGAMUWA, SRI LANKA FROM 2006 TO 2010
Withanage VH
Southern Regional Blood Center, Matara, Sri Lanka
Background: Syphilis is one of the transfusion transmitted infections which is checked
in donor blood. Syphilis disease itself has various stages. Primary and secondary
Syphilis can have symptoms but tertiary or latent Syphilis lacks the typical symptoms
and also can cause multi-organ disease. Early detection is important as this is a curable
disease with prompt treatment. A sensitive detection system should be available to
prevent the disease being spread via blood transfusions.
Aim: To screen all blood donors for Syphilis by a sensitive method as to identify
donors who are infected but in different stages.
Method: Data was collected from registers maintained at the laboratory at Southern
Regional Blood Center – Kamburugamuwa, Sri Lanka from 2006 to 2010.
Results: Total of 74,690 blood units were screened at the center during the period from
2006 to 2010 and all underwent Venereal Disease Research Laboratory (VDRL) test.
Test results are shown in the Table 1.
The confirmatory test TPPA (Treponema PallidumParticle Agglutination) was performed
on all donors who were positive for VDRL test and the results are shown in the Table 2.
All blood units with positive serological results were discarded. Further donors who
were positive from TPPA were contacted and referred to the Sexually Transmitted
Disease (STD) clinic at General Hospital, Matara, Sri Lanka for further management.
Summary: The number of donors detected with Syphilis has a considerable variation
thought out the duration under consideration. It is important to address this in a
systematic manner as syphilis is a curable disease. It is recommended to implement
proper early detection and reference for treatment systems as a priority. Also steps
should be taken to educate young donor population regarding the above issues.
Table 1
Year Number of donors became positive of VDRL test
2006 21
2007 40
2008 29
2009 10
2010 18
Table 2
Year Number of donors became positive of TPPA test
2006 4
2007 1
2008 4
2009 1
2010 5
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2.4 Rare Donor Programme
P-094
ROLE OF PULSE OXIMETRY PLETHYSMOGRAPHIC WAVEFORM
VARIABILITY IN PREDICTING ACUTE BLOOD LOSS
Hsieh H1, Ko YK2, Hung CS1
1Taiwan Blood Services Foundation, Taipei, Taiwan 2Cathay General Hospital, Taipei,
Taiwan
Background: Patients with acute blood loss must be treated with aggressive fluid
infusion. But no reliable non-invasive monitor tool or parameter were available for
assessing the condition. A lot of research papers showed positive correlation between
change of stroke volume and pulse oximeter amplitude variation before and after fluid
challenge in septic patient who was sedated with ventilator support. But there are few
relevant materials investigating spontaneous breathing patients with acute blood loss
by pulse oximeter.
Study design and methods: This research imitate the class 1 hemorrhagic shock pa-
tient with spontaneous breathing (blood loss 10–15%), via voluntary blood donor.
Cardiac sonography was used as the standard of assessment, before and after blood
donation. We accessed the change of cardiac stroke volume; pulse oximetry amplitude
variation (DPOP); serum biomarkers before and after blood donation.
Results: Thirty-two repeated blood donors and 1 first blood donor as volunteers (male,
15) were included in this study. Their mean age was 30.6 ± 6.6 years (range, 22–
53 years). Body weight was 68.91 ± 4.79 kg. Average blood loss was 12 ± 1.17% as
estimated by blood volume vs 7% of body weight and blood drawn duration was
10.31 ± 3.27 min. Bleeding rate was 0.79 ± 0.19 ml/min/kg. There was no significant
difference in systolic arterial pressure, diastolic arterial pressure, and respiratory rate
between the baseline and post blood donation conditions. However, cardiac output,
stroke volume decreased and heart rate increased after blood donation. The occult
hypoperfusion biomarkers such as Pro-BNP, Lactic acid, venous blood Gas Base Ex-
cess, were the same between pre and post blood donation. The hs-CRP was decreased
and venous blood Gas pH increased post blood donation, which necessitate further
exploration. A significant difference (P = 0.0299) in DPOP was found before and post
blood donation, and the mean DPOP were 12.93 ± 4.05% and 14.93 ± 5.61% seper-
ately.
Conclusions: This is a pilot study of a larger group healthy voluntary blood donors.
The physiological change in acute blood loss patient is quite different from blood
donor. But this, if having achievement after further research and analysis, and tools
using skillfully, can become theoretical foundation for clinical research in the
future.
P-095
RARE BLOOD DONORS IN TAIWAN
Pai SC, Chen JW, Lin SJ, Lin KS
Taiwan Blood Services Foundation, Taipei, Taiwan
Background: A rare blood group is defined as the blood groups absence of a high
prevalence antigen or absence of several antigens within a single blood group system
giving a prevalence of 1/1000 or less in the general population. As a blood provider in
Taiwan, we have maintained a rare donor panel and storage of frozen RBCs of rare
blood groups. To increase the number of rare donor, a multi-year project of screening
of donors for minor blood system including Rh, Kidd, Lewis, Duffy and MNS systems
were performed since January 2005.
Aims: The aim of the study is to investigate the phenotype frequencies of various
blood group systems and to characterize the rare donors found in the donor population.
Methods: The data from the screening project carried out between January 2005 and
March 2011 were analyzed. A total of 332,443 random voluntary blood donors were
screened for the red cell antigens Rh (D, C, E, c, e), Kidd (Jka, Jkb), Lewis (Lea, Leb) and
MNS (M) using monoclonal and polyclonal antibodies with automatic analyzers
(Olympus PK 7300; Center Valley, PA, USA). In addition, 2499 donors from foreign
blood donor group were analyzed for Duffy (Fya, Fyb) by manual tube method.
Results: During the period, 1,425,825 red cell typing were carried out on 332,443
blood donors. A total of 2335 (0.7%) donors were identified as rare. Of these rare
donors, 2059 were determined as Rh (D)), giving a breakdown for the combinations of
antigens as 1111 for rr, 728 for rr’, 144 for r’r’, 46 for rr’’, 25 for r’r’’ and 5 for r’ry.
Furthermore, 263 donors negative for high-incidence antigens and 13 donors of rare
RzRz phenotypes were identified. As regards the donors negative for high-incidence
antigens, the donors identified for the phenotype were 128 for Jk (a-b)), 100 for Fy(a-
b+), two for Fy(a-b)), four for Di(b)), 14 for i()) and 15 for k()). In the recent 2 years,
we have collected 1469 rare blood units, of which 234 were stored in frozen. Further,
these rare donors are characterized as below. Rare donors were found 64.8% from male
and 35.2% from female donors. There were 67.2% of the rare donors at the age between
17 and 40. Only 41.7% of rare donors gave blood every 3 months and 37% of them did
not give subsequent blood for over 2 years.
Conclusions: At present, we are able to provide adequate number of multi-antigen-
negative and Jk(a-b)) bloods for the blood demand in Taiwan. However, the Fy(a)),
Di(b)) and Rh null donors remain short in our donor panel. The project of screening for
rare donors should be continued and the procedures to approach these donors should
be addressed.
3. Blood Products
3.1 Blood Processing, Storage
and Release
P-096
QUALITY CONTROL OF BUFFY COAT DERIVED PLATELET
CONCENTRATIONS USED FOR TREATMENT OF CANCER
PATIENTS
Yapa DAN, Munasinghe SR, Bandara MCPK, Liyanapatabandi D
National Blood Transfusion Service, Colombo, Sri Lanka
Introduction: National Cancer Institute is the pioneering treatment centre for
oncological treatment in Sri Lanka. Transfusion of platelets to thrombocytopenic
patients is a method of optimizing their clinical condition. In component preparation,
two different methods are used for preparation of buffy coat derived platelet con-
centrate. In the first method, buffy coat derived platelets are prepared by high speed
centrifuge at 4000 rpm for 9 min and separation followed by overnight hanging and
separation of platelets without mixing using the ‘OptipressTM’ machine. The second
method of platelet preparation was to mix the overnight hanged platelets (prepared
as same as above) and then centrifuging it again followed by separation of platelets.
The quality of the final platelet concentrate is determined by the preparation method
which has a large number of steps involved. Improvement of the quality of
components is the primary task of the blood processing laboratories in transfusion
service.
Aim: This study was conducted to evaluate and compare the quality of buffy coat
derived platelet concentrates using the two separate methods of platelet preparation.
Method: In each method 150 random samples were selected. The volume, platelet
count, red cell contamination, leucocyte contamination, pH, and sterility were re-
corded. All samples were analyzed using ‘Orphee’ hematological analyzer. The pH was
determined by a pH meter and sterility assessed by culture of each sample.
Results: The standard volume of platelet pack falls between 55 and 75 ml. The
average volume of 78.68 ml in the unmixed platelet packs (the first method) was
slightly higher than this range. However mixed and separated packs (second method)
showed average volume of 55.34 ml, which falls in to standerds. The leucocyte
contamination of first method was 1.032 · 109. This was higher than the standard
cut off of 0.05 · 109. On the other hand second method showed reduced leucocyte
count of 0.072 · 109 per unit. Considering the platelet count per pack, unmixed and
separated packs (first method) showed 83.9 · 109 per pack, whereas mixed and
separated packs (second method) showed a platelet count of 70.39 · 109 which was
slightly less than first method. The pH value fell between 7.3 and 7.5 in both
methods. None of the platelet packs showed bacterial contamination. The amount of
red cell contamination was 1.33 · 109/ml and 0.05 · 109 in unmixed and mixed
packs respectively.
Conclusion: Values and the results of the quality control indicate reduced contami-
nation of leucocytes and red cells in the mixed and centrifuged method (second
method). However by achieving leuco-reduction and reduced red cell contamination,
mixed and centrifuged method produces less number of platelet per pack than the
unmixed method.
P-097
A NEW PRESTORAGE LEUCOCYTE REDUCTION FILTER FOR RED
BLOOD CELL CONCENTRATES LEADS TO SIGNIFICANT LOWER
LEUCOCYTE CONTAMINATION
Rosskopf A
Medical University of Graz, Graz, Austria
Background: Prestorage white blood cell (WBC) filtration of red blood cell concen-
trates (RCC) reduce alloimmunisation and non haemolytic transfusion reactions and
may prevent transmission of leucocyte-associated viruses, bacteria or prions. Therefore
the reduction efficacy of a filter system is of importance. We validated a new WBC
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filter, Leucoflex LCRD2, with two additional filter layers, and compared it with his-
torical validation data of our routine WBC filter LCRD (both Macopharma, Tourcoing,
France).
Methods: Whole blood donations (450 ml) were stored overnight at room temperature
(RT) and centrifuged with 4200 g for 13:30 min at RT the next day. Afterwards blood
was automatically separated, filtration (LCRD2) of buffy coat removed RCC was done
with 50, 60, 70 and 80 cm filter height (distance between filter and storage bag) and
filtration time was recorded. RCC (n = 215) were analysed for haemoglobin (Hb) and
flow cytometry based residual WBC content. The following storage parameters were
measured 1, 3 and 6 weeks after donation (n = 45): haemolysis rate, pH, glucose and
lactate. Reference data were ascertained equally 3 years before (LCRD, n = 101) with
exception for the filter height (solely 80 cm).
Results: Residual WBC could be reduced by half from 0.08 (LCRD) to 0.035
(LCRD2) · 106/U (mean). The filter height had no impact on the filtration efficacy
(0.03, 0.02, 0.03, and 0.05 for 50, 60, 70, and 80 cm respectively), but the filtration
time was extended from 22 min (LCRD, 80 cm) to 35, 42, 46, and 56 min for LCRD2 at
80, 70, 60, and 50 cm respectively. Hb content did not differ significantly (LCRD 51.4,
LCRD2 50.7 g/U). Haemolysis rate was higher with LCRD2 compared to LCRD (mean
0.35% vs 0.21%) but was within the guidelines of the Council of Europe. The other
storage parameters pH, glucose and lactate did not differ significantly.
Conclusion: The new filter for RCC Leucoflex LCRD2 is significant more efficient in
reducing WBC which could be an advantage in terms of preventing transmission of
leucocyte-associated infectious agents. Quality controls and storage parameters are
within Council of Europe guidelines. The filter height has no impact on the filtration
efficacy.
P-098
COMPARATIVE STUDY OF THE KINETIC PROCESSES OF
GROWTH FACTORS RELEASE FROM PLATELET GELS
PREPARED BY TWO METHODS
Yu J, Liu X, Wang H, Liu J
Institute of Blood Transfusion, Chinese Academy of Medical Sciences, Chengdu, China
Background: Platelet growth factors (PGFs) released by thrombin-Ca or CaCl2 acti-
vation of autologous platelet-rich plasma (PRP) are used as platelet gels (PG) in clinics
for wound healing and tissue repair. But the kinetic process of growth factors released
from the PG has not been thoroughly studied, and should be learned in order to provide
more reference for the clinical application.
Aim: To learn the time course of the release of growth factors from PGs prepared
through two methods, that thrombin-Ca and CaCl2.
Method: Platelet-derived growth factor-AB (PDGF-AB), and transforming growth
factor-b1 (TGF-b1) were measured before activation and at different time points of
1, 2, 4, 6 h after PG formation that prepared respectively by thrombin-Ca and
CaCl2.
Results: Mean PDGF-AB, TGF-b1 concentration increased to 104 ± 40, 101 ± 26 ng/
ml respectively after CaCl2 activation for 6 h, and the release amount at the first hour
were approximately 65%, 80% of the maximum respectively. Whereas the two factors
increased to 139 ± 48, 102 ± 31 ng/ml respectively after thrombin-Ca activation for
6 h, and almost compeletly released at the first hour. In addition, PDGF-AB, TGF-b1
levels and platelet counts showed a certain linear relationship. In the CaCl2 group, the
correlation coefficient r were 0.794, 0.932 respectively, whereas 0.9, 0.988 in the
thrombin-Ca group.
Conclusion: There is a fast release of PDGF-AB and TGF-b1 from PG at the first hour
after gel formation, especially the thrombin-Ca group. And CaCl2 maybe an ideal
choose to institute thrombin-Ca. This study may provide useful information for cli-
nicians to improve PG clinical application and to design improved blood-derived
biomaterial with controlled release of growth factors.
P-099
DETERMINATION OF FREE HEMOGLOBIN: COMPARATIVE
STUDY OF THREE WAVELENGTHS METHOD AND
ORTHOTOLIDINE METHOD
Yu Q, Cao Y, Liu J, Wang H
Institute of Blood Transfusion, Chinese Academy of Medical Sciences, Chengdu, China
Background: Free hemoglobin (FHb) is the conventional indicators of quality during
blood preservation process, which is associated with the distress severity of red blood
cells. Transfusion blood with elevated levels of FHb could induce adverse effects of blood
transfusion, in particular, would produce harmful effect on the nervous system and
circulatory system function. As a result, national Standard of China has put restriction
on the concentration of blood deserved to be transfused. Traditional methods for FHb
concentration is the chemical approach, including all kinds of benzidine and its
improvement, in which the orthotolidine method is the most common one. However, the
orthotolidine method enjoys obvious disadvantages, such as tedious operation and poor
stability. So another non-chemical approach, the three-wavelength method, which is
based on the light adsorption of hemoglobin itself, is beginning to be used more widely
among the blood centers.
Aims: The aim of the present work is to have a comparative study of the accuracy,
Linearity, stability, precision, recovery rate and ease of operation of the three-wave-
length method and orthotolidine one used for measuring FHb. In addition, the
advantages and disadvantages of the two methods are evaluated.
Methods: First, to detect the FHb concentration of standards and whole blood sam-
ples with the two methods mentioned above, and then do the precision, linearity,
precision, recovery, stability experiments in turn, finally compare and analyze the
results.
Results: The results obtained bydetecting the FHb concentration of FHb standardswas in
line with the real value, the accuracy could reach 106%. Moreover we gained the results
by direct calculation. Recovery rate and precision, whichwere 1.47% and 109.16% (RSD)
respectively, were in accordance with methodological requirements. The color devel-
opmentwas stablewhen detectionwas in progress.While the results could be obtained by
orthotolidine method only when the reference standard was available. The precision
(RSD = 5.01%) was no better than the three-wavelength method and recovery rate was
82.87%. The color development was extremely instable. Besides, there was linear rela-
tionship between the absorbance (A) and the concentration of FHb only in a certain range
(CFHb < 600 mg/l). When the concentration of FHb is higher than 600 mg/l, the plasma
sample should be diluted tomake its final concentration lower than 600 mg/l. The results
obtained by detecting 30 plasma samples with three-wavelength method, orthotolidine
method with dilution as well as without dilution were showed as follows, C1
(432.65 ± 115.66 mg/l), C2 (461.13 ± 92.76 mg/l), C3 (688.68 ± 161.35 mg/l). And
there is significant difference between C1 and C3 (P < 0.01), C2 and C3 (P < 0.01).
Conclusions: The FHb results obtained with the three-wavelength method is easy to
operate and as well as of high authenticity and stability; the orthotolidine method
enjoys obvious disadvantages: tedious operation steps, narrow linear range, many
matters needing attention and poor stability. Thus three-wavelength method has more
broad application prospects comparatively.
P-100
THE EXPERIENCE OF THE BLOOD COMPONENTS PROCESSING
BY AUTOMATED BLOOD COMPONENT EXTRACTORS IN
KAOHSIUNG BLOOD CENTER
Lu CT1, Tang KC1, Tsai SM1, Lin KT1, Hung CM1, Lin KS2
1Kaohsiung Blood Center, Kaohsiung, Taiwan 2Taiwan Blood Services Foundation,
Taipei, Taiwan
Background: Blood component extractors are used to extract components in a
semiautomated manner, whereas with multiple functions, the automated Buffy-coat
(BC) method is used to prepare pooled platelet concentrates from whole blood in
Europe. Instead, the platelet-rich plasma (PRP) method is used to derive platelet con-
centrates with entirely manual work in Taiwan. Taiwan Blood Server Foundation plans
to bring in blood component extractors to improve the quality of preparation of blood
components in 2011.
Aims: The aim of the study was to test the outcomes of blood components processed
by two systems, Fresenius Kabi Compomat G4 Automatic Blood Component Pro-
cessing System and Lmb Technologie GmbH Dual Press.
Methods: Blood samples were collected and prepared for blood components by the
staff of Kaohsiung Blood Center between July 2009 and July 2010. Data collected for
the study included processing time, components weight, RBC Hct, and PLT. RBC Hct
and PLT count of the PLT concentrate was analyzed by Sysmex XT 1800i Automated
Hematology Analyzer. Weight of components obtained from the extractor and manual
work was compared. The processing time in the double bag preparation was also
compared.
Results: A total of 590 samples were collected to prepare for components. The pre-
liminary results of the analyses of RBC, Plasma and PLT weight showed no significant
differences between processing methods. However, the processing time was signifi-
cantly longer for the automatic extractor. The QC tests for RBC Hct all revealed
‘qualified’ within the acceptance range. The QC acceptability rate for both 250- and
500-ml PLT concentrates were 81.3%, 91.9% and 76.7%, 96.7% for Fresenius Kabi
Compomat G4 Processing System and Lmb Technologie GmbH Dual Press, respec-
tively.
Conclusions: Though it takes a much longer time for processing, the automated
processing systems reduce daily workload of routine preparation of blood components
and offers constant products with standard quality.
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APPLICATION OF DATA LOGGER TO MONITOR THE TEMPER-
ATURE OF BLOOD COMPONENTS DURING TRANSPORTATION
AND STORAGE
Huang WH
Taichung Blood Center, Taiwan Blood Services Foundation, Taichung, Taiwan
Background: The data logger is often used for monitoring the temperature of blood
components during storage and transportation. We conducted the monitoring opera-
tion on blood components during storage and transportation according to SOP ap-
proved by TBSF.
Aims: This study aim to find the data loggers offered by three companies are appli-
cable to monitor the temperature of blood components or not.
Methods: We validated the system through running the program to find if it
affected the operations of the donation system as well as the computer. An accuracy
test on the data loggers were then conducted for blood storage equipment. After-
wards, we respectively put the three tested data loggers which are currently used in
our Center, and the standard components of outsourced calibration implementation
(C****K) under the environment of refrigeration ()20C), cold storage (1–6C), and
normal temperature (20–24C) to compare their read-out values with the standard
components; we cross-referenced these differences with the eligibility criteria of the
SOP, stating that the errors must be £1. Similarly, we conducted another accuracy
test on the data loggers for blood components during transportation under the
environment of refrigeration ()5C), cold storage (1–10C), and normal temperature
(20–24C).
Results: All three thermograph programs were running without affecting the donation
system as well as the computer. We then compared the errors between the three tested
thermographs plus thermographs in use and the standard components and found that.
For L**T**, there is one value >1C for blood storage equipment while there is no
value >1C for blood components during transportation by comparing. For T***T***4,
there is one value >1C for blood storage equipment and there is also one value >1C
for blood components during transportation. For E****T, there is no value >1C for
blood storage equipment, but instead, there is one value >1C for blood components
during transportation.
Conclusion: The test results revealed the fact that all the three data loggers from
different companies running without affecting the donation system as well as the
computer, and artificial alterations cannot be carried out against those read-out values;
their reliability is thus maintained. For the errors >1C, there is a need for us to proceed
to other discussions to find whether these errors are associated with a high product
defect rate or insufficient test samples. To conclude, all the three data loggers could be
applicable to monitor the temperature of blood components during storage and
transportation if precluding the part of ‘imperfect’ errors >1C.
P-102
MANAGEMENT OF TRANSPORT, PACKAGING AND THERMAL
INSULATION MATERIAL FOR SMALL QUANTITY OF BLOOD
PRODUCT
Yu M, Chang CC, Pi KT, Yang TT, Yang B
Hsinchu Blood Center, Taiwan Blood Services Foundation, Hsinchu County, Taiwan
Background: When the hospital receives small quantity of blood product, it should
ensure the temperature control quality and confirm the temperature during the
transport process. Meanwhile, the packaging material management mechanism is also
planned, and the application efficacy is reinforced too.
Method: Igloo 9L thermal container is used to carry one unit of blood product, and test
is then performed in accordance with different quantity of Thermal Stabilizer and
placement locations. Right above and below the blood product, it is placed with Da-
talogger, and the temperature of the blood product is recorded every 5 min for a
recording period of 4 h. The temperature control conditions of all kinds of blood
products are: For red blood cell concentrate, it is 1–10C, for plasma, it is below )5C,
for platelet it is in the range of 20–24C, for at least 2 h.
Thermal container is numbered and registered for management, and ‘borrowing list’ is
used as receipt for the withdrawal and recycling by the hospital, meanwhile, we will go
to hospital to get back the overdue borrowed thermal container and evaluate the
efficacy of the management method.
Results: When the environment temperature is higher than 25C, the result using
Igloo 9L thermal container to transport all kinds of blood products is as follows: (i)
Red blood cell concentrate is covered by four layers bubble cloths, and above it, it is
placed with a refrigerating Thermal Stabilizer, then the temperature is maintained in
the range 1–10C for 2 h and 45 min, (ii) Plasma is covered by two layers of bubble
cloths, and one refrigerating Thermal Stabilizer is placed respectively in the upper and
lower side, then the blood product is maintained below )5C for at least 2 h and
10 min, (iii) Platelet is placed within thermal container without the need of adding
Thermal Stabilizer, and it is maintained at temperature of 20–24C for at least 2 h and
30 min.
Igloo 9L thermal container is labeled with ‘Hsinchu Blood Center’, ‘Number’, and
withdrawal time, and it is also added with the hint of ‘It should be sent to the blood
warehouse within 2 h’. Use ‘Blood product transport and thermal container borrowing
form’ for inspection and follow-up, for a trial of 3 months, and the return rate rises
from 40% before the setup of control mechanism to 90%, that is, the control efficacy is
pretty significant.
Conclusions: In the past, polyfoam box is used to package blood product, due to
ineffective control, polyfoam box needs to be purchased regularly. In addition to the
waste of money in the blood center, the wasted polyfoam box will also become a big
load to the environment. After it is changed to durable Igloo 9L thermal container, in
addition to easy identification in its appearance, the considerate hint also shows the
cooperative mind of the hospital and the professional and responsible image of the
blood center.
P-103
EXPERIENCE IN INVENTORY OF BLOOD GROUP NEGATIVE
BLOOD
Ku CY, Wu LP, Pi KT, Yang TT, Yang B
Hsinchu Blood Center, Taiwan Blood Services Foundation, Jhubei, Taiwan
Background: The need of specific blood group negative blood is increasing gradually.
To establish inventory of red cell antigen negative blood is necessary for provision of
need timely.
Aims: Establishing inventory of specific blood group negative blood that need often to
speed up the process of blood supply.
Methods: We analyzed the frequency of distribution of blood group negative blood in
2009 and chose the types that needed frequently to establish stock. By searching the
data base of blood group negative blood files, the specific blood was selected and stock
daily but which have been stored for 14 days will be transferred to ordinary stock. The
efficiency of inventory management was measured and adjusted.
Results: There were 1698 units of blood stocked and 881 units were supplied for
transfusion in third quarter of 2010. The provisions of blood group negative blood were
1416 units totally, and this stock fulfilled 62.2% of demand. The details of blood
distributed are in the Table 1.
Table
Conclusions: There were around 23% of Blood which is multiple antigen negative or
high frequency antigen negative provided by other blood centers. The situation was
no change before or after this project implemented but this is the important point to
remedy. It took about 15 min to pick out a unit of desired blood from ordinary
blood warehouse but only 5 min is needed to complete the whole distribution
process if the blood was from the negative blood inventory. It meant that 62.2%
change is a great improvement because we not only speeded up the distribution
process but also saved 8800 min of work time per quarter. Moreover, the time of
working under a low temperature environment was shortened and the working
quality was improved also.
P-104
THE UTILIZATION OF BLOOD PRODUCTS IN TAIWAN
Lu SC
Tainan Blood Center, Tainan city, Taiwan
Background: TBSF was founded in 1974 and had provided blood related services for
the past 35 years. The blood donation volume has grown significantly from 3817 bags
in 1974 to 2,397,401 bags (250 ml) in 2008.
 2011 The Authors
Vox Sanguinis  2011 International Society of Blood Transfusion Vox Sanguinis (2011) 101 (Suppl. 2), 39–134
3.1 Blood Processing, Storage and Release 67
Aims: Similarly, the supply of blood products has grown from 3794 to
5,354,992 units/year in 2008. With the continuous support from enthusiastic donors,
the blood supply has not only been able to meet the demand from hospitalized patients,
but also those interested in the therapeutics aspects of blood products. However, the
future of blood donation remains uncertain as we continue to find new sources of
blood and new applications for blood products.
Methods: This study is based on the number of clinical and hospitalized cases
within the National Health Insurance database provided by the National Health
Research Institutes. Briefly, one million patients were randomly selected. Base on
their medical histories and annual usage of blood products, we can deduce the
optimal use and distribution of the donated blood to meet the annual demand. This
retrospective study is analyzed by SAS software. Detailed description of the hospital
fee, hospitalization cost, and other medical organization cost were factored in for
meta-analysis. The blood products were divided into P-RBC, FFP+FP, Platelet
concentrate, Platelet Apheresis. Statistical analysis of the data were categorized by
the various divisions within NHI, hospitals, medical department, and the incidence
of major diseases.
Results: Out of one million patients in 2006, 28,837 units of blood products were used.
P-RBC had the highest consumption with 17,668 units (61.27%) and FFP+FP in second
with 6197 units (21.49%). Under the NHI, Taipei division consumed the most units with
8973 units (33.11%) while central Taiwan area consumed 19.10% of total units. For the
consumption of each blood product, Taipei area leads in consumption in P-RBC with a
percentage higher than all other area (P < 0.05). Consumption of P-RBC from the
Gastroenterology (13.33%), Pulmonology (12.27%), and Orthopedics (12.24%) were
similar. As for FFP+FP, it is mostly used by patients from the Gastroenterology
(19.96%) and Surgery (16.83%). These two blood products demonstrated different
patient applications within different medical departments (P < 0.05). Medical centers
are the largest users consumers of blood products (44%), and P-RBC accounted for the
largest proportion (6831 units). Platelet concentrate (1896 units) is more often used
than platelet Apheresis (1254 units).
Conclusion: Based on our analysis, we have viewed the expansion in blood product
applications, including disease applications, from different areas and levels of the
hospital in Taiwan. This study not only updated us on the current status of blood
transfusion, but also clear how to optimize operations of a blood centers. This includes
management of blood source and allocating blood products supply. After the new
healthcare policy, TW-DRG, was mandated in January, 2009, we shall continue to
monitor and analyze the utilization of blood products in Taiwan.
P-105
THE EFFECT OF LYOPHILIZATION ON THE ANTIGENS AND CD
MARKERS OF RED BLOOD CELLS
Chen Q1, Tang RC1, Liu Z2
1Jiangsu Province Blood Center, Nanjing, China 2Anhui Province Blood Center, Hefei,
China
Background: Lyophilization is an important technique to preserve and long-time
storage of red blood cells (RBCs). However, little is known whether the blood group
antigens and CD markers of the freeze-drying RBCs are changed.
Aims: Our study aims to investigate the effect of lyophilization on the antigens and
CD markers of RBCs.
Methods: The blood group antigens (ABO, Rh, MNSs, Kell, Duffy, Lewis and P blood
group systems) were detected by serology; the levels of 2, 3-DPG and ATP of RBCs were
determined by ELISA; the cytomembrane CD35, CD44, CD45, CD47 and CD71 of RBCs
were measured via flow cytometry before and after freeze-drying, respectively.
Results: After lyophilization, the antigens of ABO, Rh, MNSs, Kell, Duffy and P blood
group systems remain the same except Lea and Leb antigens of Lewis blood group
system. Before and after lyophilization, there were no statistical difference on the levels
of 2, 3-DPG and ATP of RBCs and the cytomembrane CD markers of CD35, CD44, CD45,
CD47 and CD71.
Summary: Our study suggests that RBCs functions may remain unchanged after ly-
ophilization. These findings may have important implication for the clinical use of
freeze-drying RBCs.
P-106
CONSISTENCY BETWEEN THREE TEMPERATURE MONITORING
SYSTEMS AND THE CORE TEMPERATURE OF STORED BLOOD
COMPONENT
Tseng Y, Chu F, Lee T
Far Eastern Memorial Hospital, New Taipei City, Taiwan
Background: Continuous temperature monitoring of blood component storage is
important to blood component quality and is required by the Standards of AABB.
Commercially available storage device is equipped with a weekly pen and chart
recorder, and a standalone thermometer immerged in glycerol solution is also used
to manual monitoring of storage temperature periodically. With the introduction of
centralized temperature monitoring system, many blood banks adopt the system due
to its ease to use for continuous and real-time online monitoring of storage tem-
perature and the advantage of a possible central alarm function to alert the des-
ignated staff not in the vicinity of the equipment once an alarm is activated.
However, the discrepancy among the centralized temperature monitoring system,
the weekly pen and chart recorder, and the standalone thermometer is not infre-
quently observed.
Aim: This study aims to assess the consistency between three temperature monitoring
system and the core temperature of stored blood component.
Methods: The core temperature of packed RBCs was measured by a thermometer
inserted halfway into the blood bag. The thermometer was calibrated and traced to
NML/ROC national standards. The blood bag was placed into a refrigerator (Sanyo,
MBR-1404GR) equipped with a weekly pen and chart recorder (system C) and alarm
for deviation of temperature. A standalone thermometer immerged in glycerol
solution (system B) was placed just next to the blood bag. A commercially available
centralized temperature monitoring system (system A) was setup according to the
recommendation of manufacturer. After stabilization of the refrigerator temperature
for 60 min, the initial core temperature of the packed RBCs was recorded as well as
the temperature of the three systems. Then the refrigerator door was open for
10 min to let the temperature exceed the acceptable ranges for storage. The core
temperature and the temperature of the three systems were recorded every minute.
The process was repeated three times. Correlation between temperature of the three
monitoring system and the core temperature was assessed using Pearson’s corre-
lation.
Results: The average core temperature of blood bag fluctuated between 4.5 and 8.2C.
The corresponding temperature recordings ranged from 3.7 to 9.8C for system A, from
4.0 to 9.5 for system B, and from 3.8 to 13.0 for system C. Compared to core tem-
perature of blood bank, the bias was between )1.1C and +1.6C for system A, )0.5
and +1.5 for system B, and )0.8 and +5.0 for system C. Using core temperature as the
standard, the Pearson’s correlation is 0.964, 0.954, and 0.796 for system A, system B,
and system C, respectively.
Conclusion: Both manual monitoring using standalone thermometer and the cen-
tralized monitoring system showed good correlation with the core temperature of
stored component. All the three systems have a significant positive bias, especially
the pen and chart recorder system. However, with regard to the consideration
of blood product quality, this bias is acceptable. In addition, the centralized
temperature monitoring system has the advantage of continuous recording and
remote alarm function, and is easy to observe, as well as the potential to be
paperless.
P-107
AN EXPERIENCE OF A DEVELOPING COUNTRY ON
MAINTENANCE OF COLD CHAIN DURING PACKED RED CELL
TRANSPORTATION
Palle Mulle Gamlath Ralalage C, Kohombange CG, Kuruppu KKS
National Blood Center, Colombo, Sri Lanka
Background: To ensure the quality of the transfused red cells it is mandatory to
maintain them at proper storage temperature of 4 ± 2C. However during transpor-
tation it’s allowed a temperature range of 2C to 10C for up to 12 h. In most developed
countries these standards are ensured through properly insulated containers and
commercially prepared cooling elements. In most developing countries these standards
may not be maintained due to limited resources. As a developing country Sri Lanka
lacks these facilities to the optimum level. Therefore fiber cool containers and ice packs
are being used for this purpose, since transportation of red cells within the country is
important to ensure the swift provision of blood. This paper describes an experience on
maintenance of cold chain during transportation of red cells in National Blood
Transfusion Service, Sri Lanka.
Aim: Study was done to validate the cold chain maintenance exist in the system and
to develop standard instructions for cold chain maintenance.
Methodology: In a 48 · 30 · 40 cm sized cool container 2, 3, 5, 6, 10 and 20 red cell
packs were arranged at different combinations of initial temperatures and number of
ice packs, each weighing approximately 550 g. The red cell packs were arranged
avoiding direct contact with ice packs by keeping thick hardboard on top of the blood
packs and place ice packs on top of it. The temperature of the blood packs were
monitored hourly using a calibrated thermometer with a probe which kept inside the
box. The number of hours which has taken to reach the maximum temperature of 10C
was recorded.
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Results:
Table 1
Table 2
Conclusion: There are mainly two factors affecting the duration of maintenance of
required temperature range (2–10C) during transportation.
1. The ratio between red cell packs and ice packs.
2. Initial temperatures of red cell packs.
Based on this study a table of formula has been formed as a general guide to decide the
number of ice packs required during transportation.
In addition following recommendations were also made;
1. Pre transport temperature of red cell packs should be maintained between 3 and
50C to ensure optimum cold chain maintenance during transportation.
2. If starting temperature is <20C, there is a risk of freezing of blood packs due to the
cooling effect of ice packs.
3. If starting temperature is >50C, the period of cold chain maintenance (4–100C
range) would be <10 h.
P-108
THE IMPACT OF DONOR HEALTH STATUS ON THE QUALITY OF
APHERESIS PLATELETS
Jang RC1, Tu HH1, Lin KT1, Hung CM1, Lin KS2
1Kaohsiung Blood Center, Taiwan, Kaohsiung, Taiwan 2Taiwan Blood Services
Foundation, Taipei, Taiwan
Background: The quality of apheresis platelets (APs) is affected by many conditions
including method of collection, type of storage container and duration of collection.
But we don’t know whether the donor health status such as body mass index (BMI) and
lipid profiles can affect the quality of APs.
Aims: Our aims were to determine whether the donor health status has effects on
storage of APs and try to find methods to improve quality of blood products.
Methods: According to donor’s BMI and lipid level, the plateletpheresis donors were
divided into two groups; group I (BMI < 23, TG < 160, HDL > 40) and group II
(BMI > 27, TG ‡ 160, HDL £ 40). After plateletpheresis, the blood samples from APs
bags were collected on day 1 and 4, and then blood gas (pH, PCO2, PO2, HCO3
) and BE),
LDH and K+ were analyzed.
Results: A total of 80 plateletpheresis donors were enrolled and divided into two
groups (35 in group I and 45 in group II), the value of pH, PCO2, PO2, HCO3
), BE, LDH,
and K+ on day 1 and 4 (between group I and II) are shown in Table 1. Significant lower
pH, BE, HCO3
) and higher LDH, K+ were noted in group II donors.
Table 1: The value of blood sample between grade I and II
Conclusions: Obesity with abnormal lipid level did negatively impact on storage of
APs. In order to improve quality of APs, blood center should pay more attention to
blood donor health promotion. Further evaluation on other blood products should be
arranged.
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OUTPATIENT TRANSFUSIONS – OUR EXPERIENCE
Mihic-Tomic B
KBC Dr. Dragisa Misovic-Dedinje, Belgrade, Serbia
Introduction: Anemias are categorized as very frequent pathological conditions
occurring both individually and as a consequence of many other diseases.
Aim: Presentation and analysis of red blood cells consumption at the Outpatient
Treatment Clinic of the CHC ‘Dr Dragisˇa Misˇovic´-Dedinje’ during 2010–2011, as a
contribution to resolving professional, organizational and technical issues associated
with the treatment of anemias in conditions found in the outpatient clinics.
Material and methods: Data regarding red blood cell consumption were collected
using blood request forms forwarded to the Blood Transfusion Department, as well as
blood/blood component issuing charts, patients’ admission and release protocols and
histories of the disease.
Results: During 2010–2011, total of 46 patients were transfused with red blood cells at
the Outpatient Treatment Clinic of the CHC ‘Dr Dragisˇa Misˇovic´-Dedinje’. There were
totally 97 half day hospitalizations, or 2.1 visits in the average. Among them, 30
(65.2%) were female and 16 (34.8%) were male patients, mean age around 70 years (the
youngest patient was 37, and the oldest one was 92 years old). The lowest recorded
haemoglobin value before transfusion was 3.7 g/dl, and the highest was 8.9 g/dl. At
the admission to the Outpatient Treatment Clinic, all had obvious clinically expressed
symptomes and parameters of (mostly) severe anemia confirmed by laboratory find-
ings. In most patients, anemia developed as a consequence of a malignant disease and
associated with radio and/or chemiotherapy treatment (I group, 37 or 80.4%), or as a
consequence of haematological or hematooncological diseases (II group, 5 or 10.9%)
and finally as a consequence of renal or cardiac diseases (III group, 4 or 8.7%). No
unfavourable reactions were noted throughout the transfusion administrations. Since
the patients from the first and the second group were polytransfused in most cases, 40
or 60 mg of I.V. urbason was administered prior to each transfusion for prevention
purposes. Some patients from the third group were administered 1–2 ampoules of lasix
in order to prevent circulation overload.
Conclusion: An ever increasing number of patients requires blood transfusion due to
severe anemia (haemoglobin value below 4.0 g/dl). Capacity of the Outpatient Treat-
ment Clinic of the CHC ‘Dr Dragisˇa Misˇovic´-Dedinje’, where the outpatient transfusion
administration takes place, do not even closely satisfy the actual needs. That is why it is
necessary to increase the number of the outpatient treatment clinics/hospitals where
blood transfusion would be administered, and to consider the need to reestablish the
practice of blood transfusion administration at patients’ homes.
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P-111
PREPARATION OF SINGLE DONOR PLATELET WITH LOW
ANTIBODY TITERS FOR ALL PATIENTS
Romphruk A, Cheunta S, Pakote L, Kumpeera P, Sripara P, Puapairoj C, Romphruk A
Khon Kaen University, Khon Kaen, Thailand
Background and aim: Platelet concentrates from ABO-identical donors are the com-
ponents of choice for patients. However, since inventories are generally insufficient
and because there is usually a relative abundance of group O donors, perfect matches
are not always possible. It is therefore the accepted practice for platelets to be trans-
fused out of the ABO group when ABO-identical platelets are unavailable. In the
current study, group O single donor platelets (SDPs) were modified after collecting the
platelet pellet in a bag. The AB plasma was added instead of the donor’s own plasma
and stored as universal SDP.
Materials and methods: A total of 107 modified SDPs were studied. The direct agglu-
tination titers of anti-A/anti-B in the original group O SDPs’ plasma (pre-preparation)
and the residual of anti-A/anti-B in the modified group O SDPs’ were performed.
Results: The pre-preparation titers ranged from 1:4 to 1:1024. The prevalence of high
titers (i.e. at least 1:64 in our study) was relatively high, approximately 63% for anti-A
and 78% for anti-B. The titer of residual anti-A/anti-B ranged from negative to 1:8. In
most of the modified SDPs anti-A/anti-B could not be detected in the plasma (58.9%
and 52.3%, respectively).
Conclusions: The results indicate that our modified SDPs have very low titers; that is,
acting as a universal SDP which is safe for all ABO patients. This modified SDP form is
a more convenient way to overcome the risk from incompatible plasma or loss of
platelets during the process of volume reduction.
P-112
QUALITY OF PLATELET CONCENTRATES
Jaroonsirimaneekul Th, Phumiyoch N, Paupairoj C, Romphruk A
Blood Transfusion Centre, Khon kaen, Thailand
Background: Platelet concentrates (PCs) from whole blood (WB) can be prepared as
random donor platelets (RDP) or leukocyte poor platelets concentrate (LPPC). Qua-
druple bag preparation for LPPC can be done as (a) top and bottom or (b) top and top
systems. The difference between the two systems would be in the quality of the LPPC.
The current study compared LPPCs and RDP for the quality of PCs (i.e. platelet yield,
residual white blood cells) and cost per therapeutic dose.
Methods: We studied a respective 606 and 77 LPPC from (a) top and bottom and (b)
top and top and 65 units of RDP. For the LPPC preparation, four buffy coats (BC)
‘negative for infectious markers and unexpected antibody’ were pooled using a sterile
connecting device. The pooled BC were mixed at 150 rpm for 15 min and spun at
2300 rpm for 4 min. After separating the LPPC into a platelet storage bag, a platelet
sample was collected from the tubing in order to determine the platelet yield and
residual WBC. The unit cost per therapeutic dose was then calculated.
Results: The respective yield of platelets in LPPC (a), (b) and RDP were 6.6, 5.7 and
1.4 units. The respective residual WBC in the three groups were 0.8, 0.8 and
0.3 · 108 cells/unit. The platelet yield in the LPPC was significantly higher in (a) than
(b) (P < 0.05), but had no significant residual WBC (P > 0.05). The respective unit cost
of the three groups was 71, 76 and 102 USD.
Conclusion: The four BC estimates of the platelets in LPPC was similar to one thera-
peutic dose. The LPPC from the top and bottom system had a platelet yield higher than
the top and top system. LPPC have a lower residual WBC than RDP as well as a lower
preparation cost than one therapeutic dose. It is, therefore, cost effective to prepare
LPPC instead of RDP and safer from the perspective of platelet refractoriness and/or
alloimmunization.
P-113
USE OF PLATELET GEL WITH BONE GRAFTING FOR
RECONSTRUCTION OF UPPER JAW DEFECTS
Afifi SA
Suez Canal University-Faculty of Medicien, Ismailia, Egypt
Background: The use of platelet gel (PG) in tissue regeneration is a developing area and
has been employed in various fields of surgery. Although the mechanisms involved are
still poorly understood, easy application of PG in clinical practice and possible bene-
ficial outcome, including bone regeneration, reduction of bleeding and rapid tissue
healing, hold promise. The platelets must be activated to release the con-tent of gran-
ules, while the clot providing a vehicle to contain the secreted proteins and maintain
their presence at the site of application. Combining PG with bone or bone substitutes
present significant faster radiographic maturation and denser bone regeneration.
Aim: To evaluate the effect of PG mixed with autogenously iliac crest graft on bone
regeneration in different upper jaw defects.
Materials and methods: Twenty patients with upper jaw defects underwent iliac
bone grafting harvested from iliac cancellous bone. The bone graft incorporated with
PG (PG group) in 10 of them while others serve as control group. They include two
patients with tumor resection, 16 with secondary alveolar cleft repair, and two with
segmental post-traumatic bone loss. We used standard triple packs containing citrate
phosphate dextrose for blood collection at least 24 h before PG application. Platelet
poor plasma is mixed with calcium gluconate (1/0.2 rate) at 37C for 15–30 min; the
supernatant is full of thrombin precursors. In sterile Falcon tube, platelet concen-
trate, thrombin and calcium gluconate were mixed in the following proportions:
3:1:0.5 respectively. The suspension is exposed to slow shaking with the caution to
complete 10–12 times a 360 0 tube revolution, and it is left to rest for about 15 min
before mixing with bone graft. Quantitative evaluation of re-generated bone was
made with dental CT scans preoperatively and postoperatively at 3, 6, and 9 months
interval. Parameters that were assessed included: bone defect volume (preopera-
tively), graft volume (by multiplying bucco-lingual, mesiodistal, and vertical
dimensions), overall bone density, gap thickness (between the grafted area and the
adjacent normal bone) and post operative complications such as infection, collection,
oro-nasal fistula.
Results: A mixed design ANOVA was calculated to evaluate the effects of bone graft
type (PG graft vs control grafts) and time of measurement (0-, 3- and 9-month) on the
volume of regenerated bone. The average of the volume ratio of regenerated bone of
reconstructed upper jaw defects in cases with PG was statistically higher than in
controls at 9-month postoperative assessment (P = 0.043). However, there was no
statistically significant difference between them re-garding the bone density
(P = 0.89).
Conclusion: PG is a safe and cost-effective source for growth factors and easy
to extract. It could enhance the osteogenesis of alveolar bone grafting in patients
with different upper jaw defects and may be useful for sub-sequent orthodontic
therapy.
P-114
SURFACE MODIFICATION OF POLY (BUTYLENE TEREPHTHAL-
ATE) NONWOVEN FABRICS USED FOR BLOOD FILTRATION
AND THEIR BLOOD COMPATIBILITY STUDY
Cao Y, Liu J, Wang H, Yu Q
Institute of Blood Transfusion, Chinese Academy of Medical Sciences, Chengdu, China
Background: It has long been reported that during blood component transfusion
therapy, leukocytes can cause many adverse reactions, including nonhemolytic febrile
transfusion reaction, platelet refractoriness, immunosuppression. Leucocytes are also
known to accelerate the rate of storage lesion. Therefore, removal of leukocytes to low
sufficient levels is necessary to prevent undesired reactions particularly in freshly
whole blood.
Aims: The purpose of this study was to increase leukocyte retention and erythrocyte
recovery rates through surface modification, using polyvinylpyrrolidone (PVP) which
was grafted by a plasma grafting method. In addition, the blood compatibility of the
modified poly (butylene terephthalate) nonwoven fabrics (PBTNF) were also evaluated.
Methods: The PVP was introduced to the PBTNF surface by the oxygen plasma
treatment method. The immobilized PBTNF was characterized by X-Ray photoelectron
Spectroscopy (XPS) and critical wetting surface tension. Tive types of PBTNF-PVP with
different wettability were prepared to investigate the leukocyte filter efficiency and
blood compatibility. Then blood filtration experiments have been performed on the
laboratory scale Different parameters have been studied: the effect of the wettability of
PBTNF on the retention of the blood cells, the morphology of blood cells after filtra-
tion, the free hemoglobin in whole blood before and after filtration, the complement
activation and the hemolysis assay.
Results: The XPS spectra confirmed the creation of new functional groups on the
PBTNF surface. The hydrophilicity of the PBTNF surface was improved greatly by
covalent immobilization of PVP. And the wettability of PBTNF-PVP was also in-
creased as the oxygen plasma treatment power increased. After filtration, the leu-
kocytes were reduced significantly, while the erythrocytes were reduced slightly. All
five types of PBTNF-PVP’s FHb were <80 mg/l, which was consistent with the Chinese
Medical Vocation Standard <YY0329-2009 > Leukocyte reduction filters for single
use. The hemolysis ratio of origin PBTNF, PBTNF-P15, PBTNF-P25, PBTNF-P50,
PBTNF-P100 and PBTNF-P200 were about 1.00% ± 0.50%, 0.30% ± 0.32%,
0.25% ± 0.22%, 0.31% ± 0.10% and 0.45% ± 0.50%. This implies that the five types
PBTNF-PVP all are compatible with erythrocyte. All the C3a and C5a results imply
that the original PBTNF and five types of PBTNF-PVP may have no influence on
complement activation.
Conclusions: The grafting of PVP on the PBTNF could improve its leukocyte-removing
efficiency and blood compatibility, suggesting that PVP-modified PBTNF is a very
promising blood filter for selective removal of leukocytes.
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EVALUATION OF PLATELET FUNCTION DURING STORAGE
Chen MH1, Hung YS1, Li L1, Lin Tsai SJ2, Lin KS2
1Taipei Blood Center, TBSF, Taipei City, Taiwan 2Head Office Taiwan Blood Services
Foundation, Taipei, Taiwan
Background: Today, platelet components are general produced from whole blood by
centrifugation or by plateletpheresis. Platelets are enucleated cells derived from bone
marrow megakaryocytes. They play vary important role in hemostasis, blood clotting,
and thrombosis. The life span for platelets in the human circulation is estimated to be
about 10 days. However, after 5–6 days of in vitro storage, platelets lose their bio-
logical function and display morphologic change from discoid to sphere shape.
Aim: The objective of this study was to determine the platelet activation, apoptosis
and metabolism for apheresis derived platelet concentrates (APCs) and platelet con-
centrates (PCs) stored for 7 days in a platelet storage bag.
Methods: In this study, APCs and PCs collected from ALT abnormal (ALT > 45 IU/l)
disqualify components. These platelet components under controlled concentration and
volume per bag were stored in plasma up to 7 days at 22 ± 2C with horizontal agi-
tation. Swirling score was judged by squeezing the bag while holding it in front of a
light source on Days 1, 5 and 7 for APCs, Days 5 and 7 for PCs. Samples were drawn
aseptically from components with sampling site couplers inserted in a spike entry port
of the component bags. Samples for platelet counts, pH, activation and apoptosis were
drawn aseptically during storage on Days 1, 5 and 7 for APCs, Days 5 and 7 for PCs.
Platelet activation (CD62P) and apoptosis (annexin V) were determined with a triple
labeling method on BD FACSCalibur flow cytometry. Bacteria contaminations were
performed with BacT/ALERT blood culture system.
Results: We collected 51 PCs bags, forty-one by APCs and 10 by PCs in this study.
Twenty-three of the 41 APCs prepared from Haemonetics MCS+ED instrument, four of
the 23 were leukocyte reduced APCs components and 19 of the 23 were non-leukocyte
reduced APCs components. Ten of the 41 APCs prepared from Fenwal CS-3000 plus
Blood Cell separator, these were non-leukocyte reduced APCs components. Eight of the
41 APCs prepared from Trima Accel Collection system, these were leukocyte reduced
APCs components. The results indicated, the mean APCs volume levels ranging from
245 to 287 ml and PCs volume levels about 65 ml. All mean platelet counts were more
than 1.0 · 106/ml and all mean APCs yield were more than 3.0 · 1011/bag. On day 7,
no significant difference were observed in swirling score and CD62P ())/annexin V (+)
expressed but pH, CD62P (+)/annexin V ()) and CD62P (+)/annexin V (+) expressed
increased in APCs and PCs during storage. No bacteria contamination was detected by
BacT/ALERT blood culture system.
Conclusions: Our results indicated, CD62P (+)/annexin V ()) and CD62P (+)/ann-
exin V (+) expressed in platelet concentrates on days 5 and 7 rises to levels that
could compromise the quality of the platelet units. Development of platelet storage
lesions influenced especially by storage conditions and platelet concentration in
products.
P-116
EVALUATION OF THE BPFA PLUS POST-PROCESS LEUCOCYTE
DEPLETION FILTER FOR PACKED RED CELLS
Awaluddin R, Tey ST, Mohamed Rani SF, Wan MA, Mustafa N, Nadarajan VS
University Malaya Medical Centre, Kuala Lumpur, Malaysia
Background: Leucocyte reduction has been demonstrated to reduce the risk of febrile
non-haemolytic transfusion reactions, cytomegalovirus transmission and human leu-
cocyte antigen alloimmunisation in individuals considered to be at high risk for such
complications. Leucoreduction can either be performed following storage of red cell
units at 4C or room temperature depending on individual Blood Bank processing flow.
As such, leucoreduction filters should be able to perform efficiently in both conditions.
We chose to evaluate BPFA Plus post filtration filter to identify if they can meet our
needs for leucofiltration at 4C and room temperature.
Aim: To evaluate the BPFA Plus post process filter in terms of filter performance when
used to filter red cell units stored either at 4C or room temperature.
Method: Whole blood units were collected into (JMS, 450 ml) collection sets, from
healthy volunteer donors (n = 60). Units were held for 2 h at room temperature prior to
Top/Top processing to generate PRP platelets. The red cell units were held for either
<8 h at room temperature (N = 30) or, 1–2 days at 4–6C (N = 30) prior to sterile
connection and filtration with the BPFA Plus (Pall Medical). Filtration was performed
at room temperature at a height of approximately 1.2 m using gravity prime. Pre- and
post-filtration sampling was performed to assess filter performance and resultant
component quality. Filtration times were also measured.
Results: Table 1 displays data for post-filtration red cell units.
Summary/conclusion: All parameters measured met the Council of Europe Guide-
lines for leucocyte depleted red cell units except for one outlier which exhibited an
extended filtration time at room temperature (78.8 min) and 1.45 · 106 Leucocytes/
Unit. The cause of the high residual leucocytes in the outlier is indeterminate. The
remaining results were consistent in both storage groups giving a high level of
confidence in the filtration performance of the filter as shown by the median and
standard deviation. The filtration times allowed processing within routine processing
conditions.
Table 1
P-117
OPTIMAL PLASMA VOLUME FOR BLOOD COMPONENT USED
FOR EXCHANGE TRANSFUSION
Naito Y1, Mori J1, Chatani M2, Onodera H2, Yamaguchi R1, Shinozaki K2, Shiba M1,
Okazaki H1, Satake M1, Tadokoro K1
1Japanese Red Cross Society, Tokyo, Japan 2Tokyo Metropolitan Red Cross Blood
Center, Tokyo, Japan
Background: In Japan, blood component for exchange transfusion (BET) is mainly
used for hemolytic disease of the newborn due to ABO incompatibility. BET is a
mixture of O-typed red cells and AB-typed plasma. Currently, BET is prepared from
washed red cells derived from 400 ml whole blood. The red cells are then added with
240 ml plasma, which yields a hematocrit of 35%. The low hematocrit of BET often
causes problems such as anemia in transfused patients. Moreover, its storage period is
limited to 24 h after processing.
Aims: Optimal plasma volume for BET and the possibility of prolonging its storage
period were investigated by examining the in vitro quality and stability of BET with
varying plasma volume.
Methods: Irradiated BETs (Ir-BETs) were prepared as follows: red cells derived from a
400 ml whole blood were c-irradiated, washed, and added with 90, 120, or 160 ml of
plasma. Ir-BETs were stored at 2–6C for 72 h. Samples were taken every 24 h and
subjected to in vitro testing. The volume of Ir-BETs, hematocrit, protein concentration,
supernatant hemoglobin, ATP, 2,3-DPG, supernatant potassium, total supernatant
potassium and the coagulation factor activity were measured.
Results: After adding 90, 120, and 160 ml of plasma, the volumes of Ir-BETs were
284.5 ± 16.9 ml, 299.8 ± 7.0 ml, and 336.7 ± 8.6 ml and the hematocrit values were
56.3 ± 1.4%, 49.7 ± 0.9%, and 44.0 ± 1.0%, respectively. The supernatant hemo-
globin concentration did not increase markedly and the percent hemolysis after
72 h of storage was below 0.2% in all the treatment groups. Regardless of the
plasma volume, the ATP concentration remained the same and did not change
during the 72 h of storage. Regarding the 2,3-DPG concentration, at least 50% of
the initial value was maintained in all the treatment groups during the 72 h of
storage and no effect of plasma volume was found. The supernatant potassium
concentration increased during the 72 h of storage in all the treatment groups and
was highest in Ir-BET with 90 ml of plasma among the three treatment groups. On
the other hand, the total supernatant potassium in Ir-BET with 120 ml of plasma
after 48 h of storage was comparable to that in Ir-BET after 24 h of storage, which
is the storage period of the current component. The coagulation factor activity
modestly decreased during the 72 h of storage and no effect of plasma volume was
found.
Conclusions: It was suggested that a plasma volume of 120 ml was suitable for (Ir-)
BET derived from a 400 ml whole blood and it is possible to extend its storage period to
at least 48 h.
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P-118
AN ANALYSIS OF THE FACTOR VIII CONTENT IN FRESH
FROZEN PLASMA
Lu TF
Taichung Blood Center, Taichung, Taiwan
Background: The research in content of factor VIII of ABO group started in 1964. This
study aimed to estimate the factor VIII of fresh frozen plasma from Taiwan.
Aims: This study aimed to analyze changes in content of factor VIII levels of ABO
blood group before donation, processing double blood bag of whole blood (250 and
500 ml respectively), and storage after 30 days.
Methods: We used KC-4Delta blood coagulation analyzer (Sigma/Amelung label) to
test the factor VIII levels in different donation volume and centrifugation conditions
for 125 blood donors.
Results: We used t-test to analyze the different centrifugation that showed no sig-
nificant difference (P > 0.05). We found that factor VIII level was significantly lower in
group O than that in group A, B or AB individuals (P < 0.05), and the average of factor
VIII level was also significantly reduced during the period from blood donation,
processing procedure to refrigeration (P < 0.05). These three average value showed
significantly different (P < 0.05), and had decreasing trend.
Conclusions: Although thedifferent donationvolumeandcentrifugationconditionswill
not directly affect the content of coagulation factorVIII, the content of coagulation factor
VIII will be reduced after processing and storage, but the content still in the normal range.
P-119
IMPROVEMENT OF THE RED BLOOD CELL RECOVERY OF
1 UNIT RBCS FOR LEUKOCYTES-REDUCED
Chen KC1, Wang LC1, Tsai CC1, Tsai YW1, Lin CL1, Lin SJ2, Lin KS2
1Taichung Blood Center, Taichung, Taiwan 2Head Office Taiwan Blood Services
Foundation, Taichung, Taiwan
Background: RBCs Leukocytes-reduced (RLR) provided by blood centers were pre-
pared from two units of packed RBC. According to the quality control of AABB, the Red
blood cell (RBC) recovery exceeding 85% will be qualified. (The 16th AABB Technical
Manual definition). For the request of the hospitals, RLR was prepared from post-
storage one unit (250 ml) of packed RBC. After this procedure, the mean value of RBC
recovery went down to 78% that did not meet the minimal qualified standard in 85%.
Aims: The study aims to improve the RBC recovery and confirm the standard oper-
ational procedure of pre-storage 1 unit RLR.
Methods: Ten 250 ml double-bags of Whole blood (WB) were collected from random
donors who were processed by hard-spin centrifugation into a RBC concentrate and a
Fresh frozen plasma (FFP) according to SOP. Then the White blood cell (WBC) filter and
packed RBC were connected by a sterile connection device (TSCD-II; Terumo, Tokyo,
Japan), and the FFP container was still connected with the packed RBC bag; later they
were filtrated at the ambient temperature (20–24C). After the first filtration, add
plasma about 30 g in the packed RBC bag, mixing, to increase the RBC recovery by
increasing the RBC in the bag, the filter and the blood tubing and flushing them. Then
filter them together again. These procedures must be completed within 8 h after WB
collection process. Hematocrit (Hct) value was measured using an automated cell
analyzer (Sysmex KX-21N; Toa, Tokyo, Japan). Volume of blood components were
determined by dividing the net weight with standard specific gravity values, then
calculate the RBC recovery, while residual WBC count was preformed by using the
Nageotte hemocytometer.
Results: The mean (± SD) of RBC recovery value was 91 ± 3%, the Hct mean value was
66.6 ± 9.7%, themean number of residualWBCs per unit was 0.08 ± 0.03 · 106, and the
FFPweightmean value was 122 ± 2 g. All results meet the AABB standard. Conclusions:
The RBC recovery increased from 78% to 91% after adding the plasma in the RBC
concentrate bag. Though the Hct value was reduced by 3.3–66.6%, it’s still maintained
between 55% and 80%. The RLR was prepared from pre-storage one unit of packed
RBC; it could efficiently remove leukocyte from the packed RBC to decrease the
cytokine level and the bacterial contamination risk. The product will provide hospitals
real requirement, and ensure the quality of blood components.
P-120
THE FEASIBILITY OF PREPARING FRESH FROZEN PLASMA
AND PLATELET CONCENTRATE FROM WHOLE-BLOOD
DONATIONS USING A 24-H HOLD PROCEDURE
Chin FL, Lin CH, Peng SY, Yang TT, Yang B
Hsinchu Blood Center, Taiwan Blood Services Foundation, Jhubei City, Taiwan
Background: Since the blood collection sites are dispersive, the time of transporting
blood from collection sites to blood center usually affected by traffic situations. The
delay compressed the time for preparing fresh frozen plasma and platelets because of
an 8-h limitation from blood collection. We needed more manpower to complete the
work in confining period. This study compared the quality of blood components
prepared from WB stored for 8 and 24 h in 20–24C before processing with the PRP
method.
Methods: After collection, blood was stored and delivered in ambient temperature of
20–24C. For the control group, blood components were prepared in 8 h from blood
collection. The experimental group composed components which are prepared in 24 h
after collection. There are 30 bags selected for each group. The quality of plasma and
platelet concentrate were compared in the activity of factor VIII before plasma frozen
and after 30 days storage in freezer, the residual platelet in plasma, the platelet count
of platelet concentrate, the pH of platelet concentrate of near expiration, and phe-
nomena of swirling of platelet.
Results: The codes of FP8 and PL8 were refered to control group, on the other hand,
FP24 and PL24 represented the experimental group. The average activities of factor
VIII of 30-day stored FP8 and FP24 were 81.43% and 71.58% respectively. The activity
remained after 30 days of storage comparing to itself before freezing, FP8 had 84.3%
of activity remained and FP24 had 86.1% of activity remained. The difference of
plasma factor VIII activity of two group was examined by t test. There were no stat-
itically significant difference in both situations which are before freezing and after 30-
day storage. The residual platelet of all plasma were under 50 · 109/l.
The platelet count of all the PL8 and PL24 were over 3 · 1011/unit and the pH are over
7.0 in all platelets of near expiration. The phenomena of swirling is obvious in every
platelet concentrate visually.
Conclusions: Although the average activity of Factor VIII of FP24 is lower than FP8 by
12.1%, 71.58% in average of FP24 still met the requirements of fresh frozen plasma set
up by Taiwan Blood Services Foundation and the standards of Council of European
that 70% of activity remained after freezing and stored for 30 days. Not only PL8 but
also PL24 were superior to the standards that platelet count should be higher than
2.75 · 1010/unit and pH should be higher than 6.2. All data showed that prolonging
the time of whole blood storage from 8 to 24 h didn’t affect the quality of plasma and
platelet concentrate significantly. However, increasing WB storage time to 24 h is
logistically attractive.
P-121
REDUCE PLATELET REJECTION RATE DUE TO PLATELET
CLUMPING BY USING LEAN SIX SIGMA
Chia KK, Lam S, Chua SS, Heng CS, Leong TS, Abdul Razak SK, Ng KS, Shu PH
Health Sciences Authority, Singapore, Singapore
Background: The Component Processing Laboratory prepares platelet concentrate
using the Platelet-Rich Plasma method. These platelet concentrate units are visually
inspected by the laboratory staff before being issued to hospitals for patient use. On
average, about 7% of the total platelet concentrates units prepared monthly is rejected
due to the presence of platelet clumps. Our objective is to study the possible root causes
of platelet clumping, the relationship of causes and subsequently, to improve the
rejection rate.
Methods: By using Lean Six Sigma Define, Measure, Analysis, Implement, and
Control (DMAIC) as a studying tool, seven areas of possible cause were identified and
focused for the study. The team studies the relationship of the high platelet clump rate
with (i) the collection sites, (ii) the type of blood bag, (iii) the centrifuges that the unit
was processed in, (iv) the collection by day of week, (v) the time taken for blood
collection, (vi) platelet resting time, (vii) the inspector’s standard of rejection. Data
was collected for the month of May to July 2010 and from 3 August to 14 August
2010. Statistical analysis was performed using SIGMAXL software. Gage R&R study
was conducted to assess the inspector’s skill on Repeatability and Reproducibility of
platelet rejection.
Results: The statistical analysis using hypothesis testing showed no relationship be-
tween the high platelet clump rates with all the areas studied (P > 0.05). In the Gage
R&R Study, inconsistency was observed on most of the inspectors assessed. Rejection
rates of platelet units due to platelet clumps varied within and among the inspectors.
Some inspectors are also observed to be rejecting units of platelets that are deemed to
be satisfactory.
Conclusions: The platelet preparation process is demonstrated to be intact. The major
driver for the high rejection rate of platelet units due to platelet clumps seems to be
human related. Individual inspectors have varied rejection criteria. Standardization of
a rejection criteria have helped to reduce the platelet rejection rate due to platelet
clumps from 7% to an average 4%.
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AN AUDIT OF FRESH FROZEN PLASMA USAGE IN KING
KHALID UNIVERSITY HOSPITAL, RIYADH
Abdel Gader AM
King KHalid University Hospital, Riaydh, Saudi Arabia
Background: Fresh frozen plasma (FFP) is commonly used in the treatment of patents
with coagulopathies who are bleeding or at risk of bleeding, and where a specific
therapy or factor concentrate is not appropriate or unavailable. However, up to date
there are few firm indications and guidelines to its use which is frequently practiced
without seeking laboratory evidence of the degree of the coagulopathy before trans-
fusion and whether improvement in these tests has occurred post-transfusion. As re-
sults there is growing concern that FFP is used inappropriately and without scientific
rationale.
Aim of this study: This is look-back review of the practice of FFP transfusion by
clinical departments in a teaching hospital attempting to throw light on appropriate-
ness of FFP transfusions.
Materials and methods: Blood Bank records of 494 consecutive patients from the
following clinical departments at King Khalid University Hospital, Riyadh: Surgery
(n = 102), Pediatrics (n = 87), Medicine (n = 306). The results of the coagulation
screening test was recorded before and after FFP transfusion.
Results: Total 1620 units were issued for 526 patients and the results obtained were as
(data expressed as prevalences):
1. Pre- and post-FFP transfusion prothrombin time (PT) and activated partial
thromboplastin time (APTT): 56% in the Department of Surgery, 28.5% the Department
of Medicine and 32% in the Dept of Pediatrics.
2. No pre- or post-transfusion PT and APTT testing: Department of Surgery 6.6%;
Department of Medicine:8.7% and in the Department of Pediatrics 26%.
3. Only post-FFP transfusion PT and APPT was noted as follows: 33.3% in the
Department of Surgery; 51% in the Dept of Medicine and 34% in the Dept of Pediatrics.
4. Plasma fibrinogen: Pre and post-FFP transfusion fibrinogen was noted in 39% in the
Department of Surgery 6.6%; Department of Medicine: 8.7% and in the Department of
Pediatrics 26%.
Conclusion: There is wide disparity in the resort to coagulation testing before and after
the transfusion of FFP. Other than education of clinicians the employment of a
transfusion nurse to monitor use of FFP (and other blood products) would definitely
pave a way to proper evidence-based transfusion practice and could avoid the inap-
propriate use and wastage of FFP.
P-123
TRANSFUSION PRACTICE OF CRYOPRECIPITATE-REDUCED
PLASMA IN ONE INSTITUTION IN TAIWAN
Lin JS1, Chen YJ1, Lyou JY1, Chiou TJ2
1Taipei Veterans General Hospital, Taipei, Taiwan 2National Yang-Ming University
School of Medicine, Taipei, Taiwan
Background: Under economic pressure, cryoprecipitate (cryo)-reduced plasma was not
only used for correcting deficiency of coagulation factors (except fibrinogen, factor
VIII and von Willebrand factor), but also as a source of proteins responsible for osmotic
pressure of plasma and maintenance of blood volume. The transfusion practice of cryo-
reduced plasma was rarely reported.
Methods: Transfusion practice of cryo-reduced plasma in January 2011 was reviewed.
Information about age, sex, clinical conditions, international normalized ratio (INR) of
prothrombin time (PT), activated partial thromboplastin time (APTT), and serum
albumin level nearest before transfusion were collected. The reason codes of trans-
fusing cryo-reduced plasma were: (i) for managing coagulopathy, (ii) for managing
severe hypoalbuminemia (albumin £ 2.5 g/dl) in patients with ascites, pulmonary
edema, pleural effusion or shock, (iii) for managing mild hypoalbuminemia (albumin
2.6–3.9 g/dl) in patients with ascites, pulmonary edema, pleural effusion or shock, (iv)
for preventing shock in patients with burn injury or undergoing paracentesis or tho-
racocentesis.
Results: In January 2011, a total of 116 times of transfusions with cryo-reduced
plasma were analyzed. The dose of cryo-reduced plasma was 1 unit in 98 times of
transfusions, and 2 units in 18 times of transfusions. These transfusions were
administered to 72 patients (20 female, 52 male, age 20–94 years, median age:
75 years). Plasma transfusions were given to patients in intensive care units (27/
72 = 37.5%) or medical ward (31/72 = 43.1%) or surgical ward (14/72 = 19.4%). One
hepatoma patient with massive ascites undergoing paracentesis received 10 times of
daily plasma transfusions. Numbers of patients in each reason code with various times
of transfusions were shown in Table 1. Transfusion reaction (allergic reaction with
urticaria) was found in 1 (1/116 = 0.9%) transfusion. A total of 28 patients (code 1: 0
patient, code 2: 11 patients, code 3: 13 patients, code 4: 4 patients) died of their
underlying diseases during hospitalization.
Conclusion: In one hospital practice, the main reason for giving cryo-reduced plasma
was to manage hypoalbuminemia in critical patients with ascites, pulmonary edema,
pleural effusion or shock.
3.3 Plasma Products
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CHARACTERIZATION OF PLASMA PROTEIN ACTIVITY IN
CRYOSUPERNATANT
Ma L1, Lin F1, Sun P1, Diao G1, Liu Z1, Li C1, Li J2, Bai Z3, Zhou J4, Zhang X5, Li J6,
Zhang H7
1Institute of Blood Transfusion, CAMS, Chengdu, China 2Liaoning Blood Center in
China, Shenyang, China 3Yancheng Blood Center in China, Yancheng, China 4Jiangsu
Blood Center in China, Nanjing, China 5Shandong Blood Center in China, Jinan, China
6Shanxi Blood Center in China, Xian, China 7Yunnan Blood Center in China, Kunmin,
China
Background: The administration of cryosupematant plasma (CSP) has increased dra-
matically in recent years without sufficient evidence to support such change.
Aims: The study evaluated the differences between fresh frozen plasma (FFP) and CSP
as regards their content of the protein in vitro, and to show the possibility using CSP
instead of FFP as a replacement therapy in some clinical situations.
Methods: The study included 60 blood units obtained from healthy donors attending
from six blood centers in China. FFP and CSP were prepared from the same blood
units and aliquots from them were used to perform the following assays: total
protein, fibrinogen assay, coagulation factors II, V, VII, VIII, IX, X, XI and XII
activity assays, non activated partial thromboplastin time (NAPTT), antithrombin III
(AT-III) activity assays, and the von Willebrand Factor cleaving protease (ADAM-
TS13) assay. The content of each bag was calculated and the results were tested for
statistical significance.
Results: The average percent protein retention for CSP were: Total Protein, 57.7 g/l,
Fibrinogen, 166.9 mg/dl, Factor II, 101.8%, Factor V, 82.6%, Factor VII, 83.6%, Factor
VIII, 18.6%, Factor IX, 67.7%, Factor X, 94.7%, Factor XI, 61.6%, Factor VII, 100.2%,
NAPTT, 270 s, AT-III, 83.3%, and ADAMTS13, 97.8%. The mean fibrinogen and factor
VII levels in CSP were significantly less than in FFP. On the other hand, CSP appeared
to be a useful source of coagulation factors II, VII, X, XII, AT-III and ADAMTS13 as it
contained adequate amounts of these proteins.
Conclusions: CSP appears to be a satisfactory alternative to FFP in those situations in
which the presence of sufficient amounts of factor VIII, von Willebrand factor (vWF),
fibrinogen, factor IX and Factor XI in the substitution product are not required. Further
validation of these results will encourage the increase of using cryopematant.
Acknowledgements: This work was supported by grants from the research of the
technique and standards about the drug and transfusion safety in China (200902008-02).
P-125
PRELIMINARY ASSESSMENT OF COAGULATION FACTOR? IN
THE CHINESE MARKET
Zhang XJ, Ye SG, Du X, Cao H, Wang ZK, Xie Y, Li CG
Institute of Blood Transfusion, CAMS, Chengdu, China
Background: In the Chinese market, there are three human plasma-derived coag-
ulation factor VIII (F VIII) and one recombinant factor VIII, for the treatment of
hemophilia patients. Comparative assessment of these products has not been reported.
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Objective: To study these F VIII products in China, a preliminary analysis is made on
the active ingredients as well as impurity profile. The research on these factor VIII
products’ efficacy and safety serves to establish new standards for product quality and
provide some theoretical basis for applications.
Methods: A self-made Human F VIII, Green Cross’ F VIII, CSL’s Aleviate, Shanghai
RAAS’ F VIII and Bayer’s Kogenate FS are evaluated through the determination of F
II, F V, F VII, F IX, F XI and F VIII clotting capability, as well as preliminary
evaluation of vWF:Ag content. Non-reducing and reducing SDS-PAGE electropho-
resis is employed to assess purity, while protein content is determined by three
different assays.
Results: The results in the clotting activity, protein concentration and purity indicate
that there are qualitative differences among these factor VIII products.
Conclusion: Preparation by different processes may lead to different product quality
Qualitative evaluation of coagulation factor products may be influenced by different
methods, equipment and test kits employed. The present study show one of the key
quality parameters of F VIII– specific activity in these products to be greater than the
WHO requirements for a high-purity F VIII (10 IU/mg) as well as the Chinese Phar-
macopoeia 2010 (1 IU/mg) requirements.
P-126
ISOLATION AND PURIFICATION OF HUMAN A1-ANTITRYPSIN
BY A NEW TYPE OF IMMUNOAFFINITY CHROMATOGRAPHY
Zhang XJ, Ye SG, Cao H, Wang ZK, Du X, Xie Y, Li CG
Institute of Blood Transfusion, CAMS, Chengdu, China
Background: a1- antitrypsin is a primary for the a1-AT deficiency replacement
therapy biological products, now more than two-steps chromatography purification
from human plasma. One step affinity chromatography with the preparation of a1-AT
have not been reported at present.
Objective: To develop a much more inexpensive process for isolating and purifying
a1-antitrypsin from Cohn Fraction IV by a new type of immunoaffinity chromatog-
raphy and to achieve an improved utilization of the valuable source material fresh
frozen plasma.
Methods: Cohn Fraction IV was dissolved with Tris solution in a ratio of 1:12 for
0.5 h at 24C, and the suspension was centrifuged for 15 min (24C, 4750 g). After
added HL-380 (a fumed silica) and centrifuged, the supernatant was loaded through
1.2 lm filters sequentially. With a new type of immunoaffinity chromatography
medium- ‘Alpha-1 Antitrypsin Select’, a1-antitrypsin was purified further. Charac-
terization of a1-antitrypsin was performed by SDS-PAGE and Western Blot. Total
protein content was determined by the method of Bradford under UV absorption at
595 nm. The activity of a1-antitrypsin was determined using chromogenic substrate
assay.
Results: The purified a1-antitrypsin concentrate showed two protein bands on gels by
SDS-PAGE, One of the molecular weight was calculated 54 kD; the others was cal-
culated 140 kD approximately, After reducing SDS-PAGE, large molecular weight
polymer protein band of a1-antitrypsin was depolymerized, the result of Western Blot
analysis could be related to changes in reaction. The immunoaffinity chromatography
step achieved a 90% yield. Thus, an overall 95% in purity and a 41.88% yield was
obtained approximately from Cohn Fraction IV (or a 13.96% yield was obtained
approximately from human plasma).
Conclusions: The high purity and specific activity of a1-antitrypsin achieved with this
process which is could be an efficient and scale-up method for a1-antitrypsin purifi-
cation from Cohn Fraction IV.
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STANDARDIZATION IN DETERMINATION OF
CHYLOMICRONEMIA PLASMA OF DONOR BLOOD
Lin CH, Wu GL, Chin FL, Yang TT, Yang B
Hsinchu Blood Center, Taiwan Blood Services Foundation, Jhubei City, Taiwan
Background: There are six Blood Centers in Taiwan, which are Taipei, Hsinchu, Tai-
chung, Tainan, Kaohsiung and Hualien These centers are in charge of blood collection,
blood components preparation and the provision of components to hospitals. The
prevalence of donors with chylomicronemia was analyzed in the period of 2003–2007.
We found that the prevalence can be in 10 times difference among blood centers. It was
interested to figure out the causes but the first step was to eliminate the difference in
judgment. The objective of this study was to develop a consistent operational principle
and method for standardizing the determination of chylomicronemia among blood
centers.
Methods: The experienced personnel from six blood centers were invited to join the
consensus meeting. The method for determining the chylomicronemia has to be
developed under the premise that no destruction of the blood bag. The agreement was
achieved that is to develop a light box with a background which could provide a clear
cut of plasma with or without chylomicronemia.
The second meeting was held after the prototype of the light box was made. Plasma of
different titer of chylomicronemia vs varieties of backgrounds were tried to determine
the best model.
A training course was arranged after the light boxes according to the model chosen
were made and the standard operation procedure of chylomicronemia determination
was written. The same personnel joined together to get training and the evaluations of
competence were performed. Those who were qualified are designated to be the final
judgment makers of chylomicronemia of plasma of their blood center. The SOP and the
equipment were validated in August 2010.
Results: The variance of the incidence rate of chylomicronemia plasma among blood
centers was reduced. The variance was decreased from 47.8% to 29.8% after 4 months
of carrying out the standard. It showed that this standard worked well in practice.
Conclusions: We standardized the thickness of plasma in reading area, the luminosity
of light box and the cut off value of chylomicronemia. The effect of minimizing the
difference of judgment in chylomicronemia among blood centers revealed in the first
few months after the standard was put into practice. The practice of the standard has to
be checked occasionally to make sure it doesn’t lead to a deviation and still meets
hospital’s need. Besides, the incidence of chylomicronemia should be observed for a
longer period of time to figure out the trends.
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PRODUCTIVE PLASMAPHERESIS BY NIGALE NGL XJC 2000:
QUALITY CONTROLS ON PLASMA COLLECTED
D’Onofrio M1, Paesano L1, Leonardi GM1, Cirella M2, Vaccaro G1, Pecora R1, Romano
R2, Nocera C1
1ASL Napoli 1 Centro, Naples, Italy 2AORN, G. Moscati, Avellino, Italy
Background: The Nigale NGL XJC 2000, distributed by Hemotrans (Pomezia, Italy), is
a new cellular separator exclusively dedicated to plasma production by apheresis. This
instrument, characterized by a discontinuous blood flow with a single venous access,
adopts the technology developed by Latham, namely the separation of blood compo-
nents according to their density gradient by applying an appropriate centrifugal force.
In the Nigale’s kit, a blow moldeld bowl is included. Thanks to the structure of this kind
of bowl the coming in blood does not go through stratified hemocomponents, more-
over the greater rotation speed respect to Latham bowl (7.000 vs 4.800 rpm) permits to
obtain a plasma with a lower cellular contamination.
Aims: In our Transfusion Centre, we evaluated, in terms of effectiveness and effi-
ciency, the qualitative and quantitative performances of this equipment.
Methods: Between November 2010 and May 2011, two hundred plasmapheresis were
performed with this new instrument, of course after informed consent, on 150 periodic
blood donors with at least one previous experience in apheresis donation. In order to
evaluate the quality of produced plasma, on all samples, collected from all units before
freezing, factor VIII and fibrinogen were assayed, moreover sterility controls were
performed and, at the end, the cellular contamination with erythrocytes, leukocytes
and thrombocytes was evaluated.
Results: Mean factor VIII ± SD on collected plasma units was 90.31 ± 10.23% (normal
range 73.1–137.0). Mean fibrinogen ± SD was 334 ± 43 mg/dl (normal range 246–527).
All sterility controls resulted negative. Cellular contamination was not significant (mean
erythrocytes = 0.01 · 106/ll; mean leukocytes = 0.1 · 103/ll; mean thrombo-
cytes = 11 · 103/ll, with a minimum count of two and a maximum of 31).
Summary/conclusions: The last report of Superior Institute of Health show that Italy
is still far away to obtain the self-sufficiency for plasma production and conse-
quently for plasma-derivates. For this reason one of major objectives of Italian
Transfusion Centres must be to implement, in addition to classic whole blood
donation, the collection of plasma by apheresis. In this context we have evaluated
qualitative performance of this new instrument and our data (on factor VIII and
fibrinogen dosage, microbial and cellular contamination) show that plasma collected
by Nigale NGL XJC 2000 respect both Italian and European quality parameters. At
the end the availability of another cell separator dedicated to plasmapheresis, also
because offered at extremely attractive costs, may allow a greater number of targeted
donations.
 2011 The Authors
Vox Sanguinis  2011 International Society of Blood Transfusion Vox Sanguinis (2011) 101 (Suppl. 2), 39–134
74 Posters
3.4 Pathogen Inactivation
P-131
STUDY OF REDUCTION FACTOR OF HEPATITIS B VIRUS DURING
PREPARATION OF FACTOR VIII CONCENTRATE BY ELISA
METHOD
Heidari M, Nasiri S
Research Center of Iranian Blood Transfusion Organization, Tehran, Iran
Introduction: Hemophilia is one of the prevalent X-linked hereditary disease due to
deficiency of factor VIII which causes bleeding in patients. Factor VIII concentrates are
used to treat these patients. In spite of therapeutic advantages of human plasma
proteins, there is a risk of transmitting blood-borne viruses to the recipients. The
previous studies have shown that the risk of hepatitis B virus is high in the factor VIII
concentrates. Therefore, if different steps of purification lead to significant reduction of
viral load it would be important to manufacturers. In this study, viral reduction of
HbsAg was determined by ELISA method.
Method: Highly positive sample of HBsAg was prepared and the starting material of
fresh frozen plasma was virus-spiked. The factor VIII concentrate was prepared by
precipitation (PEG) and ion-exchange chromatography (DEAE-Sepharose). For deter-
mination of OD, the serial dilution (10-fold dilution factor) was prepared. Evaluation of
virus titer was performed by comparing the logarithmic dilution of starting material
with final material by ELISA method.
Results: The OD of results were entered to Excel program and the HBsAg removal
curves were demonstrated and the reduction factors were calculated. In this study
different steps of precipitation and ion-exchange chromatography showed 1.2 log and
3.1 log of virus reduction respectively.
Discussion and conclusion: Our experiments indicated that concentration of PEG,
temperature, type of gels, flow rate, elution profile (PH and ionic strength), resin
porosity and ligand density, proportion of height to diameter of column, volume of
washing buffer and the number of washing steps and also virus size, symmetry,
membrane structure, surface topography and its surface charge are important
parameters for virus removal operation. The results showed that application of this
method of viral removal method can totally remove 4.3 log during preparation of
factor VIII concentrate.
P-132
PATHOGEN INACTIVATION EFFICACY OF MIRASOL PRT SYS-
TEM AND INTERCEPT BLOOD SYSTEM FOR PLATELET-RICH
PLASMA DERIVED PLATELETS SUSPENDED IN PLASMA
Kwon SY1, Bae JE2, Lee JI2, Jeong EK2, Jeong JS2, Jung CH2, Yu DJ2, Kim IS2, Cho YJ1,
Kang JW1, Cho NS1
1Blood Transfusion Research Institute, Korean Red Cross, Seoul, South-Korea 2Hannam
University, Deajeon, South-Korea
Background: Pathogen inactivation (PI) technology for platelets suspended in additive
solutions has been implemented in some countries. Platelet additive solutions are not
in use in Korea.
Aim: This side-to-side comparison study was conducted to evaluate the efficacy of
pathogen inactivation in platelet-rich plasma derived platelets suspended in plasma
using the Mirasol PRT System (Caridian BCT) and the Intercept Blood System (Cerus).
Methods: Thirteen to 15 units of platelets were pooled using the Acrodose PL system
(Pall) and eparated into three aliquots, 50 ml for control and 275 ml each for Mirasol
and Intercept system treatment. Platelets were inoculated with the respective virus or
bacteria. Four replicates of each viral strain were used for the evaluation. For bacteria,
both low titer (102 CFU/unit) and high titer (>107 CFU/unit) inoculation with two
replicates for each bacterial strain was used. Pre- and post-treatment titer of each
pathogen was evaluated. Platelets inoculated with a low bacterial titer were stored for
5 days and culture was performed with the BacT/ALERT system (Biomerieux).
Results: The levels of inactivation expressed as log-reduction for the Mirasol and the
Intercept system for viruses were as follows: human immunodeficiency virus-1 (HIV-
1), ‡4.19 vs ‡4.23; bovine diarrhea virus (BVDV), 1.83 vs ‡6.03; pseudorabies virus
(PRV), 2.73 vs ‡5.20; porcine parvovirus (PPV), 0.28 vs 0.38; and hepatitis A virus
(HAV), 0.62 vs 0.76. Inactivation efficacy for influenza A virus H1N1 could not be
evaluated, because the virus was not detectable after inoculation into the platelet units.
The levels of inactivation expressed as log-reduction for the Mirasol and the Intercept
system for bacteria were as follows: Escherichia coli (E. coli), 5.45 vs ‡9.22; Staphy-
lococcus aureus (S. aureus), 4.26 vs ‡10.11; and Bacillus subtilis (B. subtilis), 5.09 vs
‡7.74. Post-treatment bacterial growth in platelets inoculated with a low titer of S.
aureus or B. subtilis was detected only in platelets treated with the Mirasol system.
Conclusion: Pathogen inactivation efficacy of the Intercept system for enveloped
viruses such as HIV-1, BVDV and PRV was shown to be satisfactory and comparable
with previous study results. The Mirasol system showed satisfactory inactivation
efficacy for only HIV-1. Non-enveloped viruses were not inactivated by both systems.
For bacteria, inactivation efficacy of the Intercept system was more robust for all
bacteria tested at high or low titers.
*This research was supported by a grant (2010-E34005-00) from the Korea Center for
Disease Control & Prevention in 2010.
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REAL-TIME PCR FOR EVALUATING THE EFFECTIVENESS OF
PATHOGEN REDUCTION TECHNOLOGY
Lee TH, Montalvo L, Wen L, Chafets D, Busch M
Blood Systems Research Institute, San Francisco, United States of America
Background: Although the safety of blood transfusion has improved dramatically in
the past decade, the risk of transfusion-associated infection still persists. Photochem-
ical principles have been used to achieve pathogen inactivation of blood products.
Because of lack of in-vitro infectivity assays for assessment of PRT for emerging
viruses, we have established quantitative real-time PCR with long amplicons for three
viruses including HHV-8, the human Parvovirus B19 and the Dengue virus. HHV-8 is a
cell-associated double-stranded DNA virus with capsid, Parvovirus B19 is a non-
enveloped single-stranded DNA virus, and Dengue virus is an enveloped mosquito-
born single-stranded positive RNA virus.
Aim: The objective of this study is to evaluate the effectiveness of pathogen reduction
technology (PRT) using Mirasol System for whole blood.
Methods: Cell line BCP-1 (ATCC, Manassas, VA,USA) was used as the source of
HHV-8, human plasma with high titer of Parvovirus B19 was used as the source of
Parvovirus B19, and cell culture supernatant was used as the source of Dengue
virus.
Optimization of the real-time assays included evaluation of widely employed hot start
enzymes (Roche’s FastStart and Applied Biosystems’ AmpliTaq Gold) and other
polymerase enzymes that may be particularly efficient in generating long PCR
products, such as Invitrogen’s Accuprime Taq DNA Polymerase High Fidelity,
Invitrogen’s Platinum PCR SuperMix High Fidelity, Sigma’s AccuTaq LA, Applied
Biosystems’ rTth DNA polymerase and Stratagene’s PfuUltra Hotstart DNA Polymerase.
We also compared annealing temperature, annealing time, magnesium, primer and
dNTP concentrations, extension temperature and time.
Primers were designed for HHV-8 and Dengue, spanning 233–1550 bases and 695–
1327 bases, respectively. The primers for Parvo, published by Hokynar et al, Journal of
General Virology (2000), 81, 1017–1025, spanned from 689 to 1975 bases.
Mirasol treatment: After establishment of the assay, we evaluated the efficacy of
Mirasol treatment on virus spiked to 250 ll of PBS and plasma. For each sample
type, three conditions were investigated: untreated, riboflavin only and Mirasol
(riboflavin + UV). The effectiveness of pathogen reduction was evaluated based on
the delta Ct between amplifications of Mirasol-treated spiking samples and untreated
controls.
Results: The optimization data of the Dengue primer pairs is shown in Table 1.
For HHV-8, we have generated eight primer pairs with amplicons of: 233, 515, 627,
821, 978, 1043, 1294 and 1550 bps.
For Parvo B-19, we have generated 9 primer pairs with amplicons of: 689, 706, 743,
1064, 1078, 1244, 1307, 1658, 1975 bps.
We saw a 2-log viral reduction after subjecting the HHV-8 to Mirasol treatment relative
to untreated controls.
Conclusion: We succeeded in creating assays of long-product real-time PCR for
assessment of PRT for whole blood for viruses to which culture inactivation assays are
not available or practical.
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IMPACT OF SOLVENT/DETERGENT TREATMENT OF PLASMA
ON THE GROWTH OF TRANSFUSION-RELEVANT BACTERIA
Burnouf T1, Chou ML2, Wu YW2, Su CY3, Lee LW2
1HPPS, Lille, France 2Taipei Medical University, Taipei, Taiwan 3National Yang-Ming
University, Taipei, Taiwan
Background: A solvent/detergent-filtration (S/D-F) process performed in a single-use
bag system has recently been developed for viral inactivation/pathogen reduction of
plasma for transfusion [1]. Bacterial contamination of blood/plasma may occur at the
time of venipuncture, and is usually due to improper cleaning of the donor’s arm. It is
not known whether this new S/D treatment carried out at 31C may affect or promote
bacterial growth or may impair bacterial inactivation by the complement. To our
knowledge, the impact of S/D treatment on bacteria has not been studied before.
Aim: Our goal has been to study the impact of this S/D treatment on the growth of
eight transfusion-relevant Gram-negative or Gram-positive bacteria, including spore-
forming strains, that were spiked to plasma prior to the S/D treatment.
Methods: Apheresis plasma was obtained from four donors and pooled. Plasma (P)
was spiked with high titers (>107/ml) of eight transfusion-relevant bacterial strains.
It was then treated with 1% tri(n-butyl) phosphate and 1% Triton X-45 at 31C for
90 min and extracted by 10% soybean oil at 31C for 70 min to remove most of
the S/D agents. In addition, decomplemented plasma obtained by heating at 56C
for 30 min (DP) and PBS were used as control test materials (TM). Samples were
taken at different stages of the process to determine the bacterial count by doing
serial dilutions and using a plate assay method. Bacteria growth inhibition tests
were also performed using wafers soaked with the various TM, in the presence of
the S/D agents or not.
Results: Inactivation of the Gram-negative bacteria Escherichia coli, Pseudomonas
aeruginosa, and Klebsiella pneumoniae by the complement was not altered by the S/D
treatment and reached >8.75, 4.71, and 4.12 log, respectively. Interestingly, the Gram-
positive spore forming bacteria Bacillus cereus and Bacillus subtilis were inactivated
by the S/D treatment of P (>7.04 and 1.6 log, respectively) while Staphylococcus aureus
and Staphylococcus epidermidis also showed some inactivation by S/D in PBS (1.94
and >2.02 log, respectively) but not in P or DP. There was no multiplication of Ente-
robacter cloacae during the S/D treatment and oil extraction. Growth inhibition test
confirmed the inhibition of the Gram-positive bacteria in all TM containing the S/D
agents.
Conclusion: This S/D-F process mantains the functional activity of the complement,
does not increase the risk of bacterial growth and can contribute to the inactivation of
some Gram-positive bacteria, an observation that has not been reported before. The
procedure also includes a terminal sterilizing filtration step that further secures the
bacterial safety of such S/D-F plasma.
Reference:
1. El-Ekiaby M, Sayed MA, Caron C, Burnouf S, El-Sharkawy N, Goubran H,
Radosevich M, Goudemand J, Blum D, de Melo L, Soulie V, Adam J, Burnouf T:
Solvent-detergent filtered (S/D-F) fresh frozen plasma and cryoprecipitate mini-
pools prepared in a newly designed integral disposable processing bag system.
Transfus Med 2010; 20:48–61.
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A QUALITATIVE TEST OF FRESH FROZEN PLASMA AFTER
METHYLENE BLUE AND WHITE LIGHT TREATMENT IN CHINA
Yang C, Bian G, Yang H, Li C
Institute of Blood Transfusion, CAMS, Chengdu, China
Aim: Investigate the Characterization of plasma protein activity in Methylene Blue
and white light (MB-PCT) treated fresh frozen plasma in China, by examining the
plasma sampled from three blood centers.
Method: Each 10 samples of MB-PCT treated were separately provided by Chongqing
Blood Center, Suzhou Central Blood Station and Yancheng Central Blood Station. The
paired, untreated plasma units was served as control and stored in )30C with treated
plasma, and the protein retention of blood coagulation factor, IgG, IgM, protein C,
protein S and vWF were inspected after 4 weeks using standard coagulation assays.
Results were compared with the control.
Results: In comparison with control, The average of percent protein retention in MB-
PCT treated plasma after 4 weeks were: Factor II, 93.7%; Factor V, 88%; Factor VII,
90.3%; Factor VIII, 81.3%; Factor IX, 94.3%; Factor X, 90.7%; Factor XI, 78%; Factor
XII, 86%; Fibrinogen, 91.9%; IgG, 98.2%, IgM, 94.5%, protein C, 106.7%; protein S,
86.3%; vWF, 82.3%.
Conclusion: Plasma treated with MB-PCT, shows reduction in activity of blood
coagulation factors and protein contents. Our result also suggests different procedures
of plasma collection and storage could affect the activity of blood coagulation factors
and protein retention significantly.
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HIGHLY EFFECTIVE INACTIVATION OF HEPATITIS C BY MB/
LIGHT TREATMENT OF PLASMA AS SHOWN BY A NOVEL
IN VITRO HCV INFECTION SYSTEM
Gravemann U1, FrieslandM2, Doerrbecker J2, Pietschmann T2, Steinmann E2, SeltsamA1
1Blood Center of the German Red Cross, Springe, Germany 2Twincore Center of
Experimental and Clinical Infection Research GmbH, Hannover, Germany
Background: Photodynamic treatment using methylene blue (MB) and visible light is a
well established method for virus inactivation of human plasma. It has been shown to
inactivate a broad range of different DNA and RNA viruses. Due to the absence of a cell
culture system for propagation of the hepatitis C virus (HCV), the inactivation efficacy
against HCV had up to now to be extrapolated from studies using a model virus (bovine
viral diarrhea virus, BVDV). Although HCV is known since 1989, only recently a HCV
infection system allowing the propagation of infectious HCV in cell culture has been
developed.
Aim: Aim of the current investigation was the investigation of the inactivation
capacity of the THERAFLEX MB-Plasma system by using this in vitro HCV infection
system.
Methods: HCV Jc1 virus was generated by electroporation of 10 lg RNA into Huh7.5
cells. Cell culture supernatants were harvested 48, 72 and 96 h post transfection.
Leukodepleted plasma was prepared from whole blood using standard blood banking
technology. MB/light treatment was done using the MacoPharma Theraflex MB-
Plasma bag system and the MacoTronic B2 illumination device. Plasma (n = 3;
285 ml) was spiked with cell-culture grown HCV (30 ml). Samples were taken at
different steps of the process (Table 1). After illumination with 40 J/cm2 the plasma
was re-spiked with an additional 30 ml of virus suspension to increase the sensivity
of the assay and to test for robusness of the inactivation process. Infectivity was
determined by immunohistochemistry-based endpoint titration and large volume
plating on Huh 7.5 cells. The titer which causes a positive result in 50% of all
infected cultures (TCID50) was determined according to the method of Spearmann and
Kaerber.
Results: The virus titer was determined at a dilution that was neither cytotoxic nor did
interfere with the viral titer. Results of the titrations are given in Table 1. HCV in
plasma was efficiently inactivated by the MB/light treatment below the limit of
detection already with a light dose of 20 J/cm2. After the second spike again treatment
with a light dose of 20 J/cm2 was sufficient for an inactivation of HCV below the limit
of detection.
Table 1: Inactivation of HCV by MB/light treatment
Conclusions: In routine use, MB/light treatment of plasma using the THERAFLEX MB-
plasma system (MacoPharma) is done with a light dose of 120 J/cm2. In the current
investigation it was shown that a dose of only 60 J/cm2 is sufficient to effectively
inactivate HCV with a cumulative reduction factor of ‡8.9 log steps. The procedure
therefore has the potential to significantly reduce transfusion-transmitted HCV
infections.
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COMPARATIVE EFFECTIVENESS OF PRESTORAGE VS POS-
TORAGE RIBOFLAVIN AND ULTARVIOLET-LIGHT TREATMENT
ON THE QUANTITY AND FUNCTIONALITY OF FRESH FROZEN
PLASMA CONSTITUENTS
Balint B1, Todorovic M1, Vucetic D2, Jovicic D2, Jocic M2, Subota V2, Mijuskovic Z2
1University of Belgrade, Belgrade, Serbia 2Military Medical Academy, Belgrade, Serbia
Background: Treatment of fresh frozen plasma (FFP) by Pathogen-Reduction-Tech-
nology (PRT) system – using riboflavin and ultraviolet (UV) light (Mirasol-treated FFP)
– blocks the nucleic acid replication process and leads to inactivation of residual white
blood cells (WBCs) and viruses, bacteria, fungi or other up till now unknown pathogen
agents in blood.
Aims: The goal of this research was to determine the comparative effects of riboflavin
and UV-light treatment on the FFP protein quantity and quality in prestorage vs
poststorage inactivation setting.
Methods: This study included ex vivo investigation of 20 prestorage vs 20
poststorage Mirasol-treated FFP units. Samples for research were taken before (control
groups) and after both prestorage vs poststorage (freezing/thawing) Mirasol-treatment
procedures. Plasma biochemical, immune-response (immunoglobulins and comple-
ment) and hemostatic activity monitoring (coagulation factors, antitrombin (AT)-III
and protein C – pC) were measured using multi-laboratory techniques and equip-
ments.
Results: Mean corrected final concentrations (correction factor = 0.15) of coagulation
factors and inhibitors (IU/ml) in prestorage vs poststorage Mirasol-treated FFP samples
were: FII = 0.77; FVII = 0.78; VIII = 0.52; FIX = 0.71; FX = 0.71; ATIII = 0.79 and
pC = 0.85 vs FII = 0.87; FVII = 0.77; VIII = 0.51; FIX = 0.72; FX = 0.69; ATIII = 0.84
and pC = 0.91, respectively. Final corrected plasma levels of proteins, immunoglobu-
lins and complement components were: TP = 83.1; Alb = 31.1; IgG = 5.32; IgM =
0.52; IgA = 0.93; C3 = 0.67; C4 = 0.15 vs TP = 59.3; Alb = 37.1; IgG = 8.14; IgM =
0.73; IgA = 1.6; C3 = 0.82; C4 = 0.19 in prestorage vs poststorage Mirasol-treated
FFP samples. Between Mirasol-treated FFP vs control group no significant differences
in plasma constituent levels and functionality were found. In addition, no intergroup
(prestorage vs poststorage) significancy was observed, although the obtained levels for
plasma proteins in poststorage Mirasol-treated setting were evidently higher.
Summary/conclusion: This study confirmed that in prestorage vs postorage Mirasol-
treatment no significant differences in plasma constituent quantity and functionality
was observed. Thus, Mirasol-treated FFP remains protein content activity and conse-
quently can be used in clinical settings. Lastly, previously frozen plasma or quarantine
FFP units (despite the reduced quarantine period after NAT or PCR-testing) could be
also effectively and safely inactivated (postorage setting) after storage/thawing,
directly before clinical application.
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EFFECT OF MIRASOL PATHOGEN REDUCTION TECHNOLOGY
SYSTEM ON QUALITY OF PLATELETS STORED IN PLASMA
Llohn A, Skogheim R, Flesland A, Oedegaard E, Mastroianni M, Nybruket M,
Nentwich I
Akershus University Hospital, Loerenskog, Norway
Background: Pathogen reduction in blood products may be an important tool to re-
duce risk in blood transfusions. The goal of pathogen reduction process is to inactivate
pathogens without compromising features or longevity of the blood product. One of
the several methods available for this goal is Mirasol pathogen reduction technology
system (Mirasol PRT system). Riboflavin is added to the blood product. The product is
then illuminated with UVA light. Photo toxic effect of Riboflavin light treatment is to
destroy the nucleic acid in pathogens by photo-oxidation of guanine.
Aim: The purpose of the in vitro study is to evaluate the effect of riboflavin-light
treatment on the functions of platelet concentrates made by aphaeresis.
Study design: Eleven double therapeutic units of platelet concentrates were harvested
from voluntary donors by using Hemonetics MCS+. Double units were then divided in to
two Single therapeutic units (227 ± 33 · 109 platelets). One of the units from each donor
was processed inMirasol PRT systemwhile theother unit from the samedonorwasused as
control. The experimental units were treated with 35 ml of riboflavin and UV rays (6.24/
ml, 265–370 nm) by using Mirasol illuminator (Caridian BCT). All units were stored at
22C on agitator. Samples were taken before and after Mirasol treatment with riboflavin-
light and also next day (day 1), 4, 5 and 6. Various variables measured were; platelet
count, pH, glucose, lactate and CD62. Swirling was graded from 3 (best) to 0 (absent).
Sample for aerobic and anaerobic bacterial culture were taken from all units on day 7.
Results: We observed 2.8% loss of platelets due to pathogen reduction by Mirasol PRT.
Bacterial cultures were negative for all units. Results of other variables are summarised
in Tables 1 and 2.
Table 1: Results during storage of platelets after treating with Mirasol pathogen
reduction technology (n = 11)
Conclusion: Swirling and pH showed significant decrease while metabolism and
activation of platelets was increased in Mirasol-PRT treated units as compared to
control units during storage. However, all the variables remained within the acceptable
values defined in Guide to the preparation, use and quality assurance of blood com-
ponents (Council of Europe), during storage for 5 days. Loss of platelets due to path-
ogen reduction process was much less than platelets loss reported in other pathogen
reduction technologies available at present.
Table 2: Results of control platelet units during storage (n = 11)
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VERIFICATION OF IN VITRO QUALITY OF PATHOGEN
INACTIVATED RBC USING THE S-303 TREATMENT SYSTEM
Erickson A1, Leibacher J2, Schott M1, Donnelly B1, Giesen M2, Henschler R2, Mufti N1
1Cerus Corporation, Concord, United States of America 2Institute of Transfusion
Medicine, DRK-Blutspendedienst Baden-Wu¨rttemberg – Hess, Frankfurt, Germany
Background: A new pathogen inactivation (PI) system for red blood cells (RBC) has
been developed using S-303 to crosslink nucleic acids and prevent replication of
contaminating pathogens and leukocytes. Glutathione (GSH) is included to quench
non-specific reactions. A recent Phase 1 clinical study successfully met the primary
endpoint of 24-h recovery per the FDA criteria. Subsequent development studies have
focused on expanding the S-303 PI process and optimization of the disposable sets to
show compatibility with RBC prepared by practices routinely used in the US and EU.
Aims: In previous studies the input RBC for the S-303 PI process was derived from
pooled RBC which were sampled frequently during storage. The purpose of this study
was to verify the quality of stored PI RBC using unpooled conventional RBC with
reduced sampling during storage.
Methods: On the day (D) of donation, leukocyte depleted (LD) SAGM RBC were
prepared from buffy-coat depleted whole blood (500 ml). The volume range of RBC
was 250–290 ml (N = 7). Each RBC unit was treated with the S-303 PI system by
combining RBC with GSH and a proprietary diluent solution followed by addition
of S-303 for a final concentration of 20 and 0.2 mM respectively. After an 18 h
room temperature hold, RBC units were centrifuged and the diluent solution was
replaced with SAGM. RBC units were sampled prior to storage, then stored at 4C
for 35 days and sampled at the end of storage for meaurement of parameters in
Table 1.
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Results: After PI on D1 post donation, Hb was 53.1 ± 4.6 g and extracellular protein
44 ± 16 mg/dl. The Hct on D1 was 62.3 ± 1.7% and did not change significantly over
35 days of storage. Hemolysis, K+, lactate and MCV increased from D1 to D35, whereas
pH, ATP, Na+, and glucose decreased over storage. MCHC was similar on D1 and D35.
Hemolysis on D35 ranged from 0.23% to 0.38% for six of the seven units while the
remaining unit had 0.80% hemolysis The relative standard deviation was <10% for all
parameters except hemolysis and ATP on days 1 and 35 post donation which we
postulate shows donor to donor variability.
Table 1: RBC in vitro function (mean ± SD, n = 7)
Conclusion: S-303 pathogen inactivated RBC met current EU and AABB guidelines
for LD RBC with respect to Hct and Hb as well as hemolysis after 35 days of
storage.
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IN VITRO EVALUATION OF PATHOGEN INACTIVATED RBC
USING THE S-303 TREATMENT SYSTEM
Erickson A1, Donnelly B1, Schott M1, Sherman C1, Palascak M2, Franco R2, Mufti N1
1Cerus Corporation, Concord, United States of America 2University of Cincinnati
College of Medicine, Cincinnati, United States of America
Background: A new pathogen inactivation (PI) system for red blood cells (RBC) has
been developed using S-303 to crosslink nucleic acids and prevent replication of
contaminating pathogens and leukocytes. Glutathione (GSH) is included to quench
non-specific reactions. A recent Phase 1 clinical study successfully met the primary
endpoint of 24-h recovery per the FDA criteria. Subsequent development studies have
focused on expanding the S-303 PI process by optimization of the disposable sets to
show compatibility with conventional US and EU RBC.
Aims: The purpose of this study was to demonstrate the quality of stored PI RBC using
the optimized disposable set design.
Methods: One day post donation whole blood (450 ml), stored overnight at 4C, was
leukocyte-depleted (LD) and separated into platelet poor plasma and RBC. The RBC
concentrate was suspended in SAGM; ABO matched pairs of SAGM RBC were
combined and split into units of 247–312 ml (N = 6). For each replicate, Control units
(C) were handled as conventional RBC, stored at 4C, and Test units (T) were treated
with the S-303 PI system. The S-303 PI process involved combining a proprietary
diluent solution containing GSH with RBC followed by S-303 (final concentrations:
20 mM GSH and 0.2 mM S-303). After an 18 h room temperature hold, RBC were
centrifuged and the treatment solution replaced with SAGM. RBC were stored at 4C
for 35 days and sampled throughout storage for parameters in Table 1. On days 35–
36, parameters in Table 2 were measured on aliquots of T and C which had been
rejuvenated (using a pyruvate, inosine, phosphate, adenine solution), washed in
saline, and resuspended in SAGM. Satistical significance was assessed by repeated
measures ANOVA as differences between T and C (P-value < 0.05) throughout stor-
age.
Results: After PI, T units had 52.2 ± 2.1 g of Hb; 1.7 ± 1.5% of Hb was lost during
PI processing. The S-303 PI process reduced extracellular protein 20-fold in T
(37 ± 10 mg/dl) compared to C (743 ± 123 mg/dl). After 35 days of storage ATP,
K+, Na+, MCHC and MCV were not different between T and C. Hct was signifi-
cantly lower in C, whereas hemolysis was marginally higher in C. T units had lower
pH, glucose, lactate than C. On Day 2, post PI, 2,3 DPG was significantly higher in
C (11.16 ± 1.49 lmol/g Hb) vs T (1.09 ± 0.66 lmol/g Hb). Evaluation of rejuvenated
T and C cells, a method used to model clinical transfusion, showed that T and C
cells were able to generate 2,3 DPG and ATP and had equivalent p50 values
(Table 2).
Table 1: Day 35 RBC in vitro function (mean ± SD, n = 6)
Table 2: Post rejuvenation in vitro RBC function on day 35–36 (mean ± SD, n = 6)
Conclusions: There was minimal loss in hemoglobin due to processing. After S-303
PI units had >40 g of Hb and Hct within 50–70%; hemolysis was <0.8% after 35 days
of storage. S-303 PI RBC met current EU and AABB guidelines for LD RBC with
respect to Hct, Hb, and hemolysis. Rejuvenation of RBC after 35 days of storage
resulted in measurable 2,3-DPG and similar p50 values between Test and Control RBC.
All measured in vitro parameters of S-303 treated RBC indicate suitability for
transfusion.
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TREATMENT OF PLATELET PRODUCTS WITH RIBOFLAVIN AND
UV LIGHT: EFFECTIVENESS AGAINST CLINICALLY
SIGNIFICANT BACTERIAL CONTAMINATION
Keil SD, Gilmour D, Goodrich RP, Hovenga N, Miklauz M
CaridianBCT Biotechnologies, Lakewood, United States of America
Background: Bacterial contamination of platelet products has been identified as a
significant risk associated with the transfusion of blood components. The storage of
platelet products at 22C provides a media and storage conditions that can sustain
bacterial growth. Thus, even though the contamination levels of bacteria are believed
to be extremely low, bacteria can proliferate to high titers prior to transfusion resulting
in complications including morbidity and mortality.
Aims: The goal of this study was to evaluate the Mirasol PRT System at preventing
bacterial growth in platelet products treated it either plasma or platelet additive
solution (PAS).
Methods: A panel of organisms identified in prior hemovigilance programs was se-
lected for evaluation in this study and included the following species: S. epidermidis, S.
aureus, P. acnes, S. mitis, S. agalactiae, S. pyogenes, S. marcescens, A. baumannii,
Y. enterocolitica, B. cereus (spore forming agent), E. coli, E. cloacae and K. pneumo-
niae. This included several different strains of the same organism, providing a total of
22 strains of bacteria in the study. A priority was placed on selecting bacterial strains
that had been isolated from blood. Units of both platelets stored in plasma and platelets
stored in PAS were spiked with clinically relevant bacteria loads of 5–100 CFU/
product. All products were allowed to rest for 2-h on a platelet incubator shaker at
22C prior to treatment. On day 7 post treatment, the Mirasol treated units were
sampled and screened for bacteria growth by BacT/ALERT. Positive and negative
growth controls were also included to ensure the reliability of the results.
Results: When platelet units suspended in plasma were inoculated with an initial bac-
terial load of 20–100 CFU per product and treated the Mirasol PRT process was 91%
effective at preventing bacterial growth at day 7 of storage. At lower titers (<20 CFU per
product), the effectiveness of theMirasol PRT process in the presence of plasma increased
to 98% on day 7 of storage. When platelet units treated in the presence of PAS were
challenged with an initial bacterial load of 20–100 CFU per product the Mirasol PRT
process was 98% effective at preventing bacterial growth at day 7 of storage.
 2011 The Authors
Vox Sanguinis  2011 International Society of Blood Transfusion Vox Sanguinis (2011) 101 (Suppl. 2), 39–134
78 Posters
Conclusion: Overall, when weighted for frequency of occurrence of bacterial con-
tamination reported in hemovigilence, Mirasol-treated platelets were 91–98% effective
in maintaining units negative for bacterial growth when tested against a list of bacteria
of interest. The Mirasol PRT System results presented compare favorably to bacterial
screening. Published performance suggests that bacterial screening is only around 50%
effective at detecting the presence of bacteria in a contaminated platelet product.
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PHOTOCHEMICAL INACTIVATION OF SELECT
ENVELOPED VIRUSES USING THE MIRASOL PRT SYSTEM
FOR PLASMA, PLATELETS IN PLASMA AND PLATELETS
IN PAS
Keil SD, Hovenga N, Miklauz M, Marschner S, Goodrich RP
CaridianBCT Biotechnologies, Lakewood, United States of America
Background: Viruses are categorized into two major groups, enveloped and non-
enveloped viruses. Enveloped viruses, in addition to their viral protein capsid, are
surrounded by a lipid envelope. This lipid envelope makes enveloped viruses suscep-
tible to solvent detergents and other pathogen reduction technologies that can dissolve
or modify this envelope. However, since red blood cells and platelets also contain a
lipid envelope these types of blood products cannot be treated by detergent based
reduction technologies.
The Mirasol pathogen reduction technology (PRT) inactivates a wide range of bacteria,
viruses and parasites using the naturally occurring vitamin B2 (riboflavin) and light.
The process works through direct modification of the genomic material, thus its mode
of action is independent of the presence of a lipid envelope.
Aims: The goal of this study was to test the effectiveness of the Mirasol PRT process
against the following enveloped viruses: Vesicular Stomatitis virus (VSV), Hepatitis B
virus (HBV), Murine Cytomegalovirus (MCMV), Human Immunodeficiency virus (HIV),
West Nile Virus (WNV), Sindbis (SINV), Influenza A (FLUAV), and Pseudorabies virus
(PRV). WNV and SINV are model viruses resembling Hepatitis C.
Mehods: Standard blood bank units of plasma and platelets, suspended in both plasma
and PAS, were used to test the effectiveness of the Mirasol PRT System against a wide
range of enveloped viruses. All viruses except for HBV were evaluated at third party
laboratories. Nominal sized platelet and/or plasma units were used to test VSV, HIV,
WNV, SINV, FLUAV and PRV. These viruses were tested using standard infectious dose
assays, which included both plaque and TCID50 assay types.
HBV was tested in a scaled down treatment bag designed for treatment of smaller
volume products. The virus was measured using classic PCR technique looking for the
presence of a 3.1 kb PCR product both pre-treatment and post-treatment.
MCMV was also tested in a scaled down system, which utilized a 48-well culture plate
as the illumination vessel. The small treatment volumes were necessary because the
pre-treatment and post-treatment samples were tested for their ability to transmit
MCMV in an in vivo mouse model. Both cell free MCMV and MCMV infected white
blood cells (WBCs) were evaluated in this study.
Results: The observed reductions for VSV, HIV, WNV, SINV, FLUAV and PRV are
as follows: ‡6.3, 5.9, ‡5.1, 3.2, ‡5.0 and 2.5 log/ml. The reduction observed using
the classical PCR method for HBV was 4.0 log gEq/ml with an assay detection
limit of 2.5 log gEq/ml. In the in vivo murine model, mice were challenged with
either 6.0 log CFU of cell-free MCMV or 6.0 log of infected murine WBC’s. In
both cases the Mirasol PRT treatment prevented transmission of MCMV after
transfusion.
Conclusion: The Mirasol PRT System is effective at reducing the viral loads of VSV,
HBV, HIV, WNV, SINV, FLUAV and PRV. Additionally the Mirasol PRT system was able
to prevent MCMV transmission of both cell-free MCMV and MCMV infected WBCs.
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PHOTOCHEMICAL INACTIVATION OF SELECT PARASITES
USING THE MIRASOL PRT SYSTEM FOR PLASMA AND
PLATELETS
Keil SD1, Rentas F2, Reddy HL1, Doane S1, Marschner S1, Goodrich RP1
1CaridianBCT Biotechnologies, Lakewood, United States of America 2Armed Services
Blood Program Office, Falls Church, United States of America
Background: For many years the spotlight in blood safety has been focused on pre-
venting virus transmission via tainted blood products through the development of
immunological and nucleic acid based assays. To a lesser degree, a secondary focus has
been on the prevention of transfusion transmitted bacteria, primarily through the
introduction of bacterial screening of platelet products. Parasitic infections which may
be transmitted by blood represent yet another threat to blood supply safety and quality.
The threat posed by parasitic infections arises primarily due to the presence of parasitic
vectors which exist in broad geographical regions. These regions are expanding due to
both vector migration and the migration of human populations, thus promoting the
spread of disease transmission. A rise in the presence of these agents in the general
population translates to increased potential of parasitic disease transmission via blood.
Unfortunately many of the techniques employed to screen out units containing viruses,
such as nucleic acid testing (NAT) and conventional serology, are not highly effective
for the detection of parasites. This is because many parasites have prolonged periods
where they are below the level of detection for these assay methods or reside inside
host cells where they may escape detection by these approaches.
Aims: The effectiveness of the Mirasol PRT System for platelets and plasma was
evaluated for reduction of the following parasites: Plasmodium falciparum (malaria),
Orientia tsutsugamushi (scrub typhus), Leishmania donovani (leishmaniasis), Babesia
microti (babesiosis), and Trypanosoma cruzi (Chagas’ disease).
Methods: Standard blood bank units of plasma and platelets in plasma were used to
test the effectiveness of the Mirasol PRT System against a wide range of parasites. All
parasites were evaluated at third party laboratories (American Red Cross Holland Labs,
Walter Reed Army Institute of Research, and the US Centers for Disease Control).
Units of plasma and platelets were inoculated with high concentrations of infectious
parasite. An initial pre-treatment sample and a sample after the Mirasol PRT process
were collected. The P. falciparum samples were evaluated using a thin film microscopic
technique to look for viable parasites in RBCs. The parasites O. tsutsugamushi and B.
microti were evaluated using in vivo animal models, mouse and hamster respectively.
Finally, both L. donovani, and T. cruzi were evaluated using microscopy in cultured
samples to look for viable organisms pre- and post-treatment.
Results: The observed reductions for P. falciparum, O. tsutsugamushi, L. donovani, B.
microti, and T. cruzi were as follows: ‡3.2, ‡5.0, ‡4.0, ‡4.0 and ‡5.0 log/ml. In all
cases, parasites were reduced to the limits of detection of the assay and no infectivity
was observed in animal models.
Conclusion: The Mirasol PRT System for both plasma and platelets is effective at
significantly reducing the parasitic loads of P. falciparum, O. tsutsugamushi,
L. donovani, B. microti, and T. cruzi. The broad reduction of parasites using the Mirasol
PRT System for platelets and plasma could provide an effective method for the
prevention of transfusion transmitted parasitic infections.
Table 1: Parasite reduction
3.5 Biologicals
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THE INCIDENCE OF HEMOLYSIS AND TEMPERATURE CHANGES
DURING LONG DISTANCE BLOOD TRANSPORT IN EASTERN
TAIWAN
Wang YL, Yu CM, Jiang YH
Hualien Blood Center, TBSF, Hualien, Taiwan
Background: Temperature control and maintaining blood quality during long distance
transport are major problems in blood center, these include packaging methods, per-
sonnel deployment, blood products allocation and storing facilities. This study is to set
a local standard on the different types of packaging using different transport con-
tainers by monitoring temperature changes during shipment.
Aims: After blood collection and without prior refrigeration, our goal is to gradually
lower blood products temperature, no lower than 1C during transport, to conform with
the AABB requirement of maintaining blood products temperature (except Platelet
products) during transport at 1)10C. To ensure the quality of blood products, detection
of red cell hemolysis was determined by checking hemoglobin levels in plasma.
Methods: Using three different types and sizes of transport containers: MG
(34 · 26 · 34 cm), LP (57 · 37 · 33 cm), LR (61 · 36 · 36 cm) with different amount
of ice packs, blood products were packed accordingly and temperature were monitored
during the entire period of transportation using Data-Logger. Hired temperature-
controlled transport vehicle were used for blood products shipment. Blood products were
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tested for hemolysis before and after shipment to determined significant level of hemo-
lysis according to the standard of the Council of Europe which should be below 0.8%.
Formula on Computed hemolysis: Hemolysis % = Plasma Hb (g/dl) · (1-Hct)/Total Hb
(g/dl) · 100%
Results: Shipment of blood was on the same day of blood collection with or without
prior refrigeration. Temperature recording showed that MG container showed an
average of 10.6C on arrival to the Blood Center which is the best achievement com-
pared to the other two containers with an average of 15–17C. Probable reason is that
there are more free spaces on the two other containers that can’t be filled-up with ice-
pack. Paired t test showed no significant hemolysis of red cell using the three different
containers and packing methods. Results of hemolysis were all below 0.8%.
Conclusion: This study proved our hypothesis that with proper packaging and using
temperature-controlled vehicle for shipment of blood, red cell hemolysis wasn’t in-
creased during long hour shipment. There was gradual lowering of the temperature
curve and the lowest temperature didn’t exceed the recommended lowest temperature
of 1C. Future studies could be designed to study the effect of long hour shipment on
the various chemical properties of the blood cells.
3.6 Novel Blood Products
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RECOMBINANT SOLUBLE THROMBOMODULIN IN SEPTIC
DISSEMINATED INTRAVASCULAR COAGULATION
Sugimoto M, Nishio K, Yada N, Asai H, Seki T, Fukushima H, Urizono Y, Hata M,
Okuchi K
Nara Medical University, Kashihara, Nara, Japan
Background: Disseminated intravascular coagulation (DIC) is a serious complication
in patients with sepsis which is resistant to antithrombotic therapy and occasionally
fatal.
Aims: We have evaluated the therapeutic effects of recombinant soluble thrombo-
modulin (rTM) recently developed for patients with septic DIC.
Methods: The patients with sepsis who met the Japanese diagnostic criteria for acute
DIC and showed a level of antithrombin (AT) lower than 70% were recruited and
divided into two groups, one group (Control group) treated with AT products and
Gabexate mesilate (GM), and the other group (TM group) treated with rTM in addition
to AT and GM. The differences between TM and Control groups were investigated to see
the effect of rTM on the clinical course through DIC scoring, and haemostatic and
inflammatory markers on days 0, 3, 5, 7.
Results: Twelve patients were included in the TM group, and 16 patients in the Control
group. There were no differences in the APACHEII score, DIC score, or mortality be-
tween the groups. The effects of the rTM were as follows; (i) Patients in the TM group
showed earlier DIC resolution at day 5 than Control at day 7. (ii) Hypercoagulability
state expressed by the increased levels of soluble fibrin monomer (SF) or thrombin-
antithrombin complex (TAT) was improved more quickly in TM group compared with
Control group. Because the levels of SF at day 3 and 7 in TM group were lower than
those in Control group, rTM may suppress thrombin production. (iii) AT was increased
much more at day 3 after AT product administration in TM group than in Control
group, which also can be explained by suppression of thrombin production by rTM. (iv)
Increased levels of the complex of a2 PI/plasmin, D-dimer, and fibrin/fibrinogen
degradation product were also improved earlier in TM group than Control group. (v)
TNF-a, IL-6, HMGB1 were decreased significantly at day 3 compared with day 1 in TM
group. These anti-inflammatory effect can also be evoked through decreased thrombin
production by rTM, because thrombin is a strong pro-inflammatory molecule.
Summary/conclusion: rTM may be beneficial in improving septic DIC via its anti-
thrombotic and anti-inflammatory properties.
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THE EFFECTS OF FREEZING-THAWING ACTIVATED PLATELET
RICH PLASMAS (PRP) ON THE PROLIFERATIONS OF
STAPHYLOCOCCUS AUREUS AND PSEUDOMONAS
AERUGINOSA USING DISC DIFFUSION METHOD
Lim YA1, Baik SY2, Lee WG1, Um TH3
1Department of Laboratory Medicine, Ajou University School of Medicine, Suwon,
South-Korea 2Green Cross Reference Laboratory, Yongin, Korea 3Department of
Laboratory Medicine, Inje University Ilsan Paik Hospital, Ilsan, Korea
Background: Fresh platelet rich plasma (PRP) gel has been reported to have anti-
bacterial properties, although its mechanism is not fully understood. The form of
gelatinous mass of PRP gel might work as a physical barrier against bacteria. However,
it has not been studied whether antibacterial ability of PRP is still present if PRP is not
in gel form. Also the effects on the antibacterial ability of freezing-thawing treatment
of PRP are not studied although the treatment is an activation method for the prepared
PRP as well as storage tool.
Aims: We investigated antibacterial effects on S. aureus and P. aeruginosa of acti-
vated PRP (APRP) and activated platelet poor plasma (APPP) by freezing-thawing
procedure and bovine thrombin treatment.
Methods: Twenty healthy volunteer donors were recruited in this study and 10 ml of
whole blood was drawn in CPDA-1 anticoagulation from each donors, PRP and PPP
were prepared by double centrifugation and the volume of PRP was adjusted to 0.5 ml.
After freezing at )70C and stored for more than one day, PRP and PPP were thawed at
37C and treated by bovine thrombin and CaCl2. Immediately after activation, they
were treated with heparin to prevent gel formation. Antibacterial effects on S. aureus
and P. aeruginosa were evaluated using disc-diffusion and direct dropping method. The
inhibited diameters were measured after incubation of 16–18 h at 37C.
Results: The mean platelet count of donor whole bloods was 142.3 ± 28.3 (·109/l) and
that of concentratedPRPwas804 ± 293%of them, representinghighplatelet yields of the
procedures. The inhibited diameters on S. aureus and P. aeruginosa using disc-diffusion
and direct dropping method were zero for all the 20 sets of PRP, PPP, APRP and APPP.
Conclusions: In our study, we could not find any antibacterial effects on S. aureus and
P. aeruginosa of PRP, PPP, APRP and APPP. This result may be due to the freezing-
thawing treatment and/or no gel form of PRP, because they might influence the
antibacterial effects of PRP. However, it is still not exclusive the methodological
insensitivity of disc diffusion method for the determination of antibacterial ability of
PRP and PRP.
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PROCESS OF HUMAN PLATELETS LOADED WITH TREHALOSE
BEFORE FREEZE-DRYING
Peng Y, Lu FQ
Affiliated Zhongshan Hospital of Dalian University, Dalian, China
Background and objective: The aim o f this research was to study the technology and
methods of loading lyoprotectant-trehalose into cytoplasm of human platelets before
lyophilization, to optimize experimental conditions of loading trehalose, to investigate
the changes of platelets response to agonists and activation after incubation of platelets
for 4 h at 37C in the presence of lyoprotectant-trehalose, to protract the figures of
loading efficiency and intracellular trehalose concentration vs incubation time, tem-
perature and external trehalose concentration, to optimize loading parameters.
Materials and methods: The response of platelets to different agonists thrombin, ADP,
collagen and ristocetin were measured respectively by APACT2 aggregometer before
and after loading trehalose into platelets; the expressions of CD62p and PAC-1 on
platelet membranes in the presence and absence of reversible platelets activation
inhibitors were measured by flow cytometry respectively before and after loading
trehalose into cytoplasm of platelets.
Results: The results showed that the loading efficiency was linear to incubation time
(2 h later) and incubation temperature (rang from 30 to 40C), respectively. The loading
efficiency almost reached 60% when the platelets were incubated at 37C for 4 h. The
intracellular trehalose concentration was higher with the increase of the extracellular
trehalose concentration (<50 mM). Compared to untreated groups, the values of MPV
and aggregation to different agonists in treated groups showed no significant differ-
ence, respectively (P > 0. 01). After incubation of platelets for 4 h, the expression o f
CD62p increased to some exten, thowever, the expression of CD62p decreased again
when the reversible platelets activation inhibitor PGE-1 and adenosine were added to
the incubation buffer.
Conclusion: It is concluded that 37C, 4 h and the extracellular trehalose concentra-
tion <50 mM are the optimal conditions for loading with trehalose. The processing of
loading with trehalose before platelet lyophilization has no significant effects on re-
sponse of platelets to agonists and activation.
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4. Transfusion Transmitted
Infections
4.1 Screen Strategies for TTI
P-150
This abstract has been withdrawn.
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SURVEY OF THE SERO PREVALENCE OF HUMAN
T-LYMPHOTROPIC VIRUS I/II IN HEMODIALYSIS PATIENTS
IN HEMODIALYSIS CENTERS IN SUEZ CANAL AREA
Ibrahim A1, Rushdy P2, Wissa N3, Sayed A3
1Regeonal Blood Transfusion Centre, Cairo, Egypt 2National Blood Transfusion Centre,
Cairo, Egypt 3Suez Canal Univercity, Ismailia, Egypt
Background: Human T-lymphotropic viruses, or human T-cell leukemia viruses I and
II (HTLV-I and II) are two closely related blood borne viruses of retroviridae family,
considered to be the causative agent of adult T-cell leukemia and a tropical spastic
paraparesis. Transfusion of blood components is one of the modes of viruses trans-
missions.
Aim of the work: Blood donors screening is performed in countries with high
prevalence of HTLV-I/II and also in some European countries. As little research has
been conducted in Egypt regarding the prevalence of the HTLV-I/II antibodies in
blood donors, hemodialysis patients and in at-risk groups, the aim of our study was
to determine the prevalence of anti-HTLV-I/II antibody among hemodialysis patients
in Suez Canal area, considered a high risk group for contracting blood born infec-
tions.
Methods: In the current study, we chose patients with chronic renal failure on regular
hemodialysis. Both age-matched males and females were included in the study with
mean disease duration of 4.5 years. Patients were chosen from three cities (Ismailia,
Suez and El-Areesh) representing different geographical regions. Samples were
screened by ELISA technique (Diapro HTLV-I + II). Initially reactive samples were
shipped under standard preservation procedures to SRL Company in Tokyo, Japan to be
rechecked using Western Blot technique (PROBLOT HTLV-I).
Results: Among 328 patients, four patients’ sera were initially reactive with ELISA
(Diapro-Italy) where microplates were coated with HTLV I/II-specific peptides (gp46-I,
gp46-II and p21-I). The prevalence was 1.2% with no statistically significant differ-
ences between positive and negative HTLV I/II patients regarding age, sex and disease
duration. Confirmation of the results was done in Tokyo, Japan by Western Blot for
HTLV-I (PROBLOT HTLV-I), where nitrocellulose strips contain proteins p19, p24, p53
and gp46. Only one sample was positive for P24. The other three samples were all
negative for p19, p53, p24 and gp 46, suggesting the low prevalence of the disease in
Suez Canal area.
Conclusion: The present study recorded only four transfusion dependent hemodialysis
patients out of 328 (1.2%) to be seropositive for HTLV-I/II antibodies and were negative
by the immunoblotting technique for HTLV-I suggesting the low prevalence of the
disease in Suez Canal area.
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STUDY OF PREVALANCE OF TRANSFUSION TRANSMISSABLE
INFECTION AMOUNG DONOR POPULATION IN SOUTHERN
REGION OF SRI LANKA
Vithanage A
Sothern Regional Blood Centre, Matara, Sri Lanka
Background: TTI has become a major challenge in safe blood transfusion. More
and more new techniques have been introduced to overcome this problem globally
such as Nucleic acid testing and pathogen inactivation. But all of them give and
additional cost to the health sector and introducing such technique should well
justified.
Southern region Blood center is the main blood collecting institute in southern region
of Sri Lanka handles around 17,000 volunteer donors annually. Currently in Sri Lanka
each donor pack is tested for HIV1 and 2, HBV, HBV, Syphilis and Malaria.
Aim: When compared with other countries in the region, Sri Lanka used to have a very
low prevalence of TTI especially HIV. So in this study I have tried to analyze the
prevalence of TTI in past 3 years, which will help in deciding the need of an expensive
pathogen identification technique.
Method: The date was collected from total voluntary and replacement donors from
2008 to 2010. The screening tests were done at Regional center and the confirmatory
tests at National Blood center. Screening methods for HBV and HIV were Enzyme-
linked immunosorbent assay (ELISA), for Syphilis Carbon antigen. Confirmatory
testing method for HIV was Western Blot, for HBV was ELISA and for Syphilis was
Treponema Pallidum Particle Agglutination.
Results: The prevalence (per 1000 donations) of each disease is as follows.
Table 1
Conclusion: During past 3 years the prevalence of HBV and Syphilis gradually in-
creased but the prevalence of HIV remains static and also at very low level. So the
Southern part of Sri Lanka is still a low prevalence area for HIV.
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EFFECTIVENESS OF TRANSFUSION TRANSMITTED INFECTION
(TTI) SCREENING TESTS OF DONOR BLOOD IN SRI LANKA
Dodampegamage CD1, Dodampegamage CHW2
1National STD AIDS Control Programme of Sri Lanka, Makola, Sri Lanka 2National
Blood Centre of Sri Lanka, Makola, Sri Lanka
Background: National Blood Transfusion Service is the sole provider of blood and
blood components to the state sector and nearly all private sector health institutions
in Sri Lanka. It consists of the National Blood Centre (NBC) which is the central
body, 16 cluster centers and 67 hospital based blood banks. TTI screening is
exclusively done at NBC and cluster centers by specially trained technical staff.
Currently all donated blood is tested for HIV, Hepatitis B, Hepatitis C, syphilis and
malaria. HIV, HBV, HCV screening are done in duplicate using Enzyme Immuno-
assay (EIA), Enhanced Chemiluminescence Immunoassay (ECI), particle agglutination
and rapid methods in cluster centers while, NBC uses only ECI and EIA. Positive
samples from cluster centers are sent to NBC for repeat testing after discarding the
positive packs. At NBC all the screening positives samples are tested with a different
method and only repeat reactive blood is discarded. Though other TTIs are con-
firmed Hepatitis C confirmation cannot be done due to unavailability of HBC PCR.
Syphilis is screened with VDRL and confirmed by TPPA and only confirmed positive
samples are discarded. By 2012 TTI screening is expected to be upgraded with NAT
testing.
Aim: To assess the effectiveness of Hepatitis B, C and HIV screening test methods of
Donor blood in Sri Lanka.
Method: Retrospective study was done at NBC using TTI screening records from March
to August 2010 and analyzed 1883 screening positive samples of HIV, HBV, HCV and
Syphilis from NBC and all other cluster centers.
Results: For HIV screening, cluster centers have used EIA, ECI, rapid and particle
agglutination tests 70.24%, 24.47%, 4.73%, 0.56% respectively. Out of them 98.04% of
ECI, 70.64% of EIA, 16.66% of rapid and 0% of particle agglutination positives were
repeat reactive.
In NBC 88.89% of HIV testing done with EIA and 11.11% with ECI. One hundred per
cent ECI and 46.97% EIA positives were repeat reactive.
In cluster centers 23.61%, 74.07%, 1.39%%, 0.93% of HCV testing were done with EIA,
ECI, rapid and particle agglutination respectively. From that 95% of ECI, 66.67% of EIA
and 0% of rapid and particle agglutination positives were repeat reactive.
In NBC 63.42% of HCV testing done with EIA and 36.58% with ECI. 97.25% ECI and
51.32% EIA positives were repeat reactive.
For HBV screening cluster centers have used EIA, ECI, and rapid tests 17.57%, 79.73%,
2.7% respectively. Out of them 71.19% of ECI, 46.15% of EIA and 100% of rapid test
positives were repeat reactive.
In NBC EIA and ECI were used for HBV testing 76.96% and 23.04% of the time
respectively.92% of ECI and 43.11% of EIA positives were repeat reactive.
Conclusions: NBC uses EIA and cluster centers use ECI for screening most frequently.
Positive predictive value of ECI method is higher than that of other screening methods.
Considering the blood and blood product discard, repeat testing and work load ECI is
an effective method of screening TTIs compared to other tests.
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STRATEGY OF VIRUS NUCLEIC ACID AMPLIFICATION TEST
(NAT) FOR DONOR SCREENINGS OF PLATELETAPHERESIS
POPULATION
Xiong W
Shen-Zhen Blood Centre, Shenzhen, China
Background: In order to ensure blood safety, we extended our NAT screening assay to
include plateletapheresis donors (PDs). A retrospective analysis showed that 3726 PDs
had given a total of 13,838 platelet concentrates (PC) (2010.03–2011.07). Based on
China’s State criteria, a single donation interval for whole blood donors (BDs) is every
3 months and for PDs is 15 day, but limited to 12 PC donations in a year. In practice, our
blood screening strategy is: if ELISA is (+), the donated blood is discarded and the donor
is ineligible to donate for life. If the results are ELISA())/NAT reactive, the blood is
discarded, and the donor is still eligible to donate. And if the results are ELISA())/NAT()),
blood components qualify to be distributed to clinics. Because BDs and PDs have
different donation frequencies, we need to develop a new strategy for PC donations.
Method: Our screening tests involved parallel ELISA assays using kits from two dif-
ferent manufacturers against HIV, HCV and HBV. In addition, an individual detection
(ID) NAT assay was implemented using ULTRIO reagents in the TIGRIS system. If the
results are ELISA())/NAT reactive, confirmatory tests are performed for HIV, HCV and
HBV detection respectively.
Results: The reactive rate of NAT screenings was 0.91% (34/3726). Three donors with
ELISA(+)/NAT reactive results were ineligible to donate for life. Thirty-one donors with
ELISA())/NAT reactive results had confirmatory tests. Seven of those 31 donors were
determined to be HBV DNA infected. The positive rate of confirmatory testing was
0.188% (7/3726). According to our present donor strategy, donors who are ELISA())/
NAT reactive are eligible to donate PC. In follow up testing, two of the seven PDs
developed HBsAbs. This revealed that their last PC donations might be in the ELISA
window period, but failed to be detected. In addition, our retrospective data showed
that among three donors with both ELISA (+) and NAT (+), one donor successively gave
five PC donations in half a year; however the screening-test results of his previous four
donations were ELISA ()) and NAT (). As we know, the ELISA window period for
HBsAg is 59 days and NAT window period for HBV is 34 days. The donor had caused
great potential risk to four PC recipients.
Conclusion: To give consideration to both PD’s retention and blood safety, we need a
new strategy to follow up on PDs with ELISA()) and NAT reactive results. That is: To
create a follow-up program, if NAT confirmatory testing remains positive, the donor
will be ineligible to donate for life; If NAT confirmatory test is negative, the donor will
only be eligible to donate whole blood; If two whole blood donations pass the
screening tests, the donor will regain eligibility as to be a PC donor again. Additionally,
it is important that, since China has a large population infected with HBV, the sensi-
tivity for NAT reagents be further improved.
P-155
PREVENTION FROM TRANSFUSION TRANSMISSIVE DISEASES
IN THE REGIONAL CENTER FOR TRANSFUSION MEDICINE IN
STIP, REPUBLIC OF MACEDONIA FOR THE PERIOD 2009–2010
Kamcev N, Kamceva G, Velickova N, Vitlarova JV, Panov P, Ivanovska VI, Kamceva LK
Institute of Transfusion Medicine, Shtip, Macedonia
Introduction: Blood transfusion is a transplantation of fluid tissue or an introduction
of human biological material that needs to survive in the donor organism and to play
important biological functions. During the blood and blood products transfusion, it is
possible to transmit many transfusion transmissive diseases, which increases the need
of securing safe blood transfusion.
Objective: To present the procedures and measures taken in order to prevent the
transmission of transfusion transmissive diseases in the blood and blood products
donors at the Clinical Hospital in Stip.
Materials and methods: Each blood unit was mandatory tested for HBSAG, anti-
HCV, anti-HIV and Treponema pallidum antibodies at the Regional center for
transfusion medicine. The testing was done with the ELISA technique by using the
Dade Berhing BEP 200 instrument and the tests from Siemens and Ortho for anti-
HCV. The confirmation tests were done at the Institute of Transfusion Medicine in the
capital Skopje.
Results: In total, 6067 blood samples were tested. The presence of HBAGS was de-
tected in 81 sample (1.33%), anti-HCV in 19 (0.313%), anti-HIV in one (0.016%) and
Treponema pallidum antibodies in five samples (0.082%).
Discussion and conclusion: In order to achieve high level of security of the transfu-
sion blood and blood products it is essential to use highly specific and sensitive tests,
modern equipment, well trained health personnel and sufficient financial resources
allocated specifically for that aim.
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PREVALENCE OF ANTI-HIV (I & II), HBSAG, ANTI-HCV AND
SYPHILIS IN BLOOD DONORS
Makroo RN, Walia R, Chowdhry M, Bhatia A, Rosamma NL, Kumar P
Indraprastha Apollo Hospitals, New Delhi, India
Background: Transfusion of blood and blood products carries an inherent risk of
spread of Transfusion Transmissible Infections (TTI’s). Despite careful donor selection
and the development of highly specific and sensitive techniques of testing, the
achievement of 100% risk free blood still remains an elusive goal.
Aims: The present study was undertaken to analyse the seroprevalence of markers of
Transfusion Transmissible Infections viz. Human Immunodeficiency Virus (HIV),
Hepatitis B virus (HBV), Hepatitis C virus (HCV) and Syphilis among the donors who
donated whole blood at our institute.
Methods: A retrospective analysis of the TTI marker status of 1,85,266 blood donors
who donated whole blood at the department of Transfusion Medicine, Indraprastha
Apollo Hospitals, New Delhi from 1st of January 2001 to 31st of December 2010, was
undertaken. All the donors were carefully selected to exclude paid commercial donors
and those with a history of high risk behavior. As is mandatory under the guidelines
laid down by the Drugs and Cosmetic Act, the donor samples were examined for
various infectious markers i.e. anti-HIV (I & II), Hepatitis B surface antigen (HBsAg)
and anti-HCV by Enzyme Linked Immuno-sorbent Assay (ELISA) test. Screening for
syphilis was done by employing the Rapid Plasma Reagin (RPR) test. All the donor
samples that were found positive by ELISA on initial testing, were repeat tested in
duplicate with the same sample. Samples that were found to be repeat reactive were
considered positive.
Results: Among the 1,85,266 blood donors, the total number of seroreactive cases
was 3987 (2.15%). The number of cases found seroreactive for markers of HIV,
HBV, HCV and Syphilis was 451 (0.24%), 2361 (1.27%), 703 (0.38%) and 472
(0.27%) respectively. Out of the total blood donors, 1,74,150 (94%) were males and
11,116 (6%) were females. The seroprevalence of markers of HIV, HBV, HCV and
Syphilis in male blood donors was 0.25%, 1.32%, 0.38% and 0.27%. The respective
seroprevalence in female blood donors was calculated to be 0.12%, 0.52%, 0.36%
and 0.04%.
Conclusions: Among these blood donors, the highest seroprevalence was found to be
for HBsAg followed by markers for HCV, syphilis and HIV respectively. The same order
of seroprevalence holds true for the male blood donors. However, the rest of the order
remaining similar, the seroprevalence of markers for HIV is more than that for syphilis
in the female blood donors. Because of the high prevalence of TTIs among the blood
donors, our analysis emphasizes the importance of introduction and use of improved
testing techniques like Nucleic Acid Testing (NAT) in conjunction with the existing
testing methods to further reduce the ‘window period’ and enhance the safety of blood
supply.
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HEPATITIS B CORE ANTIBODY TESTING IN INDIAN BLOOD
DONORS: A DOUBLE EDGED SWORD!
Makroo RN, Chowdhry M, Bhatia A, Arora B, Rosamma NL
Indraprastha Apollo Hospitals, New Delhi, India
Introduction: Until lately anti-HBc antibodies were considered an effective marker for
occult HBV infection and have served their role in improving blood safety. But with the
development of advanced tests for HBV DNA detection the role of anti-HBc in this
regard stands uncertain.
Aims: This study aims at determing the current role of anti HBc antibody testing in
donor screening.
Material and methods: Anti-HBc and HBsAg ELISA and ID-NAT tests were run in
parallel on donor blood samples between 1st April 2006 and 31st December 2010 at the
Department of Transfusion Medicine, Indraprastha Apollo Hospitals, New Delhi. A
positive ELISA test was repeated in duplicate, and only repeat reactive samples were
considered as ‘Positive’. A positive ID-NAT was also repeat tested and a repeat positive
ID_NAT was followed by Discriminatory NAT assay to identify HBV, HCV and HIV.
Results: A total of 94,247 samples were tested. The total core positivity rate (IgG +
IgM) observed at our centre was 10.22% (9638/94,247), while 1.2% (1134/94,247) of
donors were positive for HBsAg. Of the 8660 donors reactive by anti-HBc ELISA but
negative for HBsAg, only 0.15% (13/8660) showed the presence of HBV DNA by
discriminatory assay, while the remaining 99.85% (8647/8660), were HBV DNA neg-
ative. These constitute 9.17% (8647/94,247) of the total donor population. These are
the donors who are potentially non-infectious and may be returned to the donor pool.
Conclusion: Addition of anti-HBc to blood donor screening along with HBsAg im-
proves blood safety, however, leads to attrition of donors, especially in India which lies
in the intermediate zone of hepatitis B endemicity. The best alternative for improving
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blood safety in our country is to add NAT testing to donated blood. It will identify most
potentially infectious units of blood including window period donations and sero-
negative infections. Therefore, the applicability of anti HBc testing in routine screening
of donated blood is doubtful.
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ESTIMATION OF INCIDENCE AND RESIDUAL RISK OF
TRANSFUSION TRANSMITTED INFECTION FOR HIV, HCV AND
HBV IN HONG KONG: 2007–2009
Tsoi WC, Lee CK, Lin CK
Hong Kong Red Cross Blood Transfusion Service, Hong Kong, China
Background: Incidence rates and residual risks of transfusion transmitted infections
(TTI) are important parameters in the understanding of the current blood safety status
and the effectiveness of blood safety related measurements implemented.
Aims: Use mathematical model to estimate the incidence rates and the residual risks of
transfusion transmitted HIV, HCV and HBV infections in Hong Kong during 2007–
2009.
Methods: During April 2007 to September 2009, all donations to the Hong Kong Red
Cross Blood Transfusion Services were tested for anti-HIV-1/2 (replaced by HIV-
combo in 2008), anti-HCV and HBsAg using PRISM ChLIA (Abbott, Abbott Park, IL,
USA). Repeatedly reactive samples were confirmed by blotting tests and HBsAg
neutralization assay respectively. All donations were also screened by Nucleic Acid
Testing on individual donor samples (ID-NAT) using HIV-1/HCV/HBV triplex PRO-
CLEIX ULTRIO Assay on automated Tigris platform (Novartis, Emeryville, CA, USA).
Reactive samples were retested with discriminatory assays to determine the viral
specific reactivity. Discriminatory NAT reactive samples were confirmed by alter-
native molecular procedures. For estimation of incidence rates, seroconversion and
NAT yield among repeat donor population were used. For HBV, HBsAg serocon-
version and NAT yield among repeat donor population were adjusted for its in vivo
transient nature (multiplied by a factor of 1.2) (Weusten J et al. Transfusion 2011;
51:203–215). The incidence rate among first time donors was assumed to be twice
the rate of repeat donors. Approximately 82.10% of collections were from repeat
donors. The estimated incidence was weighted for the proportion of first-time and
repeat donors. Residual risk for each virus was estimated using the model of Residual
Risk = Incidence Rate · Window Period (in year). Reported window periods (in days)
were applied: HIV-1: 5.5 (3.5–7.9); HCV: 4.9 (4.0–5.8); HBV: 20.6 (12.0–28.0).
Results: Based upon our data and calculation, the estimated incidence rates (per
100,000 person-year) for all donations were: 2.79 for HIV, 0.93 for HCV, and 30.73 for
HBV; while the estimated residual risks per donation were: 1 in 2.38 million for HIV, 1
in 8.00 million for HCV and 1 in 58,000 for HBV. The actual risk for transfusion
transmitted HBV could be higher since cases of occult hepatitis B infection (OBI) were
not addressed in the mathematical model. During the study period, 101 cases of OBI
were detected (1 in 5120 donations); 12 in first-time donors and 89 in repeat donors.
Conclusions: In comparison with the estimated residual risks of TTI in 2006–07, the
current residual risks were substantially lower on account of the decreasing incidence
of HIV and HBV observed in the donor population. Besides, shortening of the infectious
window period of each virus after implementation of routine ID-NAT has translated
into protection of blood safety and reflected in the lessening residual risks; in par-
ticular for HBV where OBI cases were also detected. With better understanding of the
dynamics of HBV viraemia, the adjustment factor for the transient nature of HBV
markers when assayed by ID-NAT during acute HBV infection, recently proposed
Weusten and co-workers, was applied in this study and this has contributed to the
lower estimated residual risk.
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THE COBAS TAQSCREEN MPX TEST, VERSION 2.0 – EN-
HANCED MULTIPLEX BLOOD SCREENING PERFORMANCE ON
THE COBAS S 201 SYSTEM
Malhotra K, Dyer N, Lamont J, Nannen K, Jackson T, Talapatra A, Wallace S,
Harkleroad C, Kung K, Wang A, Lowe S, Quereshi F, Lee K, Takeuchi M, Dugenny S,
Brown K, Newton N, Sudershana S, Niemiec J
Roche Molecular Systems, Inc., Pleasanton, CA, United States of America
Background: The CE Marked cobas TaqScreen MPX Test, version 2.0 (MPX Test,
v2.0) offers automated, real-time PCR viral discrimination of HIV, HBV and HCV with
high sensitivity and specificity in a qualitative blood screening test. This test utilizes
the fully automated cobas s 201 system. The MPX Test, v2.0 has important changes
relative to the CE-IVD and FDA licensed cobas TaqScreen MPX Test, and improves
blood screening laboratory workflow. The system collects data from target-specific
fluorescent probes at four independent wavelengths instead of 2, allowing identifi-
cation of viruses during primary screening, thereby eliminating the need to perform
separate viral target discriminatory tests. Extraction and PCR throughput are increased
10% with a new multiplexed HIV-1 Group M, HBV and HCV control. Target primer and
probe sequences and reaction chemistry have been modified to improve overall in-
clusivity.
Aims: Develop and verify performance characteristics of a new multiplex assay to
simultaneously detect and identify HIV, HBV and HCV for blood screening, and im-
prove laboratory efficiency by eliminating the additional testing required for viral
identification.
Methods: Automated, generic nucleic acid extraction was used for isolation of viral
DNA and RNA which were amplified and detected by automated, real-time, TaqMan
PCR. Analytical sensitivity was determined using WHO International Standards of HIV-
1 Group M, HBV HCV, and HIV-2. Standard traceable to the CBER Panel was used for
HIV-1 Group O. Clinical specificity was assessed by testing 500 individual seronegative
specimens from healthy donors. Archived donor specimens (200 for each of HIV-1,
HBV and HCV) were tested to determine clinical sensitivity.
Results: The 95% limits of detection by Probit analysis were 46, 2.3, 6.8, 8 IU/ml, and
18 copies/ml for HIV-1 Group M, HBV, HCV, HIV-2, and HIV-1 Group O respectively.
Preliminary clinical specificity was 99.8%. No interference was observed in samples
with albumin (96 g/l), bilirubin (500 mg/l), hemoglobin (5 g/l), triglycerides (33 g/l),
human DNA (4 mg/l) and exogenous medications. Red blood cell contamination up to
2.5% did not interfere with the MPX Test, v2.0. For seropositive specimens, reactivity
rates were 98.5%, 100% and 97% for HIV, HBV and HCV respectively. Equivalent
sensitivity was observed in EDTA plasma and serum. The MPX Test, v2.0 on neat
samples detected HIV-1 Group M, HCV and HBV prior to State of Art serology by an
average of 14, 28 and 22 days respectively.
Conclusions: The MPX Test, v2.0 enables automated, high sensitivity screening of
blood donations, and provides real-time viral discrimination.
E-mail: Khushbeer.Malhotra@Roche.com
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EVALUATION OF THE ROCHE COBAS TAQSCREEN MPX
TEST V 2.0
Lin KT1, Tsai MH1, Wang YF1, Hung CM1, Lin KS2
1Kaohsiung Blood Center, Kaohsiung, Taiwan 2Taiwan Blood Services Foundation,
Taipei, Taiwan
Background: The Roche cobas TaqScreen MPX test, version 2.0 (MPX v2.0) is a
qualitative, in vitro, multiplex test for the detection of HIV-1 groups M and O RNA,
HIV-2 RNA, HCV RNA, HBV DNA in human plasma. Plasma may be screened either
individually or in pools. The test uses a generic nucleic acid preparation and the
extracted nucleic acids are amplified and detected using real-time PCR. The test runs
on the Roche automated, blood screening platform, the cobas s 201 (s 201) system.
The use of multi-dye technology to label specific probes, which are detected in specific
channels on the instrument, enables the simultaneous detection and identification of
HIV, HCV and HBV in a single test. However, the test will not discriminate between
HIV-1 group M, HIV-1 group O and HIV-2 since all these targets are detected in the
same channel.
Aims: The study was designed to determine the analytical sensitivity of the test for
HIV-1, HCV and HBV and the clinical sensitivity and specificity of the test by screening
plasma samples from blood donors. In addition, the reproducibility of the test on the s
201 instrument was evaluated.
Methods: Serial dilutions of secondary standards for HIV-1, HBV and HCV, those were
directly traceable to the WHO International Standards, were tested on three different
days (eight replicates per day). The analytical sensitivities of the test for these three
viruses were determined using Probit analysis.
Thirty-six replicates of dilutions of HBV, HCV and HIV-1 containing 30, 50 and
160 IU/ml respectively, were tested individually on four different days (8 replicates/
day) in order to evaluate the reproducibility of the test.
The clinical sensitivity and specificity of the test for the Taiwan blood donor
population were determined by screening about 6000 random, blood donors in pools of
six. Plasma samples from reactive pools were tested individually in order to identify the
contaminated donation and the viral contaminant.
Results: The 95% LOD for the test were 4.7, 4.7 and 57.4 IU/ml for HBV, HCV and HIV-
1 respectively. In the reproducibility study, all 36 replicates were detected for each
virus. For the clinical sensitivity determination, 5951 donors were screened in pools of
six and eight donors were NAT-only yield cases. All these donors were positive for
HBV. The results are summarized in Table 1 The NAT-only yield rate for this study was
0.13% (1:744).
The overall test failure rate was 1.9%. The failures were due to either instrument errors
or failed batches (due to failed batch controls). The IC failure rate for samples from
valid batches was 0.5%.
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TRUE POSITIVITY OF ANTI-HCV ELISA REACTIVE
BLOOD DONORS – A PROSPECTIVE STUDY DONE IN
WESTERN INDIA
Tulsiani S1, Choudhury N2, Desai P3, Shah R4, Mathur A5, Harimoorthy V6
1Jeevan Jyoti Blood Bank, Nagpur, India 2Tata Medical Sciences, Calcutta, India
3Tata Medical Hospital, Bombay, India 4GSACS, Ahmedabad, India 5TTK Blood Bank,
Banglore, India 6Prathma Blood Centre, Ahmedabad, India
Background: In India, most of the blood centers do test for Hepatitis C virus (HCV) by
Enzyme Linked Immunosorbent Assay (ELISA) method. A significant number of safe
donations are removed from the blood supply, because of the false reactive anti-HCV
screening test results.
Aims: (i) This study aimed to assess if the HCV seropositive donors were confirmed
positive by Nucleic Acid Testing (NAT) and Recombinant Immunoblot Assay (RIBA)
method. (ii) The study correlated the results of samples reactive by single ELISA kit vs
those by two ELISA kits with NAT and RIBA results. (iii) The study correlated sample-
to-cut-off (S/CO) ratio of ELISA results with those of NAT and RIBA. (iv) The study also
evaluated if there was any association of Alanine Amino Transferase (ALT) levels with
that of NAT and RIBA results.
Method: A total of 68,951 blood donors were screened by two anti-HCV ELISA kits
over a period of 15 months at three blood centers in Ahmedabad in Western India. A
total of 140 anti-HCV ELISA reactive samples were included in the study. These 140
samples were tested by NAT. The NAT negative samples were further tested by RIBA.
Analysis of samples reactive in only single ELISA kit vs those reactive by both ELISA
kits was done. Correlation of S/CO of the the individual ELISA kit was done with NAT
and RIBA result. Correlation of ALT levels with that of NAT and RIBA results was also
done.
Results: 1. Out of 140 anti- HCV ELISA reactive samples, a total of 16 (11.43%) were
positive by NAT. The RIBA results of 124 NAT negative samples were: 6 (4.84%)
positive, 92 (74.19%) negative and 26 (20.97%) indeterminate.
2. Out of 140 anti-HCV ELISA reactive samples, 87 samples were reactive by single
ELISA kit only. None of these were positive by NAT or RIBA. Of the 53 samples reactive
by both ELISA kits, 16 (30.19%) were NAT positive and 6 (16.22%) were RIBA positive
(of the NAT negative samples).
3. Significant number (81.1% in 1st kit and 88.73% in 2nd kit) of NAT negative
samples had S/CO ratio <3.8. Significant number (87.5% in 1st kit and 56.25% in 2nd
kit) of NAT positive samles had S/O ratio more than or equal to 3.8. Number of NAT
positive samples with ELISA S/CO ratio lying on either side of 3.8 varied for the two
kits. It was observed that for both the ELISA kits, significant number of RIBA negative
samples had S/CO ratio <3.8.
4. Significant correlation of ALT results with NAT results was also observed. For RIBA,
correlation of ALT with RIBA negative results was seen but not with RIBA positive
results.
Table 1: NAT and RIBA results of 140 ELISA Reactive sample
Table 2: NAT/ RIBA results of single vs both ELISA kits
Conclusion: Only a minority of blood donors with repeatedly reactive anti-HCV
screening test are positive by confirmatory testing, but all these blood units are dis-
carded as per existing legal provisions in India. Efforts should be made to retain these
donors and also donor units.
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DEVELOPMENT OF THE NEW COBAS TAQSCREEN MPX TEST,
VERSION 2.0 – FOR CADAVERIC DONORS IN BLOOD
SCREENING
Malhotra K, Dyer N, Harkleroad C, Jackson T, Nannen K, Lamont J, Willer C, Kubik M,
Talapatra A, Yee D, Sudershana S, Niemiec J
Roche Molecular Systems, Inc., Pleasanton, CA, United States of America
Background: The Roche cobas TaqScreen MPX Test, version 2.0 (MPX Test, v2.0) for
cadaveric donors is under development and is designed to offer automated, real-time
PCR viral discrimination of HIV, HBV and HCV with high sensitivity and specificity for
blood screening. This test utilizes the fully automated cobas s 201 system. The MPX
Test, v2.0 has important changes relative to the CE-IVD and FDA licensed cobas
TaqScreen MPX Test and improves blood screening laboratory workflow. The system
collects data from target-specific fluorescent probes at four independent wavelengths
instead of 2, allowing identification of viruses during primary screening, thereby
eliminating the need to perform separate viral target discriminatory tests. Extraction
and PCR throughput is increased 10% with a multiplexed HIV-1 Group M, HBV and
HCV control.
Aims: Develop and determine the performance characteristics of a test intended for
screening plasma and serum of potential organ and tissue donors. Determine suitability
for specimens obtained while the donor’s heart is still beating, and for blood specimens
from cadaveric donors.
Methods: Automated, generic nucleic acid extraction was used to isolate viral DNA
and RNA which were amplified and detected by automated, real-time, TaqMan
PCR. Analytical sensitivity in cadaveric specimens was assessed using Standards
traceable to WHO International Standards of HIV-1 Group M, HBV and HCV.
Standards traceable to the CBER Panels were used for HIV-1 Group O and HIV-2.
Clinical specificity was assessed by testing individual cadaveric plasma specimens.
Clinical sensitivity and reproducibility were evaluated by testing individual mod-
erately and highly hemolyzed cadaveric EDTA plasma specimens spiked with HIV,
HBV, and HCV. Each test sample was diluted 1:5 in cadaveric specimen diluent
prior to testing.
Results: The observed lowest level with ‡95% reactive rate in moderately-hemo-
lyzed cadaveric plasma were 250, 30, 60 IU/ml, 120 and 200 copies/ml for HIV-1
Group M, HBV, HCV, HIV-1 Group O, and HIV-2 respectively. Clinical specificity
for the moderately and highly hemolyzed cadaveric specimens was 100%. No
statistically significant differences were observed in the reactive rates for living and
cadaveric specimens when comparing reagent lots and instruments/operators
(P > 0.05). Analytical sensitivity was statistically equivalent in cadaveric plasma
and serum specimens (P > 0.05). For the sixty individual positive cadaveric speci-
mens tested the reactivity rates were 98% for HIV-1 Group M and 100% for HBV
and HCV.
Conclusions: The MPX Test, v2.0 enables automated, high sensitivity screening of
cadaveric donors, and provides real-time viral discrimination.
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COMPARISON OF INDIVIDUAL NUCLEIC ACID TESTING (ID-
NAT) AND ELISA FOR DETECTION OF HIV, HBV AND HCV IN
BLOOD DONORS AT TERTIARY CARE CENTRE
Doda V, Kaur D, Singh R, Bharti RR, Kirtamia T, Kumar V
Dr. Ram Manohar Lohia Hospital, New Delhi, India
Background: Implementation of nucleic acid testing in blood bank setting is a major
challenge for a developing nation like ours. Blood safety and cost effectiveness is the
prime concern in the current scenario. Looking into the increasing trend of positivity
for HIV, HBV and HCV markers, evaluation of whole blood donor testing by ID-NAT
for simultaneous detection of HIV, HBV and HCV was undertaken and compared with
serological tests for the same.
Aim: To compare ELISA with ID-NAT testing for detection of HIV, HBV and HCV
among blood donors at Dr Ram Manohar Lohia hospital for an additional level of blood
safety.
Methods: A retrospective study was conducted on 10,130 donors (57.3% voluntary
and 42.7% replacement donors) at blood bank in our hospital during the period of
July 2010 to May 2011. In addition to the routine mandatory screening tests as per
regulatory requirements which include screening for anti-HIV, HBsAg and anti-HCV,
all donor samples were subjected to INDIVIDUAL NUCLEIC ACID TESTING (ID-NAT)
for the same markers. NAT was done by Transcription Mediated Amplification (TMA)
technology using multiplex and discriminatory testing by Procleix Ultrio Assay
(Chiron Corp. Emeryville, CA, USA) for simultaneous detection of HIV, HBV and
HCV.
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Results: A total of 10,130 samples were tested both by ELISA and NAT, out of which
257 (2.53%) were seroreactive and 215 (2.12%) were NAT reactive.87 (0.85%) samples
were seroreactive but NAT nonreactive. There were 25 (0.24%) NAT reactive but se-
rononreactive (NAT yield) cases: 1 HIV, 1 HCV and 23 HBV. The NAT coinfection yield
cases (seroreactive for one but NAT two reactive markers) was 23; 8 HIV, 5 HCV and 10
HBV whereas only one coinfection was detected by ELISA; 1 HBV/HCV. There were
four NAT coyield cases (NAT two reactive but Serononreactive): one HIV-HBV and
three HBV-HCV.
Conclusion: This is the pioneer study from a Government tertiary care centre of the
region. Although antigen or antibody based screening test has high sensitivity, anti-
gen-antibody seronegative transmission of viral infections can still occur due to
window period. The NAT yield rate for each HIV and HCV was 0.1:1000 while for HBV
was 2.3:1000 in our centre. Thus NAT together with serology can bring blood safety
towards close to zero risk blood supply. ID-NAT is expected to contribute significantly
to scientific knowledge on the detection and dynamics of HIV, HBV and HCV infec-
tions.
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PREVALENCE OF THE FREQUENCY OF SCREENING POSITIVE
RESULTS TO TRANSFUSION TRANSMISSIBLE DISEASES
MARKERS AMONG BLOOD DONORS TO NATIONAL CANCER
INSTITUTE OF SRI LANKA – FROM 2006 TO 2010
Jayasinghe NS, Yapa DAN
National Cancer Institute, Colombo, Sri Lanka
Background: National Cancer Institute, the only hospital in Sri Lanka totally dedicated
to cancer care. It has became the leading centre for catering treatment for cancer
patients from all over the country. Transfusion of blood and blood products has been a
one of the main stray of treatment specially those who are at marrow suppressive state.
Therefore hospital blood bank has demanding requests to meet such a needy envi-
ronment. Hospital blood bank has its own way of donor recruitment system by con-
ducting mobile donor campaign and inhouse collection. Excluding of HIV, HBsAg,
VDRL and HCV infections are extremely important for safe transfusion. Testing of
blood units by screening methods for above infections has markedly decreased the
incidence of transfusion transmitted infections.
Aims: To determine the prevalence of HIV, HBsAg, VDRL and HCV screening positive
donations among voluntary blood donors who donated to our blood donor programme
following effective donor counselling.
Methods: A descriptive retrospective study was carried out by analysing all donated
test samples from the period of 2006 to 2010. HIV and HBsAg screening tests were
carried out by ELISA, Particle agglutination, and Rapid antigen assessment methods.
Hep C screening was done by ELISA and Rapid antigen tests. Cardiolipin and the
carbon agglutination tests were used to detect VDRL screening positive cases. A
details of each screening tests were collected and analysed using SPSS data analysis
tool.
Results: During the period of study, there were 79,964 blood donors gave whole blood
and it consists of 71,639 (89.58%) voluntary blood donors to the mobiles and 8325
(10.41%) to inhouse collection. Total of screening positive tests detected in HIV test is
0.21% (174), and HBsAg is 0.14%. The number of Hep C screening tests were 263
(0.37%) and total number of VDRL were 236 (0.30%). There is no statistical significant
difference between each screening method to detect screening positive cases for a
particular test.
Conclusions: There is no significant different in screening test positive results be-
tween in house and mobile blood donors. The prevalence of screening positive
donors among volunteer donors were not significantly changed over the time and
may be due to effective donor selection. The lower prevalence rate of transfusion
transmittable infection in our donor population brought safe blood transfusion to
the needy patients. Introduction of NAT screening would be helpful to minimize
further risks.
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STUDY OF NAT SCREENING IN BLOOD DONOR IN BLOOD
CENTER OF ZHEJIANG PROVINCE, CHINA
Lv H, Dong J, Wu Y, Zhu H, Li G, Zhu F
Blood Center of Zhejiang Province, Hangzhou, China
Background: Nucleic acid amplification test (NAT) for HIV-1, HCV, and HBV can
significantly improve the safety of the blood supply by detecting infectious blood
donated during the seronegative window periods. Although NAT has not yet been
mandated in China, we are the part of the largest NAT study so far conducted in China.
Aims: To evalute the feasibility of NAT for routine blood screening in blood center, to
evaluate the ULTRIO Assay on TIGRIS for its detection capability of seronegative yield
cases and clinical specificity for routine blood screening.
Methods: NAT platform (The Procleix Tigris system in individual donation format) for
HBV, HCV and HIV-1 testing of blood donor was implemented on August 1st 2010. All
samples were also tested by serology using two different EIA assays for each of the
three viruses. Samples with discordant results between ULTRIO and serology were
further tested with alternative (Alt) NAT assays. Donor follow-up testing for those
potential yield cases were further evaluated when possible.
Results: A total of 74,835 donations were included in this study until February 23rd
2011. 208 (0.28%) were ULTRIO reactive; and of these, 105 were also seropositive (14
anti-HIV, 23 anti-HCV, and 68 HBsAg); of the 103 seronegative/NAT reactive samples,
48 were ULTRIO and dHBV discriminatory assay reactive and nine were ULTRIO repeat
reactive but nondiscriminated. All them are classified as potential ULTRIO yield cases;
the remaining 46 ULTRIO-reactive seronegative samples were non-repeatable and
hence considered as false positive by the ULTRIO Assay (6/10,000). Of the 57 potential
ULTRIO yield cases, 45 were reactive in Alt NAT, 11 were Alt NAT nonreactive but were
ULTRIO or dHBV repeat reactive using a plasma bag specimen, and one FP ULTRIO.
Conclusion: Our data demonstrate that the potential ULTRIO yield rate for HBV was
1:1336 among blood donor populations in Hangzhou China. Implementation of NAT
provided a significant increment in safety relative to HBV serologic screening. Our
experiences also show that ID-NAT using ULTRIO Assay with TIGRIS platform was
feasible for routine blood screening.
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POSSIBILITY OF DETECTION OF ACTIVATED NEUTROPHILS
WITH REACTIVE OXYGEN SPECIES PRODUCTION BY USING
WBC DIFFERENTIATION SCATTERGRAM ON SYSMEX
AUTOMATED HEMATOLOGY ANALYZER
Kono M1, Saigo K2, Takagi Y3, Kawauchi S3, Wada A3, Hashimoto M4, Sugimoto T4,
Takenokuchi M2, Morikawa T3, Funakoshi K3
1Sysmex Corporation, Kobe, Japan 2Faculty of Pharmacological Science, Himeji Dokkyo
University, Himaji, Japan 3Cell Analysis Center, Scientific Affairs, Sysmex Corporation,
Kobe, Japan 4Blood Transfusion Division, Kobe University Hospital, Kobe, Japan
Background: One of the most important pathogenetic factors for acute lung injury
(ALI) including transfusion-related acute lung injury (TRALI) is neutrophil and pul-
monary endothelial cell activation induced by transfusion, resulting in increased
vascular permeability through the actions of reactive oxygen species (ROS) and other
molecules. Additionally, it has been reported that neutrophils change their morphology
and composition of cytomembrane by activation.
The leukocyte differentiation function on the Sysmex automated hematology analyzer
exposes leukocytes to a special surfactant and fluorescent dye, displays differences in
the effects of the resistance to the surfactant and the residual organelles among
different types of leukocytes by using WBC differentiation scattergrams (two-
dimensional scatter diagrams that show differences in side scatter and fluorescence
intensity) with flow cytometry, and thereby performs leukocyte classification.
Aims: In this report, we investigated that the possibility of detecting redundant
neutrophil activation, which is one of the most important pathogenetic factors for ALI,
development by using WBC-classification scattergrams.
Methods: Peripheral blood from healthy individuals was centrifuged to isolate a
polymorphonuclear (PMN) cell fraction. Whole blood or the PMN fraction was acti-
vated with phorbol myristate acetate (PMA) or formylmethionylleucylphenylalanine
(fMLP) and then analyzed using the Sysmex XE-2100, automated hematology ana-
lyzer. PMN fraction was stained with CD16b (a neutrophil specific marker) and treated
with APF (a fluorescent reagent for detecting ROS), followed by activation with PMA or
fMLP. These samples were morphologically analyzed under a confocal laser scanning
microscope (CLSM) and electron microscopes (EM). The samples were subsequently
treated with a special reagent for XE-2100 and then analyzed with a general-purpose
flowcytometer (FCM).
Results: The PMN fraction was stimulated with PMA or fMLP and analyzed using XE-
2100; in the WBC differentiation scattergram obtained in this analysis, a new cluster
appeared in the higher of side scatter in addition to neutrophil original cluster. This
new cluster was also observed in whole blood samples. FCM analysis of the PMN
fraction revealed that the cells in this new cluster were CD16b-positive and APF-
positive, thereby indicating that these cells were activated neutrophils with ROS pro-
duction. CLSM and EM findings revealed that the ROS production occurred in granules
and that these activated neutrophils had vacuoles within them.
Conclusions: Activated neutrophils with ROS production were found to have vac-
uoles in their cytoplasm. This finding suggested that activated neutrophils were
detected as another cluster at a location with a higher side scatter than that shown
by the ordinary neutrophil cluster on WBC differentiation scattergram probably
because these vacuoles increased the side scatter. These results indicated that the
Sysmex automated hematology analyzer has the potential to serve as a tool for
detecting activated neutrophils, which are the most important pathogenic factors for
ALI.
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AUTOMATED DETECTION OF WNV, HIV-1, HIV-2, HCV, AND
HBV WITH THE PROCLEIX ULTRIO ELITE AND PROCLEIX WNV
ASSAYS ON THE PROCLEIX PANTHER INSTRUMENT
Deras L, Pekny W, Self M, Scribner M, Linnen M
Gen-Probe, San Diego, CA, United States of America
Background: The Procleix WNV and Procleix Ultrio Elite Assays, qualitative nucleic
acid tests (NAT) for blood screening, are being developed for the Procleix PANTHER
instrument to test for West Nile virus (WNV), HIV-1/2, HCV, and HBV. The PAN-
THER instrument is a fully automated NAT testing platform that allows random
access of reagents and samples and has a small physical footprint. The system
processes 275 tests in 8 h and multiple assays by directly sampling from the blood
collection or pool tube. The WNV Assay is licensed in the US and CE-Marked, while
Ultrio Elite is currently under development. The PANTHER Instrument is CE-Marked
in Europe for diagnostic applications but currently under development for use in
blood screening.
Aims: To determine the preliminary performance characteristics of blood screening
assays on the PANTHER instrument and to evaluate the instrument’s random access
capability, panels of HIV-1/2, HCV, HBV, and WNV were tested.
Methods: Panels were made of HIV-1 Group M (subtypes B, G and H), Group O,
and Group N, CRF02_AG and CRF01_AE, the WHO HIV-2 RNA International
Standard (08/150), HCV (genotypes 1 and 2), and HBV (subtypes A, B, and C) (BBI,
NIBSC, DDL, ProMedDx) and tested with Ultrio Elite. Results were analyzed by
PROBIT (SAS 9.2) to determine limits of detection. Clinical specimens (n = 101)
positive for HIV-2 by serology (Bio-Rad Multispot HIV-1/HIV-2 Rapid test), (Boca
Biolistics) were tested undiluted. PANTHER instrument operation and throughput
was tested with negative, WNV and HIV-1 positive panels with the WNV and Ultrio
Elite Assays.
Results: Predicted 95% detection levels for the HIV-1 subtypes tested in this study
ranged from 1.2 to 15.6 copies/ml. The 95% detection levels of HCV-1a and -2b were
estimated at 34.0 and 64.1 copies/ml, respectively. Results with HBV subtypes ranged
from 26.3 to 88.1 copies/ml. The HIV-2 WHO standard was predicted to have 95%
detection at 11.2 IU/ml. Of the 101 HIV-2 positive clinical specimens, valid results were
observed in 100 specimens of which 57 (57.0%) were reactive using the Ultrio Elite
Assay.
The 80 negative, five WNV positive, and five HIV-1 positive specimens were randomly
loaded (not as a batch) onto the PANTHER Instrument to test with WNV and Ultrio Elite
Assays. Tests could be added while continuously processing other samples. The
instrument automatically took separate aliquots from each specimen without user
intervention and performed both assays with 100% agreement to expected results.
Testing of the 90 specimens with each of the two assays, and the Ultrio Elite and WNV
Assay Calibrators (195 total tests) completed in 6 h, 45 min.
Summary/conclusions: The Ultrio Elite Assay showed sensitive detection of HIV-1,
HCV and HBV genetic variants. Detection of HIV-2 RNA in clinical specimens was
consistent with performance reported with other commercial assays. The ability to test
for WNV, HIV-1/2, HCV, and HBV from a primary specimen tube and the random
access capabilities of the platform were demonstrated. The WNV and Ultrio Elite Assays
on the PANTHER instrument may provide a flexible and sensitive solution for NAT
blood screening.
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DEVELOPMENT OF A COMPLETE AUTOMATED BARCODE
CONTROLLED CE-CERTIFIED MINI POOL NAT EXTRACTION
SYSTEM BY THE GERMAN RED CROSS
BADEN-WUERTTEMBERG – HESSEN NAMED ZELOS ·100
Seifried E, Hourfar MK, Sireis W, Schmidt M
German Red Cross, Institute Frankfurt, Frankfurt, Germany
Background: Recipients are on risk to be infected by transfusion transmitted relevant
virus infections, if the donor is still in the diagnostic window period. Therefore a major
challenge in transfusion medicine is to develop a new screening technologies to reduce
the diagnostic window period to a minimum. The development of real-time nucleic acid
testing (NAT) systems represents a hallmark in transfusion medicine to improve blood
safety. The German Red Cross Blood Donor Services Baden-Wuerttemberg – Hessen was
one of the first who implemented mini pool NAT in 1997 on a voluntary basis for
hepatitis B, hepatitis C and HIV-1 for all blood donations. Based on an experience of
more than 10 years, a fully-automated system (named Zelos ·100) was developed in
2010 and is used for blood donor screening for hepatitis A, hepatitis B, hepatitis C, HIV-
1 and Parvovirus B19 blood donor screening in mini pools of 96 samples per pool.
Aim: The study presents an update after one and a half year of blood donor screening
with the automated mini pool NAT system named Zelos ·100. Data performed were
used for risk analysis for the automated NAT screening system.
Methods: The new automated extraction system based on a high volume bead
extraction process with a 95% level of detection (LOD) of 0.6, 6.8 and 8.9 IU/ml for
HBV, HCV and HIV-1, respectively. The new automated NAT screening system was
introduced in 2010 and replaced the manual mini pool NAT system which based on an
enrichment centrifugation for 1 h at 48,000 g. The analytical sensitivity for HBV was
improved by one log phase with the new system.
Results: Up to date, 3 million donations were screened with the automated systems. In
total 1, 6, and 1 NAT only reactive blood donations were detected by Zelos ·100 for HAV,
HCV andHIV-1, respectively. The virus loadwas in a range of 1.4 · 104–2.5 · 105 IU/ml
for HCV, 180 IU/ml for HAV and 3 · 104 IU/ml for HIV-1. Based on window period
models, the residual transfusion transmitted infectious risk was calculated to 1:458,082,
1:10.88 million and 1:4.3 million for HBV, HCV and HIV-1, respectively.
Conclusion: The development of a new automated MP-NAT system including a CE-
certification was successful. With the Zelos ·100 system, blood safety is improved, by
excluding residual risks for mix-up errors, by an enhanced analytical sensitivity for
HBV to 0.6 IU/ml and by a reduction of the time schedule for mini pool deconstruction
(within one working shift). After 1.5 years blood donor screening with the new NAT
system, eight NAT only positive blood donations were detected and transmission of
transfusion relevant viruses were prevented. The change from enrichment centrifu-
gation to a bead extraction process represents a state-of-the-art procedure, comparable
to other commercially available MP-NAT systems (like Roche s201 or Novatis Tigris
system). The new system offers several opportunities for additional improvements in
blood safety by reduction of pool sizes to ID-NAT or implementation of new param-
eters.
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SYPHILIS SEROPOSITIVE DONORS HAVE HIGHER SEROPRE-
VALENCE OF HBV, HCV, HTLV AND HIV COMPARE WITH
SYPHILIS SERONEGATIVE DONORS – 5 YEARS EXPERIENCE IN
SOUTHERN TAIWAN
Kuo-hung W1, Shu-Chin L1, Shing-Hui T1, Shih-Bin T1, Kuan-tsou K1, Chi-Ming C1,
Kuo-sin K2
1Kaohusiung Blood Center, Kaohsiung, Taiwan 2Head Office Taiwan Blood Services
Foundation, Taipei, Taiwan
Background: As syphilis, hepatitis B virus (HBV), hepatitis C virus (HCV), human T-
lymphotropic virus (HTLV) and human immunodeficiency virus (HIV) share the same
transmission route, the patients with syphilis may have higher co-infection rate with
these four viral infections compare to the patients without syphilis. Due to the co-
positive rate of syphilis serologic marker with these four viral serologic markers of
volunteer blood donors in Taiwan still unknown, we conducted this study.
Method: We retrospectively analyzed syphilis serologic marker and these four viral
serologic makers in all volunteer blood donors in Kaohsiung Blood Center of Taiwan
Blood Services Foundation (TBSF) from January 2006 to December 2010. The serologic
marker for syphilis, HBV, HCV, HIV, and HTLV was TPPA, HBsAg, Anti-HCV, Anti-HIV
and Anti-HTLV respectively. Chi-square statistics were employed to compare HBV,
HCV, HIV and HTLV serologic markers in blood donations that were syphilis sero-
positive and seronegative.
Result: There were 1,552,813 blood donations from 452,029 donors from January
2006 through December 2010. Of these, 1371 (0.09%) donations were syphilis
seropositive and 1,551,442 (99.91%) were syphilis negative. In syphilis seropositive
donations, the seropositive rate of HBV, HCV, HIV, and HTLV was 2.6%, 2.0%,
0.6%, and 0.1% respectively. Compared to seronegative syphilis donations, the
seropositive rate of HBV, HCV, HIV, and HTLV was 0.4%, 0.1%, 0.1%, and 0.003%
respectively. The syphilis seropositive donations were statistically significantly
higher seroprevalence of HBV (P < 0.001, OR, 7.002; CI, 5.02–9.76), HCV
(P < 0.001, OR, 16.976; CI, 11.65–24.75), HIV (P < 0.001, OR, 5.326; CI, 2.65–10.69),
and HTLV (P < 0.001, OR, 5.473; CI, 1.36–21.98) than syphilis seronegative dona-
tions.
Conclusion: The seropositivity of HBV, HCV, HTLV and HIV was significantly in-
creased among syphilis seropositive donors. In consideration of possible viral window
period infection, it is necessary to look back and quarantine of previously collected
units of blood and blood components from donors who subsequently become syphilis
seropositive.
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SYPHILIS TESTING OF BLOOD DONORS IN SINGAPORE
Chua SS
Blood Services Group, Health Sciences Authority, Singapore, Singapore
Background: Syphilis screening is one of the mandatory tests performed for blood
donors in Singapore. In our Blood Services Group, our routine syphilis testing
algorithm includes the initial screening using a treponemal test, the treponemal
chemiluminescence microparticle enzyme immunosaay (CMIA, ABBOTT ARCHITECT
Syphilis TP) and retest positive samples for confirmation by another treponemal test,
the Treponemal Pallidum Particle Agglutination (TPPA) test together with a nontre-
ponemal test, the Venereal Disease Research Laboratory (VDRL) test. Donations that
have a reactive TPPA and/or VDRL result are not used for transfusion and donors are
permanently deferred.
Aim: Our objective is to study the test reactive rates and to review the syphilis testing
algorithm and donor deferral strategies.
Methods: Donations tested using CMIA between the period, April 2008 to December
2010 was retrospectively evaluated. The test reactive rate was tabulated and the
number of donors deferred using the current syphilis testing algorithm were reviewed
and compared to the testing algorithm proposed in the Food and Drug Administration’s
(FDA) Draft Guidance titled ‘Revised Recommendations for Donor and Product Man-
agement Based on Screening Tests for Syphilis, June 2003’.
Results: Our current syphilis testing algorithm is similar to the recommended testing
algorithm of the FDA Draft Guidance. The only difference is the donor deferral ap-
proach. A total of 294,597 donations results were reviewed. Of the 986 (0.33%) CMIA
positive donations, 26 (0.009%) donations were tested positive for both TPPA and
VDRL method and 76 (0.03%) donations were positive for TPPA only. One hundred and
two donors with reactive TPPA and/or VDRL results were deferred permanently
according to our testing algorithm. If the FDA Draft Guidance’s testing algorithm is
followed, 26 donors will be deferred for a minimum time period of 12 months and 76
donors may potentially re-enter the donor pool with documentation of successful
treatment for syphilis.
Conclusions: The adoption of an alternative testing algorithm as proposed in the FDA
Draft Guidance may allow more donors to re-enter the donor pool. However, the
requirements of the documentations of successful treatment for syphilis must be clearly
defined.
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ANALYTICAL AND OPERATIONAL PERFORMANCE
VALIDATION OF PROCLEIX TIGRIS SYSTEM AT BLOOD
SCREENING LABORATORY
Ge G, Yao F, Wang D
Beijing Red Cross Blood Center, Beijing, China
Background: Performance Validation of a new testing system used in blood screening
laboratory is a part of quality assurance and the most important quality activity in BTS.
Understanding the performance qualification of new equipment will help operator to
use new equipment correctly and efficiently and ensure smooth blood screening
process.
Aim: Analytic and operational performance of Procleix TIGRIS System was validated
before Nucleic Acid Testing (NAT) is implemented at blood screening laboratory, to
confirm Procleix TIGRIS System’s feasibility and ensure Procleix TIGRIS System
running efficiently and testing process in control.
Method: The WHO International Standards for HIV-1 RNA, HCV RNA, HBV DNA were
used to determine the analytic sensitivity of the Procleix TIGRIS System. Severe
hemolytic and midrange lipaemic blood samples with low-load HIV, HCV and HBV
virus respectively were used to evaluate the Procleix TIGRIS System in the presence of
endogenous, interfering substances. High positive samples containing HBV (>106 IU/
ml) were used to evaluate the robustness of Procleix TIGRIS System against cross-
contamination.
Result: The 95% limits of detection (LODs) for HIV-1, HCV, HBV were 18.1 IU/ml
(range from 12.2 to 36.9 IU/ml), 7.4 IU/ml (range from 4.7 to 15.2 IU/ml), 11.7 IU/
ml (range from 7.6 to 22.5 IU/ml) respectively, for Procleix Ultrio Assay on TIGRIS
System. It is in coincidence with the analytic sensitivity claim in PI of ULTRIO. No
significant difference was observed between normal and severe hemolytic, midrange
lipaemic blood samples with HIV (40 IU/ml), HCV (10 IU/ml), HBV (20 IU/ml)
respectively testing on Procleix TIGRIS System. When Procleix TIGRIS System was
challenged with <10% positive samples (>106 IU/ml HBV) in a run, no cross-con-
tamination was observed in negative samples. However, false-positive result owing
to the aerosol could be found when the positive samples ratio increased to 20% or
50% in a run, but negative samples weren’t truely contaminated by the aerosol at
all.
Conclusion: Procleix TIGRIS System was a fully automated NAT system with high
sensitivity. The results of analytic performance validation of Procleix TIGRIS System
before NAT implementation demonstrated our lab’s capability on NAT. We also con-
firm that hemolytic, lipaemic blood samples will not interfere the NAT results signif-
icantly on Procleix TIGRIS System. And that there was no cross-contamination with no
more than 10% positve samples in a run, which made NAT available to routine samples
in our laboratory.
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SEROCONVERSION SENSITIVITY OF ELISA SCREENING
ASSAYS FOR HCV, HIV AND HBV ANTIGENS AND/OR
ANTIBODIES
Cucchietti A1, Parker S2, Oldfield L3, Limas C2, Garrod A2, Mc Bryne L3
1DiaSorin S.p.A., Saluggia, Italy 2DiaSorin S.p.A. – UK branch, Dartford, United
Kingdom 3DiaSorin South Africa (Proprietary) Limited, Kyalami, South Africa
Background: The main benefit of introducing nucleic acid amplification methods
(NAT) has been the detection of highly infectious window period (WP) donations, but
the cost effectiveness of this intervention is questioned and blood transfusion in many
parts of the world still relies on serologic screening for HBV, HIV and HCV antigens
and/or antibodies as the sole markers to prevent transfusion transmitted viral infection.
Moreover, it is in this context that the use of combo ELISAs as an alternative method to
reduce transfusion risk of WP donations, particularly in developing countries, can be
recommended, as it has been already done by the World Health Organization expert
group in their Recommendations for screening for TTIs. Therefore the use of highly
sensitive HIV, HBV and HCV screening assays is crucial for efficiently avoiding
transfusion transmitted infections and seroconversion panels are an useful tool to
evaluate their clinical sensitivity and also compare sensitivity of different commer-
cially available kits.
Aims: The performance in terms of clinical sensitivity of Murex HBsAg v3, Murex HIV
Ag/Ab Combination, Murex HCV Ag/Ab Combination ELISA assays were evaluated,
and compared with other well established blood screening assays on the market.
Methods: The Murex HBsAg v3 is a 4th generation ELISA assay for the determination
of Hepatitis B surface Antigen. The Murex HIV Ag/Ab Combination Assay is a mi-
croplate based assay for the simultaneous detection of antibodies to human immu-
nodeficiency virus types 1 (HIV-1, HIV-1 group O), detection of anti-HIV-2 antibodies
and HIV core antigen in the same well. Murex HCV Ag/Ab Combination is a 4th
generation ELISA assay for the simultaneous detection of hepatitis C (HCV) core
antigen and anti-HCV antibodies.
A set of 58, 39 and 75 seroconversion panels commercially available for HBV, HIV, and
HCV respectively were evaluated.
Results: On 58 panels, Murex HBsAg assay detected an additional five and 10 sero-
conversion panel members compared to the Architect HBsAg qualitative and quanti-
tative assays respectively. On 28 and 29 panels Murex HBsAg assay showed an higher
sensitivity (135 and 118 positive bleeds) than Vidas HBsAg (108 positive bleeds) and
Roche HBsAg (103 positive bleeds) respectively. Analysis of 39 panels tested showed
that the Murex HIV Ag/Ab (140 bleeds positive) had excellent sensitivity compared to
PRISM and Architect (134, 141 positive bleeds). Comparison to the p24 Ag only assays
from Coulter and Murex using NAT positive/Antibody negative samples showed the
Murex HIV Ag/Ab assay to be broadly equivalent (Mean delay v NAT 6.03 days,
Coulter HIV Ag 6.67 days, Murex HIV Ag 7.77 days). Analysis of 75 HCV panels tested
showed that the Murex HCV Ag/Ab had a superior sensitivity compared to Ab only
HCV assays (on average 177 bleeds earlier) and a better specificity.
Conclusions: The Murex ELISA assays demonstrated to be a state of the art immu-
noassays suitable for the screening of serum and plasma samples, with comparable
performance with chemiluminescence immunoassays. The enhanced sensitivity of
combination antigen could represents a viable alternatives for countries with limited
financial resources.
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ANALYSIS OF SYPHILIS SCREENING RESULTS ON BLOOD
DONORS IN QINGDAO AREA DURING 2008–2010
Zhou B, Xu L
Qingdao Blood Center, Qingdao, China
Background: The incidence of syphilis rises year by year in Qingdao. syphilis anti-
bodies (anti-TP) response is the second factor of blood rejection.
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Aims: To investigate the syphilis antibodies (anti-TP) response rate among voluntary
blood donation in Qingdao area, to decrease blood scrap which is caused by syphilis
antibodies response. and to reduce blood waste.
Methods: For the period 2008–2010, Detected syphilis antibodies (anti-TP) from
298,234 blood donors during 2008–2010 with Enzyme-linked immunosorbent assay
(ELISA), made statistical analysis on the results according the level of education,
occupational distribution, and the season for blood donation.
Results: The anti-TP response rate was 0.33% among blood donors in Qingdao,
according to educational level the rate of anti-TP was contrary to the response rate,
that is to say, the lower level of education was with a higher anti-TP reaction rate;
Antibody response rate in ascending order was student, soldier, staff, individuals and
unemployed; In the third season of each year, the response rate increased significantly
and achieved the highest level of 1 year.
Conclusions: We should make intervention and education to the blood donors
according their different education and different occupation;We should make pre-
liminary blood screening in the high response rate season from July to September, so
that the blood scrap rate will be reduced, thereby reducing the waste of blood re-
sources.
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THE ALERT SYSTEM FOR TESTING TRANSFUSION-RELATED
VIRAL INFECTION ON THE ELECTRIC MEDICAL RECORD
Sugimoto T, Hayakawa I, Tokuno O, Hashimoto M, Minami H
Kobe University School of Medicine, Kobe, Hyogo, Japan
Background: Testing for viral infection (HBV, HCV, HIV) in patients who have re-
ceived transfusion is a recommended procedure in Japan. To detect transfusion related
viral infection, a blood test is performed 2–3 months after blood transfusion. Our
institute uses two ways to provide the clinical physician concerned with information
about the patient’s transfusion history for further post-transfusion testing. The first is
using the record of the patient concerned. The second is using the alert system on the
electronic medical record.
Aim: To examine the efficacy of these two ways
Method: Patients transfused between September 2008 and May 2010 were studied
(3537 patients). The period was divided into three terms. Period 1 is the period
before patient records were sent (September 2008–December 2008). During this
period, the blood, transfusion division did not send patient information to the
clinical physician. Period 2 is the period during which patient records were
transmitted (January 2009–February 2010). The patient data from around 2 months
after the blood transfusion were sent to the clinical physician every month. Period
3: The period when the electronic alert system was used (March 2010–present). The
alert system is part of the electronic medical record. The patient who received
blood transfusion 60–150 days previously is picked up by this alert system, and an
alert signal is shown on a panel of the electronic medical record. The rate of
testing viral infection after blood transfusion is then calculated. The test items are
HBV: HBs-Ag or HBV-DNA (NAT); HCV: HCV Core-Ag or HCV-RNA (NAT); HIV:
HIV-Ag/Ab.
Results: The rates of post-transfusion testing for viral infection are shown in the
Table 1 below.
Table 1: Result
Conclusion: The alert system on electronic medical records is more effective for
performing transfusion-related viral infection tests.
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SEROLOGICAL CHARACTERISTICS OF HEPATITIS B SURFACE
ANTIGEN POSITIVE HBV DNA NEGATIVE DONATIONS IN HONG
KONG CHINESE
Tsoi WC1, Lim WW2, Lin CK1
1Hong Kong Red Cross Blood Transfusion Service, Hong Kong, China 2Department of
Health, Public Health Laboratory Service, Hong Kong, China
Background: The population in Hong Kong has a high prevalence of hepatitis B virus
(HBV) infection, mostly acquired vertically during early childhood. To enhance blood
safety, the Hong Kong Red Cross Blood Transfusion Service implemented nucleic acid
test (NAT) screening for HBV DNA on individual donor samples in April 2007. A subset
of donations with HBsAg positive HBV DNA negative assay results were identified.
Aims: To characterize the serological profile of these HBsAg+ HBV DNA- samples
from Hong Kong Chinese population.
Methods: Routine blood screening for HBsAg was performed by the most sensitive
serologic assay using Abbott PRISM by ChLIA. Repeatedly reactive samples were
confirmed by neutralization. All donations were screened by NAT on individual
samples (ID-NAT) using the HIV-1/HCV/HBV triplex Procleix ULTRIO Assay on TIGRIS
platform (Novartis Diagnostics) (detection limit: 10.4 IU/ml; 95% probability: 9.2–
12.2 IU/ml). NAT reactive samples were retested with discriminatory assays to deter-
mine viral specific reactivity. Available archive samples with discordant results
(HBsAg+ HBV DNA)) were further tested with triplex Procleix ULTRIO PLUS Assay and
discriminatory tests by ID-NAT (detection limit: 2.1 IU/ml; 95% probability: 1.7–
3.0 IU/ml) and for other HBV serologic markers, i.e. repeat HBsAg and anti-HBs
(Architect; Abbott), IgM and total anti-HBc (Vitros; Ortho Clinical-Diagnostics), HBeAg
(Murex) and anti-HBe (Monolisa, Bio-Rad).
Results: From April 2007 to September 2009, 517,072 donations were collected and
tested; 1815 (0.35%) of which were confirmed positive for HBsAg; of these, 166 (0.03%
of all donations, 9.15% of all HBsAg+ cases) were HBsAg+ HBV DNA) by ULTRIO
Assay. With regard to demographic data, 77 (46.4%) were from males and 89 (53.6%)
females; 143 (86.1%) from new donors and 23 (12.9%) repeat donors; mean age and SD
were 28.7 and 11.5 years old respectively. For the other serological markers: (i) repeat
HBsAg: positive (n = 48/49, 98.0%), negative (n = 1/49, 2.0%), (ii) anti-HBs: <10 mIU/
ml (n = 53/54, 98.1%), 17 mIU/ml (n = 1/54, 1.9%), (iii) IgM anti-HBc: negative
(n = 55/55, 100%), (iv) total anti-HBc: positive (n = 53/53, 100%), (v) HBeAg: negative
(n = 52/52, 100%), (vi) anti-HBe: positive (49/49, 100%). The ratios of sample reading
to cut-off value (S/CO) generated from PRISM HBsAg ChLIA for the two groups of
sample (HBsAg+, ULTRIO), ULTRIO PLUS) group and HBsAg+, ULTRIO), ULTRIO
PLUS+ dHBV+ group) were significantly different (P = 0.028). The former group
(n = 39) had a median S/CO of 17.29 (Range: 1.20–444.00) and the latter group
(n = 31) median S/CO of 87.55 (Range: 1.30–621.90).
Conclusions: In Hong Kong, where HBV prevalence is high, when donations were
screened by a highly sensitive ID-NAT, 9.1% of all confirmed HBsAg+ donations had
HBV DNA levels undetectable. The serological pattern of these donations was over-
whelmingly homogeneous: HBsAg+, anti-HBs < 10 mIU/ml, IgM anti-HBc), total anti-
HBc+, HBeAg), anti-HBe+, consistent with chronic infections. As the proportion of
HBsAg+ HBV DNA) samples was close to 10% of all HBsAg+ donations, HBsAg assay is
still pertinent in donation screening and cannot be replaced by NAT alone. HBsAg S/CO
values were higher in the ULTRIO PLUS+ group when compared with the ULTRIO
PLUS) group, but a bright-line S/CO value could not be defined to predict ULTRIO PLUS
results.
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SIGNIFICANTLY DECREASED LEVEL OF SOLUBLE FAS IN
BLOOD DONORS WITH OCCULT HEPATITIS B VIRUS INFECTION
Li LL1, Chang CT1, Chak KF2, Yang MH1, Hung YS1, Hung CS1, Tsai SJL3, Lin KS3
1Taipei Blood Center, Taipei, Taiwan 2Institute of Biochemistry and Molecular Biology,
National Yang Ming University, Taipei, Taiwan 3Head Office Taiwan Blood Services
Foundation, Taipei, Taiwan
Background: Chronic HBV infection is diagnosed by the detection of hepatitis B
surface antigen (HBsAg) and HBV DNA, while occult HBV infection (OBI) is defined by
the detection of HBV DNA and the lack of detectable HBsAg in serum. The cause of OBI
remains unclear. Recently, several cytokines have been shown to effectively suppress
HBV gene expression and replication. Moreover, soluble Fas (sFas), an inhibitor of Fas-
mediated apoptotic pathway, is suggested to be associated with the viral persistence.
Aims: In this study, we analyzed the plasma levels of IL-6, IFN-c, TNF-a, and sFas in
OBIs, asymptomatic HBsAg carriers and HBV uninfected donors to assess the possible
factors correlated with OBI.
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Methods: Sixty-nine donors were enrolled in this study: 23 OBI donors, 23 asymp-
tomatic HBsAg carriers, and 23 HBV uninfected donors. Plasma levels of IL-6, IFN-c,
TNF-a were measured by MILLIPLEX MAP Cytokine Kit. The concentration of sFas in
plasma samples were analyzed by Quantikine sFas Immunoassay. HBV DNA was
quantified with Roche COBAS TaqMan HBV Test. The differences in cytokines and
sFas between OBIs and uninfected donors or HBsAg carriers were assessed by Wilcoxon
rank-sum tests. Spearman rank tests were utilized to evaluate correlations between sFas
and clinical parameters including age, ALT, HBV viral load.
Results: It was observed that the levels of IL-6, IFN-c and TNF-a in OBI were not
significantly different from those of asymptomatic HBsAg carriers or HBV uninfected
donors. Noticeably, the level of sFas showed statistically decreased in OBI compared to
either asymptomatic HBsAg carriers or HBV uninfected donors. (2225 vs 3021 pg/ml,
P < 0.05 and 2225 vs 4342 pg/ml; P < 0.0001, respectively). The correlations of sFas to
HBV viral load, ALT, age were also examined. No significant correlation was found
between sFas and clinical parameters.
Conclusions: Our results indicated that the level of sFas was significantly decreased in
OBI. It was known that sFas inhibited Fas-mediated apoptosis of HBV-infected cells.
Therefore, decreased apoptotic inhibition might improve clearance of HBsAg and
partially explain the low levels of HBV DNA in occult HBV infection.
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THE EPIDEMIOLOGICAL CHARACTERISTICS OF HBV INFECTION
IN HIV INFECTED DONORS AND PATIENTS IN SICHUAN, CHINA
Liu Y, Xu M, Liu G, Ke L, Pan Z, Yang X, Zeng P, Li W, Wang J
Institute of Blood Transfusion, CAMS, Chengdu, China
Background: Hepatitis B viruse (HBV) and human immunodeficiency virus (HIV) have
similar routes of transmission, enabling co-infection of the two viruses a common
event. However, information on the characteristics of HBV infection in HIV infected
blood donors in China is limited.
Aims: To study the epidemiological characteristics of HBV infection in HIV infected
donors and patients in Sichuan, China.
Methods: Six hundred and fourteen blood samples fromHIV infected blood donors (417)
and patients (197) in Sichuan were collected from 2007 to 2010. All the samples were
detected for HBsAg, anti-HBs, anti-HBc, anti-HBe and HBeAg (KEHUA, China) as well as
viral loads of HBV (Qiagen, German). For the HBsAg positive samples, the neutralization
confirmatory testing were implemented by LIZHU HBsAg Neutralization. For the HBV
positive samples determined by HBsAg confirmatory testing or viral loads detection, the
viral DNA were extracted, the S region of HBV was amplified and HBV genotype was
determined by direct sequencing and phylogenetic analysis or by multiplex-PCR.
Results: A total of 79 samples out of 614 (12.9%) were detected as HBV positive
with 42 of 417 (10.1%) in blood donors and 37 of 197 (18.8%) in patients which
suggested that the HBV prevalence in HIV infected patients was significantly higher
than that in HIV infected blood donors. In addition, the HBV positive rate was
found significantly higher in the young aged group (£45 years old) HIV infected
patients than in the old aged group (>45 years old). In the 79 HBV positive samples,
three were HBsAg negative but nucleic acid testing positive while one sample was
HBsAg positive with no HBV nucleic acid detected. For the 67 successfully geno-
typed samples, genotypes B, A, C and D accounted for 56.7%, 26.9%, 10.4% and
4.5% of all samples, respectively, and one sample was detected as mixture of
genotype B and D.
Conclusions: There is high prevalence of HBV in HIV infected blood donors and
patients in Sichuan, China and genotype B and A are the main genotypes of HBV.
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HBV CORE ANTIBODY AS A MARKER FOR HBV DNA REACTIVE
DONORS’ REENTRY
Yang MH1, Chen MH1, Hung YS1, Li L1, Hung CS1, Lin Tsai SJ2, Lin KS2
1Taipei Blood Center, Taipei, Taiwan 2Taiwan Blood Services Foundation, Taipei,
Taiwan
Background: Two pilot NAT studies with the Chiron PROCLEIX ULTRIO assay and the
Roche cobas MPX assay were held in Taiwan and confirmed 23 occult HBV infection
(OBI) donors. The total yield rates and analysis of the OBI donors were beneficial to
estimate the implementation of NAT screening and to evaluate pool size. It was known
that the OBI donors were characterized by the present of HBV DNA without detectable
hepatitis B surface antigen (HBsAg) outside the window period. The levels of HBV DNA
were fluctuating. Follow-up samples from OBI donors with low and fluctuated viral
load might be negative for routine HBV NAT assays. Long-term following up the OBI
donors was help to propose an optimal algorithm for confirmation of future yield cases
and reinstatement of HBV NAT reactive donors. Study design and methods:
Twenty-three OBI donors were enrolled in this study. Besides routine HBV NAT and
HBsAg EIA, the additional serological assays such as HBV core antibody (anti-HBc),
HBV surface antibody (anti-HBs) were performed for index donation and 1-year
follow-up samples. HBV DNA results were confirmed by triplicating the HBV NAT
tests, alternative assays with higher sensitivity, or with the extraction of HBV DNA
from larger plasma volume. For the long-term follow-up samples, we only tested
HBsAg EIA, routine HBV NAT, and quantification of viral load.
Results: For index donation and 1-year follow-up samples of 23 OBI donors, the
presence of virus in plasma was confirmed. Anti-HBc remained positive for 23 OBI
donors. Only eight donors remained Anti-HBs positive, besides two were turned into
positive and two were turned into negative in follow-up samples. All samples were
tested negative for HBsAg. For long-term follow-up samples, the results showed the
fluctuation of HBV DNA in OBI donors. Only one donor had higher level of HBV DNA,
while other donors had HBV DNA level slightly higher than the detection limit of
quantification assay or turned into target-not-detected. The HBsAg remained negative
for all samples.
Conclusion: Analyzing the data, we considered anti-HBc the marker for reentry of
HBV DNA-reactive donors. In the proposed algorithm, for donors with HBsAg neg-
ative and HBV DNA-reactive results, the units were discarded and donors were
suggested follow-up testing 6 months after this donation. The follow-up samples were
tested for HBsAg and HBV NAT. The donors were permanent deferral with either
reactive/positive results. If the results were both negative/nonreactive for HBsAg and
HBV NAT, samples were tested with anti-HBc. The donors were permitted reentry
when anti-HBc came out negative. If anti-HBc were positive, donors were permanent
deferral. For decades, anti-HBc was considered not suitable for screening donors in an
HBV endemic area like Taiwan. But for occult HBV infection, the anti-HBs was not all
positive and HBV DNA level was sometimes lower than detection limit of NAT assays.
Anti-HBc was the marker that remained positive after infection. The improvement of
blood safety and donor management will be evaluated after implementing this
proposed algorithm.
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SENSITIVITY OF FIVE NEW HEPATITIS B SURFACE ANTIGEN
ASSAYS
Ly TD, Dautigny M
Laboratoire Biomnis, Ivry-sur-Seine, France
Background: HBV surface antigen (HBsAg) is the established serological marker
routinely used for the diagnosis of acute or chronic HBV infection and screening of
blood or organ donors. Moreover, HBsAg quantitative measurements may play a role in
staging disease and monitoring efficacy of treatment. Natural variation and mutations
in the HBV S gene can induce HBsAg conformational changes which may affect the
performance of HBsAg assays. In this study, we analysed the analytical sensitivity and
capability for HBsAg mutant detection of five new HBsAg assays.
Study design: The HBsAg assays in this study were Architect HBs Ag Qualitative II
(Abbott); ADVIA Centaur HBsAg II (Siemens); Elecsys HBsAg II (Roche) and its
quantitative version, Elecsys HBsAg II quant as well as another quantitative assay,
LIAISON XL Murex HBsAg Quant (Dia Sorin). In total, 273 samples were tested con-
sisting of the following panels
Panel 1: 2nd WHO international standard HBsAg (00/588) in six dilutions from 0 to
0.30 IU/ml in duplicate (n = 12);
Panel 2: Samples of genotypeA–H in singlet (n = 94) or three serial dilutions (14, n = 42)
Panel 3: 34 native mutants at two different dilutions (n = 68); three samples in single
(n = 3);
Panel 4: 18 recombinant mutants at three different dilutions (N = 54).
Results: The following table shows the results.
Table 1
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Architect HBsAg had the best analytical sensitivity and together with LIAISON XL and
Centaur achieved the best score for mutant detection even at lower concentration
whereas both versions of the Roche assays missed a couple of recombinant mutants
even at the highest concentration studied.
Conclusion: All assays showed excellent analytical sensitivity using the current
HBsAg WHO standard. Moreover, the use of a several monoclonal and/or polyclonal
antibodies allows in general a broad mutant detection. However, differences exist
regarding the concentration at which certain mutants are detected and analytical
sensitivity on wildtype is not predictive for mutant detection at the lowest level.
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PREVENTION OF ACUTE AND OCCULT HEPATITIS B VIRUS
INFECTION IN LOW AND HIGH EPIDEMIC REGIONS – 5 YEAR
EXPERIENCE OF ANTI-HBC BLOOD DONOR SCREENING IN
GERMANY
Seifried E, Hourfar MK, Sireis W, Schmidt M
German Red Cross, Institute Frankfurt, Frankfurt, Germany
Background: The German Red Cross Blood Donor Service Baden-Wuerttemberg –
Hessen introduced mini-pool nucleic acid testing (MP-NAT) for hepatitis B virus on a
voluntary basis in 1997. All blood donors were screened in addition for HBsAG. Al-
though all blood donors were screened by MP-NAT and HBsAG, some cases of
transfusion transmitted hepatitis B infections were reported based on low viremic
occult hepatitis B infected blood donors. Therefore the German authority introduced
anti-HBc blood donor screening in 2006 for all blood donations.
Aim: The current study reports about the experience with anti-HBc blood donor
screening. Based on these data risk analysis calculations as well as developments of
new screening strategies for low and high epidemic regions were performed.
Methods: From 2006 to 2010 approximately seven million blood donations were
screened for HBsAG, MP-NAT (96 samples per pool) and anti-HBc. Blood donors,
repeat reactive for anti-HBc, and negative for HBsAG and HBV MP-NAT, were screened
in addition for anti-HBs and HBV ID-NAT. Re-entry of anti-HBc repeat reactive donors
was allowed, if anti-HBs titer was higher than 100 IU/l and HBV ID-NAT was negative.
Results: Prevalence of anti-HBc reactive donations was 2% for donors in North,
Middle and South of Germany, respectively in 2006. Over the study period of 5 years,
it was stable for first time donors but reduced for repeat donors to 0.2%. In total 16
lock-back examinations of repeat donors positive for HBV DNA and anti-HBc were
investigated. Only one recipient out of 16 was anti-HBc reactive. The transfusion
transmitted infectious pathway was not confirmed, because the recipient was HBV
DNA negative. In a case/control study 118 recipients transfused with anti-HBc con-
firmed reactive blood components (anti-HBc and anti-HBe reactive components) were
compared with 120 recipients transfused with anti-HBc negative blood components.
The percentage of anti-HBc reactivity in both recipients groups were not significant
different.
Conclusions: The introduction of anti-HBc into blood donor screening was able to
improve blood safety regarding to low viremic occult hepatitis B infected blood
donors. No hepatitis B transfusion transmitted infections were observed after
introduction of anti-HBc into blood donor screening in 2006. Donor re-entry with
anti-HBs antibodies (titer higher than 100 IU/l) is a safe procedure. Nevertheless
based on our data, the most important test for donor re-entry is HBV ID-NAT for
anti-HBc repeat reactive donations. Therefore we conclude that regions with low
epidemic HBV prevalence can improve blood safety by introduction of anti-HBc
blood donor screening in addition with a re-entry procedure, if HBV ID-NAT is
negative and anti-HBs is reactive with a titer higher than 100 IU/l. In HBV high
epidemic regions, anti-HBc blood donor screening can be introduced with a re-entry
strategy of all blood donations that are negative by HBV ID-NAT. This modified
screening strategy, enables a detection of infectious occult hepatitis B donations
without loosing a high number of non infectious anti-HBc only reactive blood
donors.
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COULD BLOOD DONOR SCREENING BY HBV MINI POOL
NUCLEIC ACID TESTING AND ANTI-HBC REPLACE SCREENING
FOR HBSAG?
Seifried E, Hourfar MK, Sireis W, Schmidt M
German Red Cross, Institute Frankfurt, Frankfurt, Germany
Background: In the 1970ies blood donor screening for HBsAG has been implemented
to reduce the residual risk of transfusion associated hepatitis B virus infections. In 1997
the German Red Cross Blood Donor Services Baden-Wuerttemberg – Hessen introduced
hepatitis B virus mini pool nucleic acid testing system for all blood donations on a
voluntary basis with a maximum pool size of 96 samples per pool. Because of trans-
fusion transmitted hepatitis B infections, caused by HBV chronic infected blood donors
(occult hepatitis B infections with low virus concentration), anti-HBc screening for all
blood donation was introduced by the German authority, the Paul-Ehrlich-Institute, in
2006. Therefore all blood donations were currently screened in our blood donor service
for HBsAG, HBV MP-NAT and anti-HBc.
Aim: We analysed data between 1998 and 2010 for HBsAG, HBV MP-NAT, HBV ID-
NAT and anti-HBc, for the impact of each screening test to blood safety.
Methods: Between 1998 and 2010 3,475,605 blood donations were screened for
HBsAG, HBV MP-NAT, and anti-HBc. HBsAG as well as anti-HBc were screened by
ABBOTT PRISM technology. HBV DNA MP-NAT was performed by the German Red
Cross NAT system with an analytical sensitivity of 5.7 IU/ml.
Results: In total 697 PRISM HBsAG reactive donations have been identified among the
3,475,605 donations. 687/697 (98.6%) would also have been detected by anti-HBc
screening and 540/697 donations (77.4%) were positive by MP-NAT screening. If a
more sensitive ID NAT was applied, 612/697 (87.9%) were ID-NAT positive. Notably,
no HBsAG only reactive donation (negative for anti-HBc and HBV ID NAT) was
identified during the observed time period. In contrast HBV MP-NAT identified one
HBsAG and anti-HBc negative donation in the early infectious window period.
Conclusion: Currently blood donor screening for HBV is performed at the German Red
Cross Blood Donor Services Baden-Wuerttemberg – Hessen by testing for HBsAG, HBV
MP-NAT and anti-HBc. Retrospective analysis of data from HBsAG reactive donations
revealed that all these donations would have also been identified either by testing for
HBV MP-NAT or by anti-HBc detection. Therefore testing for HBsAG seems to be
redundant following the introduction of HBV MP-NAT and anti-HBc testing. Discon-
tinuation of HBsAG-testing may therefore be considered to reduce the cost associated
with HBV-testing without compromising blood safety.
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BLOOD DONOR SCREENING FOR HBV DNA USING NAT UNDER
ROUTINE CONDITION IN QINGDAO, CHINA, 2010–2011
Yang Y, Liu L, Xu X
Qingdao Blood Centre, Qingdao, China
Background: In Chinese Mainland, NAT screening of blood donations for HBV DNA,
HCV RNA, and HIV RNA was carried out as a pilot project in 15 blood banks in 2010.
Qingdao blood centre as the first pilot blood collecting and supplying organizations
carry on the project in 1st June, 2010.
Objectives: To evaluate the presence of HBV-DNA in blood donors based on sero-
logically negative units, who donated blood in the period from June 2010 to January
2011, in Qingdao, China.
Materials and methods: The HBV NAT yield was examined by testing about 65,800
voluntary, serologically negative blood donor samples on the cobas TaqScreen
multiplex (cobas MPX) test in pools of six with the cobas s 201. Samples positive
for HBV DNA and negative for HBsAg were confirmed by a second molecular test,
the viral DNA was quantified, and serological tests evaluating hepatitis B s antigen
(HBs-Ag), anti-hepatitis B core antigen (HBc-Ab), anti-hepatitis B e antigen (HBe-
Ab), hepatitis B e antigen (HBe-Ag) by Electro Chemiluminescence Immunoassay
(ECLIA).
Results: MN-pool NAT identified 80 reactive pools. The ID-Pool NAT identified 58
reactive pool samples. HBV-DNA quantitative determination identified 38 positive
ones. The overall HBV-DNA positive rate was 0.8&. HBV-DNA viral load, which can be
detected, range from <12 IU/ml to about 30,000 IU/ml. Among the 58 reactive pool
samples, HBV-DNA positive/anti-HBc positive ones is 41 samples, HBV-DNA positive/
anti-HBc negative ones is 12 samples.
Conclusions: Our data indicate that blood donor screening for HBV DNA using NAT
could detect more HBV infection in blood donors who are HBs Ag negative, which is
important for the prevention of transfusion-transmitted HBV infection.
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RATE OF HBV-NAT DETECTION IN REPEAT DONORS
PREVIOUSLY NEGATIVE FOR HBV DNA BY NAT AT SIRIRAJ
HOSPITAL, THAILAND
Permpikul P, Senawong S, Panchavinnin W
Faculty of Medicine Siriraj Hospital Mahidol University, Bangkok, Thailand
Background: Screening of HBV infection in donated blood by nucleic acid technology
(NAT) testing was implemented at Siriraj Hospital in 2007. Samples are screened in
pools of six donations with the Roche cobas MPX test, a multiplex PCR test for HIV-1
(groups M and O), HIV-2, HBV and HCV on the Roche cobas s 201 platform, an
automated system for blood screening. However, despite routine screening of donors
with a very sensitive HBV NAT test, a few repeat donors subsequently became HBV
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NAT reactive. This study was designed to calculate the rate of HBV NAT reactivity in
repeat donors and to classify these infections as either window period or occult
infections.
Material and methods: The donor database and records of the infectious screening
laboratory were retrospectively reviewed from April 2007 to December 2010. The
number of repeat donors was indentified and the repeat donors who subsequently
became HBV NAT reactive were examined further. The HBV viral load and HBV
serological profile were used to classify the infections as either window period or
occult. The total HBV NAT yield rate, as well as the rates for window period and occult
infections, was calculated.
Results: From April 2007 to December 2010, a total of 179,858 donations were col-
lected at Siriraj Hospital. There were 112,169 donations from 30,369 repeat donors who
donated during this period. Of these repeat donors, 24 donors (17 males and seven
females) were reactive for HBV NAT on the last donation. The HBV NAT yield rate is
1:1265 (1:1079 in males and 1:1717 in females). Based on HBV viral load and HBV
serological profile, nine donors had window period infections and 15 donors had an
occult HBV infection. The viral load in all the donors with an occult HBV infection was
below the level of detection of the test used (20 IU/ml). Thus the rate of occult
infections in repeat donors at Siriraj Hospital is 1:2024.
Conclusions: HBV DNA was detected in repeat donors at Siriraj Hospital. The majority
of these donors had an occult HBV infection with very low viral loads and it is possible
that HBV DNA detection in some of these donors could have been missed in previous
donations. These cases will be the subject of a look-back study for transfusion-
transmitted HBV.
P-187
HBV NAT REACTIVE IN NORTHERN THAI BLOOD DONORS
Leetrakool N, Fongsatitkul L, Tanan P, Somphan P, Nantachit N
Chiang Mai University, Chiang Mai, Thailand
Background: The high prevalence of HBV infection is the problem of the country in
Southeast Asian region. False negatives still persist, and HBV transmissions still
occur, especially in northern Thailand. However the new technologies, including
nucleic acid technology (NAT) testing, have affected the rates of detection in blood
donors.
Aims: The aim of this study was to evaluate the performance of two commercial
multiplex NAT tests, the Chiron eSAS Procleix Ultrio test (Ultrio test) and the Roche
Cobas s201 automated platform and the Cobas TaqScreen MPX test (MPX test) for
screening blood donations in northern Thailand.
Methods: Two commercial NAT assay systems were used: the Chiron PROCLEIX eSAS
platform with PROCLEIX ULTRIO test and The Roche Cobas s201 platform with the
Cobas TaqScreen MPX test for screening norhern Thai blood donors for hepatitis B
virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). Eighty
four HBV NAT-reactive/hepatitis B surface antigen (HBsAg)-negative donors were
tested for HBV serologic markers. The reactive samples were tested on both NAT system
and donors were followed up.
Results: The majority of the HBV reactive donors had an occult HBV infection
(65.5%), followed by donors with acute infection (34.5%). Fourty eight (57.1%) do-
nors were followed. Based on the follow-up results, 14.5% were in the window
period.
Conclusions: The blood donors with occult HBV were detected by both tests.
However, the MPX test seems to have any increased rate of detection for HBV.
However, NAT should be used in conjunction with serological testing to identify
low-level HBV infections as well as infections at the ends of the window periods of
detection.
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TRANSFUSION-TRANSMISSION OF HEPATITIS B VIRUS (HBV)
FROM A NAT-NEGATIVE OCCULT HEPATITIS B VIRUS CARRIER
Hanada D1, Kino S1, Yamauchi S1, Tomoda Y1, Kawata D1, Fujita S1, Morishita K2, Sato
S2, Ikeda H2
1Asahikawa Medical College, Asahikawa, Japan 2Hokkaido Red Cross Blood Center,
Sapporo, Japan
Background: Transfusion-transmission of HBV (TT-HBV) has become rare since the
implementation of the donor screening by nucleic acid amplification test (NAT) in 1999
in Japan. However, the risk of TT-HBV still persists. We experienced a case of TT-HBV
from an occult HBV carrier with negative individual NAT.
Case report: A 20 years old male patient suffering from multiple injuries following a
road traffic accident was conveyed to the emergency room of our hospital and received
blood transfusion including, platelet concentrates, red cell concentrates and fresh
frozen plasma during the period between September 2010 and October 2010. In Jan-
uary 2011, about 4 months after the last transfusion, post-transfusion viral test was
carried out for him according to ‘The Guideline for Transfusion Practice (Ministry of
Health, Labor and Welfare)’. He was positive for HBV DNA, negative for HCV core
antigen and negative for HIV antigen and antibody, although he had no symptom of
hepatitis. The status of his pre-transfusion HBV-related markers was tested with his
pre-transfusion blood sample, which had been stored in a deep freezer at Asahikawa
Medical University Hospital. His stored samples showed no positive result for HBV
markers before receiving a blood transfusion. The 22 blood donors were involved in his
transfusion and the look-back study with the stored blood samples of the 22 donor’s
were then carried out. The individual HBV-NAT of the 22 samples was all negative. In
February 2011, one of the 22 donors donated blood again and turned out to be positive
for HBV DNA. HBV DNA sequences of the patient and the causative donor samples
showed 99.2% homology between the 2. The screening results of the causative donor at
first-time blood donation were weak positive anti-HBc antibody (8.7C.O.I), weak po-
sitive anti-HBs antibody (29.6 mIU/ml) and negative HBsAg. His plasma was trans-
fused to the patient.
The results indicated that donated blood of the occult HBV carrier with negative
individual NAT caused the post-transfusion HBV infection. Now in Japan, blood
products from some of the anti-HBc-positive donors can be used for transfusion, if
their anti-HBc activities are weak (<12COI), HBsAg-negative and HBV pool NAT-
negative, even if anti-HBs is <200 mIU/ml.
Discussion: Although the post-transfusion HBV infection became rare, the risk of HBV
transmission still exists. To minimize the HBV transmission risk, we are now trying to
lower the cut off value of anti-HBc antibody for blood product. Also, to rescue patients
suffering from viral transmission, we should routinely carry out post-transfusion viral
test according to the national guideline.
P-189
ANTI-HBC SCREENING IN BLOOD DONORS FOR PRESENCE OF
OCCULT HBV INFECTIVITY
Dhawan H, Marwaha N, Sharma R, Chawla Y, Sharma SK, Jain A
PGIMER, Chandigarh, India
Background: Despite mandatory screening of donor blood for HBsAg, transfusion-
associated HBV (TAHBV) continues to be a major problem in India, more so in patients
receiving repeated transfusions.
Aims: The present study was undertaken to assess the prevalence of anti-hepatitis B
core antigen (anti-HBc) positivity, prevalence of antiHBs in blood donors who are
anti-HBc positive and presence of HBV-DNA in serum sample of healthy blood donors
negative for HBsAg. Since anti-HBc detection is not mandatory in India, this study
was aimed to evaluate whether anti-HBc detection could be adopted in India as a
screening assay for HBV in addition to HBsAg to improve further the safety of blood
transfusion.
Methods: Seventeen hundred serum samples negative for HBsAg collected from
healthy blood donors were tested for the presence of anti-HBc antibody. All samples
positive for anti-HBc antibody were then investigated for determination of anti-HBs
and for liver function tests (LFTs). One hundred serum samples reactive for anti-HBc
with and without anti-HBs were tested for HBV DNA by PCR method.
Results: Of the 1700 samples tested, 142 (8.4%) blood samples were found to be
positive for anti-HBc. It was lower in voluntary (6.9%) as compared to replacement
donors (10.4%) (P = 0.011). Seventy two (50.7%) anti-HBc reactive samples were also
reactive for anti-HBs with levels >10 mIU/ml and 70 (49.2%) samples were non-
reactive fore anti-HBs, these units were labeled as anti-HBc-only. These 142 anti-HBc
reactive units were also tested for LFTs (serum bilirubin, AST, ALT). All the samples had
normal serum bilirubin levels, 25 (18%) samples showed enzyme elevation. HBV DNA
was detected in one out 100 samples tested, this sample also contained anti-HBs levels
>150 mIU/ml, LFTs for this sample were within normal limits.
Conclusions: Keeping in view that 8–18% of blood donor population in India is anti-
HBc reactive (as reported in various studies from India), inclusion of anti-HBc testing
will lead to high discard rate. Anti-HBs as proposed previously does not seem to predict
clearance of the virus as the single donor who tested reactive for HBV DNA in our study
had high anti-HBs titers. Cost effectiveness of introducing universal anti-HBc
screening and discarding large number of blood units vs considering ID NAT (Indi-
vidual Donor nuclic acid testing) needs to be assessed. Awareness and education of
donors is required regarding minor modes of HBV transmission, modification of the
donor questionnaire to eliminate all donors with a history of jaundice in adult life and
more stringent one-to-one donor screening to elicit such information should be
implemented.
E-mail: hkdpgimer@gmail.com
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EVALUATION OF THE ROLE OF NUCLEIC ACID
AMPLIFICATION TESTS (NAT) AMONG BLOOD DONORS
IN SOUTH CHINA
Ou SH, Chen CR, Xie JZ, Lin YC, Ni HY
Xiamen Blood Service, Xiamen, China
Background: Nucleic acid amplification test (NAT) for HIV-1, HCV, and HBV can
significantly improve the safety of the blood supply by detecting infectious blood
donated during the seronegative window periods. Although NAT has been routine used
for blood screening in many countries since 1999, it is yet to be implemented in China.
We decided to conduct a study in Xiamen, south China to evaluate the necessity of
NAT among blood donors in China.
Aims: To evaluate the necessity of nucleic acid amplification tests (NAT) among blood
donors in south of Fujian, China.
Methods: Blood donor plasma specimens were collected at Xiamen Blood Service,
Fujian Province, China, between June 2010 and September 2010. All samples were
tested for serology using two different EIA assays for HIV, HCV and HBV. EIA negative
samples were selected for NAT. Roche COBAS TaqScreen MPX Test on the cobas s 201
system (MPX Test) was used to simultaneously detect HIV, HCV and HBV, which is a
single assay, multiplex blood screening NAT that may be performed on individual
specimens, but is designed to run in pools of six. NAT reactive samples were further
tested with the discriminatory assays using COBAS AmpliScreen Tests for the three
viruses. Donor follow-up testing for those potential yield cases were conducted if
possible.
Results: A total number of eight EIA-/NAT+(0.078%, 1/1286) cases were detected;
All were HBV cases. All these eight cases had a viral load <20 IU/ml except one
(91.9 IU/ml). Of these eight cases, seven were positive for anti-HBc (OBI) and one
were anti-HBc negative (WP cases). Follow up testing was possible on four donors,
including one WP and three OBI cases. The WP donor showed HBsAb sero-con-
version after 4 months.
Conclusions: Our data demonstrate that, after EIA screening, there is still a rate of
0.078% (one in 1286) HBV yield cases among blood donor populations in south China
and implementation of NAT can significantly improve the safety of the blood safety.
P-191
STUDY OF IMMUNOREACTIVITY OF EXPRESSED HBX PROTEIN
IN HEPG2 CELL VIA ANTIBODY TO HBX ANTIGEN
Kordestani R1, Sharifi Z2, Hosseini SM3, Mahmoudian Shushtari M1
1Iranian Blood Transfer Organization, Tehran, Iran 2Blood Transfusion Research
Center, Institute of Higher Education and Research, Tehran, Iran 3Department of
Microbiology, Faculty of Biological Science, Shahid Beheshti University, Tehran, Iran
Background: Chronic hepatitis B virus (HBV) infection is one of the main causes of
hepatocellular carcinoma (HCC) worldwide. The HBV- X (HBX) protein, a small reg-
ulatory protein that is required for the establishment of viral infection, is believed to
contribute to the development of HCC.
Aims: Expression of HBX protein in HepG2 cell to study presence of antibody to
hepatitis B virus X antigen (anti- HBX) in HBV Infected Patients.
Methods: The HBX gene was amplified from the whole HBV genome using polymerase
chain reaction (PCR). Next, the HBX gene was cloned into the eukaryotic expression
vector pcDNA3 and constructed mammalian expression vector pcDNA3- HBX
encoding the HBX gene. This expression vector was then transfected into the HepG2
cells by FuGENE 6 Transfection kit. In the end, the complete HBX gene of hepatitis B
was expressed in HepG2 cells and confirmed by sodium dodecyl sulfate (SDS)-poly-
acrylamide gel electrophoresis (PAGE) and western blotting.
Results: The PCR products were separated by electrophoresis on 1.2% agarose gel, A
band with 465 bp size was detected that showed HBX gene was amplified success-
fully using PCR. recombinant plasmid pcDNA3-HBX was confirmed by restriction
endonucleases digestion and colony-PCR and sequencing, presence of 465 bp frag-
ment showed that recombinant plasmid was made. Expression of recombinant
plasmid HBX was confirmed by SDS-Page and western blotting and a band of 17 KD
was detected.
Conclusions: The results of this study showed that the recombinant plasmid pcDNA3-
HBX was made successfully. Finally the results of western blotting showed that HBX is
a immunoreactive protein and can be used for subsequent studies.
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DISTRIBUTION OF HCV GENOTYPES AMONG VOLUNTEER
BLOOD DONORS IN CHINA
Xia W, Xu R, Fu YH
Institute of Blood Transfusion, Guangzhou, China
To determine hepatitis C virus (HCV) genotype distribution in China, a total of 507 HCV
TNA positive serum samples were collected from 17 geographic areas in China and
subjected to RT-PCR followed by direct DNA sequencing in both directions and
phylogenetic and geographic analysis of E1 and NS5B regions. E1 and NS5B sequences
were amplified from 461 and 453, respectively. According to the E1/NS5B phyloge-
netic trees, subtypes including 1a, 1b, 2a, 3a, 3b, 6a, 6n and 6v are identified among
the 17 areas of China. The major prevalent subtype is 1b, accounting for 48.93%.
Subtype 2a is the second prevalent subtype, accounting for 18.88%. HCV patterns
differed between the donors from southern China and northern China, especially in
subtypes 6a (P < 0.000, v2 = 45.175) in southern China, 1b (P < 0.000, v2 = 14.260)
and 2a (P < 0.000, v2 = 25.410) more frequent in the northern group. The 30 subtype
3a isolates formed three clusters, designed cluster I, II and III. In cluster I, all Kunming
and Fujian strains are dispersed among the strains from southwestern China (Yunnan),
Cluster II contained isolates only from GuangDong and cluster III contained isolates
from northern China. These HCV-3a samples indicate a northern China clade from
Russia and a Guangdong clade from Hong Kong. The distribution of HCV genotypes
among volunteer blood donors in china indicated that epidemiological modes may be
changed in some subtypes, with Hunan and Beijing playing a crucial role in HCV-3a
transmission, just as they are important in population migration between different
regions in China.
P-193
This abstract has been withdrawn.
P-194
EVALUATION AND COMPARISON OF THREE ANTI-HEPATITIS C
VIRUS ANTIBODY ASSAY SYSTEMS FOR DIAGNOSIS OF
HEPATITIS C INFECTION BLOOD DONORS IN TAIWAN
Tsai MH1, Lin KT1, Hung CM1, Lin KS2
1Kaohsiung Blood Center, Kaohsiung City, Taiwan 2Head Office Taiwan Blood Services
Foundation, Taipei city, Taiwan
Background: HCV EIA 2.0 or HCV Version 3.0 ELISA has been evaluated in the
immunocompetent populations with anti-HCV prevalence <10% (e.g. volunteer blood
donors). The proportion of false-positive averages approximately 35% (range: 15–
60%). To minimize the possible of false-positive anti-HCV results, the Taiwan Blood
Services Foundation have increased that all anti-HCV positive results are confirmed by
second and third anti-HCV assay.
Aims: The aim of this study was to evaluate and compare three anti-HCV tests: Murex
anti-HCV (version 4.0), Abbott AxSYM HCV 3.0 and VITROS Anti-HCV had been used
for screening blood donor samples in Taiwan.
Methods: There were 438 blood donors included in this study from August to
December 2010. All samples were analysed using three different commercially avail-
able anti-HCV test systems. They were the Murex anti-HCV (version 4.0) (Abbott
Laboratories, Diagnostics Division), the Abbott AxSYM HCV 3.0 (Abbott Laboratories,
Diagnostics Division) and the VITROS Anti-HCV (Ortho-Clinical Diagnostics).
Results: The concordance rates were 70.3% (308/438) among Murex anti-HCV (ver-
sion 4.0), Abbott AxSYM HCV 3.0 and VITROS Anti-HCV. The concordance rates of
Murex anti-HCV with VITROS Anti-HCV and Abbott AxSYM HCV 3.0 were 75%(331/
438) and 73%(324/438). In addition, the concordance rates were 91% (399/438) be-
tween AxSYM HCV 3.0 and VITROS Anti-HCV. This was significant higher than other
rates.
Conclusion: The findings of our study suggest that two immunoassays for anti-HCV
presented a high concordance, the concordance rates of AxSYM HCV 3.0 with VITROS
Anti-HCV was higher than the concordance rates of Murex anti-HCV with AxSYM
HCV 3.0 or VITROS Anti-HCV. Therefore, the results should be explained carefully,
because there were still significant differences between assay methods.
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EVALUATION OF TWO HCV COMBINED AG-AB ASSAYS IN A
BLOOD BANK CONTEXT
Kerleguer A, Girard C
CTSA, Clamart, France
Background: Early detection of HCV infection is crucial to prevent transfusion
transmitted infection in blood banks. The use of combined assays which detect
simultaneously HCV antigen and antibody reduce dramatically the window period
thanks to the antigen detection. However, the antibody detection and the specificity
remain crucial features in a blood bank context to avoid false negative and false
positive results.
Aims: To date, two HCV Ag – Ab combined assays (CE-IVD) are available: Monolisa
HCV Ag-Ab ULTRA (Bio-Rad) and Murex HCV Ag-Ab Combination (Diasorin).
The aim of this study, performed at the CTSA (Blood center of the French Army), is to
compare the performance of both assays especially the anti-HCV sensitivity and
specificity on blood bank routine samples.
Methods: A full validation of each HCV Combined assay has been performed before
starting the evaluation on the Summit microplate processor (Ortho). According to the
CTSA Quality Management System, the following parameters have been tested: con-
tamination, edge effect, repeatability, reproducibility and sensitivity on an anti-HCV
qualification panel (QHV711). The specificity has been evaluated on negative blood
bank samples (n = 425 samples). Then, both HCV combined assays have been tested
with an anti-HCV positive panel from donors constituted during the blood bank routine
activity (n = 29 samples) and with seven commercial seroconversions (n = 72 sam-
ples).
Results: No contamination around strong positive sample and no edge effect were
found with both assays during their validation on the microplate processor. The
repeatability was calculated on negative samples, weak positive samples and strong
positive samples for both assays with equivalent results (CV < 10%). The reproduc-
ibility was calculated with 13 QC for Monolisa HCV Ab-Ab ULTRA (CV = 10.3%), and
calculated with eight QC for Murex HCV Ag-Ab Combination (CV = 28%). The spec-
ificities were calculated at 100% (425/425) with Monolisa HCV Ag-Ab ULTRA and 99%
(421/425) with Murex HCV Ag-Ab Combination.
All PCR positive samples (13/29) from the CTSA routine panel were found positive with
both HCV combined assay. Among the 16 samples PCR negative, six immuno-reactive
samples were discrepant between the two combined assays: four were positive with the
Bio-Rad assay and two were positive with the Diasorin assay. Moreover Monolisa has
detected 38 positive samples and Murex 34 out of 72 seroconversions samples tested.
Conclusion: This study suggests a better sensitivity of Monolisa HCV Ag-Ab ULTRA
assay on HCV positive antibody samples and highlights its very good specificity vs
Murex. Monolisa HCV Ag/Ab ULTRA can be used instead of an HCV Ab assay with no
risk of decreasing sensitivity for HCV Ab detection while reducing the window period
by detecting HCV antigen.
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INTEREST OF CONFIRMATION TESTS IN THE DIAGNOSIS OF
HEPATITIS C VIRUS TO BLOOD DONORS IN ABIDJAN, COTE
D’IVOIRE
Sekongo YM, Kabore S, Konate S, Abisse A, Yao D, Kouamenan G, Dembele B, Siransy
B, Konan K
Centre National de Transfusion Sanguine (CNTS), Abidjan, Cote d’Ivoire
Introduction: The RIBA test anti-HCV (Recombinant Immuno Blot Assay) permit to
verify the presence in the serum, to antibodies HCV detected by ELISA. In the devel-
oping countries, including Coˆte d’Ivoire, screening for hepatitis C is limited by the
immunoassay because of the high cost of RIBA test. To reduce the number of exclusion
of blood donors who are positive to HCV in ELISA test, we conducted this study whose
objective was to demonstrate the interest of the RIBA test confirmatory diagnosis of
hepatitis C virus among blood donors in coˆte d’Ivoire.
Materials and methods: Our study took place from 2 to 23February, 2008 in the
laboratory of the National Blood Transfusion Center (CNTS) in Abidjan, Coˆte d’Ivoire,
examined 200 serum from blood donors anti-HCV positive (ELISA Murex anti-HCV
version 4.0) selected according to the ratio Elisa: low (1.01–5), medium (5.01–8) and
high (>8). The confirmatory test DECISCAN HCV PLUS BIORAD was used to test 200
HCV positive samples. The software Epi Info 6.04 fr was used for data entry and
statistical analysis.
Results: Our overall results showed that the 200 samples positive by HCV EIA, 49%
(98/200) were confirmed positive. The RIBA was indeterminate in 40% of cases (80/
200) and 11% of cases (22/200) positive signals observed with the EIA screening tests
are proven false positive (ie negative). The analysis of samples tested RIBA has allowed
us to note that 96 samples had a low ratio ELISA with 21% (20/96) were negative in
RIBA, and 79% (76/96) were indeterminate. RIBA-positive samples (98/200) had a ratio
high in 82% (80/98). Among the samples positive RIBA, there was the presence of NS3
(C33) and NS4 (C100) in 100% of (98/98). The C2 was present in 37% (36/98) of cases
and C1 in 18% of cases (18/98). Among RIBA indeterminate is noted especially the
presence of NS3 in 98% of cases (78/80) and also the presence of NS4 in 30% of cases
(24/80).
Discussion: The proteins C1, C2 and NS4 are required to confirm the diagnosis of viral
hepatitis C by RIBA.
Conclusion: These results reflect the lower specificity of enzyme immunoassays
(ELISA), hence the interest in the use of RIBA confirmation tests. We conclude that a
significant number of donors are excluded from blood donation in Cote d’Ivoire on the
basis of false obtained positive by ELISA.
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HIV/HUMAN PARVOVIRUS B19 CO-INFECTION IN BLOOD
DONORS AND CLINICAL PATIENTS IN SICHUAN, CHINA
He M, Ke L, Gao L, Pan Z, Yang X, Li W
Institute of Blood Transfusion, CAMS, Chengdu, China
Background: Human parvovirus B19 is a common human pathogen which causes a
variety of diseases. Several studies have demonstrated that the presence of a B19
persistent infection with low-level viraemia beyond 6 month post acute infection is
associated with the degree of host immunodeficiency caused by HIV infection; how-
ever, the existence, loading, evolution and distribution of B19 virus in Chinese HIV
positive individuals have not been determined.
Aims: To investigate the prevalence of parvovirus B19 infection in HIV-infected
individuals from blood donors and clinical patients in Sichuan, China, and to reveal the
evolutionary status of human parvovirus B19 distribution in this area during last two
decades.
Methods: Five hundred and seventy-three HIV serological positive individuals from
blood donors and clinic patients were investigated in Sichuan, China in last two
decades. DNA extracts were used for detection and quantification of viral genome by
Real time PCR. The Nested PCRs were used to confirm the existence of B19 genome and
the sequences were subjected for phylogeny and haplotype analysis. Seventy-nine HIV
positive individuals and 92 HIV negative individuals comprised of blood donors were
tested for B19 virus specific antibodies.
Results: Twenty-six out of 573 of HIV positive individuals tested positive for B19
genome DNA, putting overall prevalence of B19 genome DNA at 4.5% (95% CI: 2.8–
6.2%). The B19 genome DNA prevalence in HIV positive population is significantly
higher than that of normal blood donors. The quantitative DNA levels ranged from
5.3 · 102 to 1.1 · 105 copies/ml. The characteristic of these B19 genome DNA positive
samples was also studied. The seroprevalence of IgG in HIV positive samples was
significantly lower than that of HIV negative blood donors (32.6%, 95% CI, 23.0–
42.2%, P < 0.05) indicating the deficiency of producing B19 specific IgG. Genome
sequencing, phylogeny and haplotype analysis of the isolates from B19/HIV co-in-
fected samples were studied. The B19 sequences from this study were placed in
Genotype 1 subtype B19-1A which formed a monophyletic group; seven distinct
haplotypes were discovered with 60% of the B19/HIV co-infected samples sharing one
central haplotype.
Summary: Human parvovirus B19 in HIV positive patients in Sichuan, China has been
investigated. This study not only elucidates the importance infection demographic
information, the existence, loading, virus evolution and distribution of B19 in Sichuan,
Chinese HIV positive patients, but also shed lights on the diagnosis and therapy of B19/
HIV co-infection patients.
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HIGH HIV-1 GENOTYPE DIVERSITY AMONG BLOOD DONORS
IN SICHUAN, CHINA
Zeng P, Wang X, Pan Z, Yang X, Liu Y, He M, Yuan Y, Xu M, Liu G, Wang J
Institute of Blood Transfusion, CAMS, Chengdu, China
Background: The increasingly HIV-1 diversity challenges the highly active antiret-
roviral therapy treatment and vaccine development. HIV-1 has been becoming leading
cause of death among infectious diseases in China, in which Sichuan province is one of
the high prevalence areas. Although there have been several studies examining the
genetic diversity in HIV-1 infected individuals from high risk populations in China,
there are very limited data from HIV-1 infected volunteer blood donors.
Aim: Molecular epidemiological method was applied to determine genotype diversity
in Sichuan province among the HIV-1 infected blood donors.
Method: HIV-1 confirmed reactive serum samples were collected from HIV-1 confir-
matory laboratory, Institute of Blood Transfusion, Chinese Academy of Medical Sci-
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ences during 2007–2010. HIV-1 Pol including whole protease and partial reverse
transcriptase (RT) genes was amplified, sequenced, and analyzed for the subtype
determination.
Result: Ninety-nine amplified sequences had the following genotype characteristics: G
(1/99, 1.0%), F1 (1/99, 1.0%), circulating recombinant form (CRF) 08_BC (2/99, 2.0%),
CRF01_AE (44/99, 41.4%), and CRF07_BC (54/99, 54.6%). Five subtypes or CRFs of
HIV-1 were identified in Sichuan province from 2007 to 2010, and the main prevalence
strains were CRF01_AE and CRF07_BC.
Conclusion: HIV-1 infection in Sichuan blood donors reflects highly genetic diversity.
This is the first report on HIV-1 genotype diversity in Sichuan province among infected
blood donors. Our further study will link the epidemiology characteristic results to
monitor the HIV-1 genotypes evolutionary trends in Sichuan blood donors as a part of
an overall China HIV control project.
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SURVEY OF HEPATITIS B VIRUS (HBSAG), HEPATITIS C VIRUS
(HCV-AB) AND SYPHILIS COINFECTION AMONG HIV POSITIVE
BLOOD DONORS BETWEEN 2006 AND 2010
Lin MC, Hsiao CC
Taiwan Blood Services Foundation, Taipei, Taiwan
Background: HIV, HBV and HCV are major public health concerns. Because of shared
routes of transmission, HIV-HCV coinfection, HIV-HBV coinfection and HIV-syphilis
coinfection are common. HIV-positive individuals are at risk of coinfection with HBV
and HCV infections. The prevalence rates of coinfection with HBV and HCV in HIV-
blood donors have been variable worldwide depending on the geographic regions, and
the type of exposure.
Aim: This study aimed to retrospecticly examine HBV, HCV and Syphilis coinfection
serologically and determine the shared and significant factors in the coinfection of
HIV-positive blood donors.
Methods: This descriptive, cross-sectional study was carried out on 351 HIV-positive
blood donors including 333 males and 18 females in Taiwan, to survey coinfection
with Syphilis, HBsAg and anti-HCV. The retrospective demographic data of the subjects
was collected and the donors’ serums were analyzed by TPHA/ELISA kits including
Syphilis, HBsAg and anti-HCV. The collected data was analyzed with MINITAB soft-
ware and Chi-square. Fisher’s exact test with 5% error intervals was used to measure
the correlation of variables prevalence rates.
Results: The results of the study indicated that the prevalence of coinfection in HIV-
positive blood donors with syphilis was 13.1% (46 in 351), hepatitis viruses was
5.98% (21 in 351), out of whom 14 (3.99%) cases were anti-HCV positive, 7 (2.0%)
cases were HBsAg positive, and 3 (0.9%) cases were both HBsAg and anti-HCV
positive.
Table 1: Prevalence of Syphilic, HCV and HBV positivity among HIV blood donors
Conclusion: There was a significant correlation between coinfection with syphilis,
HCV and HBV and/or both among HIV-positive patients depending on different
variables including sex, age status exposured to risk factors.
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CURRENT INCIDENCE AND ESTIMATED RESIDUAL RISK OF
TRANSFUSION-TRANSMITTED HUMAN IMMUNODEFICIENCY
VIRUS INFECTION IN QINGDAO, CHINA
Feng Q, Zhou B
Qingdao Blood Center, Qingdao, China
Background: Accurate estimation of the risk of human immunodeficiency virus (HIV)
infection through transfusion is essential for monitoring blood safety. The risk, how-
ever, is so low that it can only be estimated by mathematical modeling.
Aims: This study evaluates the HIV antibody screening strategy of duplicate enzyme-
linked immunosorbent assay (ELISA) in QingDao Blood Center and therefore estimates
current incidence and the residual risk of transfusion-transmitted HIV infection.
Methods: Data from QingDao Blood Center between January 2006 and May 2011 were
used. During the study period 312,394 donations from voluntary blood donors,
including new donors and regular ones. The data of screening and confirmatory test
results for this study were collected from the electronic data files with the software of
Tangshan standardized management system for modern blood centers, containing
information on donor profiles. We estimated the risk of HIV transmission caused by
transfusion on the basis of the window period associated with the use of current,
sensitive enzyme immunosorbent assays and recent data on HIV incidence among
blood donors.
Results: A total of 312,394 donations from voluntary blood donors in QingDao Blood
Center were screened for HIV antibody, including 118,715 (38%) regular donors and
193,679 (62%) new ones. There were 18 HIV-positive donations (nine in regular do-
nors and nine in new ones) which occurred predominantly in males. By calculating,
the incidence rates of HIV-positive was 7.58 and 4.65 donors per 100,000 person-
years in repeated donors and new ones respectively, and the new frequency of
infecting HIV was 0.116 and 7.10 donors per 100,000 person-years. The mean in-
terdonation interval in years was 239 days that was obtained by dividing the number
of donations by the number of donors and by multiplying this ratio by the duration of
the study period. The length of the preseroconversion window period for anti-HIV was
derived from published data: 22 days. Using serological methods, the residual risk
using a statistical model was 1:186,512. Otherwise, we tested 81,989 donors’ samples
by NAT pilot project between July 2010 and May 2011, and the residual risk was
1:208,975.
Conclusions: The estimates of the transfusion risk of HIV infection in each country is
important, both to assess the impact of current preventative strategies and contribute
datas to policy decisions to reinforce transfusion safety. The major factor contributing
to the differences in risk between QingDao and other areas with similar testing regimes
is the lower prevalence of HIV in the source populations. Except for adorpting NAT, we
recommend further improvements to more efficient selection of blood donors for high
incidence HIV-positive in regular donors. The greater challenge is to identify, recruit,
and retain a pool of donors with lower prevalence of the target diseases.
4.5 Bacteria
P-201
THE PRELIMINARY STUDY OF PHOTOSENSITIZER YWW007 ON
PLASMA INACTIVATION OF BACTERIAS
Bian G, Yang CH, Yang H
Institute of Blood Transfusion, CAMS, Chengdu, China
Objective: To investigate the effects of different concentrations of YWW007 pheno-
thiazines photochemical to different kinds of bacterias in blood plasma.
Methods: Using Bacillus cereus, Pseudomonas aeruginosa, Staphylococcus aureus,
Staphylococcus epidermidis and E. coli as model bacterias, the bacterias were seeded
into 5 ml plasma, a new synthesized phenothiazine derivative YWW007 was tested for
its ability of bacterias inactivation with different concentration in 4, 8, 12 and 16 lM,
2.33 ± 0.17 mW/cm2 intensity of absorption wavelength of 600–700 nm red light was
used to irradiate for 30 min.
Results: The ability of inactivating bacterias was as follow: Bacillus cereus > Staph-
ylococcus aureus > Staphylococcus epidermidis > E. coli > Pseudomonas aeruginosa.
During the growth of bacterials, when the value of the OD is about 0.6, the inactivation
of bacterias is better than other values. In addition, when the concentration of the
YWW007 is only 4 lM, the Gram-positive bacterias, such as Bacillus cereus, Staph-
ylococcus aureus and Staphylococcus epidermidis were inactivated. Furthermore, the
ability of inactivating bacterias was weaker in the Gram-negative bacterias, for in-
stance, E. coli as well as Pseudomonas aeruginosa, especially when the value of the OD
is more than 1.
Conclusion: YWW007 in the procedure of Gram-positive bacterias inactivation is
better than Gram-negative bacterias inactivation. Moreover, the ability of inactivating
bacterias is much better when the bacterias in the logarithmic growth stage.
P-202
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4.6 Parasites
P-203
SEROEPIDEMIOLOGY OF TOXOPLASMA GONDII INFECTION
AMONG HEALTHY BLOOD DONORS IN TAIWAN
Hsieh H1, Ji D2, Chiang T2
1Taiwan Blood Services Foundation, Taipei, Taiwan 2Research and Diagnostic Center,
Centers for Disease Control, Taipei, Taiwan
Background: Toxoplasmosis is one of important zoonotic diseases worldwide, which is
caused by Toxoplasma gondii. The seroprevalences of toxoplasmosis varied in different
countries from 20% to 40% in UK, 50–60% in USA to 80–90% in France. However,
little is known about seroprevalence among Taiwanese.
Methods: Serological and molecular biological methods were used for the toxoplas-
mosis confirmation in CDC. Taiwan Blood Services Foundation was collaborated in this
study, and a total of 1600 blood samples of healthy blood donors were collected from
six branch blood service centers.
Results: The preliminary results indicated that the IgG positive rate in Hualien, Taipei,
Hsinchu, Taichung, Tainan and Kaohsiung were 14%, 9%, 8%, 8%, 9% and 7%,
respectively, and total positive rate was 9.8%. Two IgM positive cases were detected. But
their IgG avidity was high and real-time PCR was all negative. Altogether, the pre-
liminary results indicated there was no Toxoplasma gondii contamination in the blood
bank so far. IgG positive was more prevalent among blood donors who used not-boiled
underground water (OR = 1.07, P < 0.05), low education status (OR = 0.76, P < 0.05)
and ate raw shellfish such as scallop and Taiwanese abalone (OR = 1.98, P < 0.05).
Conclusion: These findings highlighted the prevalent T. gondii in healthy blood
donors in Taiwan, and risk factors should be addressed for disease control
measures.
4.7 Newly Emerging
Pathogens and Other
Transfusion Related
Pathogens
P-204
HUMAN HERPESVIRUS TYPE 8 IN END-STAGE RENAL DISEASE
PATIENTS WITH BLOOD TRANSFUDION
Su C-C, Tsai JP, Lin MN
Buddhist Dalin Tzu Chi General Hospital, Chiayi County, Taiwan
Background: Human herpesvirus type 8 (HHV-8) is the etiologic agent of Kaposi’s
sarcoma (KS). The incidence of KS in renal transplant patients is much higher than in
healthy controls and the risk of KS is higher among recipients who were anti-HHV-8-
positive before transplantation. Patients with end-stage renal disease (ESRD) are
candidates for renal transplantation and usually receive blood transfusion, but the
prevalence of HHV-8 infection in ESRD patients with or without blood transfusion has
not been well documented.
Aims: To compare the prevalence of HHV-8 infection in ESRD patients with or
without blood transfusion and age-matched healthy controls.
Methods: Blood samples from 97 ESRD patients and 97 age- and sex-matched healthy
controls were collected and analyzed for lymphocyte and monocyte counts, HHV-8
antibody and DNA, and anti-HIV.
Results: ESRD patients had significantly lower lymphocyte counts, higher monocyte
counts, and higher prevalence of lymphopenia and monocytosis than did healthy
controls (P < 0.0001, each). The seropositive rate and titers for HHV-8 antibodies in
ESRD patients were significantly greater than those in healthy controls (P < 0.002,
both). The mean age of the seropositive male patients (58.7 years) was significantly
younger than that of females (67.4 years) (P = 0.0176). The high seropositive rate in
ESRD patients was not associated with lymphopenia, monocytosis, diabetes, dialysis
duration, or history of blood transfusion. All subjects were negative for anti-HIV. One
diabetic ESRD patient was positive for both HHV-8 antibody and HHV-8 DNA
(18,720 copies/ml).
Conclusions: ESRD patients have high seropositive rates for HHV-8. ESRD patients,
particularly those positive for HHV-8 DNA, should be closely monitored for HHV-8-
associated clinical manifestations if they are to receive renal transplants.
P-205
ESTABLISHMENT OF AN IN VITRO CULTURE SYSTEM AND THE
METHODOLOGY FOR EVALUATING AN INFECTIOUS TITER OF
HEPATITIS E VIRUS (HEV) USING HEV-RNA-POSITIVE
PLASMA OBTAINED FROM BLOOD DONORS IN JAPAN
Owada T1, Suzuki K1, Matsumoto C1, Igarashi M1, Sobata R1, Kaneko M1, Matsubayashi
K2, Uchida S1, Satake M1, Tadokoro K1
1Japanese Red Cross Society, Tokyo, Japan 2Hokkaido Red Cross Blood Center, Sapporo,
Japan
Background: The hepatitis E virus (HEV) was found to be transmitted by blood
transfusion and to occasionally cause severe hepatitis, although it has been generally
considered that hepatitis E is a water-borne disease and mostly found in developing
countries. Recently, HEV has been recognized to be spreading widely throughout the
world including industrialized nations. Thus, the possibility of HEV infection via
transfusion is a major concern globally. It is necessary to establish an evaluation
system for HEV infectivity, which will be applicable to evaluating strategies for
ensuring blood product safety.
Aims: It has recently been reported that the virus obtained from plasma has a different
composition in the envelope-like structure from that obtained from feces. Hence, it is
necessary to establish a culture system using HEV-RNA-positive plasma obtained from
blood donors and cell lines, and to expand this system to a methodology for evaluating
an HEV infectious titer referred to as the tissue culture infectious dose (TCID). More-
over, the numerical relationship between the copies of HEV RNA and HEV TCID was
investigated.
Methods: Fourteen plasma specimens containing HEV of genotype 3 were employed,
which were either positive or negative for specific IgM and IgG. The cell lines of human
hepatoma cells (PLC/PRF/5) and human lung adenocarcinoma cells (A549) were
inoculated with viral specimens for 2 h at 37C. The cells infected with HEV were
incubated in a maintenance medium containing 30 mM Mg2+ and 2% FCS. This
medium was collected and replaced every week. HEV RNA copies were determined by
real-time RT-PCR analysis. The establishment of HEV infectivity was confirmed by the
detection of viral progenies in recovered media after 3 weeks of incubation. High-load
HEV particles were collected by ultracentrifugation (82,700 g), and limiting dilution
assay was carried out to confirm the TCID of HEV.
Results: Viral progenies were detected in recovered media when the HEV JRC-HE3
strain [IgG()), IgM (+)] or HEV UA1 strain [IgG(+), IgM(+)] was used, indicating that
HEV-positive plasma can express infectivity on cells. No cytopathic effect was ob-
served in any case. The viral progeny concentration reached approximately 108copies/
ml as a result of a longer incubation of HEV-infected cell lines. Moreover, 109.72copies/
ml of the JRC-HE3 strain was obtained by ultracentrifugation. Limiting dilution assay
showed that at a 104-fold dilution of this concentrated JRC-HE3, the infectivity of the
strain was expressed. These findings lead us to the conclusion that 1TCID in this
situation corresponded to 105.42copies of HEV.
Summary/conclusion: We were able to establish an in vitro culture system using
HEV-RNA-positive plasma obtained from blood donors in Japan. The methodology for
the titration of HEV infectivity may be applied to evaluating strategies for ensuring
blood product safety, e.g. pathogen inactivation.
P-206
PARVOVIRUS B19 CONTAMINATION IN CHINESE PLASMA
POOLS AND PLASMA DERIVATIVES
Ke L, Li L, Zhang Y, Xie Y, Li W
Institute of Blood Transfusion, CAMS, Chengdu, China
Background: Human parvovirus B19, a member of the genus Erythrovirus within the
subfamily Parvovirinae, is a common human pathogen which causes a variety of
diseases, such as erythema infectiosum in children, aplastic crisis, chronic pure red cell
aplasia, foetal hydrops, foetal death, and so on. The B19 virus can be transmitted via
blood/blood products and its resistance to common viral inactivation/removal methods
raises the importance of B19-related blood safety. Because of known risks in indi-
viduals with chronic anaemia and those who are pregnant or immunocompromised,
European Pharmacopoeia and FDA impose a limit of £104 IU/ml for all plasma-derived
products. However, the prevalence and levels of B19 in Chinese blood products have
not been investigated.
Aims: The aim of this study was to determine the prevalence and the levels of B19
DNA in plasma pools destined for fractionation and in a wide variety of plasma
derivatives made by Chinese manufacturers.
Methods: Two hundred lots of blood products and 90 lots of plasma pool samples
made during 1993–1995 and 2009–2011 from four Chinese blood product manufac-
turers were analyzed for B19 viral DNA content using an in-house developed Q-PCR
assay which detects all three genotypes of the human erythrovirus DNA simulta-
neously. Results were confirmed by nested-PCR.
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Results: The prevalence of B19 DNA in plasma pools were 16.3% (13 out of 80 lots)
and 10% (two out of 20 lots) from two manufacturers, and the levels of B19 DNA
varied ranging from 2.0 · 103 to 5.85 · 107 geq/ml. The resolving processes are
ongoing. The prevalence of B19 DNA were 30% with median level of 2.74 · 103 and
11.1% with median level of 1.24 · 106 in albumn and IVIG, respectively made during
1993–1995. The prevalence of B19 DNA were 5.6% with median level of 5.83 · 103,
25% with median level of 1.12 · 105 and 50% with median level of 3.32 · 104,
respectively among IVIG, factor VIII and Fibrinogen made during 2009–2011; how-
ever the prevalence of B19 DNA was not detected in albumin made in the same
period. In comparison, the prevalence and level in factor VIII and Fibrinogen are
relative high.
Summary/conclusions: B19 DNA was detectable in 20–30% of Chinese plasma pools
and blood derivatives and the levels of B19 DNA varied among different products. The
high prevalence of B19 DNA in Chinese plasms pools and blood products poses high
risk to public health, and Chinese SFDA needs to consider to require B19V testing in
plasma pools and plasma derivatives.
P-207
DENGUE FEVER VIRAL EXPOSURE RATES AMONG
AUSTRALIAN BLOOD DONORS DURING LOCAL OUTBREAKS
Flower RLP1, Fryk J1, Hyland C1, McBride J2, Ritchie S2, Faddy H1
1Australian Red Cross Blood Service, Brisbane, Qld, Australia 2James Cook University,
Cairns, Qld, Australia
Background: Dengue is not endemic in Australia; rather in North Queensland, out-
breaks occur seasonally. One of the largest epidemics in the last 50 years took place in
2008/2009, affecting a significant geographical area of North Queensland, with sep-
arate outbreaks in Cairns (and surrounding regions; DENV-2,3,4 08–09) and Townsville
(DENV-1,3 09). Collectively, in these outbreaks there were more than 1000 confirmed
clinical cases, with the majority of cases occurring in the Cairns region. Given the
absence of an approved screening test, the strategy utilised by the Australian Red Cross
Blood Service (Blood Service) for managing the risk of transfusion-transmitted dengue
was exclusion of at risk donors. During this epidemic, supplementary questioning for
all donors was implemented to determine exposure risk, and fresh components were
not manufactured from at risk donors.
Aims: This study aimed to estimate dengue fever viral exposure rates among Aus-
tralian blood donors during this large epidemic.
Methods: Samples were collected from blood donors during the 2008/2009 epidemic
and 3 months after the last confirmed cased. Selected samples were tested for the
presence of the dengue NS1 antigen with commercially available ELISA-based assay
kits from PanBio.
Results: Nineteen of 1020 donations collected in Cairns during the epidemic and se-
lected for testing showed repeat reactivity towards the NS1 antigen, and one of 67
donations collected in Townsville during the epidemic and selected for testing showed
repeat reactivity towards the NS1 antigen. Viral RNA was not detected in any of these
NS1 reactive donations.
Summary/conclusions: This study suggests recent dengue exposure in a self-declared
asymptomatic population, and provides an understanding of the rate and dynamics of
asymptomatic dengue infection in North Queensland during these recent outbreaks.
Discordant results between NS1 and viral RNA detection needs further evaluation.
Collectively, this study justifies the use of DENV management strategy during a DENV
outbreak in north Queensland.
P-208
A DUPLEX TRANSCRIPTION-MEDIATED AMPLIFICATION
ASSAY FOR THE SIMULTANEOUS QUANTITATION OF PARVO-
VIRUS B19 DNA AND QUALITATIVE DETECTION OF HEPATITIS A
VIRUS RNA ON A FULLY AUTOMATED INSTRUMENT SYSTEM
Gao K, Linnen J, Nugent T, Janssen A, Wellbaum J, Cory R, Le T, Do D, Babizki M
Gen-Probe Inc., San Diego, CA, United States of America
Background: To reduce the risk of contamination of plasma derived products with
parvovirus B19 (B19) and hepatitis A virus (HAV), nucleic acid testing (NAT) is
performed as an in-process test for both Source Plasma and recovered plasma. The US
FDA recommends and European regulations require (for certain plasma products) B19
testing to ensure that the viral load of B19 DNA in manufacturing pools does not
exceed 104 IU/ml. In process testing for HAV is also commonly performed to achieve
an increased margin of safety but its implementation is not universal.
Aims: To develop and assess the performance of a duplex transcription-mediated
amplification (TMA) assay for the simultaneous quantitation of B19 DNA and the
qualitative detection of HAV RNA on the fully automated TIGRIS System.
Study design/methods: We evaluated precision of B19 quantitation and linearity
(quantitative range) from 300 to 175,000 IU/ml using standard panels and diluted
parvovirus clinical specimens. To assess the accuracy of quantitation of parvovirus
genotypes 1, 2, and 3, the 1st WHO International Reference Panel (NIBSC code: 09/110)
was diluted and tested at 104 IU/ml. The limit of detection (LOD) for HAV was
determined using the WHO First International Standard for HAV (NIBSC code: 00/560)
and was also evaluated in the presence B19 concentrations up to 109 IU/ml.
Results/findings: A quantitative range of >2.5 logs was demonstrated, indicating
suitability for screening for high titers of B19 DNA in plasma pool sizes ranging
from 16 to 512 donations. Reproducible quantitation of diluted parvovirus clinical
specimens was observed; intra-sample variation ranged from 0.02 to 0.09 log IU/ml
standard deviation (SD) over the range of concentrations tested (approximately 600–
37,500 IU/ml). Genotypes 2 and 3 were quantified nearly equivalently to genotype 1,
with <0.2 log IU/ml difference. The 95% LOD for HAV RNA was determined to be
0.84 IU/ml (95% fiducial limits: 0.59–1.48). Hgh titers of B19 had little effect on HAV
analytical sensitivity, as 96% detection of HAV at 1 IU/ml was observed in the presence
of 109 IU/ml of B19.
Conclusion: These results showed the feasibility of a duplex assay on the fully
automated TIGRIS System for quantifying B19 DNA over a quantitative range that
would allow screening for high titer B19 samples in commonly used pool sizes.
Additionally, we showed sensitive detection of HAV RNA, even in the presence of high
titers of B19. Overall, these results demonstrated that this assay may be useful for in
process testing of Source and recovered plasma to further improve the safety of
plasma-derived products.
P-209
HTLV-1 AND -2 SEROPREVALENCE AMONG UNITED STATES
BLOOD DONORS, 2000–2009
Murphy L1, Kaidarova Z2, Bravo M3, Kiely N3, Kamel H3
1UCSF/BSRI, San Francisco, CA, United States of America 2BSRI, San Francisco, CA,
United States of America 3Blood Systems Inc., Scottsdale, AZ, United States of America
Background: HTLV-1 and -2 infection is prevalent at low levels in the United States,
and monitoring of HTLV prevalence among large numbers of blood donors screened at
donation may provide useful data for public health surveillance.
Aims: To measure contemporary HTLV-1 and -2 seroprevalence and demographic
associations among US blood donors.
Methods: Computerized data on all first-time blood donors in a large network of
United States blood centers was examined during the period 2000–2009. HTLV-1/2
antibody was measured by enzyme immunoassay (EIA) screening with reactive samples
retested with an EIA from an alternate manufacturer (ALT EIA). From 2006 to 2009,
confirmatory data was available from either the California Dept of Health or the Innolia
recombinant immunoblot. Prevalence rates were calculated, and odds ratios (OR) and
95% confidence intervals (CI) for associations with demographic characteristics were
assessed using multivariate logistic regression.
Results: Among 1,904,155 first-time blood donors, HTLV-1/2 ALT EIA reactivity de-
creased from 10 per 10,000 in 2000 to 5 per 10,000 in 2009 (P trend < 0.0001). During
the latter years with confirmatory testing data, about one quarter of ALT EIA reactives
were confirmed, yielding a prevalence of 1.43 per 10,000 (95% CI 1.19–1.72 per
10,000). HTLV-1 was half as common as HTLV-2 (prevalence 0.40 per 10,000 vs 0.87
per 10,000; HTLV positive but untypable prevalence was 0.25 per 10,000). Prevalence
increased with age through middle age and then decreased in older age. HTLV-1/2
infection was associated with female sex (OR = 2.28, 95% CI 1.43–3.65), age 50–59
(OR = 15.58, 95% CI 6.01–40.38), Black (OR = 9.16, 95% CI 4.75–17.67) and Asian/
Other (OR = 9.24, 95% CI 4.63–18.44) race/ethnicity, and inversely with university
education (OR = 0.51, 95% CI 0.27–0.96). There was minimal geographic variation,
although donors from the southwestern US had the highest prevalence.
Conclusions: HTLV-1/2 prevalence is decreasing slowly among US blood donors, both
over the 10 years of this study and compared to published studies from the 1990’s. This
is consistent with a birth cohort effect whereby donors born in the 1950s and 60s with
the highest HTLV prevalence are now less likely to be first time donors. HTLV asso-
ciations with female sex, nonwhite race and lower educational achievement are con-
sistent with those from previous studies. With 3.2 million first-time donors annually,
US blood banks still detect almost 500 HTLV infections per year which require
counseling and medical followup.
P-210
HTLV-1 INFECTION AMONG BLOOD DONORS IN SOUTH CHINA
Ou SH, Xie JZ, Chen CR, Lin YC, Ni HY
Xiamen Blood Service, Xiamen, China
Background: HTLV-1 is causatively associated with adult T-cell leukemia (ATL) and
HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). It is known
that transmission of these viruses may occurs through blood transfusions. No effective
treatment drugs and preventive vaccines have been successfully developed yet for
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HTLV-1 infection. Therefore, the effective method for disease control is to take mea-
sures to block the transmission routes of the virus.
Aims: To assess the distribution of HTLV-1 in blood donors and particularly the risk of
infected HTLV-1 during the blood transfusion.
Methods: Blood samples were obtained from unpaid blood donors (n = 131,823) from
the Xiamen Blood Services from February 1st, 2004, to March 31st, 2009. Primary
screening for HTLV-1/2 antibody was performed using the anti-HTLV (1 + 2) Antibody
ELISA Kit. Positive samples first screened by ELISA were reconfirmed by western
blotting (WB) and/or real-time fluorescence PCR (Taqman-MGB probe).
Results: Twenty-four (0.02%) cases were identified as positive for HTLV-1. Sixteen of
them were identified as the HTLV-1 A subtype (Cosmopolitan), 15 strains belonged to
the Transcontinental Subtype, and one strain belonged to the Japanese Subtype.
Conclusions: HTLV virus-infected individuals occur in Xiamen blood donor and
mainly concentrated in the southeast coastal areas. To prevent HTLV transmission via
blood transfusions and to improve blood safety, it is necessary to detect the virus in a
timely manner in areas with high incidence and central cities with high population
mobility. More systematic studies need to be performed on the molecular epidemiology
of HTLV in Xiamen and surrounding areas.
5. Immune Haematology
5.1 Red Cell Immunology:
Serology
P-211
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THE SELECTION OF SCREENING CELLS FOR THE DETECTION OF
ANTI-DIA ANTIBODY
Wang CL, Chang SL, Chen WF, Lin M, Ho HT
Mackay Memorial Hospital, Taipei, Taiwan
Background: The selection of screening cells is very important because it may di-
rectly affect the antibody detection rate. Prior to 1984, there was no difference in
selecting screening cells between the white and Taiwanese. From 1984 to 1988, we
had only identified 11 cases of Anti-Mia antibody. Since the Mia-positive screen cells
became available in 1990, the most common alloantibody now in Taiwan had swit-
ched to anti-Mia which relegating anti-E and anti-c to the second and third places. As
currently known to us, Mia antigen are positive in 7.3% of Taiwanese and 88% of
Amis aboriginal population. Similarly for anti-Dia antibody, it rarely occurred in
Taiwan and we encountered only nine cases before the year of 2000. Since then, its
detection rate gradually increased after Dia-positive cells added in the screen panel.
Here we reported the recent status of anti-Dia antibody, another emerging alloanti-
body in Taiwan.
Patients and methods: We collected the pretransfusion testing data of our hospital
patients from January 2001 to December 2010. Three-cell antibody screening kits (O
type, DAT negative cells) were provided by Taiwan blood donation center and Formosa
Biomedical Technology Corporation. Both manual polybrene (MP) method and LISS
indirect antiglobulin test (LIAT) method were used.
Results: Among all patients received the pretransfusion testing, there were 3666 cases
positive for identifiable alloantibodies. The average detection rate of anti-Dia antibody
was 1.4% (51/3666).
Table 1
Year 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 Total
Alloantibody
identified
274 201 219 269 441 369 364 456 539 534 3666
Anti-Dia 0 3 3 3 7 8 9 9 6 3 51
Conclusion: At 37C anti-Dia is a clinically significant IgG antibody which may cause
newborn hemolytic diseases and hemolytic transfusion reaction. We prefer to use the
MP method due to its easier performance for issuing blood, especially with 96.8% Dia-
negative rate in Taiwan. The LIAT method is more sensitive but time-consuming as
compared to MP method. Antibody screening is indispensable in the compatibility test
for issuing blood. Professor Marie Lin recommends screening cells must include all
antigens with 3% or higher incidence in Taiwan, namely Mia and Dia in addition to
frequent antigens of the white people. In order to enhance the antibody detection rate
for transfusion safety, she considers the antigen distribution and dosage response. For
the former, separate distribution of Mia, Dia, and E, c antigens in three screening cells
is suggested. For the latter, it is better to choose homozygous cells than heterozygous
cells.
P-213
DETECTION OF ALLOANTIBODIES IN PATIENTS WITH WARM
AUTOANTIBODY
Chang FJ, Ho HT, Hong CC, Lo CW, Hsu TY, Lin M
Mackay Memorial Hospital, Taipei, Taiwan
Background: Patient with hematological disease especially autoimmune hemolytic
anemia (AIHA) was usually thought to have higher chance to carry red cell alloanti-
body. In our previous study in early 1980s we reported one case with alloantibody
(anti-M) out of nine cases of AIHA (11%), and in 1997–1998 we reported two cases
with alloantibodies (anti-E, anti-E+‘Mia’) out of eight cases AIHA (25%). We reviewed
serological study records of warm autoantibody during 22 months period (2005 Jan-
uary–2006 October) at Blood Bank, Mackay Memorial Hospital.
Materials and methods: A total number of 34 cases with warm autoantibody were
studied (serological investigation and brief clinical record review). Serological study
include antibody identification by manual Polybrene method and LIAT; adsorption and
elution of autoantibody.
Results and discussion: Of 34 patients with warm autoantibody, 16 patients were with
hematological disease (five cases ITP, two SLE, two AIHA, two MDS, each one case of
acute leukemia, lymphoma, anemia, hypereosinophilic syndrome and hemophagocytic
syndrome) -first group. The other 18 cases with warm autoantibody of non hemato-
logical diseases including pneumonia, liver cirrhosis, etc -second group. The alloan-
tibody associated with first group patients was each one case of anti-‘Mia’, anti-E+c,
anti-C+e and anti-Wra, with the alloantibody frequency of 25% (4/16). Alloantibodies
associated with second group were three cases anti-E, three anti-‘Mia’, each one case of
anti-D, anti-E+c, anti-E+Jka and anti-E+Jka+Fya, with alloantibody frequency of 55%
(10/18).
The alloantibody frequency associated with hematological disease and AIHA was kept
around 11–25% since 1980s in our hospital, however, it is surprisingly to find that the
alloantibody was more frequently (55%) associated with patients of non hematological
disease who carry warm autoantibody. The reason for these difference is probably due
to the patients with hematological diseases are usually under immunosuppressive
treatments.
Conclusion: Difference from previous assumption that patients with AIHA have more
chance to carry alloantibody in addition to warm autoantibody, while in this study
we found that the patients of non hematological disease with warm autoantibody on
the contrary have more chance to carry alloantibody (55%) than patients with
hematological disease (25%) including AIHA. This probably due to patients with
hematological disease are usually undergoing immunosuppressive treatments.
P-214
ANTI-LEA IN LE(A)B+) INDIVIDUALS
Chan YS, Lin M
Mackay Memorial Hospital, Taipei, Taiwan
Background: There are differences in Lewis phenotype as well as phenotype distri-
bution between Taiwanese and Caucasians. In Taiwan except for Taiwan Aborigines
(2% of total population) having Le(a + b)) phenotype, the majority Taiwanese are 0%
Le(a + b)), 25% Le(a + b+), 67% Le(a)b+) and 8% Le(a)b)). During studying the
Le(a + b+) phenotype we observed various different strength of Lea and Leb antigens in
this phenotype. In our hospital transfusion service we also encountered different
pattern of Lewis antibody production among our patients, especially surprisingly to
find anti-Lea among Le(a)b+) patients.
Materials and methods: During 5 years period (2005–2010), Blood Bank of Mackay
Memorial Hospital issued 188,625 units of red cells, detected 130 cases of Lewis
antibodies during antibody screening and pretransfusion testing. The routine procedure
of antibody screening and cross matching are by manual Polybrene method. The
antibody was further evaluated by LIAT with or without prewarmed technique. Clinical
history of 35 patients including 10 patients with anti-Lea, four with anti-Lea + Leb,
and nine with anti-Leb in Le(a)b)) phenotype; 10 with anti-Lea in Le(a)b+) pheno-
type; and two with anti-Leb in Le(a + b)) phenotype were studied.
Results: The clinical history of 35 cases studied showed no significant difference
between patients producing Lewis antibodies in various phenotypes. Among 27 cases
(7 + 20) with anti-Leb, only one case were group O, so almost all of them were anti-
LebL.
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Table 1: The Lewis phenotype of 130 cases with Lewis antibody
Discussion: It was generally believed that the individuals with Le(a)b+) phenotype
should not carry Lewis antibody since their serum contain Lea and Leb. However,
in this study we found 10 patients carried anti-Leb (although six of them had
recent transfusion). In the previous serological study of Le(a + b+) phenotype, we
found not only Leb were weak in some cases, but Lea could also be weak in some
other cases. This makes us considered the molecular basis of Le(a)b+) could also
be possible to be due to variant FUT3 in our population (to explain carrying anti-
Lea). Molecular genetic study of Asian Lewis blood group system warrant further
study.
P-215
MICROPLATE POLYBRENE METHOD FOR BLOOD BANK
AUTOMATION
Lin M, Chan JP, Chang FJ, Chen WF
Mackay Memorial Hospital, Taipei, Taiwan
Background: Application of manual Polybrene method (MP) in pretransfusion testing
has been widely used in Asian countries especially Taiwan and China. This method was
reported by Lalezari and Jiang (Transfusion 20: 206–2011) in 1980. We introduced MP
to Taiwan in1983 and to China in 1990s. MP soon proved to be the most suitable
method for Taiwan. It is a sensitive, simple, rapid and inexpensive method for com-
patibility testing to standardized pretransfusion testing procedures. Within a few years,
MP was incorporated successfully into routine pretransfusion testing procedures
throughout the whole of Taiwan. In the current trend of automation in laboratory
medicine, however, blood bank is the only exceptional area in Taiwan to be automated.
Although several tertiary hospital blood banks owned Western automation machines,
however, since the relative shortage of blood bank staffs in Taiwan as compare to
Western country, the efficacy of machine was not fully operated (MP is a rapid
method). Another reason for not fully used is probably due to inexpensiveness of MP
method. Therefore we initially try to automate the MP method by using microplate
(microplate Polybrene method, MPP).
Materials and methods (modifying MP method forMPP): Microplate: Nunc 96 well,
U-shaped bottom, nontreated microplate.
Reagents: properly modifying the concentration, constituents and volume of LIM,
Polybrene and resuspending solutions used in MP for MPP.
Procedure: modifying the reacting temperature and duration for MPP.
Results and discussions: Since the volume of microplate well is small (300 ll).
Therefore we modified the reagent volume and procedures (duration and temperature)
for MPP method to get proper sensitivity and specificity. We also add procedure to
avoid picking up too many nonspecific cold agglutinins as MP do. The initial results
are shown in the following table. The results of MPP correlated well with Cellbind test.
The initial results were promising.
Table 1
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THE COMPUTER CROSSMATCH: THE 5 YEARS EXPERIENCE IN
THE CZECH REPUBLIC
Bohonek M1, Horcickova D1, Lejdar T2
1Central Military Hospital Prague, Prague, Czech Republic 2TIS s.r.o. Brno, Brno, Czech
Republic
Background: The computer (electronic) cross match (CCM) is a method for blood
compatibility screening. It is based on correctly collected donor/recipient data, and its
safe input to the information (computing) system. Consequently, the software, while
using the pre-set constant pre-requisites, determines whether the chosen erythrocytic
preparative is acceptable for the blood recipient’s transfusion, or whether serological
cross match needs to take place.
Method: The computer cross match is an additional module for laboratory information
(computing) system in a blood bank lab. It provides electronic control over fulfillment
of the conditions for blood administration, with no need for serological cross matching.
Conditions which must be met for the CCM:
1. The electronic (computer) request only,
2. Patient is suitable for the CCM and his/her request is conforming; the unsuitable
cases must be clearly defined,
3. Compatibility of patient and donor blood group,
4. Negative red cell antibodies (examination is not older than 42, or 14 days in case
of a pregnant woman),
5. Laboratory testing are preferentially provided by a fully automated system; if
provided manually, the minimum of two identical results must be delivered,
6. The computer system, as well as the CCM, must be validated.
Unacceptable scenarios for the CCM:
1. Patient was evaluated to be unsuitable for the CCM in the past,
2. Blood grouping was not verified,
3. Presence of red cell antibodies, now or in patient’s history,
4. Red cell antibodies screening was done 43+ days ago,
5. Last blood is more than 72 h old and was not put through the new antibody
screening,
6. Attributes of haemolysis are present.
Practice in the Czech Republic:
The CCM has been in use routinely since August 1, 2005 in Central Military Hospital
Prague. The fully automated system Galileo ImmucorGamma is used for blood
grouping serology and antibody screening. The CCM is used in 82% cases (Tab No 1).
The CCM brings the following benefits: (i) it saves time (especially with massive
transfusions), (ii) it saves costs, (iii) it cuts staff.
Table 1: Statistics of CCMs in CMH Prague
Conclusion: The CCM is a save, economical and fast solution, suitable for all types of
hospitals.
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AMOXICILLIN/CLAVULANATE-INDUCED HEMOLYTIC
ANEMIA: A CASE STUDY
Lin TY, Lu YC, Lin CM, Wu PL
Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chia-Yi, Taiwan
Background: Amoxicillin/clavulanate is known to cause hemolytic anemia (HA). A 3-
years-old child with bronchitis was treated with amoxicillin/clavulanate days before.
The patient revealed pale, yellowish skin, tachycardia and hypotension on admission.
Her hemoglobin (Hb) dropped from 11.7 to 3.0 g/dl in 5 days. Serum lactate dehy-
drogenase (LDH), haptoglobin and urine all showed evidences of hemolysis. No glu-
cose-6-phosphate dehydrogenase defeciency was found.
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Aims: Our aim was to prove patient’s hemolytic crisis was caused by amoxicillin/
clavulanate. Non-immunologic protein adsorption (NIPA) onto red blood cells (RBCs)
was thought to be the amoxicillin/clavulanate’s hemolytic mechanism.
Methods: Our investigations included direct antiglobulin tests (DATs), indirect anti-
globulin tests (IATs). The antibody screen and identification was verified by LISS (low
ionic strength solution), manual polybrene (MP) tests. Serum and eluate from the
patient were tested against amoxicillin/clavulanate treated RBCs. Patient’s serum was
also tested against untreated RBCs in presence of amoxicillin/clavulanate. We also
compared the patient’s and normal serum samples (non-diluted and diluted one in 20)
for proving NIPA.
Results: The DAT result was negative before administration of amoxicillin/clavula-
nate. After applying amoxicillin/clavulanate, patient’s RBCs showed strongly positive
DAT (anti-IgG negative, anti-C34+), but the eluate was nonreactive with commercial
panel cells. The autologous control was positive either IAT or MP. However, patient’s
serum showed positive by IAT, but negative by MP. The patient’s sera did not react with
RBCs in presence of amoxicillin/clavulanate, but the patient’s sera and normal sera
reacted with amoxicillin/clavulanate -treated RBCs. We discontinued amoxicillin/
clavulanate use and patient received two units of RBCs transfusion. Prednisolone was
also used at the same time. Patient’s Hb and LDH levels returned to near normal values
6 days later. There was no direct clinical infection evidence contributing to hemolytic
event.
Conclusions: Combined with patient’s history, clinical data and laboratory results, we
strongly suspected the HA was caused by amoxicillin/clavulanate. More specialized
laboratory examination may be required to confirm this definite diagnosis. The MP test
may not be sensitive enough for survey drug related HA.
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PREVALENCE OF RH PHENOTYPES AND PROBABLE GENO-
TYPES IN RH (D) NEGATIVE BLOOD DONORS AT SPS APOLLO
HOSPITALS, LUDHIANA, PUNJAB, INDIA
Narang H
SPS Apollo Hospital, Ludhiana, India
Background: The Rh (Rhesus) blood group system is clinically the most important
blood group system after ABO system. The Rh blood group system currently consists of
about 50 defined blood group antigens, amongst which the five antigens, D, C, c, E and e
are the most important ones. These antigens are encoded by two adjacent gene loci, the
RHD gene and the RHCE gene. The Rh phenotypes are readily identified by the presence
or absence of Rh surface antigens. The exact genotype of any individual can only be
identified by DNA analysis. The Rh phenotype is clinically significant and ensures that
the patient is not exposed to an antigen, he is likely to develop antibodies against.
Aims: To study the prevalence of Rh antigens (phenotype) in Rh (D) Negative blood
donors and to classify them in the probable genotype categories.
Methods: The study was conducted at Department of Transfusion Medicine at SPS
Apollo Hospitals, Ludhiana, India from January 2006 to December 2010. All blood
donors during this period were initially typed for Rh D antigen, using anti-D mono-
clonal antisera (ERYCLONE) manufactured by Tulip Diagnostics (P) Ltd. The blood
donors testing Rh D Negative were then tested for other Rh antigens using monoclonal
anti-C, anti-c, anti-E and anti-e, manufactured by Tulip Diagnostics (P) Ltd.
Results: A total of 17,616 blood donors were tested from January 2006 to December
2010. Out of which 1539 (8.73%) were Rh D Negative. The prevalence of Rh antigens in
Rh D Negative blood donors was antigen C 13.2%, E 7.2%, c 99.9% and e 90.8%. The
probable genotypes amongst these blood donors was r/r 7.6%, r¢/r 0.52% and r¢¢/r 0.63%.
Conclusion: The Rh antigens C, c, E and e are highly immunogenic. It is recommended
to test all blood donors for these antigens so that antigen negative blood could be
transfused to the patients for increased blood transfusion safety. It is also recom-
mended to blood centres to have a database of all the blood donors, which can be
utilised for patients especially Rh D Negative patients.
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ANTI-A, B ANTIBODY FOUND IN A BLOOD GROUP A RECIPIENT
FOLLOWING LIVER TRANSPLANTATION
Yen HM, Liu YH, Kan MY, Li CT, Su CC
Buddhist Dalin Tzu Chi General Hospital, Chiayi County, Taiwan
Background: Owing to limited sources ABO minor-mismatched organs were often
used for clinical transplantation. ‘Passenger’lymphocytes producing antibodies against
recipient’s RBCs may provoke immune-mediated hemolysis following organ trans-
plantation, known as ‘passenger lymphocyte syndrome (PLS)’.
Aims: To work out a patient suspicious for PLS.
Methods and results: A 22-year-old, blood group A female patient experienced
hemolysis 10 days after receiving liver transplantation from a group O donor. Her Hb
fell from 14.2 g/dl before and down to 8.5 g/dl 10 days after transplantation. Serum
typing demonstrated anti-A and anti-B antibodies. The result of serum irregular
antibody screening was negative. DAT was positive for IgG and anti-A, B was eluted
from her RBCs. PLS was diagnosed. She was successfully treated with combination of
group O RBC transfusion, steroid, and immunosuppressants.
Summary: PLS is a complication of ABO minor-mismatched organ transplantation,
particularly occurring in a blood group A or B recipient from a group O donor. It
usually develops within 1–3 weeks following transplantation and is a self-limited
process. Transfusion of compatible RBC or plasma component, plasmapheresis, and
anti-CD20 monoclonal antibody are most considered therapeutic strategies.
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A NEW RHCE ALLELE WITH 358G>C (ALA120PRO) MUTATION
AFFECTING THE EXPRESSION OF RH3 AND RH4
Tobita R1, Okajima S1, Tsuneyama H1, Saito M1, Morimoto K1, Enomoto T2, Sasaki K3,
Isa K3, Ogasawara K3, Uchikawa M1, Nakajima K1
1Japanese Red Cross Tokyo Blood Center, Tokyo, Japan 2Saitama Red Cross Blood
Center, Hidaka, Japan 3Japanese Red Cross Central Blood Institute, Tokyo, Japan
Background: The Rh antigens arise from polymorphism in two highly homologous
and closely linked genes, RHD and RHCE. The RHD gene encodes the D polypeptide,
whereas RHCE encodes the polypeptide carrying C (RH2) or c (RH4) together with either
E (RH3) or e (RH5) antigens. Numerous variant RHCE alleles with reduced expression of
C, c, E, and e antigens have been described in several populations, especially in
individuals of African origin and Caucasian.
Aims: We report the molecular genetic analysis of two Japanese individuals with weak
expression of c and E antigens.
Methods: Standard serological tests were performed using polyclonal and monoclonal
antibodies. Expression of Rh antigens on the RBCs was measured by a flow cytometer
using FITC-labeled anti-human IgG. Relative fluorescence intensity was calculated
using R1R2 RBCs as the control. Genome DNA was isolated from whole blood cells and
cDNA was synthesized by RT-PCR using mRNA extracted from reticulocyte. RHD,
RHCE, and RHAG genes were amplified by PCR and nucleotide sequences were ana-
lyzed. Expression study of RhCE antigens on CHO-K1 cells was performed using the
constructs of RHCE-expression vector.
Results: Both Japanese individuals were typed as D + C + c + E + e+ but weakened
reactivity was noticed for c and E antigens. Flow cytometric analysis revealed that the
relative fluorescence intensities of c and E were 5–6% and 7%, respectively as
compared with those of the R1R2 RBCs. Nucleotide sequence analysis revealed that
both individuals had common RHD and RHAG, but had heterozygous G/C at position
358 in exon 3 of the RHCE. By cloning, the 358G>C (Ala120Pro) mutation was
observed in RHcE. When expression study using the constructs of common and
mutant RHcE was performed, no c and E antigens were observed on the transfectant
of the mutant RHcE.
Conclusion: We identified a new RHcE allele having 358G>C (Ala120Pro) mutation
from Japanese individuals with weak expression of c and E antigens. This mutation is
presumed to be positioned at transmembrane domain of the RhCE polypeptide.
Expression study of the mutant RHcE was correlated well with the serological results.
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AN EFFICIENT MASSIVE ‘MIA’ SCREENING METHOD BY
AUTOMATIC BLOOD GROUPING SYSTEM
Liu ML1, Hsieh CH1, Hung YS1, Hung CS1, Lin Tsai SJ2, Lin KS2
1Taipei Blood Center, T.B.S.F., Taipei, Taiwan 2Head Office Taiwan Blood Services
Foundation, Taipei, Taiwan
Background: In Taiwan, the frequency of ‘Mia’ is 7.3% and the indigenous people have
higher frequency, Amis 88.4%. The area of aboriginal distribution stretches along in
eastern Taiwan; it causes higher risk of transfusion reactionwith ‘Mia’. The Hualien Blood
Center in eastern Taiwan offer specific antigen-negative RBC to patients in hospitals.
Considering the high frequency of ‘Mia’ in Hualien areas, screening ‘Mia’ antigen of
donors in the eastern Taiwan by traditional manual method will spend time and cost.
Aims: The aims of this study are to prevent higher risk of transfusion reaction with
‘Mia’, design a protocol to screening ‘Mia’ antigen of donors by PK7300 automated
blood analyzer and confirming ‘Mia’ antigen-positive by manual method.
Methods: Donor samples from Hualien blood center in Taiwan were screened fromMay
to October in 2010. The anti-’Mia’ were prepared by donor’s plasma with anti-’Mia’ and
twice diluted with normal saline. Twenty-five microlitre 1.7% red blood cells suspension
and 25 ll anti-’Mia’ were transferred to the microplates in PK7300. The microplates were
incubated at 30C for 1 h. The results were interpreted automatically by machines
according to their optimized threshold of SPC, P/C and LIA. To validation of method, we
prepare ‘Mia’ antigen-negative samples test with donor’s plasma with anti-’Mia’ in
PK7300 for specificity test, and ‘Mia’ antigen-positive samples for sensitivity test. Those
samples were performed parallel test with Manual Polybrene method. QC control was
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performed with 5 ‘Mia’ antigen-positive samples and 5 ‘Mia’ antigen-negative samples in
each batch. Refer to the donor’s plasma cannot detect all of the Miltenberger antigens,
only the ‘Mia’ antigen-positive screening result samples were confirmed with the other
donor’s plasma with anti-’Mia’ by Manual Polybrene method. Those ‘Mia’ antigen-po-
sitive results were recorded into the blood management system.
Results: We prepare two lots of anti-’Mia’ from two different AB blood type donor’s
plasma. Test with 10 and 5 ‘Mia’ antigen-negative samples for two lots of anti-’Mia’ are
all negative for specificity test, respectively. Test with 10 and 5 ‘Mia’ antigen-positive
samples for two lots of anti-’Mia’ are all positive for sensitivity test, respectively. The 40
random samples were parallel test by PK7300 and Manual Polybrene method with two
lots of anti-’Mia’ and present expected result. In this study, 800 ‘Mia’ antigen-positive
donors were identified from 10,365 blood donors within 6 months. The frequency of
‘Mia’ in this study is 7.72%.
Conclusions: In this study, we provide an economic and efficient method of screening
‘Mia’ blood phenotype from large number of blood donors by automatic blood
grouping instruments. Those ‘Mia’ antigen-positive results were recorded into the blood
management system. It can be reduce ‘Mia’ antigen-positive blood providing to the
patients who have anti-’Mia’ to prevent higher risk of transfusion reaction with ‘Mia’ in
eastern Taiwan.
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PREVALENCE OF RED CELL ALLOANTIBODIES IN
HEMODIALYSIS PATIENTS IN SOUTHERN TAIWAN
Yang YT, Lin SH, Li YS, Chiang MH, Chiang TH, Lin TM
E-Da Hospital/I-Shou University, Kaohsiung, Taiwan
Background: Red blood cell (RBC) alloantibodies may be formed following repeated
RBC transfusions. However, RBC transfusions are frequently used in the management
of patients with dialysis-related anemia. Consequently, they are subject to all hazards
associated with RBC alloimmunization. The objective of this study was to compare the
prevalence of RBC alloantibodies between hemodialyisis and general non-hemodialysis
hospital-based patients at the Blood Transfusion Unit of E-DA Hospital, Kaohsiung,
Taiwan.
Materials and methods: A retrospective study was performed utilizing data of anti-
body screening tests for transfusion from 2005 to 2010. The transfusion records of a
total number of 30,071 hospital-based patients were reviewed for the frequency of
alloimmunization. Among them, 965 patients were from the unit of hemodialysis of the
Nephrology ward at E-DA Hospital. The RBC antibody screening and identification
were performed by manual polybrene method and indirect antiglobulin tests.
Results: The overall prevalence of alloimmunization after blood transfusion was
0.82% (253/30,071). There was a significantly higher RBC alloimmunization rate of
4.24% (41/965) in hemodialysis patients (P < 0.001). The majority of these patients
(81%) had a single alloantibody, whereas the remaining 19.0% had multiple antibodies.
The mean number of transfusion received by the immunized hemodialysis patients was
25.7 units, while all immunized patients received an average of 9.5 units. The differ-
ence was significant (P < 0.001). The anti-Mia antibody was the most common allo-
antibody encountered (46.3%) followed by the anti-E antibody (36.6%) and the anti-c
antibody (7.3%).
Conclusions: The rate of RBC alloimmunization after blood transfusion was signifi-
cantly higher in hemodialysis patients. Our study confirms the significance of post-
transfusional alloimmunization as a complication in hemodialysis patients and they had
a higher risk of red cell alloimmunization than other general hospital-based population.
The majority of alloantibodies demonstrated were anti-Mia, anti-E and anti-c. Since it is
generally not difficult to find donor red cells negative for these antigens, the study also
emphasizes the necessity to perform immunohematology studies for Mia and E antigens
prior to blood transfusion, particularly in cases that require multiple transfusions for a
long period of time such as in hemodialysis patients.
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DEVELOPMENT OF A DOUBLE VERIFICATION BLOOD TYPING
SYSTEM IN BLOOD BANK USING HEALTHCARE FAILURE MODE
EFFECTIVENESS ANALYSIS
Chang CS1, Feng WJ2, Wu YC1, Yeh CJ1, Lin YC1
1Chung Ho Memorial Hospital, Kaohsuing Medical University, Kaohsuing, Taiwan
2Department of Business Management, National Sun Yat-Sen University, Kaohsuing,
Taiwan
Background: To eliminate ABO testing error in the blood bank we develop a double
verification blood typing system (DVBTS) using both manual test tube method and
automatic gel test and based on healthcare failure mode and effect analysis (HFMEA) in
Kaohsiung Medical University Hospital.
Method and material: A proactive thorough analysis of transfusion process in the
blood bank using HFMEA was performed to determine the critical process in ABO
testing. Before implementation of DVBTS, a total of 165,000 transfusion episodes were
reviewed from July 2007 to June 2010. Among these episodes, ABO testing was done in
14,184 out of 61,077 blood samples. There were 30 ABO mismatched transfusion
including wronged sampling 20 (1/3054), blood typing error 3 (1/4728), and wronged
patient identification 7 (1/23,571). A Double verification blood typing system was
implemented.
Result: The preliminary report showed the feasibility of DVBTS in clinical blood
banking. After implementation of DVBTS in July 1st 2010, we did the pilot perfor-
mance evaluation the performance. A total of 3268 out of 31,610 transfusion episodes
were asked for ABO typing test from July 1st, 2010 to January 31, 2011. Only two
mismatched typing between the tech and AutoVue were identified. Also we can find
the specific ABO red blood cell typing in DVBTS. So DVBTS can eliminate the potential
risk of ABO testing error caused by the tech in the blood bank.
Inclusion: DVBTS with HFMEA is a useful tool to reduce the potential serious trans-
fusion fatalities due to ABO testing caused by the tech in the blood bank. Further study
is warranted.
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A RARELY ANTIBODY OF JK3 IN BLOOD BANK OF TAIWAN
Chiu YT, Lu YC
Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chia-Yi, Taiwan
Background: The patient is a 74-year-old female with diabetes mellitus (DM) and
hemodialysis history, due to discovery of liver abscess with slightl fever requiring
surgical operation for teatment. The pathology results pre op were Hb: 7.5 g/dl;
Hct:23.8%. Four RBC units and six FFP units were requested to cover the surgery. We
discovered that irregular antibody screening cell has 1+ responses, Another technique,
the MP, AHG phase method of panel cell also has the same response. Taken together,
these results demonstated the presence of an alloantibody. After inquiring the about
the patients medical history, it was found that the patient had hemodialysis and blood
transfusion records in other hospitals; No blood transfusion response.
Aim: When irregular antibodies are found, the antibody must be identified as irregular
antibodies may cause hemolytic transfusion reactions, which may lead to mortality.
Method: Direct antiglobulin tests (DAT) performed using antihuman globulin (poly-
specific), panel cell (Sanquin), enzyme-treated panel cell (papain) by MP, AHG the
phase method also has 1+ responses proving the existence of irregular antibodies.
Results: The patient’s serum with panel cell has positive (1+) response, using enzyme-
treated panel cell increase to enhanced response, (2+), direct antiglobulin tests (DAT)
was positive (±), patient’s auto-control was negative. Using anti-serum tested the pa-
tient’s phenotype is Jk (a)b)). (Table.1)
Table 1: Panel results
Conclusions: JK (a)b)) is rare in most population of the world. These individuals with
the blood type detected after has immunized to Kidd antigens during transfusion or
pregnancy. The Kidd system antibodies will cause the delayed hemolytic transfusion
reaction. Our hospital only found two Anti-Jk3 cases from 2000 to 2010. At present,
the blood center has set up the files for rare blood-type blood donors, and makes the
blood to frozen, thawed deglycerolized red blood cell (can be preserved for 10 years) to
supply to the rare blood-group patients for emergency purpose.
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THE PREVALENCE OF ‘HIGH TITER’ ANTI-A OR ANTI-B IN
GROUP O SINGLE- DONOR APHERESIS PLATELETS IN TAIWAN
Wang YH1, Chang WC1, Wu PF1, Chen JC1, Yang YT2, Lin TM2
1National Cheng Kung University College of Medicine and Hospital, Tainan, Taiwan
2Department of Laboratory Medicine, E-DA Hospital/I-Shou University, Kaohsiung,
Taiwan
Background: Owing to low availability of type-specific single-donor aphersis
platelets (SDPs), transfusion services sometimes issue ABO-mismatched platelets.
However, hemolytic transfusion reactions are rare but potentially severe complication
in minor ABO-mismatched platelet transfusions. Group O SDPs are most commonly
impliced due to the presence of unusually high titers of anti-A or anti-B antibodies
in the large volume plasma. The specific aim of this study was to determine the
prevalence of ‘high-titer’ anti-A or anti-B in group O single- donor apheresis
platelets in Taiwan.
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Materials and methods: Anti-A and anti-B titers were determined in plasma samples
of one hundred group O SDPs by using tube methods of indirect agglutination. The
reciprocal of the highest dilution giving macroscopic agglutination was considered as
the agglutinin titer. Results:
Titers of at least 16 and/or 256 from either buffered (generally reflective of IgM
antibodies) or AHG phase, respectively. Significantly high IgM titers of anti-A and
anti-B were found in 35% and 42%, whereas, high IgG titers of anti-A and anti-B were
found in 29% and 33%, respectively. There are 17 samples with both IgG high-titer of
anti-A and anti-B. Of these 17 samples, IgM high-titer of both anti-A and anti-B were
found in eight samples.
Conclusion: The prevalence of high-titer anti-A or anti-B in group O SDPs is rela-
tively high in Taiwan. Thus, the risk of minor ABO-mismatch and potential intra-
vascular hemolysis during group O SDPs transfusion may occur. Therefore, the anti-A
and anti-B of group O SDPs should be determined, prior to out-of-group platelet
transfusion.
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EVALUATION OF EIGHT-COLUMN GEL CARD BASED ON THE
COLUMN AGGLUTINATION TECHNIQUE (DG GEL)
Kokubunji A1, Takenouchi H2, Murata R1, Kajiki Y2, Sakamoto A2, Ikemoto J1, Kubuki
Y2, Fujimori Y1, Simoda K2, Kai S1
1Hyogo College of Medicine, Nisinomiya, Japan 2University of Miyazaki Hospital,
Miyazaki, Japan
Background: There is an increase in the number of laboratories that replace con-
ventional tube tests with column tests for pre-transfusion purposes. The type of mi-
crotube gel column used in Japan is a 6-column format. However, there are also the DG
Gel cards (Diagnostic Grifols S.A., Barcelona, Spain) consisting of a plastic support of
eight microtubes. The column tests offer many advantages over traditional methods:
improved sensitivity and specificity, no-wash antiglobulin procedure, standardized
procedures, improved turnaround time and enhanced regulatory compliance.
Aims: The aim of the present study was to evaluate the estimated diagnostic accuracy
of the new Grifols DG Gel system and to compare the data with the well-established
DiaMed-ID system and the conventional tube test in Japan.
Methods: ABO/D grouping test, antibody screening test, antibody identification and
DAT (direct anti-globulin test) were compared using samples in routine tests performed
in two different facilities. Grifols DG Gel cards and DiaMed-ID cards were examined
in one facility. In addition, conventional tube tests were compared in another facility.
Specific reagents were used for card tests and tube tests.
Results: Of the 432 analyses performed for the ABO/D grouping on DG Gel cards and
ID-cards, 431 (99.8%) were concordant. One discrepant result was a false-positive on
an ID-card for an unexpected antibody. Of the 421 analyses performed for the ABO/D
grouping on DG Gel cards, ID-cards and tube tests (three methods), 420 (99.8%) were
concordant. The discrepant result (weak-positive on tube test) was a false-negative on
DG Gel cards and ID-cards for reverse grouping test. Of the 445 antibody screening
and identification performed on DG Gel cards and ID-cards, discordant results were
observed in five samples (1.1%). Three samples were cases of an antibody detected by
DG Gel cards only and two samples were cases of an antibody detected by ID-cards
only. Of the 426 antibody screening and identification tests performed using all three
methods, discordant results were observed in seven samples (1.6%). Of the seven dis-
crepancies, one was nonspecific positive result on ID-cards, one was a case of an
antibody detected by DG Gel cards only, two were cases of antibodies detected by DG
Gel cards and tube tests, and three were cases of negative or undetected reactions in
the three methods. Of the 31 DAT performed in the three methods, discordant results
were observed in four samples (12.9%) that showed negative in the tube test. Of the
four discrepancies, one was a case of an autoantibody and three were nonspecific
positive results on DG Gel cards and ID-cards.
Conclusions: Grifols DG Gel system is a valid method comparable to the DiaMed-ID
system and conventional tube tests. The 8-column card of the DG Gel system might
represent an advantage since it allows higher numbers of tests per cycle. Patient safety
is expected to improve based on sensitivity, specificity, time saving and cost-effec-
tiveness in the laboratory.
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SCREENING FOR RED CELL ANTIBODIES IN BLOOD DONORS
AND RECIPIENTS IN SAURASHTRA REGION OF GUJARAT,
INDIA
Sawant R, Bhatt J, Karia C, Radadia B, Dave M, Mukhida S
Rajkot Voluntary Blood Bank and Research Centre, Rajkot, India
Introduction: Antibody screening for donors and patients is performed at very few
centres in our region. Many patients currently receive only saline cross-matched blood
due to lack of proper Antibody screening protocols.
Aim: To determine the extent of red cell antibodies in donor and patient population in
Saurashtra region.
Materials and methods: Thirty-four thousand eight hundred and twenty-seven blood
donors and 14,209 patients blood samples were screened for presence of red cell
alloantibodies using a two cell panel with the (Galileo) SPRCA technology. All positive
cases were further tested for antibody identification with the 11 cell panel (Diamed ID
Diapanel)
Results: 0.12% (43 of 34,827) donors and 0.73% (104 of 14,209) patients showed
presence of red cell alloantibodies. The occurance of antibodies in female donors
(0.35%) significantly higher than in males (0.11%). 16.2% donors had a positive DAT.
Positive antibody screening results were observed in 0.87% of female patients and
0.64% of male patients. Thalassaemia (21%), non hemolytic Anemia (12.5%) and AIHA
were the most common clinical conditions (10.5%) associated with irregular red cell
antibodies. The most common antibodies identified were anti -e, anti -E, Anti- D and
Anti- K.
Conclusion: Presence of red cell alloantibodies is detected in significant number of
patient population especially those with hemolytical disorders. Screening protocols for
red cell allo- antibodies shall remain a challenging task for future.
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PREVALENCE OF ALLOANTIBODIES TO GP.MUR AND DIEGO
PHENOTYPES IN SOUTH KOREA DETERMINED BY THE USE OF
SCREENING CELLS CONTAINING MUT/MUR KODECYTES
Heathcote DJ1, Kwon SW2
1CSL Limited, Melbourne, Vic., Australia 2Asan Medical Center, Seoul, South-Korea
Background: The hybrid glycophorin GP.Mur is commonly seen in Chinese and South
East Asian populations but little is known of its incidence in the South Korean population
andwhether or not alloantibodies toGP.Mur are seen. Commercial screening cells that are
internationally compliant and which also have the ability to detect antibodies to variant
glycophorins and Dia have not previously been available to diagnostic laboratories.
Aims: To antibody screen a minimum of 4000 hospital in-patients using screening
cells expressing MUT, Mur and Dia antigens. To phenotype 100 random patients for the
presence of the GP.Mur phenotype using a monoclonal anti-Mur antibody.
Results: A total of 4830 antibody screens were conducted using DiaMed Column
Agglutination Technology at three major South Korean public hospital laboratories:
ASAN Medical Centre, Chonnam Hwasun National University Hospital and Pusan
National University Hospital. Positive samples were shipped to CSL Limited, Parkville,
Australia for antibody identification. Clinically significant antibodies were identified in
0.7% of patients. As expected, antibodies to Dia were detected in significant numbers
but antibodies to hybrid glycophorins were only seen in one patient. No GP.Mur
phenotypes were detected in the 100 samples tested.
Conclusion: Alloantibodies to hybrid glycophorins were not commonly detected in
this population and the incidence of the GP.Mur phenotype appears to be <1%, much
lower than that seen in China and South East Asia. Antibodies to Dia are present in
significant numbers.
P-230
EVIDENCE FOR AN INFLUENCE OF THE SECRETOR STATUS ON
THE LEVELS OF THE ABO ISOANTIBODIES
Joshi S, Jaboob N, Al Harthy A
Institute of Health Sciences, Muscat, Oman
Background: ABO-iso-antibodies are naturally occurring antibodies and are regularly
present if corresponding antigen is absent. The antibodies are developed during early
childhood of 3 months and remains throughout the adult life. The levels of antibodies
tend to vary from one individual to another under the influencing factors like age, sex,
infections, vaccination etc.
Aims: The present study was undertaken to find an influential role of the secretor
status on the levels of the ABO-antibodies among the Omani healthy youths.
Methods: The students, the age group of 17 years and above at the Institute of Health
Science, Muscat were participated in this prospective study. Standard serological
methods by tube technique were employed. Secretor status on saliva samples of the
participants was determined by haemaggltination inhibition of anti-A, anti-B and/or
anti-H reagents. Level of the antibodies in serum of the participants was determined by
titration against the reagent red cells of appropriate ABO phenotype. An individual
having a titer value of 128 or more was defined as having high titer while the one with
the titer of 1:64 or less was considered as having a low titer of the antibody. Statistical
analysis was performed on the data using a 2 · 2 contingency table with the Fisher’s
exact test.
Results: Eighty four of 130 participants in the study showed a high titer (‡128)
antibodies while 46 individuals displayed a low titer (£64) for the antibodies. Inter-
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estingly, as many as 77 persons showed a high titer values among 95 subjects classified
as ‘Secretor’. On the other hand, 28 individuals of 35 ‘non-secretor’ had a low level of
the antibodies. Statistical analysis showed the association of secretors status with the
levels of the ABO-isoantibodies was extremely significant (the two-tailed P-value
being <0.0001).
Conclusion: Individuals classified as ‘secretors’ often have a high-titer ABO iso-
antibodies.
P-231
RED CELL ALLOIMMUNIZATION IN TRANSFUSION DEPENDENT
THALASSAEMIA PATIENT’S IN SAURASHTRA REGION OF
GUJARAT, INDIA
Bhatt J, Karia C, Radadiya B, Dave M, Mukhida S, Sawant R
Rajkot Voluntary Blood Bank and Research Centre, Rajkot, India
Background: Thalassaemia Major is a common hemoglobinopathy in Saurashtra re-
gion of Gujarat, India. However, very little is known about the frequency of red cell
alloimmunization in this transfusion dependent Patient group.
Aim: To Study the Red cell alloimmunization in Transfusion dependent Thalassaemia
Patients in our region.
Materials and methods: Retrospective analysis of data was done and a total of 160
Thalassaemia Major patients data was found to be complete and available for analysis.
Patient’s clinical; immunohematological and biochemistry reports were reviewed. The
age at which RBC allo/auto antibodies developed and the complete transfusion history
was noted.
Results: Sixteen out of 160 (10%) Thalassaemia Major Patients developed RBC allo-
antibodies. The auto control and DAT was positive in six cases of which four (25%)
Patient’s had an allo-antibody underlying the autoantibody. Antibodies against the
antigens in Rh system (25%) and Kell (18.75%) were the most common clinically sig-
nificant allo-antibodies identified. Anti-K developed in 3 (18.75%) Patient’s, Anti-E in 3
(18.75%) Patient’s, Anti-D in 2 (12.5%) Patient’s and Anti-Kpa in 3 (18.75%) Patient’s.
All allo-antibodies developed between the age of 1–24 years, earliest alloimmunization
to RBC transfusions was observed in a Patient only after receiving three blood
transfusions. Only 5% of Thallasaemia Patients were on leucodepleted blood
component therapy.
Conclusion: The various contributory factors leading to alloimmunization in our
Thalassaemia Major Patients need to be identified. Lack of completely matched blood
(many centers still provide only blood compatible in saline phase of cross-matching)
and non-leucodepleted blood components could be major contributory factors to
transfusion complications in Thalassaemia Major Patients.
Provision of pre storage leucodepleted blood and phenotyped matched RBC transfusion
can prevent of delay alloimmunization in Thalassaemia Major Patients.
P-232
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EVALUATION OF THREE ANTIBODY DETECTION METHODS IN
PRETRANSFUSION SCREENING FOR ANTI-MIA AND ANTI-E
WITH AND WITHOUT DITHIOTHREITOL TREATEMENT
Lin JS, Wu CW, Young LH, Kuo SF
Changhua Christian Hospital, Changhua, Taiwan
Background: The manual polybrene method (MP) is recommended and adopted as
routine in most blood banks for antibody detection in pretransfusion testing in Taiwan.
Although MP is time-saving with high sensitivity, it can not differentiate cold active or
clinically insignificant IgM from IgG types of alloantibodies which was characterized
in a previous study (Lo et al, Vox Sanguinis 2002). Moreover, as increasing use of
automation in pretransfusion testing, the performance of automated detection of anti-
Mia and anti-E, the two most prevalent alloantibodies in Taiwan, remains unclear when
considering it as a substitute for MP in antibody detection in terms of antibody
characteristics.
Aims: The present study was to compare MP, indirect antiglobulin test using low ionic
strength solution (LISS-IAT) and automated column agglutination test (CAT) for
detection of anti-Mia and anti-E with and without Dithiothreitol (DTT) treatment.
Methods: Serum or plasma sample submitted to pretransfusion testing and finally
confirmed to have either anti-Mia only or anti-E only were prospectively recruited. MP
was used as routine to detect antibodies. All samples were subject to LISS-IAT and CAT
for antibody detection as comparison. LISS-IAT was performed according to the AABB
guideline. The anti-human globulins used in LISS-IAT were polyspecific (Immuncor
Gamma, Noreross GA, USA). CAT was performed on a fully automated AutoVue system
using BioVue Polyspecific Anti-Human Globulin cassettes (Ortho-Clinical Diagnostics,
Raritan, NJ, USA). A repeated testing was performed using samples treated with DTT
(Amresco, OH, USA) according to the AABB guideline. All screening red cells used in
this study were 3% MediPro reagent RBCs (Formosa Biomedical Technology, Taiwan)
which was the only available and commercial in-vitro diagnostic product able to detect
antibodies including anti-Mia and anti-E in Taiwan.
Results: Twenty-seven and 30 samples containing anti-Mia only and anti-E only,
respectively, were recruited. Before DTT treatment, the detection sensitivity of anti-Mia
was 85.2% (23/27) for LISS-IAT and 81.5% (22/27) for CAT, whereas the detection
sensitivity of anti-E was 83.3% (25/30) for LISS-IAT and 76.7% (23/30) for CAT. With
DTT treatment, 10 and 12 positive samples became negative for anti-Mia and anti-E,
respectively, when tested by MP. When interpreted along with the reaction of DTT
control, only 18.5% (5/27) and 13.3% (4/30) of them were respectively confirmed to
have anti-Mia and anti-E of IgM type only. Among these IgM-positive samples detected
by MP, only 20% and 0% of samples were respectively positive (before treatment) for
LISS-IAT and CAT for anti-Mia detection, whereas only 20% of them were positive for
both LISS-IAT and CAT for anti-E detection. After exclusion of IgM-positive samples,
the adjusted rates for anti-Mia detectoin were both 90.9% (20/22) for LISS-IAT and
CAT, whereas, for anti-E detection, they were 88.5% (23/26) and 80.8% (21/26) for
LISS-IAT and CAT, respectively.
Summary and Discussion: Without consideration of immunoglobulin classes, the
antibody detection rates of LISS-IAT and CAT for anti-Mia and anti-E were inferior
to MP. However, thsee two methods were less sensitive to antibodies of IgM class,
when encountering these clinically insignificant antibodies which happen in most
situations.
P-234
PREVALENCE OF RED CELL ALLOANTIBODIES IN ANTENATAL
WOMEN IN SRI LANKA
Kohombange CG
National Blood Centre, Colombo, Sri Lanka
Background: In Sri Lanka, antenatal antibody screening is specifically focused on Rh-
D negative women, in order to prevent hemolytic disease of fetus and newborn (HDFN)
due to most immunogenic anti-D. Due to the scarcity of resources, antenatal antibody
screenings of Rh-D positive women is not being routinely carried out. It is necessary to
determine the prevalence of clinically significant antibodies with respective to HDFN in
the population of antenatal women to expand the antenatal antibody screening in Sri
Lanka.
Aim: 1. To determine the prevalence of red cell alloantibodies among antenatal
women.
2. To assess the prevalence of clinically significant alloantibodies in them with
respective to HDFN.
Methodology: A descriptive cross sectional study was done at the Immunohematology
Reference Laboratory, where all antibody screening positive samples are being sent
from 87 regional blood banks in the country, for antibody identification.
All positive antenatal antibody results recorded at the Immunohematology Reference
Laboratory during 01/06/2010–31/12/2010 period were analyzed.
Results: Out of all 291 antenatal women, 135 (46.4%) had anti- Le-b, 26 (8.9%) of
them had anti-Le a and in 37 (12.7%) both anti-Le a and Le b were present. Anti D was
present in 66 (22.7%). Multiple Rh antibodies were identified in some women. Out of
the sample anti-D and anti-C were in 03 (1.0%) and anti-D and anti-E were in 02
(0.6%). Anti-E and anti-c were present in 01 (0.3%) woman. In 13 (4.5%) anti-Mur was
positive. In 03 (1.0%) anti-P1, which was room temperature reactive was present.
One woman each (0.3% each) had anti- Le b with anti-MUT, anti-D with anti Le-a, anti
Le-b with anti-Kell and anti-D with anti Le-b.
Out of the 291 antenatal women 89 (29.4%) had alloantibodies which could have
caused HDFN. From these 89 women, who had clinically significant alloantibodies
(with respective to HDFN), 66 (74.16%) had anti-D and 23 (25.84%) had antibodies
other than anti-D.
By applying z-test it was found that the prevalence of clinically significant antibodies
other than anti-D was significantly less (P < 0.001) from the population of antenatal
women with clinically significant antibodies (with respective to HDFN).
Conclusion: The most prevalent antibody among antenatal women is anti Le-b fol-
lowed by anti-D. Anti-Le a and anti-Le-b occurs together, as the third. According to
this study, other Rh antibodies never appear to occur alone, but as multiple Rh anti-
bodies.
Apart from anti-D prevalence of other antibodies which could have caused HDFN were
statistically insignificant, but the clinical significance is yet to be assessed by the
outcome of these pregnancies in the local setup. Though this is a statistically
insignificant prevalence to this study population, which includes mainly Rh-D negative
women, which is the minority in respective to RH-D status, these results may not be
applicable to Rh-D positive antenatal women.
Therefore, furthure studies have to be carried out to determine the prevalence of
clinically significant antibodies among Rh-D positive antenatal women.
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FREQUANCY OF ALLO ANTIBODIES TO RH SYSTEM IN
TRANSFUSION DEPENDANT PATIENTS, IMMUNOHAEMATOL-
OGY REFERENCE LABORATORY, NATIONAL BLOOD CENTER,
SRI LANKA
Rupasena IP
National Blood Centre, Colombo, Sri Lanka
Background: Rh blood group system is one of the most immunogenic system with 49
Rh antigens. The most important of there is D and then C, c, E, and e. Anti-D is highly
immunogenic and known to cause severe immediate or delayed haemolytic transfusion
reactions and it is the most common cause of severe haemolytic disease of the fetus and
newborn (HDFN). Clinically anti-c is the most important Rh antigen after anti-D and
may cause severe HDFN.
Aim: This study aims to demonstrate the frequency of Rh allo antibodies in transfu-
sion dependant patients, Immunohaematology reference laboratory, National Blood
Centre, Sri Lanka.
Method: Retrospective analysis was conducted for the period of 6 months from July
2010 to December 2010, based on transfusion request forms received by Immuno-
haematology reference laboratory, National Blood Center, Sri Lanka. The study in-
clude transfusion dependant patients such as Thalassaemia, Aplastic anaemia,
Leukamia, Renal failure, Anaemia of chronic disease and medical and obstetric
emergencies.
Results: There were total number of 914 samples received by the Immunohaematology
reference laboratory during the mentioned period, out of that 326 (35.66%) were males
and 588 (64.34%) were females. Out of this, total number of 107 (11.7%) patients
developed Rh alloantibodies. Development of one allo antibody was detected among 75
(70.1%) of patients, 28 (26.15%) developed two alloantibodies and 4 (3.75%) patients
developed more than two alloantibodies. The most frequent alloantibody found was
Anti-D (35.53%) followed by Anti-E (31.78%), Anti-C (1.86%) and Anti-c (0.93%).
When considering two alloantibodies, most common combination was Anti-E+c
(14.95%) followed by Anti-D+C (6.55%), Anti-D+E (1.86%). Anti-C+E, Anti-D+Le a,
Anti-E+kell showed similer rate of incidence with the value of 0.93%.
Conclusion: The frequency of alloimmunization to red cell antigens is high among
transfusion dependant patients. Majority of patients developed Anti D antibodies. Rh
phenotype match blood is recommended for transfusion dependant patients.
P-236
ANTIBODY CONTROL IN THE DELIVERY TERM, YES OR NO?
Mihic-Tomic B
KBC Dr. Dragisa Misovic-Dedinje, Belgrade, Serbia
Introduction: According to the up to date recommendations of the developed coun-
tries, the first antibody screening regardless the RhD blood group is performed from the
12 till the 16th gestation week. RhD status is checked in the 28th gestation week (in
duplicate), when antibody screening is also performed and which is repeated once more
in the 36th gestation week.
Objective: Presentation of the frequency of anti erythrocyte antibodies, both in RhD
positive and RhD negative pregnant women, in the delivery term (from 37 to 42
gestation week), as well as the evaluation of the clinical justification of performed
testing.
Material and methods: At the Prenatal Protection Laboratory of the Clinical Center Dr
Dragisˇa Misˇovic´-Dedinje, from January 1st till September 15th 2010, 600 pregnant
women were tested during the delivery term. Tube method with the use of Biotest
reagents was applied for the determination of blood groups, while screening and anti
erythrocyte antibody identification were performed using tube gel method with test
erythrocytes and panel manufactured by DiaMed and the Blood Transfusion Institute of
Serbia.
Results: From January 1st till September 15th 2010, 600 analyses of ABO system
blood groups and RhD status, as well as the antibody screening were performed: 476
(79.3%) pregnant women were RhD positive and 124 (20.66%) were RhD negative.
Among 476 RhD positive, combination of two antibodies was detected in one pregnant
woman (0.21%): Fyª i M. Out of 124 RhD negative investigated pregnant women, IgG
class autoantibody was found only in one (0.80%).
Conclusion: Based on our preliminary results, antibody screening in the delivery term
in RhD positive pregnant women is both clinically and cost effectively unjustified, as
well as the repeated antibody screening (after the 36th gestation week) in RhD negative
pregnant women.
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PREVALENCE AND SPECIFICITY OF ALLOANTIBODIES IN
KOREAN POPULATION
Gwiyoung O, Hur JY
Eone Reference Laboratory, Seoul, South-Korea
Background: Alloantibody testing has been used for prenatal and pretransfusion
study. The prevalence and specificity of antibodies are different among population and
ethnic groups.
Aim: We investigated the frequency of alloantibodies in Korean population and
compared with the previously reported experience.
Methods: We showed the prevalence of alloantibodies on 62,595 specimens from all
over Korea from July 2009 to May 2011. We used DiaMed, Diacell, and DiaPanel
reagents (Cressier, Switzerland) for alloantibody screening and identification. Results:
The overall prevalence of alloantibodies was 0.5% (337/62,595). The specificity of
alloantibodies was as follows: anti-E (46.0%), anti-Lea (17.5%), anti-M (9.6%), anti-c
(9.6%), anti-D (6.6%), anti-Leb (6.6%), anit-e (6.0%), anti-C (5.3%), anti-Jka (2.3%),
anti-Fyb (1.7%), anti-P1 (1.0%), anti-S (0.7%), anti-K (0.3%), and anti-N (0.3%).
Among positive antibody screening sera, the majority had single alloantibody (78.1%),
whereas remaining 21.9% had multiple alloantibodies.
Conclusions: The prevalence of alloantibodies was in agreement with the previous
comparative study whereas the specificity of frequent alloantibodies were somewhat
different.
P-238
ANTI-JSB COMPLICATING THREE CONSECUTIVE PREGNANCIES
CULMINATED IN FETAL LOSSES TO AN OMANI WOMAN: A
CASE STUDY
Joshi S1, Al-Muheidhari R2, Ashraf T2, Al Bulushi S2
1Institute of Health Sciences, Muscat, Oman 2Central Blood Bank, Ministry of Health,
Muscat, Oman
Background: Feto-maternal incompatibility of the Kell blood groups yields a serious
out come of the pregnancy as the antigens of this system are well developed during the
early fetal life. If the mother has antibodies to the high frequency antigens of this
system, it certainly pause a greater risk of the HDFN and pose a challenge to every one
of the stake-holders including blood bank.
Aim: The present report deals with an investigation on a case of maternal anti-Jsb
giving rise to the fetal losses in three pregnancies.
Methods: Standard serological methods and investigative protocol were used in the
study.
Results (case report): HAQ, age 27 years was followed up at the Central Blood Bank,
Bosher, Oman for the antibody work up during the three pregnancies in 2007, 2009 and
2010. She was grouped as O, Rh (D) positive with antibody screening test positive. The
atypical antibody reacted with all the red cells of the commercial cell panel indicating
towards the specificity to the high frequency antigen. Since the patient’s red cell
reacted with anti-H, a possibility of her being ‘Bombay’ (Oh) phenotype was ruled out.
So also, her red cells were typed positive for some high frequency antigens like I, k
(small), Kpb and Lub ruled out a possibility of specificity towards these antigens. Since
antibody displayed a strong agglutination with the red cells pre-treated with proteo-
lytic enzyme, though it was abolished against red cells pre-treated with AET reagent,
hence a possibility of anti-Inb was also ruled out. Negative results on DAT and auto-
control test on the patient indicated that the antibody involved was an allo-antibody
reacting to a high frequency antigen. Her serum was referred to the International Blood
Group Reference Laboratory, Bristol, U.K. where the antibody was identified as anti-Jsb.
Conclusion: Anti-Jsb associated fetal losses in three consecutive pregnancies reflect
the nature of an antibody to Kell blood group system.
P-239
COMPARISON OF THE FOUR METHODS REGULARLY USED FOR
PRE-TRANSFUSION ANTIBODY SCREENING
Lee CC1, Chang LF2, Wang HL2
1Cheng Hsin General Hospital, Taipei, Taiwan 2Yuan-Pei Technical University,
HsinChu, Taiwan
Background: The goal of this study is to compare four methods commonly used in
serology, including manual polybrene (MP), Polyethylene glycol antiglobulin (PEG),
Low ionic strength saline (LISS) and Sanquin Cellbind immunofixation column, which
were used to screen antibodies in clinical tests. The study tested the sensitivity of
different antigen-antibodies respectively and compares the specificity of four methods.
Also compared the reactions of four methods with known positive specimens and
compare their specificity with unknown specimens.
Methods: Commercial human based blood grouping anti-sera, screening panel 123
cells (Sanquin Netherlands), 100 detected and frozen known patient antibodies and 187
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routine pre-transfusion specimens were used for (i) To compare the sensitivity and
specificity of four methods by rare blood grouping anti-sera (C, E, D, c, e, S, s, K, k, Fya,
Fyb, Jka, Jkb) and screening panel 123 cells. (ii) To test the known positive specimens
with screening panel 123 cells and compare the specificity of different methods. (iii) To
identify the antibodies of routine pre-ransfusion specimens by screening panel 123 (the
blind test).
Results: Cellbind column could detect anti-D, anti-C, anti-E, anti-e and anti-c. All of
them had the titer 1:1024. There were eight among the 13 antibodies had the highest
titer. The results of retesting 100 frozen known positive specimens by four methods, we
found the positive rate were 91%, 66%, 81% and 79%, respectively. The highest was
MP, followed by PEG and Cellbind and the lowest was LISS. In the blind test, there were
six positive reactions by MP and Cellbind (6/187) and four positive reactions by LISS
and PEG (4/187). This result showed the sensitivity of MP and Cellbind was higher in
clinical tests.
Discussion: According to the results tested by serial dilution of commercial anti-sera,
Cellbind and PEG had same higher sensitivity (8/13) and then MP and LISS. Since the
MP is the routine antibody detection method in Taiwan, the 100 known frozen spec-
imens have been tested once in the hospital. It could be the reason that MP showed the
better reproducibility in comparison with other three methods by those specimens. The
other method shows its advantage to some antibodies, such as PEG to antibody M and
Cellbind to antibody E, Lea or Mia. In the blind test, MP and Cellbind could detect six
positive results higher than LISS and PEG detect four antibodies. It indicated Cellbind
was able to be used regularly in clinical test as MP.
Conclusion: By the comparison, we demonstrated the advantage of Cellbind is high
sensitivity and equal detection rate with conventional methods. It could replace the
time-consuming PEG and less sensitive LISS to be a regular examination. Moreover, it
could be used for confirmation test when the result interpretation by MP test was not
clear and definite.
P-240
CLINICAL AND LABORATORY PRESENTATIONS OF
PAROXYSMAL COLD HEMOGLOBINURIA IN A PEDIATRIC
PATIENT
Yang LH, Ho CC, Kuo SF, Lin JS
Changhua Christian Hospital, Changhua, Taiwan
Background: Paroxysmal cold hemoglobinuria (PCH), also known as Donath-Land-
steiner syndrome, is an autoimmune hemolytic disease caused by polyclonal cold-
acting IgG autoantibodies. PCH primarily affects children but is rarely reported in
Chinese. Clinical features and laboratory findings of a pediatric patient are herein
presented.
Case report: A 5-year-old boy, native of Taiwan, was admitted with a chief complaint
of fever for 2 days. One day before admission, abdominal pain occurred but was relived
by enema. Dark urine was also noted three times later. The past history and physical
examinations were not remarkable. The results of routine chemistry tests were within
normal limits except a high serum level of C-reactive protein (9.25 mg/dl). Blood
hemoglobin concentration was 13.0 g/dl. Urinalysis showed hemoglobinuria in the
absence of microhematuria. Three days after admission, blood hemoglobin concen-
tration decreased to 7.0 g/dl. Meanwhile, laboratory workup revealed mild hyperbi-
lirubinemia (total bilirubin 1.7 mg/dl; direct bilirubin 0.33 mg/dl) and severe
deficiency of serum haptoglobin (<10 mg/dl). Intravascular hemolysis probably asso-
ciated with infection was thus impressed. Serological tests demonstrated positive direct
antiglobulin test (anti-C3d) and negative indirect antiglobulin test. Antibody detection
performed on the eluate was negative. However, a positive Donath-Landsteiner test
suggested the presence of anti-P biphasic hemolysin in the sera of patient. Autoim-
mune hemolytic anemia consistent with paroxysmal cold hemoglobinuria was there-
fore confirmed. After empirical antibiotic treatment, vital signs and blood hemoglobin
concentrations were gradually improved without any sequela.
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RHD PARTIAL DBT TYPE 2 SEROLOGY
Lai M, Leone G
Catholic University, Rome, Italy
Backgraund: The DBT type 2 is frequently miss-typed in routine blood typing.
Characteristically the subjects carrying this RHD phenotype are classified as RhD po-
sitive. The problem arises when the same subjects, due to pregnancies or blood
transfusion, produces anti-D antibodies.
Aim: Elucidate the serology of the DBT type 2 with different anti-D reagents.
Methods: We have found a DBT type 2 in a blood donor. Blood typing was performed
with the Galileo (Immucor) and with the Autovue Innova (Ortho Clinical Diagnostics).
The IgM MoAbs were tested with column agglutination technology using the NaCl
Cards (Diamed ID microtyping system); 50 ll of the 0.8 RBC suspension and 25 ll of
each MoAb were added to each microtube of the ID cards, incubated for 15 min at
room temperature, centrifuged, and read according to the manufacturer’s instructions.
The IgG MoAbs were test with the same method but using the Liss Coombs Cards
(Diamed ID microtyping system). The IgM MoAbs used were: RUM-1 (Ep 6.1), and
TH28+ MS26 (Immucor); MS201 (Sanquin); BS232 (Ep 6.4), BS226 (Ep 6.4), BS232+
BS221 [IgG] + H4111B7 [IgG] (Biotest, Dreieich, Germany); 175-2 (Ep6.1) (Diamed);
HM10 (Ep 6.6), P3x61 (Ep 6.4), P3x21211F1 (Ep 8.2), and P3x21223B10 (Ep 9.1)
(Diagast, Loos, France); and D7B8 (Ep 6.4) + 1121G6+ LORIFA (Ortho Clinical Diag-
nostics, Raritan, NJ). The IgG MoAbs tests were: P3x35 (Ep 5.4), P3x290 (Ep 3.1),
P3x249 (Ep 2.1), P3x241 (Ep 5.4), and HM16 (Ep 6.4) (Diagast). Partial RHD genotyping
was performed using a commercial PCR kit with SSP Kit Partial D-TYPE (BAGene).
Results: The double RhD typing with the Galileo (Clone RUM-1 and TH28/MS26)
resulted positive (pos.) 4+. The RhD typing with the Autovue Innova (Clone D7B8)
resulted pos. 4+. The screening of irregular antibodies was pos. 4+, the characterization
of the antibody gave: anti-D titer 1/128 plus anti-KELL titer 1/32_. The IgM MoAbs in
gel technology saline gave the following results: Rum-1 pos. 4+, 175-2 pos. 4+, BS232
pos. 4+, BS226 pos. 4+, HM10 pos. 4+, P3x61 pos. 4+, P3x21211F1 pos. 4+,
P3x21223B10 pos. 2+, CAZ negative, MS 201 pos. 2+. The IgG MoAbs gave the fol-
lowing results: P3x35 negative, P3x290 negative, P3x249 negative, P3x241 negative,
and HM16 pos. 4+. Blended MoAbs in saline gave the following results: H1121G6+
LORIFA + D7B8 pos. 4+, MS26+ TH28 pos. 4+, BS221+ H4111B7+ BS232 pos. 4+. From
Partial RHD genotyping resulted a DBT Type 2.
Discussion: The DBT phenotype is strongly reactive with most of the IgM MoAbs
commercially available for routine blood typing. This is a problem because this phe-
notype was found in women typed as RhD positive, which produced anti-D antibodies.
Between the IgM antibodies tested in saline, all except the CAZ were positive. Between
those that were positive two MoAbs, the MS 201 and the P3x21223B10 were weakly
positive 2+. So it seems that these three anti-D reagents are capable of indicating the
presence of the DBT type 2 phenotype.
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AUTOMATION TECHNIQUE IN RED CELL ANTIBODY
SCREENING: EXPERIENCE OF A TEACHING HOSPITAL IN
NORTHEASTERN MALAYSIA
Mohd Noor H, Ramli M, Saw TH, Mohd Azmi MF, Lim SH, Sukri S, Wan Yaakub WR
Hospital Universiti Sains Malaysia, Kelantan, Malaysia
Background: Alloimmunization to foreign red cell antigens is a major complication in
routine blood transfusion services. Automation of immunohaematological tests is
advantageous. The adaptation of this automated instrument for antibody screening
resulted in detection of widest possible range of antibodies with substantial time and
cost savings.
Aims: The aim of this study was to determine the prevalence positive antibody
screening among patients in Hospital Universiti Sains Malaysia using automation
technique in 2010. The results were compared with data in 2009 using semi-automated
technique.
Methods: This is a retrospective study over a period of 9 months (January–September
2010) involving 20,590 samples. All samples requested for Group Screen and Hold
(GSH) underwent antibody screening using a indirect agglutination (IAT) method on a
Diamed ID screening cell using Techno Twin Station (Diamed, Switzerland). Results
were compared with antibody screening performed in January to September 2009
using semi-automated technique.
Results: A total 20,590 samples were screen for antibody within 9 months period in
2010. One hundred and sixty (0.78%) samples were found to be positive antibody
screening. Red cell alloantibodies were identified in 75% (120/160) of samples. In 25%
(40/160) of the samples, no specifities could be identified. Anti Mia (32/120) was the
most common antibody detected followed by anti E (24/120).
In 2009 a total of 22,019 samples were send for antibody screen. Positive antibody
screening were seen in 111 (0.50%) samples. Ninety-eight (88.2%) samples had
specificity and 13 (11.8%) samples showed no specificity. The most common
antibody identified was anti E (19/98), followed by a combination of anti Lea and
Leb (13/98).
Conclusions: Rate of detection of red cell antibodies were increased with greater
sensitivity by automated techniques than semi automated techniques. The studies are
the basis for introduction of the automated technique into routine use for antibodies in
blood donors and recipients.
E-mail: drhaslina@kb.usm.my
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DETECTION OF DEL IN AN AUTOMATED SEROLOGICAL WEAK
D TEST
Smallridge G1, Frame T1, Thompson D1, Revelli N2, Villa MA2, Moreno Jime´nez G3,
Sa´nchez Gordo F4, Polo Escriche A5, Garcia Sanchez F6
1Immucor Inc., Norcross, GA, United States of America 2IRCCS Ca’ Granda Ospedale
Maggiore Policlinico, Milan, Italy 3Servicio de Donacio´n de Sangre, Hospital Virgen de
la Salud de Toledo, Toledo, Spain 4Centro Regional de Transfusio´n Sanguı´nea de
Ma´laga, Malaga, Spain 5Centro de Transfusio´n Banco de Sangre de La Rioja, Logron˜o,
Spain 6Centro de Transfusiones de la Comunidad de Madrid, Madrid, Spain
Background: It is standard practice to perform an antiglobulin weak D test on donor
samples that react negative with monoclonal Anti-D reagents in direct agglutination,
to minimize risk of blood from donors that are weak D or D variants such as DVI being
mislabelled as D Negative, as red cells with these antigens may cause alloimmunization
when transfused to a D Negative recipient.
During the last year, there have been several reports of donors that test positive in the
weak D test automated on the Galileo or NEO instruments (Immucor, Roedermark,
Germany) have negative results indirect antiglobulin (weak D) testing with other
methods.
Methods: Donor samples were initially tested on Galileo or NEO instruments using
Novaclone (Dominion Biologicals, Dartmouth, Canada) (clone D-175) and ImmuClone
Anti-D Rapid (Immucor, Roedermark, Germany), (clone RUM1) reagents in direct
agglutination.
Samples reacting negative in these tests were reflexed to the automated indirect
antiglobulin ‘weak D’ test on the same instrument using Capture R Select and
Novaclone Anti-D (containing IgG clone D415). Samples reacting positive in the
weak D test were confirmed by antiglobulin tests in column agglutination (Bio-rad,
France; Biovue, Ortho Clinical Diagnostics, Raritan NJ, USA) or tube tests (Anti-D
Novaclone and Transclone Anti-RH1(D) Fast M (Bio-rad, France). Samples that were
positive in the automated weak D test, but other methods were investigated using
additional methods including absorption/elution (Gamma Elu-kit II, Immucor) and
DNA-based methods (BAGene RHType kit, BAG Health Care GmbH, Lich, Germany),
Bloodchipv2.0 (Progenika, Derio, Spain) and RHD Beadchip (BioArray Solutions,
Warren, NJ, USA).
Results: Between three laboratories, a total of 35 samples were found that reacted
negative for D in direct agglutination, but positive in automated solid phase weak D
test, but negative in tube or column agglutination tests for D.
Some of these samples were tested by absorption-elution and found to be D positive.
DNA testing was performed on 30 of the samples, and all were found to have the
nucleotide change 885G>T (amino acid change M295I).
Summary/conclusions: The term DEL is used to describe cases where a very low level
of RhD antigen is detectable only by absorption/elution method which is not suitable
for routine use. There have been a small number of documented cases where DEL blood
has caused alloimmunization. For this reason, there have been suggestions that DNA
methods should be implemented to eliminate DEL donors from the D Negative donor
pool.
The M295I mutation, in combination with phenotype Ccee (which the majority of these
samples had) is characteristic of DEL. This mutation causes weak D type 11 when
combined with with CCee phenotype.
Detection of these samples that were negative in other weak D methods indicates that
the automated NEO/CaptureR Select/Novaclone Anti-D weak D test is markedly more
sensitive than other routine serological methods for D antigen detection. The
sensitivity of this method provides higher safety for detection of the weakest variants
of D and its use reduces the attractiveness of DNA testing of D negative donor
samples.
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JK(A)B)) PHENOTYPE SCREENING AND GENOTYPING
ANALYSIS IN CHINESE POPULATION
Ji YL1, Wei L1, Ait Soussan A2, Zhao Y1, Luo H1, Zhang RQ1, Fu YS1, De Haas M2, Luo
GP1, Van der Schoot CE2
1Guangzhou Blood Center, Guangzhou, China 2Sanquin Research and Landsteiner
Laboratory, AMC, University of Amsterdam, Amsterdam, The Netherlands
Background: The distribution of Jk(a)b)) phenotype is very rare in all populations
except for Polynesians (0.1–1.4%) and Fins (0.03%). After transfusion or pregnancy,
the people with this rare phenotype can be immunized and produce anti-JK3. In East
Asia, Japanese, Taiwanese, and Chinese Han populations from northern and middle
regions have been tested and show a rare distribution of the Jk(a)b)) phenotype of <1/
10,000, whereas a comparatively higher frequency of 0.025% was found in Thai do-
nors. In this study, Chinese donors living in the East-southern region of China were
screened to detect the frequency and genetic basis for Jk(a)b)).
Aims: To detect the frequency and genetic basis of Jk(a)b)) in the Han Chinese
population in East-southern region of China.
Methods: Totally, 100,000 donors from East-southern region of China were screened
using the 2 M urea lysis method. The Jk(a)b)) phenotype was confirmed using routine
IAT methods. DNA samples from Jk(a)b)) probands were isolated. The coding regions
(from exon 4 to exon 11) and the adjacent parts of intron of the JK gene were PCR
amplified and sequenced. The JK gene of the available family members was also
sequenced.
Results: Nineteen Jk(a)b)) donors were obtained. So, the frequency of Jk(a)b))
among the Chinese Han population living in East-southern region was found to be
nearly 0.02% (19/100,000). DNA from 15 of the donors was available. In addition, one
patient with anti-JK3 was genetically characterized. Only two (already described)
mutant alleles derived from wild-type JKb sequence were detected. These were 1) the
IVS5-1 G>A, previously found in all reported rare Polynesians and result in skipping of
exon 6 and 2) c.896G>A (p.299Gly>Glu) (n = 3) only reported in Taiwanese. A
recessive hereditary pattern of Jk(a)b) was obtained based on sequencing results from
the available family members.
Conclusions: A relatively high frequency of Jk(a)b)) (1/5000) was found among the
Chinese Han population in the East-southern region in China. The two common JKnull
mutations should be involved in high-throughput genotyping, aimed to identify rare
blood donors in East Asian population.
P-245
NOVEL ALLELES AT THE KELL BLOOD GROUP LOCUS THAT
LEAD TO THE KELL VARIANTS PHENOTYPE
Ji YL1, Ligthart PC2, Wigman L3, Veldhuisen B3, Ait Soussan A3, Van der Schoot CE3,
De Haas M3
1Guangzhou Blood Center, Guangzhou, China 2The Department of Immunohaematology
Diagnostics, Sanquin Diagnostic Services, Amsterdam, The Netherlands 3Sanquin
Research and Landsteiner Laboratory, AMC, University of Amsterdam, Amsterdam, The
Netherlands
Background: Sanquin Blood Supply determines the K antigen expression in all blood
donors. Last year, an exercise was started to identify serologically k-negative donors
among the K-positive ones. Subsequently, the K+k) phenotype is confirmed by
molecular testing. If in these donors a K2 allele is detected, follow-up serological
analysis (absorption and elution technique to detect a low level of k expression) and
sequencing of the KEL alleles is performed.
Aims: To investigate KEL genotypes that lead to Kmod and Knull phenotype in the
Dutch population.
Methods: Three individuals with the K/kmod phenotype, three with the K/knull phe-
notype, one with a K+/k) phenotype, and two with Knull phenotype were identified
and phenotypes were determined by standard serological methods. Allelic discrimi-
nation (TaqMan technology based) was used for K1/K2 genotyping. Then, the 19 exons
and the intron-exon regions of the KEL gene were directly sequenced and compared
with KEL wildtype. Expression of Kell antigens were determined by flowcytometry
using anti-CD238 (recognizing all Kell antigens), anti-K and anti-k monoclonal anti-
bodies (tested in six available samples).
Results: Three novel mutations were identified in each individual with K/kmod
(Q362K), K+/k) (R700X), and Knull (R492X) phenotypes, respectively. The five re-
ported variations, (R516X)null, (R406X)null, (G573G)el, (IVS3 + 1G>A)null, and
(R516X)null, were also detected in seven donors. Flowcytometry showed an overall
decreased expression of Kell antigens and an increased K expression compared to that
of heterozygous K+/k+ controls for five samples with normal K expression and weak or
absent k expression using standard serological methods.
Conclusions: Three novel molecular alterations at the Kell blood group locus were
defined in the Dutch population. The increased K expression in individuals with K/
kmod or K/knull phenotypes suggests that the XK protein is the rate-limiting factor for
surface expression of Kell antigens.
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THE RH-MLPA ASSAY ALLOWS THE RAPID RECOGNITION OF
PHENOTYPICALLY RHD-NEGATIVE CHINESE INDIVIDUALS
WHO DO NOT NEED RHD-NEGATIVE BLOOD
Ji YL1, Wigman L2, Wei L1, Veldhuisen B2, Luo H1, Ait Soussan A2, Zhao Y1, Zhang
RQ1, Fu YS1, De Haas M2, Luo GP1, Van der Schoot CE2
1Guangzhou Blood Center, Guangzhou, China 2Sanquin Research and Landsteiner
Laboratory, AMC, University of Amsterdam, Amsterdam, The Netherlands
Background: In the Asian population the frequency of RhD-negativity is very low
(<1%). Consequently, in the Asian transfusion practice the availability of RhD-negative
blood is limited. Not all Asian persons that are serologically typed as RhD-negative have
a deletion of the RHD gene. Many of these persons carry an RHD-variant, called D-
elution (DEL), which is expressed at such a low density that it can only be detected upon
the absorption and elution technique. Persons who have a DEL variant can safely receive
RhD-positive blood. However, at the moment there is no simple method to distinguish
patients carrying a DEL variant from truly RhD-negative patients. Hence patients with a
DEL variant unnecessarily receive RhD-negative blood.
Aims: To evaluate the use of the RH Multiplex Ligation-dependent Probe Amplifi-
cation (MLPA) genotyping assay for the identification of RH-DEL in a Chinese phe-
notypically RhD-negative donor population.
Methods: In total, 200 Chinese donors with RhD-negative phenotype were recruited
from Guangdong province in China. Standard serological methods were used to
determine the RhD and RhCE status in these donors. The MLPA RHD/CE assay, which
can discriminate between 44 RhD and RhCE variants, was used to genotype the RHD
and RHCE status in these donors. Furthermore, this assay can determine RHD copy
number variation (zygosity). When the MLPA was not able to assign a variant, direct
sequencing of all exons of the RHD gene was performed.
Results: Using the MLPA assay in 197 of the 200 Chinese RhD-negative donors, loss
of the RHD gene and/or aberrant RHD genes could be determined. In 127 individuals
(63.5%) the absence of all RHD exons was confirmed. Asian type DEL (G1227A) was
detected hemizygously in 38 donors and homozygously in four donors (21% of the
phenotyped RhD-negative donors). In 11.5% of the donors, the hybrid allele RHD (1–
2)-CE (3–9)-D (10) (19 hemizygously and four homozygously) was detected. Three
donors were identified with two different RHD alleles [hybrid allele RHD (1–2)-CE (3–
9)-D (10) and DEL (G1227A)]. The DFR-2 variant and weak D type 15 was he-
mizygously present in two donors separately. The MLPA could not assign a variant in
three donors. Two donors carried the RhD negative variant hemizygously (c.711delC)
by sequencing of the RHD gene. One donor with two RHD alleles, one of them is
hybrid allele RHD (1–2)-CE (3–9)-D (10) detected by MLPA and the other allele show
a new RHD variant (c.1154G>T, p.385Gly>Val) by sequencing.
Conclusions: The MLPA assay is a fast, easy and robust method to genotype RhD-
negative donors in the Chinese populations. This assay can be used to genotype the
serologically RhD-negative patients, to determine which patients have a DEL variant.
These patients can then receive RhD-positive blood during transfusion, restricting the
use of the rare RhD-negative blood.
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A NOVEL AM ALLELE WITH 595C>T MUTATION IDENTIFIED IN
TWO UNRELATED CHINESE INDIVIDUALS WITH THE AM
PHENOTYPE
Li T1, Song N2, Yao Z2, Deng Y3
1Institute of Blood Transfusion, CAMS, Chengdu, China 2Institute of Blood Transfusion,
Chinese Academy of Medical Sciences, Chengdu, China 3Meishan Blood Center,
Meishan, China
Background: The Am phenotype is a rare subgroup of ABO blood group system. Am
red cells are not agglutinated, or agglutinated only very weakly, by anti-A and anti-
AB, and Am serum doesn’t contain anti-A.
Aims: This study analyzes the molecular genetic basis of two Am individuals, and
increases genetic information about the Am phenotype.
Methods: In two unrelated Chinese individuals who were typed as Am subgroup by
serological tests, complete exon 6 and7 in theABOgeneswere amplified byPCR. The PCR
products were directly sequenced and cloning sequenced to identify their genotype.
Results: A novel allele was identified in the both two Am Chinese individuals. Com-
pared to ABO*A102 allele, one missense mutation was detected in the Am allele, in
exon 7 at position 595, where C was replaced by T.
Conclusion: The mutation at nucleotide 595, which alter amino acid 199 from Argi-
nine to Cysteine, resulted in the great reduction of activity of the A glycosyltransferase.
It is indicated that the amino acid 199 may reflect the importance of this region for the
ABO transferase efficiency.
P-249
MOLECULAR ANALYSIS OF BV PHENOTYPE OF THE ABO
BLOOD GROUP SYSTEM IN HONG KONG CHINESE
Yip SP1, Tong CY2, Tsoi WC2
1The Hong Kong Polytechnic University, Hong Kong, China 2Hong Kong Red Cross Blood
Transfusion Service, Hong Kong, China
Background: Bv phenotype, being recognized as a distinct category of B subgroups,
was first reported in 1964 and is characterized by that Bv red cells do not react with
polyclonal anti-B adsorbed with rabbit cells. It was considered that the Bv determi-
nant corresponded to the portion of the B antigen present on rabbit red cells. In a
survey carried out in 1984–1989, among 567,210 Chinese blood donors in Hong
Kong, 46 cases of B
v
(one in 12,400) and eight cases of ABv (one in 70,900) were
found.
Aims: The study was undertaken to determine the molecular basis of Bv phenotype in
blood donors in Hong Kong.
Methods: Eighteen blood samples were collected from blood donors with Bv (n = 17)
and ABv (n = 1) phenotypes. The ABO phenotypes were determined by standard
serologic techniques. Commercial polyclonal anti-B (DiaMed AG, Cressier, Switzer-
land) was adsorbed at least twice with equal volumes of washed and packed rabbit
red cells at 4C for 2 h. The adsorbed anti-B was used to confirm the Bv phenotype
which gave negative reaction with routine ABO grouping technique. The ABO
genotype was determined by an established multiplex polymerase chain reaction
(PCR) followed by single-strand conformation polymorphism. DNA sequencing and
PCR cloning were used to characterize the mutations underlying the Bv phenotype.
Restriction digestion methods using SsiI and PvuII were then designed to genotype
all samples. Separate digestion was also performed on 20 randomly selected indi-
viduals of normal group B and 22 subjects possessing weak B antigens including B3
(n = 9), AB3 (n = 4), Bw (n = 6) and ABw (n = 3), where Bw refers to weak B antigens
for which the specific B subgroup status could not be assigned unambiguously.
Results: All 17 samples phenotyped as Bv were heterozygous for a B allele. Two
mutations were separately identified on a typical B101 background: non-synonymous
substitutions 721C>T (Arg241Trp) and 695T>C (Leu232Pro) defining alleles Bw03 and
Bw11 respectively, according to the registration of alleles in the Blood Group Antigen
Gene Mutation Database. Bw11 was found in heterozygous state in 16 out of 17
samples (94%) studied by digestion with restriction enzyme SsiI. Bw03 was found
heterozygous in only one sample (6%) by digestion with PvuII. None of these two
mutations were detected in the normal B and the weak B samples. No mutation was
found in all the exons of the variant B allele of the ABv sample.
Conclusions: This is the largest series of molecular studies of Bv phenotype published
in the literature. Two Bv alleles were identified: Bw03 and Bw11; the latter being the
commonest cause of the Bv phenotype in the Chinese population in Hong Kong. These
two mutations have been found in individuals with B subgroups, but have never been
described as associating with Bv phenotype expression. Simplified molecular methods
have been devised to enable genotyping of the two Bv-associated mutations for routine
analysis in service laboratories.
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AX03 AND AEL02 ARE HIGH FREQUENCY ALLELES IN GROUP
O JAPANESE WITH WEAK SERUM ANTI-A AND THOSE
ACCOUNT FOR B(A) PHENOTYPE
Ogasawara K1, Isa K1, Masuno A2, Saito M2, Morimoto K2, Uchikawa M2, Okazaki H1,
Tadokoro K1
1Japanese Red Cross Central Blood Institute, Tokyo, Japan 2Japanese Red Cross Tokyo
Blood Center, Tokyo, Japan
Background: Red cells of B(A) phenotype react with murine monoclonal anti-A re-
gents but not with human polyclonal anti-A. The generation of B(A) is caused by the
overlapping specificity of B-transferase that creates a few amount of A antigen.
Especially, highly active B-transferase and bifunctional B-transferases having amino
acid substitutions, such as Ser235Gly and Pro234Ala, are responsible for B(A) phe-
notype.
Aim: In the present study, we describe two different A alleles account for B(A) phe-
notypes.
Methods: Twenty-four B(A) blood samples, and 42 blood samples with weak serum
anti-A selected from 132,220 group O donors were examined. Serological tests were
performed using automated blood grouping system (PK7300) and manual tube method
including adsorption-elution tests. Genome DNAs were extracted from whole blood
and ABO genotype was determined by PCR-SSP and nucleotide sequencing.
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Results: RBCs of 24 donors were strongly agglutinated with anti-B and weakly
agglutinated with murine monoclonal anti-A, but not with human polyclonal anti-A.
Adsorption-elution test was also negative with polyclonal anti-A and thus those were
typed as B(A). PCR-SSP and nucleotide sequencing revealed that 17 of the 24 B(A)
individuals had the genotype Ax03 (R102)/B and other seven individuals had Ael02
(A110)/B. Ax03 had 646T>A (Phe216Ile), 681G>A, 771C>T, and 829G>A (Val277Met)
mutations as compared with common A allele. Ael02 had 467C>T (Pro156Leu),
646T>A (Phe216Ile), and 681G>A mutations. When 42 group O individuals with weak
serum anti-A were examined for DNA analysis, 20 of them had Ael02/O and six had
Ax03/O. No A antigen was detected on their RBCs by adsorption-elution test using
both monoclonal anti-A and polyclonal anti-A. We identified one Ael02/O and one
Ax03/O from 2015 Japanese with common group O.
Conclusion: Two different known alleles, Ax03 and Ael02, are responsible for both
B(A) and group O when those are heterozygote with B allele and O allele, respectively.
Because RBCs of the individuals having Ael02 or Ax03 were not reacted with poly-
clonal anti-A, it should be given some attention in transfusion practice and DNA based
ABO grouping.
P-251
USE OF CELL STUDY MODELS TO CONFIRM THE WEAK ABO
PHENOTYPES CAUSED BY POINT MUTATIONS AMONG
TAIWANESE
Chen DD1, Tseng CP2, Wang WT1, Sun CF1
1Chang Gung Memorial Hospital, Tao-Yuan, Taiwan 2Chang Gung University,
Taoyuan, Taiwan
Background: Numerous phenotypes with a weak expression of the A or B antigens,
including A3, Ax, Ael, cis-AB, B3, Bx, Bel, and B(A), have been found on the red
blood cells (RBCs) and are usually defined by the serological characteristics. Some of
these minor alleles have mutation(s) in the coding sequence of the ABO gene, and
most of the mutations are single-nucleotide substitution leading to an amino acid
alteration.
Aim: However, whether these mutated ABO alleles lead to the serological subtypes are
not well defined and is investigated in this study.
Methods: We used site directed mutagenesis to generate expression constructs with
point mutation corresponding to the ABO subtypes found in Taiwan.
Results: These subtypes included A2 (A207; 539 G to C), A3 (A303; 838 C to T),
weak A (Ael07; 829 G to A), and Bel (Bel03; 502 C to T). The constructs were
transfected into the cells followed by flow cytometry analysis to compare antigen-
expressing intensity on the cell surface for each ABO subtype. These percentage of
the A antigen-expressing cells decreased by 75.07%, 53.23%, 62.33% for A2, A3, and
weak A1, respectively. Similarly, the B antigen-expressing cells decreased to 57.45%
for Bel.
Conclusion: These data demonstrate that the point mutation occurred in various ABO
subtypes is the key to weaken ABO gene expression and plays an important role in the
regulation of ABO gene expression.
P-252
CHIMERISM OF ABO BLOOD GROUP IN TAIWAN
Yang MH1, Liu ML1, Feng S1, Hung YS1, Hung CS1, Lin KS2
1Taipei Blood Center, Taipei, Taiwan 2Taiwan Blood Services Foundation, Taipei,
Taiwan
Background: Chimeras are individuals that have more than one genetically-distinct
population of cells. This phenomenon is recognized in skin and blood. The chimerism
was confirmed by the analysis of the red blood cell antigens, which revealed the
presence of two different populations. For example, if two populations of red cells were
group A and group O, the serology resulted in mixed filed agglutination. Unlike chi-
merism, mutations in antigen-related genes resulted in subgroups which had only one
genetic population. Genotyping the ABO blood group of chimeras showed ambiguous
or inconsistent results. This report described two chimerism donors. Donor A, who is
blood group A with mixed field agglutination; Donor B, who is blood group AB and the
mixed filed agglutinations were observed.
Study design/methods: Serologically, donors’ red cells were tested with antisera by
tube method and gel-based micro typing system. Both donors’ genotypes were initially
determined by detecting SNPs in ABO gene. When the partial digestion patterns were
observed in PCR-RFLP, further ABO allele was determined by allele-specific PCR
analysis. Microsatellite genotyping confirmed the genetics bases of donors’ blood cells.
Family study of donor B was performed.
Results: Donor A’s red cells showed mixed filed agglutinations with anti-A and anti-
A1. This donor was suspected to be an A3 subgroup. The PCR-RFLP showed partial
digestion pattern, which indicated a very weak A allele. The sequence analysis of two
exons showed only O allele. We analyzed 16 microsatellite markers, no tri-allele or
tetra-allele was shown. Further allele-specific PCR was performed to selectively am-
plify A allele. The result proved donor A had an A allele. Donor B’s red cells showed
mixed field agglutinations with anti-A, Anti-B and anti-A, B. This donor was A3B3
phenotype. Her spouse was common group O, and her two offsprings were common
group A and group B. The PCR-RFLP of donor B’s DNA showed only A and O alleles.
The initial genotyping result was inconsistent with phenotyping data. Direct
sequencing of exon 7 showed a mixture of A, B and O alleles. Six loci of microsatellite
markers demonstrated tri-allelic patterns and the marker AMEL indicated a Y chro-
mosome. The chromosome analysis of donor B’s white blood cells revealed the 46XX/
46XY chimerism. Analyzing 40 cells, 27 were 46XY, and 13 were 46XX. Allele-specific
PCR confirmed A, B and O alleles.
Conclusion: In this study we reported two chimerism cases. Donor A was an A/O
chimera. This donor had two populations of cells which had large difference in the
number. The minor population was shown by partial digestion pattern of PCR-RFLP
and allele-specific PCR. Female donor B was speculated to be an AB/O chimera. Six loci
of microsatellite markers demonstrated tri-allele results. Y chromosome was detected.
For both donors; it will take further family studies tracing back to their parents and
more sensitive assays to clarify the paternal or maternal DNA contribution. Discrep-
ancies between blood group genotype and RBC phenotype do occur. More DNA-based
genotyping techniques will be implemented to study this complicated genetic phe-
nomenon.
P-253
ABO GENOTYPING BY MINISEQUENCING IN KAOHSIUNG
BLOOD CENTER
Lin S1, Lin H1, Lin K1, Hung C1, Lin K2
1Kaohsiung Blood Center, Kaohsiung, Taiwan 2Head Office Taiwan Blood Services
Foundation, Taipei, Taiwan
Background: ABO discrepancy is a common problem in serological blood grouping.
To determine correct blood group, many genotyping methods are applied to identify
ABO alleles. The PCR-RFLP is used to detect ABO alleles in our laboratory for many
years. However, it still has some limitations. Here we perform a minisequencing
method to type ABO alleles and evaluate the suitability to clarify mismatched ABO
typing result or subgroups encountered in routine work.
Aims: The aim of the present study is to evaluate the applicability of minisequencing
method for genotyping ABO alleles.
Methods: About 60 samples included both ABO subgroups and mismatched typing
result were selected and analyzed by PCR-RFLP. The DNA fragments of exon 6 and
exon 7 were amplified by duplex PCR and minisequencing reaction were performed
with SNaPshot kit and single base extension primers. The products were analyzed by
DNA genetic analyzer and GeneScan software.
Results: In many subgroup cases, five common alleles (ABO*A101, ABO*A102,
ABO*B101, ABO*O01, ABO*O02) can be identified. The 14 samples exhibited an O
phenotype with weak reaction of reverse typing can be clearly genotyped and assigned
according to the reference table. Only few samples are ambiguous results.
Conclusion: Our results have revealed that minisequencing analysis enables simple
and rapid multiplex genotyping of ABO alleles. It can provide an accurate genotyping
result than PCR-RFLP.
P-254
MOLECULAR BASIS OF NOVEL ALLELE AEL08 OF ABO BLOOD
GROUP
Hong XZ, Ying YL, Xu X, Zhu F, Lv HJ, Yan L
Blood Center of Zhejiang Province, Hangzhou, China
Objective: To analyze the molecular genetics basis for Ael08 allele of ABO blood
group. Methods:
The ABO group antigens on red cells of the proband were identified by monoclonal
antibodies and the ABO antibody in serum was detected by the standard A, B, O cells.
The weak antigen on RBCs was detected by absorption-elution test. The exon 5 to exon
7 coding region of ABO gene was amplified by polymerase chain reaction (PCR) and
the PCR product was sequenced directly for exon 6 and 7 after the double enzymes
digestion. The amplified product for exon 5–7 was also cloned by TOPO TA cloning
sequencing kit to split the two alleles apart and chosen colonies were sequencing
bidirectionally for exon 5–7 of ABO gene.
Results: Weak A antigen was found on red cells of the proband which can only be
identified by the absorption-elution test, there was also anti-B and weak anti-A
antibody in his serum. There was 261G deletion heterozygote and 297A/G in exon 6
and showed 467C/T, 46T/A, 681G/A, 771C/T, 829G/A, 804insG/G heterozygotes in
exon 7 by directly DNA sequencing. After cloning and sequencing, it was obtained one
common allele O02 and a novel ABO allele which was nominated as Ael08 by dRBC
NCBI. The sequence of Ael08 has one nucleotide changes at 804 position G insertion (as
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previously described by Olsson) compared with that of A10, which results in read
frameshift and the encoded product is 37 amino acids longer than the A1 transferase.
Conclusions: A novel allele Ael08 was identified and insertion G at 804 position of N-
acetylgalactosaminyltransferase gene (A gene) can result in Ael phenotype.
P-255
TWO MAJOR GYP (B-A) ALLELES IN JAPANESE WITH STONES
ANTIGEN (MNS15)
Yabe R1, Morimoto K1, Ogasawara K2, Uchikawa M1, Nakajima K1
1Japanese Red Cross Tokyo Blood Center, Tokyo, Japan 2Japanese Red Cross Central
Blood Institute, Tokyo, Japan
Background: The MNS blood group system is second only to the Rh blood group
system in its complexity. The MNS antigens are carried on glycophorin A (GPA),
glycophorin B (GPB), or hybrids of GPA and GPB. The low incidence MNS antigen Sta
is most commonly associated with a GYP(B-A) hybrid but also can be associated with
GYP(A-B-A) or GYP(A-E-A) hybrid gene. Sta antigen is specified by a hybrid junction
formed between the exon 2 of GYPB (or GYPA) and exon 4 of GYPA upon transcript
processing. It occurs with relatively high frequency among Asians, but its incidence is
rare in Caucasians and Africans. GP.Sch phenotype is encoded by a GYP(B-A), which
represent distinct genetic isoforms (type A, type B and type C) in the location of
crossing-over sites1).
Aims: We report here the molecular background of Sta gene identified in unrelated Sta
heterozygote from Japanese population.
Methods: Screening with monoclonal anti-M and anti-N against bromelin-treated
RBC was performed using automated blood grouping system (PK7300). When positive
reaction with anti-M or anti-N was observed, Sta, M, N, S and s antigens were
examined by tube method. DNA samples of 115 St(a+) individuals were extracted from
whole blood. DNA fragment of the GYP(B-A), including from pseudoexon 3 of GYPB
to exon 4 of GYPA, was amplified by PCR and nucleotide sequence was analyzed.
Results: Serological tests revealed that 1003 in 24,292 (4.1%) Japanese individuals
were typed as St(a+). MNSs typing on St(a+) red cells showed that 36% of the St(a+)
individuals had S+. This frequency was significantly higher than that of the randomly
selected Japanese (S+ was approximately 10%). PCR amplification and nucleotide
sequence analysis revealed that all 115 St(a+) individuals had GYP(B-A) hybrid allele.
These alleles were classified into seven groups on the bases of intron 3 sequence. Two
of them were major alleles with frequencies of 63% (72 in 115) and 30% (35 in 115),
and the GYP(B-A) crossing-over sites in intron 3 were 356–488 and 722–762,
respectively. These alleles were identical to the previously described Sta type B and type
C genes, respectively. Interestingly, 50% (36 in 72) individuals with Sta type B were S+,
whereas only 6% (two in 35) individuals with type C were S+.
Conclusion: In Japanese, St(a+) frequency was 4.1%. The Sta type B allele was most
frequent in St(a+) Japanese and 50% of them appeared to be associated with GYPB*S.
Reference:
1. Haung CH, Blumenfeld OO (1991) J Biol Chem 266: 23306–23314.
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GENETIC ANALYSIS OF 16 PARA-BOMBAY PHENOTYPE
INDIVIDUALS – A NOVEL NON-FUNCTIONAL FUT1 ALLELE
AND AN NEW EVIDENCE OF GENETIC LINKAGE WITHIN FUT1
AND FUT2 GENE
Chi Q, Zhang A, Ren B, Guo Y
Fujian Provincal Blood Center, Fuzhou, China
Background: The mutation of FUT1 gene results in decreased synthesis of H antigen,
will lead to the para-Bombay phenotype. Relatively high frequency (one in 8500) of
para-Bombay phenotype in Fujian province and a potential h2-Se357,716 heplotype
had been reported in our previous study. In this study, another 16 individuals with
para-Bombay phenotype have been analyzed.
Aims: The goals of this study were to analyze the genetic characteristics of the para-
Bombay individuals in Fujian province, to found new h alleles, and to prove the
hypothesis of genetic linkage within FUT1 and FUT2 by more experimental data.
Methods: The subject of para-Bombay phenotype were collected and identified from
the sample with ABO discrepancy in blood screening, and were confirmed by sero-
logical analysis. The sequences of FUT1 and FUT2 gene of para-Bombay individuals
were analyzed with direct sequencing of PCR products and gene cloning products.
Result: Four different alleles (h1, nt547–552Dag; h2, nt880–882Dtt; h3, nt658ct; h9,
nt424ct) were observed in this study. The FUT1 genotypes of these para-Bombay
individuals were h1/h1 (nine individuals), h1/h2 (four individuals), and h3/h2 (one
individual), h2/h2 (one individual), h1/h9 (one individual), respectively. Two prevalent
h alleles, h1 and h2, with the frequency of 68.75% and 21.87%, are predominated in h
alleles leading to H deficiency. A mutation of nt357ct was detected in all FUT2 gene,
another mutation of nt716ga was detected in the individuals with h2 gene, no null
FUT2 gene was detected.
Conclusion: A novel h alleles (h9) with a nucleotide 424C>T point mutation was
discovered. This study confirms the previous observations that h1 and h2 alleles are
predominate in Fujian H deficient individuals. The fact that all Se357,716 only have
found in individuals with h2 gene and more haplotype of h2-Se357,716 observed in
this study, confirms the previous hypothesis of genetic linkage within the FUT1 and
FUT2.
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APPLICATIONS OF NOVEL MOLECULAR TYPING TECHNIQUES
IN THE AUSTRALIAN RED CROSS BLOOD SERVICE
Hyland C1, Millard G1, Condon J1, Liew Y-W1, Roxby D2, Flower R1
1Australian Red Cross Blood Service, Brisbane, Qld, Australia 2SA Pathology Flinders
Medical Centre, Adelaide, SA, Australia
Background: To overcome the limitations of conventional immuno-haematological
methods, molecular techniques are emerging as important investigation tools. In the
Australian Red Cross Blood Service, certain problematic samples have been referred for
external investigation by Progenika Biopharma (Spain), where samples are analyzed in
a two step process: firstly with BLOODchip Reference (a blood group genotyping DNA
array platform) and if required, by other molecular techniques such as sequencing, to
further investigate the problem.
Aim: The aim of this study was to determine the extent to which samples referred
during 2009–2011 for SNP typing and, if appropriate, sequencing, were resolved after
molecular testing.
Methods: DNA was extracted using the Qiagen EZ1 DNA blood kit method. DNA was
checked for concentration and purity and then sent to Progenika Biopharma (Derio,
Spain). The Progenika protocol commences with SNP analyses with the BLOODchip
Reference database. This genotyping platform detects 128 SNPs in 10 red blood cell
and 12 human platelet antigen systems, including 72 SNPs that render 101 variants of
RhD group (10 Del, 47 Partial D, 21 Weak D and 23 D negative). This analysis is
complemented with other techniques such as RhD zygosity, RhD exon scanning or
coding region sequencing, if the problem is not resolved with the previous test.
Results: A total of 52 samples were sent for analysis, comprising 32 patients, seven
donors and 13 maternity samples.
Review of the reasons for referral showed 40 (76.9%) were due to serologic
inconsistencies in the RHD group, and 8 (15.4%) in other groups, including ABO (3),
MNS (2), Duffy (1), Colton (1) and RhCE (1). Four cases (7.7%) were from patients who
had received multiple transfusions and had auto-antibodies, leading to difficulties
when undertaking extended antigen typings by regular serological methods.
Testing with BLOODchip Reference analysis resolved 78.8% (41) of all cases and a
further 7.7% (4) were resolved by sequencing. One sample (1.9%) was tested for
zygosity. In 5.8% (3) cases, one for ABO, one for MNS and one for RHD, the group of
interest was confirmed by genotyping and therefore classified as resolved although it
was noted antibodies of unexplained specificity were present. Finally a further 5.8% (3)
cases remained partially unresolved.
Summary/conclusions: In 94.2% of cases that were unresolved with serology,
molecular genetic techniques contributed to a resolution.
This study shows that genotyping is particularly valuable in resolving serological
inconsistencies in the RhD group (including donors and patients such as pregnant
women) and for typing in multi-transfused patients.
In conclusion the application of novel molecular typing techniques has demonstrated
considerable utility to complement serology in the resolution of problematic samples in
these investigations.
Acknowledgements: We wish to acknowledge the professional services of Progenika
Biopharma and the contribution of the R&D scientists in the compilation of this abstract
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THE SINGAPORE RARE DONOR PROGRAM – THE SEARCH FOR
DIB (DI2) NEGATIVE DONORS
Ng WY, Loke JWI, Chan M
Health Sciences Authority, Singapore, Singapore
The primary role of any blood transfusion service is to provide patients needing
transfusion with compatible blood. This provision is at times complicated by the
presence of clinically significant alloantibodies. Transfusion in such cases is made
compatible only with blood lacking the antigen against the offending alloantibody.
The Dib blood group antigen is prevalent in most populations. Transfusing patients
immunized with anti-Dib will pose tremendous challenge to most transfusion services
due to the rarity of the Dib-negative phenotype. It is therefore unsurprising that Dib-
negative phenotype is categorized as a rare phenotype among other international rare
 2011 The Authors
Vox Sanguinis  2011 International Society of Blood Transfusion Vox Sanguinis (2011) 101 (Suppl. 2), 39–134
108 Posters
donor programs such as the American Rare Donor Program (ARDP) and the World
Health Organization International Donor Panel (WHO IDP).
In efforts to support the need for such phenotype and to further develop the Singapore
Rare Donor Program, the Blood Services Group undertook a project to screen and
identify Dib-negative donors. A two-stage screening strategy incorporating both
serological and molecular methods was necessary due to the unavailability of
commercial anti-Dib phenotyping reagent.
Three hundred and eighty-seven EDTA-anticoagulated random blood donor samples
collected between June and August 2010 were screened for the antithetical Dia antigen
(DI1) using serological methods. Dia screening was performed with anti-Dia (Diamed,
Switzerland) using indirect antiglobulin test (IAT) method on an automated column
agglutination technique system (Techno Twinstation; Diamed, Switzerland). Identified
Dia-positive samples were subjected to a secondary molecular screening using
Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) to
determine zygosity of Diego antigens. Gene amplification was targeted towards
SLC4A1 gene, while RFLP was performed using MspI restriction enzyme, a method
previously described by Baleotti et al., 2003. The genotype and predicted phenotype of
these samples were determined based of the fragment sizes of the PCR product. PCR-
RFLP sample that demonstrated DI1/DI1 genotype which encode for Dib-negative
phenotype was sequenced for confirmation.
Of the 387 samples screened, 18 (4.7%) were found to be phenotypically Dia-positive
while the remaining 369 (95.3%) were Dia-negative. PCR-RFLP on the 18 Dia-
positive samples produced expected fragment sizes of 363, 275 and 88 bp. Seventeen
(4.4%) of these samples demonstrated all three fragment sizes, indicative of a
heterozygous Dia-positive and Dib-positive phenotype: while an undigested PCR
product was demonstrated for 1 (0.3%) sample. DNA sequencing of the undigested
PCR product confirmed the DI1/DI1 genotype for the expected rare Dib-negative
phenotype.
The need to screen blood donors for rare blood types, such as Dib-negative phenotype,
remains a struggle for many blood centres. The process remains extremely resource-
intensive but yet necessary, if compatible blood for patients exhibiting antibodies
toward these high incident blood group antigens is needed. The lack of licensed blood
grouping reagents and unfavourable geographical distribution of rare blood types
make the task even more daunting.
Although the Singapore Rare Donor Program is at its infancy stage and has seen some
successes at incorporating some of our unique screening strategies with our existing
donor recruitment and freezing programs, the need to synergize with other like-minded
blood centres remains imperative.
Table 1: Screening results for Dib-negative donors
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MOLECULAR GENETIC ANALYSIS FOR THE VARIANT PHENO-
TYPES OF THE ABO BLOOD GROUP SYSTEM
Zhang A, Chi Q, Guo Y, Ren B
Fujian Provincal Blood Center, Fuzhou, China
Background: The AB0 blood group system is the most clinically significant system in
transfusion and transplantation medicine. In addition to common ABO blood group,
many variant phenotypes that are the so-called ABO subgroup have been found. To
understand the molecular genetic basis of this polymorphic system, we have analyzed
genomic DNAs obtained from Chinese individuals possessing variant ABO phenotypes
including A2, Ax, Ael, cis-AB, Bw, and Bel.
Methods: Serologic investigations were performed with standard methods. DNA se-
quences from exon 6 to exon 7 were analyzed using genomic DNA by polymerase
chain reaction and direct DNA sequencing or sequencing after gene cloning.
Results: We identified nine different alleles which contained two novel A allele. One
novel A allele being different from the allele A101 by 467C>T, 721C>T missense
mutation in exon 7 responsible for the Ax phenotype, the other being different from
the allele A101 by 467C>T, 607G>A missense mutation in exon 7 responsible for the
A2 phenotype. Correspondingly resulting in the amino acid changes Pro156 Leu, Arg
241 Trp and Pro156 Leu, Glu 203 Lys in the A glycosyltransferases. The mutations were
not found in 50 randomly selected samples. Seven allele were previously reported ABO
alleles.
Conclusion: Two novel A allele responsible for Ax and A2 subgroup were firstly
reported. Amino acid substitutions resulted from novel mutations 721C>T and
607G>A on ABO gene may change conserved regions of the enzyme and reduce the
activity of the glycosyltransferases, leading to the variant phenotype. Our datas still
indicate that different alleles could cause the same AB0 variant phenotypes,
molecular bases for the variant phenotypes in Chinese population have highly
polymorphism.
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VALIDATION OF HRM PROCEDURES FOR GP.MUR AND DIA
GENOTYPING
Flower RLP1, Lopez G1, McBean R1, Wilson B1, Liew Y-W1, Christensen A-M2,
Hyland C1
1Australian Red Cross Blood Service, Brisbane, Qld, Australia 2Queensland University
of Technology, Brisbane, Qld, Australia
Background: Antibodies to the Dia polymorphism and to neoantigens (Mut, Mur, and
Hil) found on GP.Mur can cause haemolytic transfusion reactions and haemolytic
disease of the foetus and newborn. Dia and GP.Mur are found in 5–8% in East Asian
populations. The aim of the study was to establish and apply high resolution melt
(HRM) genotyping procedures to type these polymorphisms. For Gp.Mur the intronic
crossover site was targeted for development of a novel typing procedure.
Aim: To apply molecular genetic techniques to type and investigate the levels of these
polymorphisms found in Asian ethnic groups in donor cohorts Australia.
Methods: Standard serological procedures were performed to detect Dia and GP.Mur
pos donors. Using primers from published methods and novel primers for the intronic
crossover in GpMur, HRM genetic typing was performed using an HRM kit (Qiagen).
DNA from donors that were serology-positive and serology-negative were investigated
to validate published methods for GPMUR typing and a novel HRM genotyping pro-
cedure. A similar characterisation was carried out for the published HRM typing
procedure for the Dia SNP.
Results: HRM genotyping showed 100% concordance with serology. GP.Mur was
detected in 3% of selected donor samples by both serology and genotyping. For
GP.Mur, the full profile of neoantigens and the expected intronic crossover were de-
tected, no variant types were found. Dia/Dib HRM typing revealed 1 Dia homozygote
(1.8%) and 7 Dia/Dib heterozygotes (12.8%) in a preliminary study.
Summary and Conclusions: HRM genotyping reliably genotyped the Dia SNP and
GPMUR. In this selected study cohort, the antigen frequency for GP.Mur was 3% and
for Dia a surprising 14.6%. Currently, 8% of the Australian population is of Asian
ethnicity and in some donor cohorts, the frequency of these ethnic-associated blood
group types is considerably higher than expected in Australia.
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BLOOD GROUP GENOTYPING IN CHRONICALLY TRANSFUSED
PATIENTS: COMPARISON WITH THE ERYTHROCYTE
PHENOTYPING METHOD
Bakanay-Ozturk SM, Ozturk A, Ileri T, Ince E, Yavasoglu S, Akar N, Uysal Z, Arslan O
Ankara University Medical School, Ankara, Turkey
Background: Chronically transfused patients such as thalassemia major and sickle cell
anemia carry in their circulation the donor derived erythrocytes from previous
transfusion. This prevents the occurate phenotyping of erythrocytes. Discordance be-
tween the real phenotype of the patients and the phenotype of the transfused red blood
cell (RBC) units results in alloimmunization. This is associated with hemolytic trans-
fusion reactions, shortening of the erythrocyte life span and increased frequency of
transfusion. Although strategies to provide phenotype-matched RBC units by many
blood banks in the world have partially controlled the high rate of alloimmunization
among this population, the risk still remains.
Aim: To perform blood group genotyping of chronically transfused patients in a single
center and compare the results with the results of erythrocyte phenotyping.
Method: Genotyping was performed by using sequence specific primer based PCR for
RhD, RhCcEe ve Kell (KEL1, KEL2), Kidd (Jka, Jkb), Duffy (Fya, Fyb) antigens in 38
patients (age range: 1–67) (34 beta thalassemia major, two sickle cell anemia/Sbtal, one
congenital dyserythropoietic anemia, one chronic anemia) receiving their RBC units
from a single blood center. Phenotyping was performed by gel agglutination method.
Results: Among the 36 patients who had been phenotyped by gel agglutination
method and compared with the genotyping results, 19 had discordance between
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phenotype and genotype in a total of 25 antigens. The most frequent haplotypes were
RHD*+ (97%), RHCE*Ce (61%) and RHCE*ee (68%), KEL*2/KEL*2 (95%), JK*A/JK*B
(58%) and FY*A/FY*B (43%). Twelve patients had genotype-phenotype mismatch
which had the risk of alloimmunization in case of phenotype matched transfusion. One
patient had weak D, three patients had FY*null haplotype. The alloimmunization ratio
was 7% (3/38). Patients who were alloimmunized were adult patients. None of the
thalassemia patients had allo-antibodies.
Conclusion: This study supports the use of molecular genotyping in chronically
transfused patients to determine blood group antigens occurately and provide
genotype-matched RBC units to prevent alloimmunization. In spite of the high
genotype-phenotype mismatch, the alloimmunization ratio was low, the causes of
which should be further investigated. If the phenotyping can not be done before the
first transfusion, erythrocyte genotyping should be performed to prevent false phe-
notyping after multiple transfusions.
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GENOTYPING ANALYSIS OF KIDD, KELL, DUFFY, SCIANNA
AND RHCE BLOOD GROUP ANTIGENS POLYMORPHISMS BY
PCR-SSP IN SOUTHEAST CHINESE BLOOD DONORS
Chen Q1, Zeng R2, Tang RC1, Huang CY1, Liu Z3
1Jiangsu Province Blood Center, Nanjing, China 2Institute of Dermatology, Chinese
Academy of Medicine, Nanjing, China 3Anhui Province Blood Center, Hefei, China
Background: Molecular testing is more precise compared to serology and has been
widely used in genotyping blood group antigens. Single nucleotide polymorphisms
(SNPs) of blood group antigens can be determined by the PCR-SSP assay. Commercial
platforms can be expensive and are not approved in China. The genotype frequency of
Kidd, Kell, Duffy, Scianna, RhCE blood group antigens in Jiangsu province were un-
known.
Aims: To detect the genotype frequency of Kidd, Kell, Duffy, Scianna, RhCE antigens
in Jiangsu using molecular methods with laboratory developed tests.
Methods: DNA was extracted from EDTA-anticoagulated blood samples of 146 vol-
untary blood donors collected randomly within 1 month. Standard serologic assay for
red blood cell antigens were also performed except the Scianna blood group antigens.
PCR-SSP was designed to work under one PCR program to identify the following SNPs:
Jka/Jkb, K/k, Fya/Fyb, Sc1/Sc2, C/c and E/e.
Results: Serologic antigen results were identical to the phenotypes that were predicted
from genotyping results. The gene frequencies for Jk*A and Jk*B were 0.51 and 0.49,
respectively; for Fy*A and Fy*B 0.94 and 0.06; for RHCE*C and RHCE*c 0.68 and 0.32;
and for RHCE*E and RHCE*e 0.28 and 0.72. Among 146 blood donors, all were k/k and
Sc1/Sc1, indicating allele frequencies for KEL*2 and SC*1 close to 1.00.
Summary: The use of PCR-SSP working under the same condition for testing multiple
antigens at the same time is practical. This approach can be effective and cost-efficient
for small-scale laboratories and in developing counties. These molecular tests can also
be used for identifying rare blood types.
5.3 Platelet Immunology
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GENE MUTATION RELATED TO CD36 DEFICIENCY BY PCR-SSP
IN CHINESE CANTONESE
Ye X, Wang J, Shao Y, Xia WJ, Chen YK, Ding HQ, Deng J, Xu XZ
Guangzhou Blood Center, Guangzhou, China
Background: CD36 deficiency is proved to be important in some clinical situation, but
the related mutation frequency in China is not known.
Objective: In this study, we used sequence-specific primer-PCR to detect the frequency
of CD36 gene mutation in GuangDong district of China.
Methods: A total of 470 blood samples from unrelated health donors were involved
and the PCR-SSP method was used.
Results: We detected 30 samples from these donors having CD36 gene mutation, the
mutation types and frequencies are as follows: three for C268T (0.64%); 14 for 329–
330del AC (2.98%); two for C380T (0.43%); two for C760T (0.43%); eight for A1237C
(1.70%); and only one combined mutation for C268T and 560T ins (0.21%).
Conclusion: Here, we first used the PCR-SSP method to detect the mutation fre-
quencies of CD36 in China. The 329–330del AC appears to be the major mutation type
of CD36 and the A1237C comes to be the secondary in GuangDong. Our results are
somehow different from previous studies which have reported that the major types of
CD36 gene mutation were: C268T, 329–330del AC and 949in A.
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ANALYZING THE BCL-XL LEVEL IN PLATELETS OF
IDIOPATHIC THROMBOCYTOPENIC PATIENTS
Chiueh TS, Chang TY, Chen YC, Chen CM
Tri-Service General Hospital, Taipei, Taiwan
Background: Thrombocytopenia could result from decreased thrombocytogenesis in
bone marrow or increased destruction in situations of infection, hemorrhage, auto-
immune, splenomegaly etc. However, idiopathic thrombocytopenia is quite often ob-
served in clinics. Life span of platelet in blood is about 7–10 days. The ‘multiple hits’
model, whereby damage by external hits and clearance of older platelet by the retic-
uloendothelial system, is believed to regulate life span and number of platelets
eventually. Another recently emerged ‘internal timer’ model demonstrates an apoptotic
pathway in platelets that dominated their survival in vivo. In the mouse model,
mutations in the anti-apoptotic protein Bcl-xl, the Bcl-2 family protein, were shown to
reduce platelet life span and cause thrombocytopenia. Bcl-xl could be the key com-
ponent of apoptosis pathway in platelets, and might function as a timer of their life
span. A decline in Bcl-xl levels would trigger Bak activation and initiate apoptosis
Aim: The aim of this study is to evaluate the Bcl-xl content of platelets collected from
idiopathic thrombocytopenic patients.
Methods: Whole blood specimens were collected from 15 patients who have lower
platelet count (between 100,000 and 150,000/ll) with most thrombocytopenic eti-
ology excluded. Platelets from these patients were separated by two-step centrifu-
gation and the Bcl-xl content of platelets was analyzed by Western blotting.
Results: The Bcl-xl amount was estimated by normalizing with the GAPDH protein
level. We found these patients’ platelets have no consistent lower amount of Bcl-xl
protein. Only two of 15 patients’ platelets contain less Bcl-xl protein. The ratio range is
from 0.80· to 1.94· compared to the normal patients. However, simply analyzing the
centrifuged intact platelets may not actually represent the instant degradation of Bcl-
xl. The apoptotic pathway may proceed quickly in platelets right after Bcl-xl degra-
dation, so it is hard to detect low level amount of Bcl-xl in platelets which were still
alive.
Summary: Here we demonstrated that there is no significant difference of Bcl-xl
protein level between idiopathic thrombocytopenia patients and normal controls.
Additional studies such as investigation of Bcl-xl stability or evaluation of upstream
proteins of apoptotic pathway need to be done to demonstrate the relation of platelet
apoptosis and idiopathic thrombocytopenia in human.
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EXPRESSION OF ANTI-PLATELET GLYCOPROTEIN SPECIFIC
AND ANTI-HLA ANTIBODIES IN IDIOPATHIC THROMBOCYTO-
PENIC PURPURA PATIENTS
Xia W, Fu YH, Ye X
Institute of Blood Transfusion, Guangzhou, China
In order to investigate the expression of the anti-platelet glycoprotein specific
antibodies and anti-HLA antibodies in idiopathic thrombocytopenic purpura (ITP), 45
patients with ITP were seleceted. An easy PCR-SSP assay was used to detect single-
nucleotide polymorphisms or deletion in HPA and HLA systems. The anti-platelet
glycoprotein specific antibodies and anti-HLA antibodies in plasma or platelet eluate
were tested with a solidphase ELISA. There were 45 patients expressed anti-platelet
glycoprotein specific antibodies in plasma or platelet eluate, among which anti-GPII b/
IIIa/and anti-GpIb/IX are most common. There were 11 patients expressing both the
anti-platelet glycoprotein specific antibodies and anti-HLA antibodies in plasma.
Pedigree study was used in two patients. In conclusion, the results suggested that
detection of the anti-platelet glycoprotein specific antibodies and anti-HLA antibodies
in plasma or platelet eluate is significant in diagnosis for idiopathic thrombocytopenic
purpura.
Table 1: The expression of the anti-platelet specif
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Table 2: Co-expression of the anti-platelet specif
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FVIII GENE VARIATIONS IN HEMOPHILIA A PATIENTS OF
SOUTHWEST CHINA
Diao G, Ma L, Liu Z, Sun P, Lin F, Li C, Xiao X
Institute of Blood Transfusion, CAMS, Chengdu, China
Background: Hemophilia A (HA) represents the most common and severe inherited
hemorrhagic disorder in southwest part of China. It is caused by variations in the FVIII
gene, which leads to a deficiency or dysfunctional factor VIII protein, resulting in
frequent spontaneous bleeding in joints, muscles and internal organs.
Aims: This study aimed to detect FVIII gene variations in HA patients of southwest
part of China, and to establish a diagnostic strategy for HA genetic diagnosis in this
area.
Methods: Long-distance PCR (LD-PCR) with three primers was used to detect the
inversion of intron 22. In order to increase the sensitivity and accuracy of the method,
the original one-tube reaction was splited into two separate reactions. Each of them
contained two of the three primers. One reaction could detect the non-inversion form
of intron 22. Meanwhile, another reaction could demonstrate the inversion form with
different length of PCR products compared to the former one. For the detection of
intron 1 inversion, method of two multiplex PCR reactions was adopted. Each reaction
contained three of the total four primers, forming different length of the PCR products
when there was inversion or not. As to strengthen the reliability of mutation scanning
in the whole FVIII exonal regions, PCR amplification followed by the direct sequencing
was used to identify the mutational points.
Results: The results of detailed detection were presented among the patients with HA
in southwest part of China. There were six families and five individuals identified with
inversion of intron 22, and one families recognized as inheritance of intron 1 inver-
sion. By direct sequencing, there were two families and eight individuals were iden-
tified with exonal mutations, although in different points. There was no exonal
deletion or duplication event detected in this study. The overall mutation detection rate
of HA was 100%.
Conclusions: A diagnostic strategy for HA genetic diagnosis in southwest part of
China was proposed in this study. Both of the PCR methods used to detect the inver-
sions were reliable, and sequencing method was also a powerful tool in the identifi-
cation of FVIII gene exonal mutations.
Acknowledgements: This study was supported by grants from the research of project
in the Science & Technology Pillar Program of Sichuan Province(2010SZ0130).
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INITIAL ESTABLISHMENT FOR ASSAY METHOD OF HEPARIN
IN ANTITHROMBIN? CONCENTRATES
Cao H1, Hu J2, Zhang X1, Wang ZK1, Du X1, Ye S1, Wang Y2, Xie Y1, Li C1
1Institute of Blood Transfusion, CAMS, Chengdu, China 2China Biologic Products, Inc.,
Chengdu, China
Background: Antithrombin III (AT-III) concentrates are employed as prophylaxis or
treatment of thromboembolic disorders in patients with congenital or acquired defi-
ciencies ofAT-III, but so far there has beennomature product in China.Nowadaysmost of
available therapeutic AT-III concentrates are obtained by affinity chromatography to
heparin, so heparin content is an important indicator for AT-III concentrates quality.
Heparin can bind with AT-III to form the antithrombin-heparin complex which inacti-
vates thrombin, factor IXa, factor Xa and etc, so the role of AT-III should be taken into
account in heparin assay. In the coagulation method for assay of heparin content in
Chinese Pharmacopoeia (2010 Edition), interference of AT-III in the tested samples is not
eliminated, therefore thismethod is not suitable for heparin detect in AT-III concentrates.
Aims: To establish a efficient method for assay of heparin content in AT-III concen-
trates.
Methods: The standard heparin was proportionally diluted with reaction buffer to
obtain the gradient concentrations, which were 0.12, 0.1, 0.05, 0.025, 0.0125, 0 IU/ml.
Then 40 ll of diluted standard heparin was mixed with AT-III standard material in 96
well microplates. After incubation at 37C for 3 min, 40 ll of prewarmed factor Xa was
added, and lasting for another 2 min, and then add 40 ll of chromogenic substrate S-
2765 for 2 min in 37C. The whole reaction was terminated by adding 50% acetic acid.
Measure the absorbance at 405 nm, and draw the calibration curve of heparin, then
heparin was analyzed in the tested AT-III concentrates according to the calibration
curve of heparin.
Results: When 0.5, 1.0 and 1.5 IU/ml of AT-III standard material, the activity unit of
the factor Xa is 21 nkat/ml, at 0–0.05 IU/ml of heparin content the correlation
coefficients of the three heparin calibration curves are all >0.99, however at 0–
0.12 IU/ml of heparin content the correlation coefficients are all <0.90. At 0.5 or
1.0 IU/ml of AT-III standards material and 21 nkat/ml of factor Xa, there is no evident
discrepancy in the heparin content of tested AT-III concentrates and good repeat-
ability is achieved.
Conclusions: We have initially established the assay method of heparin in AT-III
concentrates. Under the conditions of 0.5 or 1.0 IU/ml AT-III standards material and
21 nkat/ml factor Xa, the heparin content ranging from 0 to 0.05 IU/ml can efficiently
be determined in AT-III concentrates.
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A CASE REPORT ON NEONATAL ALLOIMMUNE
THROMBOCYTOPENIA DUE TO ANTI-CD36 (NAKA) IN TAIWAN
Lee HL, Lin M, Chu CC, Xie XH, Liang DC
Mackay Memorial Hospital, New Taipei City, Taiwan
Background: Naka antigen (CD36) was first reported by Dr. Ikeda et al in 1989. Naka is
an isoantigen expressed on platelets and monocytes. Some Naka ()) individuals do not
present CD36 on platelets and monocytes, or sometime is only absent on platelets
(referred as Type I and Type II CD36 deficiency, respectively). It has been reported that
Type I CD36 deficient mothers produce isoantibodies during pregnancy and give birth
to babies with thrombocytopenia.
Case Report: A full-term baby was delivered by caesarian section from a healthy
mother (gravida 2, para 1). The Taiwanese boy, now 17 years old, was 3500 g at birth
who presented fever and jaundice after 4 days. His Hb and Ht were normal but the baby
developed severe thrombocytopenia (<40,000/ll). Neonatal alloimmune thrombocy-
topenia (NAITP) was suspected and the baby was treated with a single dose of intra-
venous immune globulin (IVIgG) (1 g/kg) at day 7. The maternal blood was collected
for further analysis.
Methods: The maternal serum was first screened for platelet antibodies with her
husband and a panel of 108 random donors using a solid phase red cell adherence
assay (SPRCA). CD36 phenotype on the mother platelets and monocytes was confirmed
by flow cytometry with monoclonal antibodies. Specificity of alloantibodies was
identified using monoclonal antibody immobilization of platelets assay (MAIPA) and a
commercial kit (PakLx; GTI diagnostics) based on Luminex bead technique. Lastly, the
genomic mutation of CD36 gene was determined by sequencing after amplification of
12 coding domain sequences (CDS).
Results: The maternal serum showed positive reaction with 105 of 109 donors’
platelets (96.3%). This outcome corresponds to the frequency of Naka antigen in the
Taiwanese population. Further phenotyping revealed that father and baby carried Naka
antigen and that mother was Naka ()) phenotype for platelets using SPRCA. In addi-
tion, the mother was confirmed as a type I CD36 deficiency, as both her platelets and
monocytes lacked reactivity with monoclonal anti-CD36 by flow cytometry. It agrees
with the presence of anti-Naka in the maternal serum. Recently, the mother serum was
retrospectively tested by MAIPA and PakLx kit. It showed that her antibodies reacted
with isolated CD36 molecules.
Sequencing further identified two mutations in the mother CD36 gene. One was a
known dinucleotide deletion on the third CDS (referred as CD36:c.329_330delCA,
previously named as 539–540del) leading to frame-shift. The other was not previously
reported and was a 6 bp deletion starting on nucleotide position 6 after the end of CDS
11 (referred as CD36: c.1254 + 6 delTATTTG). However, this deletion cannot be used to
predict any interaction on the splicing process.
Conclusion: This is the first NAITP case caused by anti-Naka, which has been reported
at transaction of Taiwan society of blood transfusion in 1995. But the underlying
molecular mechanism leading to CD36 deficiency is still not clearly understood and
need further study.
 2011 The Authors
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CLINICAL FEATURES AND DETECTION OF ANTIPLATELET
ANTIBODIES IN CHILDREN WITH IMMUNE
THROMBOCYTOPENIA
Chen C
Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan
Background: Primary immune thrombocytopenia (ITP) is one of the most common
acquired bleeding disorders of childhood. It’s well known that pediatric ITP is most
commonly associated with a preceding viral infection. Furthermore antiplatelet anti-
bodies react against platelet glycoproteins and cause autoimmune thrombocytopenia
purpura.
Aim: This study was to evaluate the relationship between clinical presentations, an-
tiplatelet antibodies and antecedent of preceding infection in children with ITP.
Methods: Twenty-five children diagnosed with ITP were identified following a ret-
rospective review of medical records at two medical centers in north Taiwan. We
investigated and evaluated the demographics, clinical and laboratory features, as well
as previous infection and vaccination history of 25 children with ITP. Detection of
plasma platelet antibodies by ELISA (PakPlus GTI, Waukesha, WI, USA) was used.
Statistical analyses were performed using the R statistical software. In univariate
analysis, the means of continuous variables were compared with two-sample t test,
whereas the associations between categorical variables were analyzed with Fisher’s
exact test.
Results: Among the 25 children, 10 were males and 15 were females. The mean age at
onset was 5.7 years, with 9 (36%) patients <2 years, 10 (40%) patients between 2 and
10 years, and 6 (24%) patients >10 years of age at the onset of ITP. There was no
apparent proclivity of season of onset for the occurrence of ITP. The mean platelet
count at diagnosis was 12.1 · 109/l (range, 2 · 109/l–43 · 109/l), with 20 patients
(80%) with initial platelet count <20 · 109/l. Eighteen (72%) patients had antecedent of
preceding infection (API), while 7 (28%) patients did not. There were no significant
differences between patients with and without antiplatelet antibodies regarding the
gender, age and season of onset, initial platelet count, API. Analyzing antiplatelet
antibodies, 15 (60%) were positive and 10 (40%) were negative. Antibodies reactive
with GPIIb/IIIa, GPIa/IIa, GPIb/IX, and GPIV were detected in 47%, 20%, 6.6%, and
6.6% patients, respectively. Three patients (19.8%) had antibodies against more than
one glycoprotein (P < 0.001). Further analysis of demographic and clinical parameters
by the type of antiplatelet antibodies revealed that patients without API were more
likely to have anti-GPIa/IIa than those with API (42.9% vs 5.5%, P = 0.048). There were
no significant differences in patients with or without anti-GPIIb/IIIa, and in patients
with or without anti-GPIb/IX with respect to the gender, age and season of onset,
initial platelet count, API.
Conclusions: In our study, antiplatelet antibodies were detected in 60% patients with
ITP and anti-GPIIb/IIIa was the most common type which compatible with the previous
studies. Detection of the specific platelet antibodies was helpful selected matched
platelet. In addition, API was associated with absence of anti-GPIa/IIa antibody. On the
other hand, patients without API perhaps showed multiple types of platelet antibodies.
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MATERNAL ALLOIMMUNIZATION TO GRANULOCYTE-
SPECIFIC ANTIGENS AND NEONATAL ALLOIMMUNE
NEUTROPENIA
Mineeva NV, Elkhina EV, Zavarzina OA, Bodrova NN
Russian Research institute of Haematology, Sankt Petersburg, Russia
Background: Placental transfer of maternal allo- and auto-antibodies can cause the
destruction of neutrophils in fetus and/or infant after birth and cause the immune
neonatal neutropenia. There are no data available about the granulocyte antibody
appearance among pregnant women in Russia. The aim of our study was to estimate
the granulocyte antibody appearance among pregnant women.
Methods: We’ve tested sera from 94 pregnant women and nine women having neu-
tropenic newborn infants. The gel agglutination assay (ID-microtyping system DiaMed)
and granulocyte agglutination test were used for granulocyte antibody detection. All
sera were tested with five donor granulocyte samples. Sera of nine women having
newborn infants with neutropenia were tested with father’s granulocyte samples.
Results: Sera of 94 women were tested. No granulocyte-specific IgG-antibodies were
found among studied pregnant women, but six women (6.2%) had IgM-antibodies
found by granulocyte agglutination test. Six of 94 pregnant women (6.2%) had lym-
phocyte-specific IgG-antibodies. Also we’ve tested sera of nine women having new-
born infants with neutropenia. Three of these women had granulocyte-specific IgG-
antibodies. One woman had granulocyte autoantibodies, and another one had both
granulocyte-specific alloantibodies and autoantibodies. We didn’t detect the granu-
locyte-specific allo- and autoantibodies in sera of four women having newborn infants
with neutropenia.
Conclusion: The study confirmed neonatal immune neutropenia, caused by the
granulocyte antibodies, in five cases. However, there were no antibodies detected in
sera of 94 pregnant women.
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DISTRIBUTION PROFILE OF HUMAN NEUTROPHIL ANTIGEN-3A
AND -3B AMONG TAIWANESE
Lai SK, Chu CC
Mackay Memorial Hospital, New Taipei City, Taiwan
Background: Transfusion-related acute lung injury (TRALI) is rare, but most fre-
quently causes mortality and morbidity after blood transfusion. It has been reported
that alloantibodies against human neutrophil antigen HNA -3a is associated with some
severe or fatal TRALI cases. The molecular mechanism of HNA-3a/3b has been
uncovered in 2010. It showed that HNA-3 is a biallelic system resulting from a single
nucleotide exchange (G461A or Arg154Gln) in the choline transporter-like protein 2
gene (SLC44A2).
Method: An in house polymerase chain reaction with sequence-specific primers (PCR-
SSP) was designed and assessed in our laboratory. To evaluate the risk of developing
HNA-3a alloantibodies in Taiwanese, HNA-3a/3b genotyping was firstly performed
among unrelated healthy individuals.
Results: In our preliminary genotyping, 79 (40.9%) Taiwanese individuals among 193
were homozygous for HNA-3a, 24 individuals (12.4%) were homozygous for HNA-3b
and 90 individuals (46.6%) were heterozygous for HNA-3a/3b. Accordingly, the gene
frequencies of HNA-3a and -3b were 0.6425 and 0.3575, respectively. Test for Hardy-
Weinberg equilibrium did not deviate from expectation.
Conclusion: In this preliminary screening, the frequency for HNA-3b homozygote is
two time greater among Taiwanese (12.4%) than in German (5.5%). This implies that
Taiwanese may be more potent in inducing HNA-3a antibodies. The rate of immuni-
zation among German was reported to be 7% against HNA-3a and 0.5% against HNA-
3b. The immunogenicity against HNA-3 among Taiwanese is still undefined and will
needs to be determined in future studies to evaluate if the risk of inducing HNA-3a
antibodies is greater or lesser in Asia.
Female donors homozygous HNA-3b are more likely to develop anti-HNA-3a
antibodies during pregnancy, and therefore more likely to induce a risk in platelet
transfusion. Genotyping the HNA-3 system among female platelets donors would be
helpful in identifying blood donors involving a transfusion risk and in reducing TRALI
caused by HNA-3a alloantibodies.
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THE DISTRIBUTION OF HUMAN NEUTROPHIL ALLOANIGENS IN
THE CHINESE HAN POPULATION OF SHANGHAI
Yang Y, Zhu AX, Zhang JM, Zhu ZY
Shanghai Blood Center, Shanghai, China
Background: The antibodies for human neutrophil antigens were thought as a key role
in the pathogenesis of TRALI. It is not completely clear about the distribution of HNA
antigens in Chinese population, and the current family plan policy may lessen the
possible incidence of HNA antibodies.
Aims: To establish a method to evaluate the frequencies of HNA antigens in Chinese
and provide related information for potential TRALI diagnosis.
Methods: Three hundred and twenty-one unrelated healthy and 28 pregnant were
studied, all of them were from Shanghai. A universal PCR-SSP genotyping method for
HNA-1 ()a, b, c), HNA-3 ()a, )b), HNA-4a (+,)) and HNA-5a (+,)) was set up, PCR-
RFLP and PCR-sequencing were then utilized as double check methods. HNA-2 antigen
was analyzed by Flow-cytometry in 76 unrelated healthy in parallel with 28 pregnant
individuals.
Results: The results of PCR-SSP were confirmed by PCR-RFLP or PCR-sequencing. The
gene frequencies of HNA-1a, HNA-1b, and HNA-1c were 0.667, 0.333 and 0 respec-
tively. HNA-3a and HNA-3b were 0.650 and 0.350. The frequency of HNA-3b in
Shanghai was higher than Caucasian as well Guangdong Han population, while other
systems were similar with those in Guangdong Han population. HNA-4a was 1 and
HNA-5a was 0.897. The HNA-2 expression presented variation among different per-
sons, we can classify results into five groups both in the healthy and the pregmant, (i)
negative (CD177+ <10% neutrophil cells); (ii) most negative (10–20%); (iii) partial
negative while partial positive (20–75%); (iv) most positive (75–90%). (v) positive
(>90%). The percentage of listed five types in healthy were 0%, 7.9%, 65.79%, 21.05%
and 5.3% respectively, but the results in the pregnant were 10.71%, 1.32%, 35.71%,
32.14% and 14.29% respectively. And the reaction strength varied among different
individuals too.
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Conclusions: The universal PCR-SSP can be used for genotyping of HNA-1, 3, 4, 5
systems. Human neutrophil antigens in the Han population of Shanghai have distin-
guishable polymorphism. HNA-1c and HNA-4a negative were not found in this study.
HNA-3b had a higher frequency which possibly accompanies corresponding antibodies
which were supposed to be a role in TRALI in Han. Both of the positive CD177
expression and the negative expression are more in the pregnant than that in the
healthy, the clinical significance of the difference may deserve further investigation in
more pregnant population.
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TOXIN OF STREPTOCOCCUS PNEUMONIA BACTERIA INDUCES
NB1 GENE TRANSCRIPTION IN HNA-2A NEGATIVE
NEUTROPHIL SUBPOPULATION
Santoso S, Bayat B, Tjahjono Y, Werth S
Clinical Immunology and Transfusion Medicine, Giessen, Germany
The recruitment of neutrophil to infection site is the first step of host defence system
against invasive organisms. Molecules accelerating neutrophils diapedesis toward
infection site play therefore an important role. Recently, our group has demonstrated
that human neutrophil antigen-2a (HNA-2a, NB1) interacts with PECAM-1 on
endothelial cells and mediated thereby neutrophil diapedesis. HNA-2a shows bimodal
expression pattern (HNA-2a positive and HNA-2a negative populations) on neutrophil
surface, which can be upregulated during bacterial infections. However, the mecha-
nism arranged behind is not yet known. In this study, we investigate the impact of
pneumolysin (PLY), the most potent bacterial toxin of Streptococcus pneumonia, on
the regulation of HNA-2a cell surface expression.
Neutrophil treated with PLY migrated faster through endothelial cells in comparison to
untreated neutrophils in the flow chamber experiment. Interestingly, flow cytometry
analysis with different mabs against HNA-2a showed significant upregulation of NB1
on HNA-2a ()), but not on HNA-2a (+) neutrophil subpopulations. This result could be
confirmed by the use of cell sorted neutrophils. Treatment of HNA-2a ()) sorted
neutrophils with PLY caused increase of total NB1 protein as well as NB1 surface
expression as shown by immunoblot and flow cytometry, respectively. In the control
experiment, neutrophils derived from HNA-2a defective individuals (NB null) did not
show any NB1 production after PLY treatment.
Our results indicate that bacterial toxin is able to activate neutrophil signaling
pathway, which initiates the gene transcription in HNA-2a negative neutrophil
subpopulation. This mechanism is probably the most important step for the NB1
mediated neutrophil diapedesis during bacterial infections.
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NEUTROPHIL ACTIVATION BY HNA-2A ANTIBODIES IS
MEDIATED BY MAC-1 INTEGRIN
Santoso S1, Jerke U2, Bayat B1, Kettritz R2
1Clinical Immunology and Transfusion Medicine, Giessen, Germany 2Medical Faculty of
the Charite, Experimental and Clinical Research Center, Berlin, Germany
Antibodies against human specific neutrophil antigen-2a (HNA-2a; NB1) play a role in
immune mediated neutropenia and transfusion-related acute lung injury (TRALI). In
our previous studies, we found NB1 dependent neutrophil activation and superoxide
production in neutrophils after exposure with anti-HNA-2 antibodies. Since NB1 is a
GPI-linked protein lacking a cytoplasmic domain, signal transduction could not be
directly ascribed.
In this study, we searched for integral membrane protein on neutrophils, which may act
as NB1 co-receptor for the transduction of outside-in signalling.
Digitonin lysates of intact neutrophil membrane were immunoprecipitated by anti-NB1
and analysed by MALDI-TOP analysis. A major protein, Mac-1 integrin, which forms a
complex with NB1 protein, could be identified by this approach. This result was
confirmed by immunoblotting analysis using a panel of mabs against NB1 and Mac-1
integrin as well as by real-time analysis of protein-protein interaction by surface
plasmon resonance technology (SPR). Furthermore, the involvement of NB1/Mac-1
complex in signalling process could be identified by lipid raft analysis. Inhibition
studies using selected mab against Mac-1 blocked neutrophil activation and
superoxide production induced by HNA-2a antibodies. This study demonstrated for
the first time the mechanism of NB1-antibody mediated activation in neutrophils,
which may add our understanding in the pathomechanism of TRALI.
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THE FREQUENCIES OF HUMAN NEUTROPHIL ANTIGENS (HNA)
AMONG THE JAPANESE POPULATION
Matsuhashi M
The University of Tokyo, Tokyo, Japan
Background: Antibodies against human neutrophil antigens (HNA) are involved in the
pathogenesis of a variety of clinical conditions, such as neonatal immune neutropenia
(NIN), refractoriness to granulocyte transfusions, febrile transfusion reactions. Recently,
their involvement in the pathogenesis of transfusion-related acute lung injury (TRALI),
a severe complication of blood transfusion, was confirmed. Five HNA systems, namely
HNA-1 to -5 have been characterized. HNA-1, -2, -4 and -5 antigens are attributed to
polymorphisms or deletion on CD16, CD177, CD11b and CD11a, respectively. The HNA-
3 antigen was recently determined to be dependent on a single amino acid substitution
on choline transporter-like protein-2. HNA-1, -2, and -3a alloantibodies have been
implicated in the pathogenesis of TRALI, and in especial HNA-3a alloantibody has been
found in the severe cases requiring artificial ventilation or with fatal reactions. The
detection of anti-HNA antibodies is essential for the diagnosis of the pathological
conditions in which these antibodies are involved, as well as for their prevention.
Therefore the determination of the distribution of HNA in a population is important for
the prediction of the risk of alloimmunization to HNA. The HNA frequency distributions
have been reported among different populations in US, Europe, Asia and Africa. Also,
reports from Japan have described the frequency of some, but not all, HNA.
Aim: In the present study, we aimed to investigate the frequency distribution of all
HNA among the Japanese population.
Methods: Healthy volunteer donors were genotyped for the HNA-1 (92), HNA-3 (93),
HNA-4 (122), and HNA-5 (111), using the Luminex (PCR-rSSOP, WAKFlow-HNA;
Wakunaga pharmaceutical Co., Hiroshima, Japan) or PCR-SSP. Also, HNA-2a pheno-
type in 96 donors was determined by GIFT, using specific antisera and monoclonal
antibodies.
Results: The gene/antigen frequencies were as follows: HNA-1a: 79 (85.9%), -1b: 62
(67.4%), -1c:0 (0%); HNA-2a: 94 (97.9%); HNA-3a: 83 (89.2%), -3b: 56 (60.2%); HNA-
4a: 122 (100%), -4b: 0 (0%); HNA-5a: 109 (98.2%), -5b: 30 (27.0%). The gene fre-
quencies were as follows. HNA-1a (0.573), -1b (0.427) -1c (0); HNA-3a (0.645), -3b
(0.355); HNA-4a (1.000), -4b (0.000); HNA-5a (0.856), -5b (0.144).
Conclusion: We describe the frequencies of HNA among Japanese population. This
study will be helpful in the future for the prediction of the risk of alloimmunization to
HNA, especially to determine the risk of HNA alloantibody production by transfusion
of HNA incompatible blood and feto-maternal incompatiblity.
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LENTINAN INDUCES CYTOTOXIC T-CELL RESPONSES
DEPENDANT ACTIVATION OF HUMAN MONOCYTES CELL LINE
(THP-1) CELLS VIA DECTIN-1
Chen Q1, Tang RC1, Liu Z2, Li M3
1Jiangsu Province Blood Center, Nanjing, China 2Anhui Province Blood Center, Hefei,
China 3Institute of Dermatology, Chinese Academy of Medicine, Nanjing, China
Background: Lentinan, a b-1, 3/b-1, 6-glucan isolated form Lentinula edode, has been
used as an adjuvant for tumor immunotherapy in Japan and China. Early studies
mainly focused on anti-tumor activities of innate immune cells induced by Lentinan.
Dectin-1 is the key pattern recognition receptor for b-glucans. Activation of dectin-1
signaling on dendritic cells (DCs) can trigger adaptive T cell responses (Th1 and Th17).
Aims: Our study was to investigate whether dectin-1 on monocytes/macrophages
stimulated by Lentinan could prime the anti-tumor cytotoxic T-cell responses.
Methods: The mRNA level of IL-12 and dectin-1 were detected by real-time RT-PCR.
Western blotting was used to analyze the protein expression of dectin-1. The con-
centration of IL-12p70 was determined by ELISA. Allogeneic mixed lymphocyte
reaction between THP-1 cells stimulated with Lentinan and T cells was performed. LDH
release test was used to evaluate cytotoxicity of CTL.
Results: Exposure of THP-1 cells to Lentinan led to increased gene expression of IL-
12p35, IL-12p40, dectin-1 and secretion of IL-12p70 and dectin-1. Lentinan stimulated
THP-1 cells promoted the expansion and differentiation of cytotoxic T lymphocyte (CTL)
which could kill the colorectal cancer cells Sw480, Caco-2 in vitro. Anti-IL-12p70
neutralizing antibody and dectin-1 inhibitor blocked the tumor cytotoxicity of CTLs.
Conclusions: These data suggest Lentinan primed the anti-tumor cytotoxic T-cell re-
sponses dependent the activation of dectin-1 on monocytes/macrophages. Transfusion
of CTL induced by Lentinan may be a promising treatment for tumor patients.
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HUMAN NEUTROPHIL ANTIGEN-1 GENE FREQUENCY IN THAI
BLOOD DONORS
Kumkaen K1, Ploidonka M2, Padpon I2, Kongmaroeng C2
1Blood Bank, Division of Clinical Pathology, Rayong Hospital, Bangkok, Thailand
2Faculty of Medical Technology, Huachiewchalermprakiet University, Samut Prakan
Thailand
HNA-1 antigens are located on the human neutrophil Fc gamma-receptor IIIb (Fcc
RIIIb). These antigens encoded by the FCGR3B gene. Alloimmunization against these
polymorphisms can result in immune neutropenia and transfusion-related acute lung
injury (TRALI). The aim of this study was to determine the gene frequencies of the
HNA-1a, -1b and -1c alleles in 175 unrelated healthy Thais from blood donors using
sequence-specific primers. All participating individuals gave the informed consent. The
result showed that the HNA-1a and HNA-1b gene frequencies in Thais (0.72 and 0.28,
respectively) were statistically significant different (P < 0.001) from Asian Indians,
North Americans, Africans and Tunisians. In contrast, the present data showed that the
HNA-1 allele frequencies in Thais are similar to Asians, Chinese, Japanese and Korean
populations, respectively. The HNA-1c antigen was not present in this study. This
information may be helpful in the future for HNA gene and disease association studies.
5.5 Fetal Maternal
Immunology
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HEMOLYTIC DISEASE OF NEWBORN DUE TO MATERNAL
ANTIBODY OF KIDD BLOOD GROUP SYSTEM AT MACKAY
MEMORIAL HOSPITAL
Chu CF, Cheng PY, Hong CC, Chan JP, Lin M, Ho HT
Mackay Memorial Hospital, Taipei, Taiwan
Background: The hemolytic disease of newborn (HDN) is caused by the destruction of
red cells due to the incompatibility between the mother and her infant blood. The
infant red cells become sensitized and coated with the IgG alloantibody of maternal
origin. The infant IgG-coated RBC may undergo accelerated destruction both before
and after birth. Jaundice, pallor, an enlarged spleen or even hydrops may be present in
severe cases. Kidd sensitization is an uncommon cause of HDN. From 1984 to 2011,
there were only five cases of HDN with Kidd antibodies at Mackay Memorial Hospital,
in which four with anti-Jkb and one with anti-E + c + Jka.
Report and Review of Cases: Here we reported a recent case and summarized all cases
in the following table. In April 2011, a male baby weighing 3276 g was born to a
G2P2A0 mother via normal spontaneous delivery at Mackay Memorial Hospital. His
condition was stable with good activity and appetite. He developed jaundice on the
fourth day after birth. The yellowish skin discoloration and icteric sclera were noted. The
laboratory data showed total bilirubin 17.7 mg/dl, Hb 11.3 g/dl, reticulocyte 5.7% and a
normal level of G6PD level. He was then admitted under the diagnosis of hyprebiliru-
binemia for further care. The blood bank examination demonstrated positive results (1+)
for both direct and indirect Coombs tests. The presence of anti-Jkb antibody was
detected in both maternal and infant serum by manual polybrene method. The anti-Jkb
antibody was also eluted from the infant RBC by LIAT method. No other antibody was
identified. The mother was group A, Jkb negative and the infant was group A, Jkb
positive. There was no maternal history of blood transfusion. Thus, the etiology of this
infant’s HDN was maternal anti-Jkb who had a Jkb positive infant. The infant received
phototherapy and the level of bilirubin gradually recovered to normal.
Table 1
Conclusion: Neonatal hyperbilirubinemia (bilirubin > 15 mg/dl) in Taiwan is mainly
due to ABO maternal-fetal incompatibility, erythrocyte G6PD deficiency, and low
birth weight. However, some cases remain unknown in the etiology of HDN. Other
than ABO blood group system, maternal irregular antibodies against Rh, MNS, Kidd,
or Duffy systems have been reported. The antibody of Kidd system responsible for
HDN was first reported in 1953 (anti-Jkb) and in 1959 (anti-Jka). The Jk antibody is
clinically significant since it can cause acute and delayed transfusion reaction as well
as HDN. Fortunately, most cases had mild hemolysis and the babies required no
treatment. Since we encountered only five cases in the past 27 years, antibody
against the Kidd system must be very rare in Taiwan and all our cases of immuni-
zation are resulted from previous pregnancies. For your reference of interest, the
phenotype frequency of Kidd system in Taiwan are 28.3% in Jk (a+b)), 35% in Jk
(a)b+), and 36.7% in Jk (a+b+), as observed in our previous study on 60 healthy
individuals.
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STUDY OF IMMUNE ANTI-D IN PREGNANT WOMEN IN
SRI LANKA
Somasiri PNR, Zanooz MF
National Blood Center, Colombo, Sri Lanka
Background: Immune anti-D is the most common cause of haemolytic disease of fetus
& newborn in any population. In Sri Lanka the Rh D negative population is 5%.
Routine antibody screening for unexpected antibodies are carried out at booking visit
& 28 weeks of gestation.
In Sri Lanka routine administration of Anti-D Prophylaxis (RAADP) has not been
universally advocated to Rh D negative pregnant women in the recent past. Therefore
Rh D HDFN is not uncommon in Sri Lanka.
Aim: The study was planned to find the significance of age, parity, anti-D titer & the
significance of RAADP to the development of HDFN in Sri Lankan population.
Method: Data were collected retrospectively for the study from January 2010 to
December 2010.
All 85 immune anti-D cases reported to immunoheamatology Laboratory of National
Blood Center of Sri Lanka were selected.
Their age, parity, length of pregnancy of the detection of immune antibody & antibody
titer were collected.
Antibody titer testing is done only at the immunoheamatology laboratory in Sri Lanka,
by titration method using freshly prepared pooled O R1r red cells from donors. Titer of
32 & above was considered as significant high titer.
Parity of the 85 cases analyzed were categorized into Primipara (P1), 2nd pregnancy
(P2), multipara (P3 + P4), & grandmultipara(more than five pregnancies).
Results: Of the 85 reported cases 4 were in 15–20 year, eight were in 21–25 year, 26
were in 26–30 year, 30 were in 31–35 year, 15 were in 36–40 year & two were in 41–
45 year age groups.
Of the 85 reported cases of immune anti-D, 10.6% were detected in the 1st pregnancy,
29.5% were detected in the 2nd pregnancy, 50.6% were detected in maltipara in
subsequent pregnancies & 9.4% were detected in grand paltiparous women for the 1st
time. RAADP was not routinely administered, nor were there proper data available
regarding prophylaxis anti-D to cover sensitizing events, but 500–1500 IU of anti-D was
administered to all Rh D negative women following delivery of Rh D positive fetus &
quantification tests were not preformed in any of the cases following a sensitizing event.
Of the 85 cases, 30.58% of immune anti-D were detected at the booking visit. 46.15%
of them had high titer of immune anti-D & 16.6% of them were primi mothers, 8.3%
were in their 2nd pregnancy, 66.66% were multipara & 8% were grandmultipara.
Of the 85 cases, immune anti-D was detected for the 1st time while screening for
unexpexted antibodies at 28 weeks of gestation in 69.42%, 52.54% had high titer,
19.35% were primi mothers, 22.58% were in their 2nd pregnancy, 48.38% were
multipara & 9.6% were grandmultipara.
Conclusion:
1. Most of immune anti-D positive mothers were in 26–35 year age group.
2. Multiparous women develop immune anti-D more frequently than primipara.
3. Majority of cases immune anti-D was detected in antibody screening at 28 weeks of
gestation.
4. Multiparous women were more prone to develop high titer of immune anti-D levels
than primipara & women in 2nd pregnancy.
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HAEMOLYTIC DISEASE OF NEWBORN BABIES IN SRI LANKA
De Alwis H, Dissanayake PRJ
National Blood Transfusion Service, Colombo, Sri Lanka
Introduction: Haemolytic disease of new born is a condition in which the red cells of
the foetus or newborn are destroyed due to maternal antibodies which passage across
the placenta. The production of these antibodies is due to incompatibility of blood
group between mother and foetus.
Rh HDN develops when a Rh negative mother previously sensitized with Rh D Antigen
due to previous pregnancy or past Rh D positive cellular component transfusion.
During pregnancy commonly they get sensitization with feto maternal haemorrage at
the last trimester and at delivery. Also there can be other sensitizing events during
pregnancy.
HDN due to ABO incompatibility is mild and more common than Rh HDN. Unlike Rh
HDN ABO HDN does not present in utero and does not cause hydrops fetalis.
It usually occur when mother is blood group O & fetus is blood group A or B and
having maternal high titer of IgG anti A & anti B (>1:64). Less commonly it occurs with
blood group A or B Mother having fetus B or A respectively.
Aim: The objective of this study is to see the frequency of HDN in new born babies and
to find the most common causes for HDN in Sri Lanka.
Meterial and Methods: A retrospective study was done for 3 months duration in a
teaching hospital in Sri Lanka. The new born babies who were suspected for Rh, ABO
HDN and Jaundice were followed up. The dirct anti globulin test (DAT), blood group &
Rh, serum bilirubin and Hb were done in all of them.
Results: The two cases of ABO HDN both mothers were Blood Group O Rh positive and
babies were Blood Group A positive. These two babies were given double phototharpy
and exchange transfusion was not done.
Table 1
February March April Total
Number of deliveries 355 488 466 1309
Number of DAT 183 240 241 664
Number of DAT positive 0 0 0 0
Number of DAT negative 183 240 241 664
Number of cases with clinical jaundice 1 1 1 3
Causes for clinical jaundice total no %
Jaundice due to ABO HDN 2 0.15
Jaundice due to septicemia 1 0.08
Conclusion: For 1309 deliveries there were only three cases of clinical jaundice and
two cases were due to ABO incompatability and one case due to septicemia. There were
no cases of Rh system or Kell blood group.
The above results show HDN is rare in Sri Lanka and the more common cause for HDN
is ABO incompatibility.
Also these results show DAT is of little value in newborn babies as a screening test for
HDN.
In Sri Lanka RhD HDN is rare because all Rh D negative mothers with antibody
screening negative are given anti D prophylaxis during pregnancy and after delivery
for prevention of HDN.
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CLINICAL STUDY ON THE RELATIONSHIP BETWEEN TITERS
AND MATERNAL BLOOD GROUP ANTIBODIES AND THE
INCIDENCE OR SEVERITY OF HDN
Lu FQ, Peng Y
Affiliated Zhongshan Hospital of Dalian University, Dalian, China
Background and Objectives: Haemolytic disease of the newborn (HDN) is a clinical
condition in which foetal red blood cells are destroyed by maternal alloantibodies di-
rected against red cells antigens acquired from the father. ABO-HDN occurs almost
exclusively in infants of blood groupA or Bwho are born to groupOmothers because IgG
anti-A or -B occurs more commonly in group O than in group A or B individuals. The
placenta is relatively impermeable to naturally occurring IgM anti-A/anti-B antibodies.
However, immune anti-A and anti-B of the IgG type will cross the placenta andmay thus
cause ABO-HDN. The aim of the study was to evaluate the relationship between the titers
and sorts of maternal IgG type blood group antibodies and the incidence or severity of
HDN, and to provide the basis in diagnosing, predicting, and preventing of HDN.
Methods: The titers and types of IgG blood group antibodies of 80 antenatal O group
mothers (who had non O group husbands) were determined during prenatal diagnosis
using the blood group serology method. The bilirubin and hemoglobin level of new-
born infants were tested with routine methods.
Results: The percentage of the 80 cases whose titers of blood group antibody levels
were equal or more than 1:64 in group O mother to group A father(O-A), group O
mother to group B father (O-B), and group O mother to group AB father (O-AB) was
68%, 64%, and 71%, respectively, P > 0.05. With increasing of titers of anti-A/(B)
antibodies of IgG type (higher than 1:512 or more), the incidence or severity of HDN
was higher, P < 0.01. The percentage of HLA antibodies in serum of mothers who had
newborns suffered from mild or severe HDN was 85% and 47%, respectively, There was
a significant difference between the two groups, P < 0.01.
Conclusion: The incidence or the severity of HDN was related to the types and titers of
prenatal antibodies of IgG type, with the increasing of the titers of blood group anti-
bodies of IgG type, the incidence or severity was higher. The incidence of HLA antibodies
in serum of pregnant women against their husbands was related to severity of HDN.
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RELATIONSHIP BETWEEN THE MIDDLE CEREBRAL ARTERY
PEAK SYSTOLIC VELOCITY AND ANTIBODY TITER IN
ISOIMMUNIZED PREGNANCIES
Lai M1, Triunfo S1, Rosati P2, Scambia G1, Leone G1
1Catholic University, Rome, Italy 2Institute of Obstetrics and Ginecology, Rome, Italy
Background: Antibodies titration is still a cornerstone in the management of isoim-
munised pregnancies. However often antibody titration did not strictly correlated with
the fetus anemia condition. The introduction of middle cerebral artery peak systolic
velocity (MCA-PSV) permitted the non invasive detection of fetus anemia.
Aims: Detect the relationship between antibody titration and the MCA-PSV to permit
a better management of pregnancies.
Methods: We studied the relationship between 259 antibodies titers in 72 pregnancies
and the MCA-PSV values expressed as the multiples of the median (MoM), considering
two screening values values 1.5 and 1.29. For antibodies titrations we performed serial
twofold dilutions of the serum using the gel technology (Biorad). The antibodies were:
61 pregnancies (232 titrations) with anti-D, titer from 1 to 8192; 11 pregnancies with
non-RhD antibodies, titer from 1 to 4096.
Results: The association between antibody titer ‡32 andMoM ‡1.3 was significant odds
ratio 3.496 (CI 95% 1.504–8.123), P = 0.004; the association between antibody titer ‡64
and MoM ‡1.3 was significant odds ratio 3.556 (CI 95% 1.660–7.614), P = 0.001; the
association between antibody titer ‡128 and MoM ‡1.3 was significant odds ratio 4.578
(CI 95% 2.417–8.669), P = 0.000; the association between antibody titer ‡32 and MoM
‡1.5 was significant odds ratio 10.639 (CI 95% 1.420–79.684), P = 0.02; the association
between antibody titer ‡64 and MoM ‡1.5 was significant odds ratio 6.827 (CI 95%
1.588–29.335), P = 0.01; the association between antibody titer ‡128 and MoM ‡1.5
was significant, odds ratio 10.015 (CI 95% 2.966–33.819) P = 0.000. The association
between antibody titer ‡16 and MoM ‡1.3 was not significant, odds ratio 2.371 (CI 95%
0.879–6.394), P = 0.088; the association between antibody titer ‡16 and MoM ‡1.5 was
not significant, odds ratio 5.301 (CI 95% 0.699–40.168), P = 0.107.
Discussion: In our study we quantified the relationship between the antibody titration
and the MoM of MCA-PSV at 2 values ‡1.3 and ‡1.5 in isoimmunized pregnancies.
This permitted us to detect the critical value of antibody titers significantly related with
the MCA-PSV. At antibody titer 32 both the MCA-PSV MoM 1.3 and 1.5 begin to be
statistically associated. Until now, the antibody titer importance was evaluated
empirically. We think that the measurement of the relationship between these two non-
invasive tests can be useful for the management of isoimmunized pregnancies.
Reference
1. Moise KJ, Jr. Management of rhesus alloimmunization in pregnancy. Obstet Gynecol
2002;100(3):600–11.
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CASE REPORT OF TESTING & MANAGEMENT OF BOMBAY (OH)
RH D NEGATIVE PREGNANCY
Zanooz MF, Somasiri P
National Blood Center, Colombo, Sri Lanka
Background: The Bombay phenotype (Oh) is a rare red cell type that is characterized
by the deficiency of H antigen on the surface of the red cell & the presence of anti-H in
their serum. Inheritance of Rh phenotype is independent to the inheritance of Bombay
phenotype. This case report illustrates the clinical course & management of a Bombay
Oh Rh D negative pregnant mother.
In Sri Lanka all Rh D negative pregnant women are screened for unexpected antibodies
in early pregnancy as there is a possibility of developing Anti-D & the consequence of
sever heamolytic disease of the fetus & newborn when the partner is Rh D positive.
To detect any unexpected antibodies, Anti-H needs to be absorbed in the Bombay O Rh
D Negative pregnant mother. Cells selected for absorption of anti-H should absorb only
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anti-H antibodies & not any other clinically significant alloantibodies which could be
present during pregnancy.
Aim: To describe the antenatal serological testing & management of Bombay Oh, Rh D
negative pregnancy with the available facilities in Sri Lanka.
Method: The following steps were taken to absorb anti-H antibodies.
Her extended red cell phenotyping was done using commercially prepared antisera
following manufacturer’s guidelines. A regular voluntary nonremunerated donor with
a red cell phenotype similar to that of the mother (Rh, Kell & Kidd matched) was
selected & the cells treated with papain & used for absorption of anti-H antibodies at
40C, room temperature & 370C.
Following absorption, antibody screening was performed at 370C IAT phase to detect
for any clinically significant unexpected antibodies.
Results: Antibody screening was negative following absorption.
Conclusion: Following absorption antibody screening was negative for unexpected
antibodies. Thus this mother is a candidate for routine administration of anti-D pro-
phylaxis (RAADP) at 28 & 34 weeks of gestation. Cord blood grouping & Rh pheno-
typing & DAT should be performed at delivery of baby & if cord blood is positive for Rh
D phenotype, fetomaternal hemorrhage should be estimated & adequate anti-D pro-
phylaxis should be administered to mother to prevent sensitization against Rh D.
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PREVALENCE OF UNEXPECTED ANTIBODIES AMONG
PREGNANT WOMEN
Krishani MDA
General Hospital Kaluthara, Kaluthara, Sri Lanka
Background: In pregnant women it is essential to do blood group and unexpected
antibody screening at booking visit. Then depending on the results there is an algo-
rithm to follow which is given in BCSH (British Committee for Standards in Hema-
tology) guidelines. In Sri Lanka the current practice is to perform ABO and Rh D
grouping in all pregnant women at the booking visit and then to perform antibody
screening in Rh D negative women only. Blood bank General Hospital Kaluthara fol-
lows the same practice for many years. Additionally, blood bank G H Kaluthara re-
cently started to perform antibody screening in pre transfusion compatibility testing
for pregnant women at the time of delivery to provide blood.
Aim: To study the prevalence of unexpected antibodies among pregnant women and
then to compare the prevalence between Rh D positive and Rh D negative women.
Results: The total number of antibody screening tests carried out from January to June
2011 was 520. There were nine anti Le b antibodies, one anti Le a antibody and one anti
E antibody among these pregnant women. In this group there were 461 Rh D positive
pregnant women and seven had anti Le b antibodies, one anti Le a antibody and one
anti E antibody. Out of 59 Rh D negative females in the study group only two Le b
antibodies were identified.
Conclusion: Antibody prevalence among all pregnant females was 2%. While the
unexpected antibody prevalence was 2% in Rh D positive females the higher preva-
lence of 3% was observed among Rh D negative cases.
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THE FREQUENCY OF GENETIC DIFFERENCES ON HUMAN
PLATELET ANTIGENS OF PREGNANT WOMEN AND THEIR
NEWBORNS, A STUDY CONDUCTED IN A COMMUNITY
HOSPITAL IN NORTHERN TAIWAN
Yang WH, Liu KT, Chang JL
Taoyuan Armed Forces General Hospital, Taipei, Taiwan
Neonatal alloimmune thrombocytopenia (NAIT) is a clinical syndrome that resembles
hemolytic disease of newborn. The cause of NAIT is that human platelet antigens
(HPA) in the neonatal are attacked by antibodies from mothers. The aim is to
investigate the genetic difference of HPA between mothers and their newborns, and to
assess the relationship between the difference and frequency of antibody production.
ELISA kits were used for detection of HPA antibody in the plasma of the mothers.
Thirty pairs of mothers and newborns were genotyped by molecular methods using
DNA extracted from their whole blood or umbilical cord blood. The result indicates
that HPA-1a, -4a, -5a, and HPA-6a were expressed in all mothers and newborns. HPA-
5b and -6b are rare while HPA-1b and -4b are absent. The frequency of HPA-2a in
mothers and newborns is 93.3% and 96.7% while that of HPA-2b is 3.3% and 6.7%,
respectively. The frequency of HPA2a is 93.3–96.7 and that of HPA-2b is 3.3–6.7%.
The frequency of HPA-3a in mothers and newborns is 66.7% and 63.3% while that of
HPA-3b is 33.3% and 36.7%. The frequency of HPA-15a is 44.3% both in mothers and
newborns but that of HPA-15b is 51.7%. The discrepant rate of antigen between
mothers and newborns is 83.3%. The most discrepant is HPA-3b which is different in
40.0% of the mothers and newborns. The highest ratio of the antigen is HPA-3b with
20.0% that the mother is homozygous and the newborn is heterozygous. The plasma
samples of the mothers are absent of anti-HPA antibody. Only anti-HLA was found in
two mothers. Discrepancy of HPA in mothers and newborns is not the main cause of
anti-HPA antibody.
6. Clinical Transfusion
6.1 Neonatal and Pediatric
Transfusion
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RATIONAL USE OF FFP IN NEONATES BY COMPARATIVE
ASSESSMENT BETWEEN ITS TRANSFUSION BEFORE AND
AFTER APPLICATION OF ACUB TRAINING FOR PEDIATRICIAN
IN SHEBIN EL KOM TEACHING HOSPITAL
Fouda F
Shebin El Kom RBTC, Shebin Elkom, Egypt
Background: Blood is a limited resource which should be conserved and use properly.
Therefore it’s essential to look in to the existing blood transfusion practices and collect
background information about the type of existing blood transfusion practices and
modify theses practices for appropriate utilization of blood.
FFP transfusionmaybe a life saving in certain circumstances but it can also cause adverse
effects such as anaphylactic reactions, TTIS, TRALI and venous thrombo-embolism. Thus
it should be used only when there’s a clear clinical indication for its use.
Last year a study was carried out to assess rational use of FFP in neonates treated in
neonatology department in Shebin El Kom teaching hospital and the study concludes
that this hospital was not rational in prescribing FFP for neonates and we interpreted
this behavior due to lack of awareness of pediatricians about guidelines on clinical use
of FFP.
We were able to establish training for pediatricians on ACUB. This was started from
January 2011 by helding workshops and giving lectures.
The present study has therefore looked at the appropriate use of FFP on the basis of
transfusion triggers against standard guidelines.
A comparison between FFP Transfusion before and after application of ACUB program
had given an idea about current patterns of FFP transfusion and will help to develop
strategies to optimize transfusion practices.
Aim: A study was carried out to assess the rational use of FFP products in neonates
treated in neonatology department in Shebin El Kom teaching hospital by comparative
assessment between its transfusion before and after application of ACUB training for
pediatricians.
Materials & Methods: Blood issuing Registers.
Statistics.
Blood request form.
Neonatology department Registers.
Result: Analysis of consumption of FFP showed that from 1 October 2009 to 30
September 2010 a total of (226) Pedi pack unites (50 ml) for (56) patient were
administered and from 1 October 2011 to 30 June 2011 a total of (110) for (57) patient
were administered in neonatology department in Shebin El Kom teaching hospital.
Indication of FFP Transfusion in neonates before and after application of ACUB
training are shown in the illustrated tables.
Table 1: Decision to transfusion Afetr ACUB training
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Table 2: Indications of pedi pack plasma transfusion in neonates from 1 October 2009
to 30 September 2010
Conclusion: The study concludes that ACUB implementation succeeded in tremen-
dously minimizing the inappropriate use of FFP showing increase for appropriate use
of FFP for neonates after implementing ACUB program than before its implementation
(77.2%/30.4%).
This study highlights: 1. The importance of continuous medical education & training
for pediatricians who prescribe blood components.
2. More attached to the blood bank, prior to issuing to avoid unnecessary issues.
3. Re – auditing the usage of blood after education sessions will also help to minimize
inappropriate use.
(a) This idea is not new but it was applied in this place for the first time.
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PLASMA EXCHANGE AS RESCUE THERAPY FOR CRITICAL
SYSTEMIC LUPUS ERYTHEMATOSUS: ONE CENTER
EXPERIENCE
Chiueh TS, Chang DM, Lu CC, Chen CH
Tri-Service General Hospital, Taipei, Taiwan
Objectives: To analyze the role of plasma exchange as a rescuing therapy for critical
systemic lupus erythematosus (SLE) patients.
Methods: A retrospective review was conducted to evaluate the patients with SLE
undergoing rescuing plasma exchange (RPE) due to critical manifestations such as
diffuse alveolar hemorrhage (DAH), neuropsychiatric syndromes of SLE (NPSLE),
catatrophic antiphopholipid syndrome (CAPS), hemophagocytosis syndrome, throm-
botic thrombocytopenic purpura (TTP), and symptomatic cryoglobulinemia between
February 1985 and January 2010. The primary outcome detection contained all cause
mortality and SLE disease activity index (SLEDAI) scores one month after RPE. The
secondary outcome measurement included complications such as infection and
hemolysis one month after RPE.
Results: The study population comprised 33 patients with SLE. The mean time for the
duration of the disease was 68.4 months, from the diagnosis of SLE to the first RPE
(range from 1 week to 22 years). The mean age at first RPE was 38.7 years. The 23
events of DAH attacked in 20 patients, while eight patients for NPSLE, three patients
for CAPS, three patients for pancytopenia, one patient for TTP, and one patient for
symptomatic cryoglobulinemia were evaluated. The overall sessions of PE performed
were 232 times, with a median for each patient of six sessions per course (range 1–33).
There were two patients died due to septicemia, one patient for DAH with acute
respiratory failure, one patient for CAPS, one patient for TTP and one patient for
cardiac thrombus with systemic thromboembolsim. The overall survival rate of all
patients was 83.8%, while 87% in DAH, 75% in NPSLE. One case had experienced
anaphylaxis, while cytomegalovirus viremia occurred following PE in two patients.
There were 51.4 percents of patients receiving low dose prednisolone therapy before
the events of RPE. The patients received pulse methylprednisolone therapy (750–
6000 mg) simultaneously or separately with RPE. In total courses, the mean SLEDAI
scores were 24.6 and 8.0 before and three weeks after the RPE, respectively. Never-
theless, only one patient received cyclophosphamide (CY) pulse therapy. The health
care system disbursed all expenses for PE.
Conclusions: Transient RPE combine with following methylprednisolone pulse ther-
apy instead of pulse CY therapy successfully saved the patients with life threatening
complications. Clinicians could cautiously prescribe early RPE and pulse steroid
therapy in critical circumstance to prevent laborious complications.
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COMPARISON OF ‘DOUBLE RBC’ PHLEBOTOMY AND WHOLE
BLOOD PHLEBOTOMY IN THE TREATMENT OF
ERYTHROCYTOSIS
Choe H, Park G, Kwon SW, Lee KH, Lee JH, Lee JH
Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Background: Whole blood phlebotomyhas long been a primarymethod of treatment for
erythrocytosis patients. In this study, we have employed ALYX (Fenwal, Lake Zurich, IL,
USA) component collection system as a modified RBC phlebotomy in erythrocytosis
patients. This system has been used for collecting double red blood cell (RBC) units from
donors but not as a treatment modality for erythrocytosis patients.
Aims: The aim of this study was to evaluate the effectiveness and the safety of ‘double
RBC’ phlebotomy (DRP) using ALYX in erythrocytosis patients and to compare the
result with conventional whole blood phlebotomy (WBP).
Methods: We retrospectively reviewed electronic medical records of 110 erythrocy-
tosis patients who visited Asan Medical Center in Seoul, Korea from June 2008 to May
2010 and received either DRP (n = 11) or WBP (n = 99), and we compared the effec-
tiveness of both treatment methods. To rule out possible inter-individual differences,
we also evaluated the changes of hematologic results in 19 erythrocytosis patients who
received both methods in the course of their treatment. The removed volume was 360–
420 ml of RBCs in DRP and 400–600 ml of whole blood in WBP. None of the patients
received other medications or medical interventions as the treatment of erythrocytosis.
Before each phlebotomy procedure, vital signs were checked to exclude any unstable
patients. Hematologic parameters including hemoglobin and hematocrit as well as
WBCs and platelets were measured before and after phlebotomies. The Mann–Whitney
Test was used for statistical analysis of the differences in changes of WBC, hematocrit,
hemoglobin, and platelet between DRP and WBP methods. Paired-t test was used for
the comparison of the test parameters of DRP and WBP within the same patient.
Statistics was done using SPSS v. 17.0 (SPSS, Chicago, IL, USA).
Results: The mean decrease in hematocrit for each phlebotomy method was 6.3 ± 2.2%
in DRP and 3.1 ± 2.2% in WBP, and the difference was statistically significant
(P < 0.001). The mean decrease in hemoglobin for each method was 2.3 ± 0.7 g/dl in
DRP and 1.1 ± 1.6 g/dl in WBP and this difference was also statistically significant
(P < 0.001). There were no statistical differences in changes of WBCs and platelets
between the two methods (P > 0.05). In patients who received both types of treatment,
mean decrease in hematocrit was 7.6 ± 2.0% by DRP, but only 2.8 ± 2.0% by WBP, and
this difference was also statistically significant (P < 0.001). Hemoglobin was also de-
creased more by DRP than by WBP (P < 0.001) in the same group of patients but
differences in changes of WBCs and platelets were not significant (P > 0.05). Adverse
reactions occurred in 1/3 of patients during DRP but were limited to mild citrate toxicity.
Conclusion: DRP was superior to WBP in terms of decreasing more hematocrit and
hemoglobin in erythrocytosis patients. DRP method could help reduce the frequency of
hospital visit by the patients. DRP using ALYX system was a safe and more effective
technique for the treatment of erythrocytosis than WBP.
P-292
EARLY RELAPSE OF THROMBOTIC THROMBOCYTOPENIC
PURPURA(TTP)/HEMOLYTIC UREMIC SYNDROME (HUS)
REFRACTORY TO PLASMA EXCHANGE ASSOCIATED WITH
CATHETER RELATED ACINETOBACTER BAUMANNII
BACTEREMIA
Chang JW, Tsai CS, Lin TH, Hsieh HH, Tsai YU, Lu KM
TCVGH, Taichung, Taiwan
Abstract: Thrombotic thrombocytopenic purpura (TTP)/Hemolytic-uremic syndrome
(HUS) is a syndrome characterized by thrombocytopenia, microangiopathic hemolytic
anemia, fever, neurologic manifestation and renal failure. Most of the cases are idio-
pathic. Plasma exchange is one of the standard treatment for TTP/HUS. However,
secondary TTP/HUS associated with bacterial, viral and mycobacterial infections,
drugs, autoimmune disease, pregnancy, solid tumors and bone marrow transplantation
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have been described. Early relapse associated with catheter-related bacteremia is a rare
occurrence. The patient we report had a classic presentation of TTP/HUS that responded
to plasma exchange but relapsed earlier as reflected by the increased schistocytosis,
decreased hematocrit, decreased platelet counts and increased lactate dehydrogenase.
This relapse may be attributed to Acinetobacter baumannii bacteremia, secondary to
chemo-port infection. After removal of the chemo-port, the syndromes of TTP/HUS
had improved without additional plasma exchange. The importance of identifying the
possible bacterial colonization of an indwelling catheter is thus emphasized.
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THERAPEUTIC LEUKAPHERESIS IN SARDJITO HOSPITAL
YOGYAKARTA INDONESIA: A START STEP
Triyono T1, Sukorini U1, Vrielink H2
1Sardjito Hospital/Faculty of Medicine Universitas Gadjah Mada, Yogyakarta,
Indonesia 2Sanquin Blood Foundation, Amsterdam, The Netherlands
Background: Leukemia is one of the hematological malignancies, and the incidens
tends to increase in recent years. Leukemic patient with leukocyte counts >100 · 109/l
are at risk for leukostasis, especially patient having an acute myeloid leukemia. Leu-
kostasis might cause multi-organ and tissue failure or death attributed to the circu-
lation of high number of leukemic blast cells. Pulmonary and neurologic complications
are extremely serious and most common causes of morbidity and mortality in leu-
kostasis. It has been shown that in hyperleukocytosis, leukapheresis can reduce the
chance in early mortality, therefore, the leukocyte count should be reduced as soon as
possible. Induction chemotherapy could not be used for this purpose, so therapeutic
leukapheresis can be applied besides immediate start with cytoreductive agents.
Aim: To see whether leukapheresis in the system of the Sardjito Hospital, Yogyakarta,
Indonesia could be of help in fast reduction of the leukocyte count in leukemic patients
at risk of leukostasis.
Methods: Data were collected from leukemic patients who were treated with thera-
peutic leukapheresis procedures in the Sardjito Hospital in the period of February 2010
until June 2011. The procedures were performed using MCS+ applying the TLR pro-
tocol. The patient’s pre- and post-procedure leukocyte count were determined before
and 1 h after the procedures respectively.
Results: A total of 22 procedures in 19 patients were performed during the period.
Eighteen patients were diagnosed having an acute myeloid leukemia, and one patient
having an acute lymphoid leukemia. The age of the 11 male and eight female patients
was ranged from 22 until 78 years. The median pre-procedure leukocyte count was
394 · 109/l (65 · 109/l–517 · 109/l). The mean decrease of leukocyte count after the
leukoreduction procedure was 21%(6–46%).
Conclusions: The therapeutic leukapheresis procedures could reduce leukocyte count
quite efficaciously. In our hands, this procedure should be considered for decreasing
risks of leukostasis in patients with leukemia.
P-294
RETROSPECTIVE ANALYSIS OF INDICATIONS FOR
THERAPEUTIC PLASMA EXCHANGE FOR 18 MONTHS AT
NATIONAL HOSPITAL OF SRI LANKA
Perera W
Post Graduate Institute of Medicine, University of Colombo, Colombo, Sri Lanka
Introduction: Therapeutic plasmaperasis, which was recognized modality of man-
agement, in wide range of immune and non immune mediated clinical conditions, had
gained increased popularity in the recent past in this part of the world. Newly estab-
lished specialist unit of the existing blood bank facility of National Hospital of Sri
Lanka, had recently encountered many requests for therapeutic plasmaperasis for wide
range of indications some of which are not documented but are acceptable given the
complexity of the conditions and the lack of knowledge of the outcome.
Therefore this study is aimed at identifying and categorizing the conditions on which
therapeutic plasmaperasis were requested. Moreover this is done as a preliminary step
in the process identifying the categories of the conditions, especially non conventional
indications, and the clinical outcome of therapeutic plasma exchange (TPE) as a
treatment modality in those conditions.
Objectives: List the indications and the frequencies of TPE procedures for 18 months
starting from 1st January 2010 and categorize them according to the basis of evidence,
(i) Evidences supported by randomized controlled trials, (ii)Consensus of help in
treatment, (iii) Suggestion of the help in treatment, (iv) Refuted by randomized con-
trolled trials, and (v) Indications on which no data available with regard to the
plasmapherasis and analyze them to identify the pattern of indications.
Methodology: TPE form and the Register maintained in this respect were used for the
data source from which indications were gathered. Those indications were matched
against indication categories for TPE and any undocumented indications, if any, were
recorded in the category of unrecognized indications.
Analysis and Discussion: Most requesters were fallen in to the category of definite
indications (299 out of the total of 446) and the percentage was 67.4 and the category
of indications with consensus of helpfulness had 38 procedures (8.5%).
There were no procedures for the third category of indications and the forth category of
illnesses for which therapeutic plasma exchange was refuted as a treatment modality
had five procedures done (1.12%).
Most significant finding of the study was 104 procedures of therapeutic plasma
exchange were done for indications for which plasmaperasis was not previously
recognized as a therapeutic modality.
Therefore based on the results of this study, it is nessecery to identify the conditions for
which TPE was used as a treatment modality and the outcome of the conditions in these
instances.
6.3 Evidence Based
Transfusion Medicine
Practice
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A STUDY ON GYNAECOLOGICAL & OBSTETRIC TRANSFUSIONS
IN COLOMBO SOUTH TEACHING HOSPITAL IN SRI LANKA
Aarewatte PAPM
National Blood Transfusion Service, Colombo, Sri Lanka
Background: The health service in Sri Lank has a well established nationally coor-
dinated Blood Transfusion Service which serves the entire country through the action
of 85 hospital based blood banks and the entire system is managed by the National
Blood Transfusion Centre and 16 Regional Blood Transfusion Centers. In this study, the
hospital based blood bank situated at the Colombo South Teaching Hospital in the
western province was taken as the study focal point. Colombo South Teaching Hospital
is one of the main tertiary care institutions in the district of Colombo (bed strength
1105).
Aim: Information on the use of red cells and the characteristics of transfusion
recipients is limited in Sri Lanka. Collection of such data may improve the under-
standing of fluctuations in demand, help to predict future trends in red cell use, and
define the potential value of blood sparing techniques.
Method: This study is mainly focused on the blood requests sent from Gynaecology &
Obstetric units in the Colombo South teaching hospital.
Patient information abstracted and relevant to the current study included patient
indication for transfusion, date of birth, date of hospital admission, ward at which the
patient was seen, nadir hemoglobin level, total number of transfusions administered
and indication of transfusion. We collected information from hospital blood bank
using a one page preprinted report form.
Following records and registers were used as sources of data extraction.
1. Blood Bank red cell request form (Health – 137).
2. Patient’s BHT.
3. Anesthesia record sheets.
4. Patient’s other investigation reports. (Hb %, Hct, Blood picture reports attached to
BHT),
5. Red cell issue registers in the Blood Bank.
Results: Pattern of blood requests were mainly in two ways, routine requests and
urgent requests, according to the sample analysis majority (70.5%) were routine re-
quests while 28.5% were urgent requests. Results are shown in Tables 1 and 2.
Table 1: Analysis of gynaecological & obstetric transfusion
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Table 2: Pretransfusion hemoglobin concentration among tran
Conclusions: The decision to transfused blood depends mainly on pre operative
haemoglobin level, blood loss, and clinical condition of patients. Though guidelines
and instructions are available to aid the clinicians for taking decisions on adminis-
tration of red blood cells, for most of the patients the decision to transfuse may have
been entirely based on a clinical observation or condition that was not recorded
accurately.
There is no universal ‘trigger’ for red cell transfusions, i.e. a given concentration of
haemoglobin at which transfusion of red cells is appropriate for all patients. Clinical
judgement plays a vital role in the decision to transfuse red cells or not. The findings
of this study should be presented to the hospital transfusion commitee, and
strategies to improve transfusion-guideline compliance and transfusion documenta-
tion should be considered. The initial recommendations include increasing education
of clinicians.via informative conferences as well as the use of more informative
letters.
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DISCREPENCY BETWEEN SEROLOGIC AND GENOTYPE TESTING
RESULTS OF ‘MIA’ BLOOD ANTIGEN AND ANTISERUM IN
TAIWAN
Chen T, Sun C
Chang Gung Memorial Hospital, Taoyuan County, Taiwan
Background: The Miltenberger subsystem (Mi) series includes a group of antigens
formed from hybrid glycophorin genes. Mi.III (GP.Mur) is reported to have a mean
frequency of 7.3% among Taiwanese. Since the specificities of Mi.III (GP.Mur) antisera
are not further specified, such antisera and the cells identified by them have been
applied a collective term as anti-’Mia’ and ‘Mia’(+) cells in Taiwan. Anti-’Mia’ anti-
bodies are the most common clinically important antibodies detected in Taiwan. Tai-
wan Society of Blood Transfusion have issued a guideline of including a ‘Mia’(+) cell in
the antibody screening panel. However, the sensitivity and specificity of this detection
strategy have never been validated.
Aims: To evaluate the current practice of using ‘Mia’(+) screening cells to detect anti-
’Mia’ antibodies in comparing with glycophorin genotyping method.
Methods: Blood samples were obtained from randomly selected patients. Antisera
containing anti-’Mia’ specificity were collected routinely in our blood bank. Manual
polybrene method without a supplementary antiglobulin phase was used for serologic
test. Each blood sample was tested with anti-’Mia’ from five different individuals.
Genomic DNA was extracted from the whole blood using QIAamp DNA Mini Kit. The
primers used were referenced to a previous study conducted by Palacajornsuk, et al.
The results of serologic test were compared with PCR-sequencing data. The study was
approved by our Institutional Review Board.
Results: Among 389 individuals tested by PCR, 25 samples were positive. All of them
belonged to GP.Mur genotype, which was confirmed by sequencing. The prevalence of
Mi.? (GP.Mur) is 6.4% (25/389). Among 1945 serologic tests for these 389 samples, 210
tests showed a positive reaction (1+ or more). Among them, only 84 positive results
belonged to PCR(+) samples. The sensitivity and specificity of our routine practice
using ‘Mia’(+) screening cells to detect anti-’Mia’ antibodies are thus estimated to
67.2% (84/125) and 93.1% (1694/1820), respectively. The positive predictive value is
40% (84/210).
Summary/Conclusions: The ‘Mia’(+) screening cells used in Taiwan blood bank rou-
tine were harvested from blood donors tested with anti-’Mia’ antisera. This practice is
based on an assumption that Mi.III (GP.Mur) is the overwhelming glycophorin variant
in Taiwan. Our results showed that the Mi.III (GP.Mur) has a prevalence of 6.4% in
Taiwan, and no GP.Hut, GP.Hop, GP.Bun, or GP.HF were detected. However, our study
also showed that our screening system for detecting anti-’Mia’ has a low sensitivity of
67.2% with a specificity of 93.1%. Since a previous study suggested the presence of
other glycophorin variants in Taiwan, the results suggested the existence of other (Mi)
phenotypes and the current detecting method may not be sufficient to identify anti-
bodies other than anti-GP.Mur. A larger series is needed to discover the significance of
other (Mi) phenotypes and the potential value of adding them to the screening system.
The low sensitivity of ‘Mia’(+) cells for screening anti-’Mia’ is another issue warrant
further study.
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AUDIT OF BLOOD USAGE FOR CANCER PATIENTS IN SURGICAL
WARDS AT NATIONAL CANCER INSTITUTE, SRI LANKA
Manchanayake SMGS1, Morawake PR2, De Silva RB3
1National Blood Center, Colombo, Sri Lanka 2National Cancer Institute, Colombo, Sri
Lanka 3Lady Ridgeway hospital, Colombo, Sri Lanka
Background: The current practice of National Cancer Institute, Sri-Lanka is to send
blood samples for grouping, cross matching and reservation of blood prior to most
elective surgical procedures. The cross matched blood for surgical patients are reserved
for 5 days. It is observed that many units of blood ordered for elective surgeries were
never being utilized. Non-utilization of reserved blood is a waste of resources, where
blood is used infrequently and out-dating of blood due to unnecessary storage affects
badly on maintaining stocks.
Adapting to a local maximum surgical blood order schedule reduces unnecessary cross
matching for most surgical procedures. It includes full ABO and Rh D grouping and
antibody screening for all samples. If unexpected alloantibodies were not detected in
the patient’s serum, blood of same ABO and Rh D group can be issued after cross
matching by the appropriate rapid procedure. Otherwise antibody negative blood
should be reserved prior to surgeries.
Aims: To analyze the cross matching and transfusion practice for patients in surgical
wards at the National Cancer Institute of Sri Lanka and to see the possibility of
implementing a maximum surgical blood order schedule for elective cancer surgeries.
Method: A retrospective analysis of blood usage was conducted for one year duration
from January to December 2010. Data were collected from blood bank records and
bloods transfusion request forms sent from all surgical wards including general sur-
gery, orthopedic, oral maxillofacial and gynaecology & obstetrics units. Indications for
requests, number of units cross matched and transfused for all requests were recorded
and cross match to transfusion (CT) ratio and transfusion index (Ti) were calculated for
each surgical procedure. CT ratio of 2–3:1 has been held to be acceptable for a hospital
which corresponds to a blood usage of between 30% and 50%. Ti value of 0.5 or above
is considered indicative of significant blood utilization.
Results: Out of total 1997 requests, 1585 have been sent for grouping and reserving of
blood prior to elective surgeries, for which, 3153 units were cross matched and 596
packs were transfused (18.9%). The overall CT ratio was 5.3:1 and Ti value was 0.37.
Seventy 5% (30 for 40 listed cases) of procedures in this study had CT ratio above 3:1
and 65% of procedures had Ti value was <0.5 (26 out of 40 listed cases).
Economical CT ratio and Ti were observed in oesophagectomy, gastrectomy,
abdominoperinial resection, anterior resection, pelvic exenteration, nephrectomy,
colectomy, mandibulectomy and hemimandibulectomy. High CT ratio and low Ti
values were seen in total mastectomy, total thyroidectomy, cervical and inguinal block
dissection, vaginal hysterectomy, radical hysterectomy, orchidectomy, penil amputa-
tion, maxillectomy, laryngectomy, parotidectomy and wide local excision of malignant
lesions.
Conclusions: Eighty percent of blood cross matched for elective cancer surgeries were
not transfused for these patients. The grouping and antibody screening policy can be
recommended for many surgical procedures and introduction of maximum surgical
blood order schedule could be attempted for National Cancer Institute of Sri Lanka.
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ORGANIZATION FACTORS AFFECTING RED BLOOD CELL
TRANSFUSION IN A MEDICAL CENTER
Lin YC, Chang CS, Lin YC, Wu YC, Yeh CJ
Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
Aim: A computerized transfusion decision support system (CTDSS) has been used in
Kaohsiung Medical University Hospital since September 2004. In this study, the factors
affecting red blood cell (RBC) transfusion were investigated.
Materials and Methods: Totally 20,551 RBC-transfusion episodes between January
and December 2008 were reviewed. The nearest hemoglobin concentrate before
transfusion is defined as the transfusion trigger. The physician compliance, the factors
associated with the transfusion triggers and post-transfusion hemoglobin increment
were investigated.
Results: The physician compliance is 83.1%. The transfusion trigger of all RBC
transfusion episodes is 8.32 ± 1.84 (mean ± standard deviation) g/dl. The transfusion
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triggers are statistically significant in terms of both different order sources and disease
types (P < 0.05). The post-transfusion hemoglobin level increased in two-thirds of the
episodes. The percentages of hemoglobin increments after transfusion are dependent
on the transfusion triggers.
Conclusions: A transfusion episode with a lower pre-transfusion hemoglobin level
would have a higher possibility of hemoglobin increment after transfusion. CTDSS
should be more powerful and effective to intervene in the appropriateness of trans-
fusion practice.
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TO DETERMINE THE MEAN HEMOGLOBIN DROP PER MONTH
(30 DAYS) IN? THALASSAEMIA MAJOR MALE PATIENTS
(12–16 YEARS) BEING MANAGED IN NATIONAL
THALASSAMIA CENTER, SRI LANKA
Rupasinghe K, Kumari NS
Teaching Hospital, Kurunegala, Kurunegala, Sri Lanka
National Thalassamia center is the main center in Sri Lanka where 810 b Thalassemia
major patients are being managed, and is attached to the Teaching Hospital Kurunegala
(Bed Strength1318). The center consists of inward fascilities, theater facilities and
laboratory facilities directly funded both by the government of Sri Lanka and by the
world health organization as well. These patients are registered since the first day of the
diagnosis and are being managed whole throughout.
Aim: To determine the mean hemoglobin drop per month (30 days) in b thalassaemia
major male patients(12–16 years age)who are being managed in National thalassaemia
center, Sri Lanka. Above group was selected as the study group to exclude discrepancies
due to the level of physical activities and gender. As they used to visit clinics monthly
for assessment it wasn’t been a burden for the patients to participate for the study.
Method: The data collected from January 1st 2010 to December 31st 2010. Both pre
and post transfusion hemoglobin levels were recorded calculated the drop using pre-
vious months records. No exclusion criterias considered othere than gender and age.
Post transfusion Hb – Pretransfusion Hb = Hb drop in 1 month.
Last visit this visit Hematology analyzer was used to detect Hb levels.
All the patients were transfused different amounts (450–325 ml/visit) of packed leuco
reduced red cells until they reach the Hb level of 14 g/dl approximately.
The patients were not informed about the study as a control group was not selected.
Collected Data and Analysis
Total no of patients (Beta thalassamia major) attached = 810
Males 12–16 years old = 76
Exclusions = 734
Mean Hemoglobin drop in 1 month = 5.24 g/dl
Discussion: As the participants were not informed about the study few possible
exclusion criteria’s may have biased the study as being ill [viral fever, gastroenteritis
(3DOTS) etc], participating in competitive sports, attending house hold work, part time
jobs,..etc.
Conclusion: The mean hemoglobin drop for a month of 30 days were detected as
5.24 g/dl in b thalassemia major male patients in age group of 12–16 years who are
being flowered up in National Thalassaemia Center, Sri Lanka.
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IMPORTANCE OF THE EXPECTED ELEVATION VALUE OF
SERUM ALBUMIN BEFORE REPLACEMENT THERAPY:
COMPARISON BETWEEN BROMCRESOL GREEN- AND
BROMCRESOL PURPLE- MEASURED ALBUMIN
Fujihara H, Yamada C, Watanabe H, Shibata H, Funai Y, Kaneko M, Takeshita A
Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
Background: Pharmaceutical albumin has been used excessively in Japan. Japan
consumed one-third of the world supply in the 1980s. While some projects to decrease
dependence on albumin based treatments, Japanese consumption of pharmaceutical
albumin was 57,541 kg in 1999, which was 1.6 and 6.2 times more than that of the
USA and UK, respectively.
Aims: Since then, the target elevation value of serum albumin was adopted in the
‘Japanese Guideline for Blood Transfusion, updated in 2005, to determine the necessary
dosage of pharmaceutical albumin for patients. The optimum dosage is calculated by
the formula; the expected necessary dosage (g) = the expected elevation value (g/
dl) · amounts of whole plasma (dl)/0.4. It contributed considerably to decrease con-
sumption to 0.64 in a past decade (2009). Recently, the measurement method of serum
albumin is shifting from bromcresol green (BCG) assay to bromcresol purple (BCP)
assay because the latter has less contamination than pure albumin. In this study, the
clinical importance of the target value of serum albumin was reevaluated for the BCP
assay.
Methods: We analyzed the serum albumin value by BCG and BCP analyses in 251
cases, and examined the correlation between them.
Results: AlbBCP = 1.1 AlbBCG – 0.5 served as the standard curve and total correlation
of coefficient value (r) was 1.0. We changed the target elevation value in our institute
according to the standard curve from 2.5 to 2.2 g/dl in chronic diseases and 3.0 to
2.7 g/dl in acute diseases. However, the entire hospital consumption of pharmaceutical
albumin was 3476 g/month, increased 23%. Extensive examination revealed the poorer
correlation between them 6 months later. We analyzed a further 28 cases whose serum
albumin levels were <3.0 g/dl with BCG assay. AlbBCP = 1.0 AlbBCG – 0.3 served as
the new standard curve and the correlation of coefficient value (r) was 0.9. After we
modified the target elevation value to 2.0 g/dl for chronic disease and 2.5 g/dl for
acute disease, the consumption of pharmaceutical albumin was 2860 g/month, re-
turned to the previous level of 6 month ago. The coefficient value (r) was significantly
poorer in lower serum albumin levels, and the serum albumin value did not elevate
more than expected after pharmaceutical albumin treatment in such cases (P < 0.05).
Conclusion: The indication of pharmaceutical albumin varies and is complex espe-
cially in cases whose serum albumin level is lower. Target elevation value of serum
albumin might be continuously effective in reducing the consumption of albumin.
However, we have to understand the difficulty in estimating the required clinical
dosage of pharmaceutical albumin from laboratory data even if we adopted more
advanced assay. Simultaneously, we need more information about efficacy on each
background disease accompanying hypoalbuminemia.
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BLOOD TRANSFUSION IN TOTAL HIP ARTHROPLASTY
Qin L, Tan B, Huang CY
West China Hospital, Chengdu, China
Total hip arthroplasty (THA) is associated with a relatively large bleeding and a need
for perioperative transfusion. Postoperative anemia may delay recovery, but transfu-
sion increases the well-known risks, such as transmission of infection or transfusion
infections. The objective of this study is comparing the difference between patients
who underwent total hip arthroplasty with or without allogenic blood transfusion.
Materials and Methods: We reviewed 354 patients underwent total hip arthoplasty
from January 1, 2010 to March 3, 2011. Blood transfusion data, blood indicators before
and after surgery were obtained from laboratory information system (LIS), patients
characteristics, length of hospital stay, infection status were obtained from hospital
information system (HIS). We then compared the indicators between the two groups.
Results: Two hundred and fifty-seven (72.6%) patients received blood transfusion.
Female patients had higher probability of allogenic blood transfusion than male pa-
tients(87.6% vs 54.3%). 77.2% patients over 55 years old received blood transfusion,
whereas only 56.6% patient under 55 years old received blood transfusion. Patients
receiving blood transfusion had longer length of hospitalization (14.32 ± 7.35,
12.84 ± 11.38, P < 0.05) than patients not transfused. Preoperative Hct was indepen-
dent indicator for blood transfusion in THA surgery, other indicators, Hb, Plt, total
protein, albumin, PT, APTT had no relationship with blood transfusion in surgery.
Conclusions: Age, gender and Hct were correlated with blood transfusion in THA
surgery. Patients who received perioperative blood transfusion had longer hospital stay
than whose not transfused.
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NEW AUSTRALIAN PATIENT BLOOD MANAGEMENT
GUIDELINES – THE PERIOPERATIVE MODULE & THE LIKELY
NEED FOR SYSTEM CHANGES
Hogan C, Roberts J, Hyland P; on behalf of the Clinical Reference Group: McNicol
Larry, Balogh Zsolt, Farmer Shannon, French Craig, Gruen Russell, Seigne Richard,
Teague Daryl, Thompson Amanda, Truskett Philip, Vinen John
National Blood Authority – Australia, Canberra, ACT, Australia
Background: Currently, in Australia, a suite of clinical scenario based Patient Blood
Management Guidelines (PBMGs) are being developed to replace the 2001 National
Health Medical Research Council (NHMRC)/Australasian Society of Blood Transfusion
(now ANZSBT) Appropriate Blood Use Guidelines, which were blood product based.
These PBMGs are being developed under the auspices of the NHMRC by the National
Blood Authority – Australia (NBA) and the Australian and New Zealand Society of
Blood Transfusion, and involve a range of relevant medical and other experts. The
second module of this suite focuses on Perioperative care.
Aims: To produce an expert Guideline for Perioperative Patient Blood Management,
including pre-operative haemoglobin optimization, intra-operative and post-operative
interventions to diminish blood loss, improve outcomes and also reduce the likely need
to transfusions.
Methods: A major systematic literature review was undertaken. The Patient, Inter-
vention, Comparison, Outcome (PICO) schema was used in this review. NHMRC defined
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processes were used to form an evidence matrix for each question. Following this,
formal Evidence Statements were developed for each research question. Arising from
these, formal Recommendations and Practice Points were crafted to guide clinical
practice in the pre-operative, intra-operative and post-operative phases of care.
Results: Specific Recommendations and Practice Points were developed in a wide
range of areas of Perioperative practice, including: Establishing multidisciplinary
multimodal perioperative PBM programs, pre-operative anaemia assessments and
treatments, iron therapy and the use of erythropoietin stimulating agents, the timing of
cessation of platelet antagonists, intra-operative haemodilution procedures, the utility
of thromboelastography to guide transfusion support, the use of fibrinolytic inhibitors,
post-operative cell salvage measures, transfusion triggers and use of recombinant
Factor VIIa in prophylaxis.
Conclusions: Systematic detailed literature review and our guideline development has
demonstrated there is a significant range of perioperative interventions that may im-
prove haemoglobin, diminish blood loss and reduce the need for transfusion support.
However, in the current Australian or New Zealand hospital settings, there are likely
significant logistic and resource implications to the full implementation of the rec-
ommendations in these new Perioperative Patient Blood Management Guidelines.
These Guidelines are scheduled for release in October 2011.
E-mail: chris.hogan@nba.gov.au
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A RANDOMIZED COMPARISON OF HEMOGLOBIN
CONTENT-BASED VS STANDARD (UNIT-BASED) RBC
TRANSFUSION POLICY EFFICIENCIES
Atilla E1, Topcuoglu P1, Yavasoglu S2, Karakaya A1, Gencturk C1, Bozdag S1, Arslan O1
1Ankara University, Faculty of Medicine, Ankara, Turkey 2Serpil Akdag Blood Bank,
Ankara, Turkey
Background: Although the volume of the RBCs has been identified according to the
standards, the Hb content of them are all different. In practice, the RBC transfusions are
based on the number of units. No study has yet been carried out to compare an Hb
content-based RBC transfusion with a unit-based one.
Aims: In this study, we aimed to compare the efficiencies of these two different RBC
transfusion methods.
Methods: Eighty-nine patients were enrolled for the study. The median age was 46.
Male:Female ratio was 55:34 and diganoses were; 44 acute leukemia, 17 lymphopro-
liferative disorder, 11 plasma cell disorders, 15 bone marrow defects, one sickle cell
disease and one solid tumor. Ninety-two of the 178 transfusion episodes were ran-
domly allocated to the study group and 86 of them to the control group. The calcu-
lations were done by Hemosoft Blood Banking Management & Information System.
The Hb level of the units was calculated with respect to the donors’ Hb concentrations.
Within the study group, the required Hb amount was calculated based on the patients’
height, actual body weight and their actual and targeted Hb. The Hb levels of the RBCs
within the inventory were checked and if an available RBC with the required Hb
amount was found, used in order to reduce the number of RBCs transfused. The number
of units as ordered was used in cases where there were no available matching RBC and
within the control group. Posttransfusion Hb was checked 2 h after transfusion.
Characteristics of the patients, within the study group and the control group, were
similar. Fifty-one patients had only one transfusion episode and 38 patients had two or
more (range 1–7).
Results: Two units were ordered for 84 of the 92 episodes within the study group
and 3 units were ordered for eight of them. A suitable matching unit was found for
38 of the episodes. (41.3%; 38/92). Two-unit orders were reduced to one within 30
episodes and three unit orders were reduced to two within eight episodes (19,8%; 38/
192). The possibility of finding a suitable unit was higher within low weight-short
patients and within a bigger size of inventory. The ratio of achieving the target Hb
within the study group and the control group (P = 0.1), within the matched and
unmatched groups (P = 0.3) and within the control group and the unmatched group
(P = 0.4) were similar. The relation between the Hb content of the RBC and the rate
of achieving the target Hb was found to be significant (P = 0.01). The relation be-
tween the shelf life of the RBC and the rate of achieving the target Hb was found to
be insignificant.
Conclusions: We demonstrated that the efficiencies of Hb content-based and unit-
based RBCs transfusion policies were similar. Less number of RBCs were used by Hb-
content based transfusion policy. We also demonstrated that the possibility of finding a
suitable Hb content match was directly proportinal to the size of the inventory and
inversely proportional to the weight and height of the patient.
E-mail: erdenatilla@gmail.com PICO
P-304
PREPERATION OF AMAXIMUM BLOOD ODERSCHEDULE IN A
GENERAL HOSPITAL IN SRI LANKA
Silva KC, De Alwis I
General Hospital, Kalutara, Sri Lanka
Background: General Hospital, Kalutara is a tertiary care hospital situated in the
western province of Sri Lanka, which has major specialties namely, Medical, Surgical,
Gynecology & Obstetrics and Peadiatrics units. In one study carried out recently, found
that the cross match, transfusion (C:T) ratios were 1:1, 2:1, 4:1 and 9:1 among Pea-
diatrics, Medical, Surgical and Gynecology & Obstetrics units, respectively. This study
paved the way for us to prepare a Maximum Surgical Blood Order Schedule(MSBOS)
and to implement it in surgical units. MSBOS is a table of elective uncomplicated
surgical procedures where surgeries are grouped into two categories. Those that are
catered by group and antibody screen (G&S) only and those for which blood is cross
matched according to an agreed schedule.
Aim: To find out the C:T ratios and Transfusion Index (TI) for common surgeries that
are performed at General Hospital, Kalutara.
1. To group surgeries which have a C:T ratio of over 3:1 and/or TI of <40% in G&S
category, and to group others into the category that need blood to be cross matched.
Results: Laparoscopic cholecystectomy, laparotomy, haemorrhoidectomy, herniot-
omy, tracheostomy, mastectomy, thyroidectomy, pyelolithotomy, ureterolithotomy,
Internal Fixation of fractures, vaginal hysterectomy abdominal hysterectomy and
myomectomy have C:T ratio of over 3:1. Leg Amputation has 3:1 C:T ratio. All the
above surgeries except laparotomy & myomectomy have a TI of <40%.
Conclusion: Laparoscopic cholecystectomy, laparotomy, haemorrhoidectomy, herni-
otomy, tracheostomy, mastectomy, thyroidectomy, pyelolithotomy, ureterolithotomy,
Internal Fixation of fractures, vaginal hysterectomy abdominal hysterectomy are
grouped into G&S category.
Myomectomy, Laparotomy & leg amputation are grouped into surgeries that need one
blood unit to be cross matched.
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ACTIVITIES REPORT TO SUPPORT BLOOD OF MAJOR SICKLE
CELLS PATIENTS TO THE NATIONAL BLOOD TRANSFUSION
CENTER (CNTS) IN ABIDJAN, COˆTE D’IVOIRE: JANUARY–
AUGUST 2010
Sekongo YM, Konate S, Kouamenan G, Ako C, Abisse A, Yao D, Kabore S, Siransy B,
Dembele B, Tchimou J, Konan K
Centre National de Transfusion Sanguine (CNTS), Abidjan, Cote d’Ivoire
Introduction: Sickle cell disease is a condition that requires monitoring and a specific
treatment because of complications related to anemia, vascular occlusives crises and
infections. If multiples drugs have been proposed in order to correct the insolubility of
sickle cell hemoglobin, transfusion therapy retains its usefulness to improve tissue
oxygenation and reduce the severity of the problem vascular occlusive by cleaning
hemoglobin S. However, handled carelessly, the transfusion may be more harmful than
helpful. In order to ensure better blood safety, to improve both life expectancy and
quality of life for sickle cell disease patients, to guarantee the availability of blood
products, we decided to set up a support unit of blood for sickle cell disease in the
National Blood Center Transfusion (CNTS) of Abidjan. The objective is to ensure better
management of transfusion for the patients with sickle cell disease.
Patients and Methods: We conducted a prospective study from January to August
2010, to the CNTS, in Abidjan, Coˆte d’Ivoire. It covered 37 major sickle cell disease
patients, followed in this structure and with a serious complications of the disease
requiring either transfusion or bleeding due to hyperviscosity.
Results: From an epidemiological and clinical: the average age of patients was
21.6 years. The vascular occlusives crisis alone accounted for 49% of the reasons for
consultation. The average annual crisis was 5. The homozygous form (SSFA2) pre-
dominated. 91.9% of our patients have been previously transfused. The heart anemic
led the anemic complications. Pneumonia predominated table infectious. The acute
chest syndrome (STA) had a majority in ischemic complications.
In terms of support transfusion: the rate of pre-transfusion Hb average of 7.54 g/dl.
The average percentage of the S fraction is 93.6%. Seven patients had a previous
alloimmunization anti-erythrocyte. Thirty-four patients have benefited from transfu-
sion of which 25 have used a manual exchange transfusion, three patients were
regularly bled and one patient was removed from the program because of an impasse
and is currently on erythropoietin therapy.
In evolutionary terms: changes in transfusion program was marked by improvement of
complications, a lower percentage of Hb S, an improvement in hemoglobin.
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Conclusion: The transfusion management of patients with severe sickle cell at CNTS in
Abidjan found that alloimmunization post transfusion is a problem in our working
conditions. The transfusion program is necessary for the improvement of the quality of
life in sickle cell disease severe. Erythropoietin is an alternative for patients with
alloimmunization.
6.4 Haemorrhage and Massive
Transfusion
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ANALYSES OF ACQUIRED HYPOFIBRINOGINEMIA INDUCED BY
PERIOPERATIVE MASSIVE BLEEDING TREATED WITH
CRYOPRECIPITATE
Yamada C, Fujihara H, Kaneko M, Watanabe H, Shibata H, Funai Y, Furumaki H, Nagai
S, Ishizuka K, Takeshita A
Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
Background: Cryoprecipitate, prepared from frozen plasma in hospitals, is effective
for treatment of acquired hypofibrinoginemia induced by perioperative massive
bleeding. According to USA guidelines, it may be indicated when plasma fibrinogen is
considerably low, although there is no clear recommendation for its use. The indication
of the infusion of cryoprecipitate should be based on the bleeding tendency, bleeding
volume and coagulation data.
Aims: We analyzed our six experiences of its use to understand the appropriate
indication and benefit of cryoprecipitate.
Methods and Results: Cryoprecipitate was prepared from fresh frozen plasma in our
hospital. It included 703 mg/dl (625 mg/dl, 440–1208 mg/dl) fibrinogen and 150 ml
(150 ml, 120–180 ml) was generally used per case. (Case 1) A 83-year-old woman,
whose fibrinogen level decreased to 50 mg/dl during an aortic valve regurgitation
operation, bled 3699 ml. Cryoprecipitate was infused, increasing the fibrinogen level to
136 mg/dl (272%), and the bleeding stopped significantly. (Case 2) A 36-year-old
woman, whose fibrinogen level decreased to 83 mg/dl during an operation for intra-
uterine fetal death, bled 2947 ml. Cryoprecipitate was infused, increasing the fibrino-
gen level to 115 mg/dl (139%), and her massive bleeding was immediately stopped.
(Case 3) A 43-year-old man, whose fibrinogen level decreased to 132 mg/dl in a thoratic
aortic aneurysm operation, bled 9703 ml. Cryoprecipitate increased the fibrinogen level
to 155 mg/dl (117%) and his massive bleeding was stopped. (Case 4) A 14-year-old boy,
whose fibrinogen level decreased to 57 mg/dl during an operation for scoliosis, bled
5100 ml. Cryoprecipitate increased the fibrinogen level to 160 mg/dl (281%) and
stopped his bleeding tendency. (Case 5) A 73-year-old woman, whose fibrinogen level
decreased to 109 mg/dl during a thoratic aortic aneurysm operation, bled 6210 ml.
Cryoprecipitate increased his fibrinogen level to 133 mg/dl (122%) and the bleeding
dramatically stopped. (Case 6) A 37-year-old woman, whose fibrinogen level decreased
to 97 mg/dl during a placenta previa operation, bled 4290 ml. Her bleeding stopped
after cryoprecipitate increased her fibrinogen level to 185 mg/dl (191%).
Conclusions: In all these cases, a rapid and considerable increase in fibrinogen level and
significant improvement in bleeding tendency were observed after treatment with
cryoprecipitate. In our experience, bleeding tendencies were not amplified in cases where
the fibrinogen level was >100 mg/dl; in such cases, infusion of cryoprecipitate might be
rarely indicated. Therefore, fibrinogen levels should be closely monitored in treatment
with cryoprecipitate. The staff of the transfusion unit should continuously provide such
data to anesthesiologists and surgeons, as well as information on its proper usage, to
improve the perioperative management of blood transfusions and adjuvant therapies.
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RED CELL AND ALBUMIN RESUSCITATION FOLLOWING ACUTE
MASSIVE HAEMORRHAGE ALTERS HAEMOSTASIS
Fung YL1, Foley SR2, Simonova G2, Varzeshi M2, Manning MC2, Dunster KR2, Staib A3,
Fraser JF1
1The University of Queenland & The Prince Charles Hospital, Brisbane, Qld, Australia
2CCRG, The University of Queensland & The Prince Charles Hospital, Brisbane, Qld,
Australia 3Emergency Department, Princess Alexandra Hospital, Brisbane, Qld,
Australia
Background & Aim: Blood transfusion is a critical component of acute haemorrhage
management. However, there is limited prospective controlled data on alterations to
haemostasis following acute haemorrhage and the effects of transfusion. Our aim was to
characterise haemostasis in an in vivo ovine model after acute haemorrhage and the
subsequent resuscitation with (i) 4% albumin (Alb) or (ii) fresh (<5 do) homologous ovine
packed red blood cells (oPRBC) or (iii) aged (>30 do) homologous oPRBC. The ovine
model was selected as sheep have been found to be a suitable species for translational
coagulation studies (Siller-Matula et al, Thromb Haemost. 2008;100(3):397–404).
Method: Healthy male sheep were anaesthetised then bled of 30% of their blood
volume. Thirty minutes later they were resuscitated with replacement volumes of either
Alb alone, or 2 units of fresh oPRBC topped up with Alb to replacement volume, or
2 units aged oPRBC topped up with Alb. After which they were monitored for four
hours. Blood samples were collected pre-haemorrhage (baseline), post-haemorrhage
and every hour post-transfusion. Samples were analysed using the rotational throm-
boelastometry device, ROTEM. The contribution of the extrinsic coagulation factors,
fibrinogen and platelets to clot formation was assessed by EXTEM, with the specific
contribution of fibrinogen and fibrin polymerisation to clot formation by FIBTEM.
Results: Relative to baseline levels, the acute massive haemorrhage did not signifi-
cantly alter the clotting time (CT), which measures how fast the formation of fibrin
starts, maximum clot firmness (MCF) which reflects clot quality or clot formation time
(CFT) which describes the kinetics of the formation of a stable clot through activated
platelets and fibrin.
Platelet counts were also not significantly altered (data not shown).
All three forms of resuscitation decreased the MCF and alpha angle of EXTEM for up to
4 h post-resuscitation.
The EXTEM, CFT was also significantly increased (P < 0.01) with all forms of
resuscitation.
Table 1: Tracked changes to haemostasis
Discussion & Conclusion: In this model, acute massive haemorrhage did not signifi-
cantly alter haemostasis, as determined by rotational thromboelastometry, but resus-
citation did. Decreases in EXTEM MCF and EXTEM alpha angle, and increases in
EXTEM CFT following resuscitation suggest that these changes are associated with
alterations to plasma clotting factors, specifically functional fibrinogen and/or factor
XIII, rather than platelet number. Further detailed investigation into these plasma
factors is required to clarify this.
P-309
TRANSFUSION OF FRESH OR AGED RED CELLS AFTER
HAEMORRHAGIC SHOCK REDUCES SELENIUM AND
GLUTATHIONE PEROXIDASE
Fung YL1, McDonald CI2, Thom O2, Fraser JF1
1The University of Queenland & The Prince Charles Hospital, Brisbane, Qld, Australia
2CCRG, The University of Queensland & The Prince Charles Hospital, Brisbane, Qld,
Australia
Background: Packed red blood cell (PRBC) transfusions are a routine part of acute
haemorrhage and anaemia management. However, little is known about the effect of
transfusion per se on the levels of antioxidant trace elements and the associated
antioxidant response. Reductions in certain trace elements such as selenium, can re-
duce the antioxidant response and increase susceptibility to oxidative stress. Oxidative
stress is a significant factor in the development of tissue/organ injury especially after
trauma and cardiac surgery, both situations where transfusion is common.
Our aim was to investigate if and how transfusion of packed red cells (PRBC) altered the
host’s antioxidant trace element levels and their antioxidant response. This was
performed in an in vivo ovine model of haemorrhagic shock and transfusion.
Methods: Ovine blood (400 ml) was collected from healthy male marino sheep, and
processed into ovine PRBC (oPRBC), then stored at 4C for up to 42 days. Twelve
healthy male merino sheep were anaesthetised and haemorrhaged 30% of their blood
volume. Haemorrhagic shock (determined by cardiac output and mean arterial pres-
sure) was maintained for 30 min. Sheep were assigned into two transfusion groups; (i)
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2 units of fresh [2–5 d.o. (mean 3 d.o.) n = 6] or (ii) aged PRBC [32–32 d.o. (mean 37
d.o.) n = 6]. Only cross-match compatible oPRBC’s were transfused, and both cohorts
were topped up with 4% albumin to meet full volume replacement. Blood samples were
collected pre-haemorrhage, post-haemorrhage and 4 h after transfusion. These blood
samples as well as samples from the transfused oPRBC, were tested for trace elements:
selenium, copper, zinc and antioxidant response: glutathione peroxidise and super-
oxide dismutase.
Results: Haemorrhagic shock did not significantly alter trace element levels or anti-
oxidant response of the host.
The transfusion of oPRBC (irrespective of age) significantly reduced all three trace
element levels and glutathione peroxidise response in the host.
Both fresh and aged oPRBC contained very low levels of selenium and copper but high
levels of zinc.
Table 1: Glutathione peroxidase (GPx), superoxide dismutase (SOD), ovine packed red
blood cells (oPRBC). Values expressed as mean ± SD. Asterix * indicates P < 0.05 with
respect to baseline by unpaired t-test
Conclusion: In this in vivo ovine model, haemorrhagic shock did not alter the host’s
antioxidant response. But volume replacement transfusion did reduce selenium,
copper and zinc levels, and glutathione peroxidise response in the host. As gluta-
thione peroxidase response is associated with circulating selenium levels, the very
low selenium levels in transfused oPRBC may have contributed to the observed
reduced antioxidant response. Such a reduced antioxidant response could contribute
to further tissue damage in transfusion recipients with increased reactive oxygen
species generation. Further studies are required to determine if there is an association
between the transfusion of PRBC and a reduced antioxidant response in human
patients.
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HAEMORRHAGE, MASSIVE TRANSFUSION AND NOVOSEVEN
IN PATIENT WITH ABRUPTIO PLACENTAE
Jovanoska V
Institute of Transfusion Medicine Republic of Macedonia, Prilep, Macedonia
Aim: To present a case of abruption placentae with massive haemorrhagie treated with
massive transfusion and Novoseven.
Introduction: An abruptio placenta is one of the important causes of ante partum
hemorrhage and cause for massive postpartum hemorrhage (MPPH) that might be fatal.
Excessive uterine bleeding seen vaginally or concealed placental abruption with large
clot formation may lead to consumptive coagulopathy and disseminated intravascular
coagulation (DIC)
Case Presentation: In our depat ment came request for 5 units of blood (deplasmated
eritrocites in SAG-M) for patient NN, 39 years, Dg. abruption placentae treated with
cesarean section who present a massive haemorrhagie during the operation. Immidi-
ately we started with monitoring of coagulation-PT, APTT and TT, and follow the
number of platelets and fibrinogen. Eight units of Eritrocites, 5 units of FFP and
2000 UI of crioprecipitat was given.
Close monitoring of PT, APTT, TT and platletes number was done during the treatment.
Neawborn suspected for ARDS was sent at the Clinical hospital in Skopje, while the
mother was treated in our hospital in Prilep. number of Platelets was low around
45,000)and vaginal bleeding was still present. We decided to give Amp Novoseven in
dose of range 90 lg/kg.
Bleeding was stoped and because of low number of platletlets, stabilized patient was
sent in Clinical hospital Skopje for further observation, with recomandation to start
with LMH treatment. Stabilisation of all parametars was achieved From the next day
LMWH was given and continued during 1 month with monitoring of PT, APTT and TT
and Platelets. All results was normal.
Conclusion: In the patient with abruption placentae we should be prepared for massive
haemorrhagie. Correction of hypovolemia, coagulopathy and bleeding should be done
promptly. Novoseven is a drug of choice to stop bleeding in such cases.
6.5 Adverse Events, including
TRALI
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DISTRIBUTION OF HAPTOGLOBIN GENE DELETION IN THE
TAIWANESE POPULATION
Chen WF, Chu CC, Lin M
Mackay Memorial Hospital, New Taipei City, Taiwan
Haptoglobin (HP) is a hemoglobin-binding protein of the plasma. Haptoglobin-
deficient patients were first reported in Japan to present anaphylactic shock after blood
transfusion and their HP gene was completely deleted. This gene deletion is now
referred as the HPdel allele. The HPdel allele is restricted to East and Sourtheast Asian
populations, it is not found in South Asians (India), Europeans or Africans, and the
HPdel allele frequency ranges from 1.1% to 3.8% throughout Asia.
A simple polymerase chain reaction (PCR) protocol, used to detect the allele deletion,
had been established. This method was used in the Mackay Memorial Hospital
laboratory to assess and therefore to prevent anaphylactic transfusion reactions
associated to the deletion.
In this study, DNA samples were obtained from 193 healthy random individuals. Our
preliminary screening showed nine individuals heterozygous for the HPdel allele which
should corresponds to an HPdel allele frequency of 2.33%. Accordingly, the prevalence
of haptoglobin-deficient phenotype with homozygous deletion can be estimated to be
approximately 0.054% in the Taiwan population.
This study indicates that the potential risk of anaphylactic shock caused by haptoglobin
deficiency in Taiwan is alarmingly high and identical to previous findings in other
Asian groups. Regrettably, no institution so far has ever initiated a routine preventive
testing. This simple PCR method is helpful in clarifying if HPdel allele is the causing
factor in patients suffering from a non-hemolytic transfusion reaction, such as allergy
or anaphylactic shock. To provide matched blood to haptoglobin-deficient patients, we
propose that a registry program of plateletpheresis donors, like the red cell rare donor
database, should be established in Taiwan’s blood centers.
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IDENTIFICATION OF IGA DEFICIENCY AMONG JAPANESE
PATIENTS WITH NONHEMOLYTIC TRANSFUSION REACTIONS
AND BLOOD DONORS BY SIMPLE ELISA
Shimada E1, Shimoyamada T1, Watanabe Y1, Anazawa M1, Nakamura J1, Abe T1, Sato
R1, Tonami H2, Suzuki Y2, Okazaki H1, Satake M1, Tadokoro K1
1Japanese Red Cross Society, Tokyo, Japan 2Japanese Red Cross Tokyo Metropolitan
Blood Center, Tokyo, Japan
Background: Anaphylactic transfusion reactions (TRs) are reported among IgA-defi-
cient patients with anti-IgA antibodies. Identification of IgA deficiency is important for
patients with nonhemolytic transfusion reactions (NHTRs) to determine the cause of
TRs and to prevent TRs in subsequent transfusions. For donors, it would also be
important to prevent their possible TRs in the future and to be able to donate blood for
IgA-deficient patients as registered members of an IgA-deficient donor pool. We al-
ready have identified haptoglobin deficiency among Japanese patients with NHTRs and
normal blood donors by simple sandwich ELISA.
Aims: The aim of this study is to identify IgA-deficient individuals among Japanese
patients with NHTRs and normal blood donors by simple ELISA and to determine its
prevalence.
Materials and Methods: Testing for serum IgA by simple ELISA. Twenty-five micro-
liters of a serum sample was added to a microplate precoated with anti-human IgA
rabbit IgG and incubated for 10 min at RT. After washing the microplate, 50 ll of
diluted HRP-conjugated-anti human IgA goat anti-serum was added to the microplate
and incubated for 20 min. Enzyme activity was determined using the TMB substrate
after washing the microplate. Three standard IgAs (3, 30 and 300 lg/dl) and positive
and negative controls were assayed simultaneously. A test sample was identified as
IgA-deficient if its optical density was lower than that of the standard IgA of 3 lg/dl.
Identification of IgA-deficient individuals among Japanese patients and donors A total
of 16,181 patients who had experienced NHTRs were reported by hospitals to the
Japanese Red Cross Society between 1995 and 2010, among which 2487 showed
anaphylactic TRs. They were tested for serum IgA by this ELISA when their serum IgA
concentrations were lower than 10 mg/dl, as measured by peak-rate nephelometry.
Blood donors (n = 733,802) who visited the Japanese Red Cross Tokyo Blood Center
between 2009 and 2010 were also tested for serum IgA if they showed low IgA
concentrations as measured by nephelometry. Anti-IgA antibodies produced in IgA-
deficient individuals were determined by ELISA and western blot analysis.
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Results: IgA-deficient individuals whose serum IgA concentrations were <3 lg/dl
could be identified within 1 h by our simple ELISA. Six patients were identified as
having IgA deficiency. All of them produced high titers of anti-IgA (IgG class). Three of
them had developed severe anaphylactic shock. Seventy-two blood donors were
identified as being IgA-deficient. Anti-IgA antibody was detected in 17/72 (23.6%).
Conclusions: IgA-deficient patients with high-titer anti-IgA were identified among
Japanese patients with NHTRs [6/16,181(0.038%)] or among those who experienced
anaphylactic TRs [3/2,487 (0.12%)]. IgA-deficient individuals were also identified
among Japanese blood donors with a prevalence of 72/733,802 (0.01%), which is about
one-tenth of that in European and North American countries. Most of the cases of
anaphylactic TRs developed in patients without IgA deficiency. However, the higher
prevalence of IgA deficiency among the patients with NHTRs, particularly among those
with anaphylactic TRs compared with the normal donors, suggests a higher risk of such
TRs in IgA-deficient patients.
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A SENSITIVE HOMOGENEOUS IMMUNOASSAY FOR SERUM
IGA
Miyoshi Y1, Shimada E1, Mazda T1, Shimoyamada T1, Watanabe Y1, Okazaki H1, Satake
M1, Ohshima H2, Tadokoro K1
1Japanese Red Cross Society, Tokyo, Japan 2Tokyo University of Science, Chiba, Japan
Background: IgA-deficient individuals are at risk of anaphylactic transfusion reac-
tions. Precise measurement for low levels of serum IgA is necessary to identify IgA-
deficient individuals without an overestimation of such individuals and to prevent the
transfusion reactions. Luminescent oxygen channeling immunoassay (LOCI) is a sen-
sitive and homogenous assay consisting of two steps: (i) the formation of immune
complexes using two different types of beads and (ii) the measurement of luminescence
induced by singlet oxygen molecules.
Aims: The aim of this study is to develop a new sensitive immunoassay for the
measurement of low levels of serum IgA using AlphaLISA technology, a type of LOCI.
Materials and Methods: Reagents and equipment IgA purified from pooled human
plasma was purchased from Athens Research Co. and used as a standard. The un-
conjugated acceptor beads, streptavidin-conjugated donor beads, and 384-well mi-
croplates used in this study were supplied by Perkin Elmer Co. A rabbit anti-human IgA
antibody (DAKO #A0262) was immobilized onto unconjugated acceptor beads using
sodium cyanoborohydride to prepare anti-IgA-antibody-conjugated acceptor beads. A
biotin-conjugated anti-IgA antibody was prepared using a rabbit anti-human IgA
antibody and water soluble NHS-biotin (Vector Lab. Co.). The intensity of luminescent
signals was measured using an EnVision plate reader in the AlphaScreen mode (Perkin
Elmer Co.) Measurement of IgA concentration Twenty microliters of a mixture con-
taining anti-IgA-antibody-conjugated-acceptor beads, a biotinylated anti-IgA and a
test sample was dispensed to each well of a 384-well microplate and incubated for 1 h
in the dark at RT. Streptavidin-conjugated donor bead solution (5 ll) was added to the
mixture and incubated for 30 min in the dark at RT. The IgA concentration of the test
sample was calculated from the measured intensity of the signal. After the optimal
conditions of the reaction were determined, the sensitivity, specificity and reproduc-
ibility of the assay method, and the effects of coexisting materials were analyzed.
Results: At the optimized concentration of each reagent and using 5 ll of a sample,
the detection limit of this assay was 50 IgA ng/dl. The analytical range expanded from
50 to 100,000 ng/dl. The detection limit decreased to <5 ng when the sequence of the
addition of the reagents was improved. A luminescent signal was generated by normal
human serum but was not generated by IgA-deficient serum. There was no effect of
bilirubin (up to at least 10 mg/ml) or chyle (up to at least 4700 folmazine turbidity
units) on signal intensity. However, a high concentration of hemoglobin (more than
50 mg/ml) or neat serum/plasma reduced the intensity of signals. Serum/plasma
samples were suitable for testing at more than 10-fold dilution. The intra/inter-day
coefficients of validations were 2–10%.
Conclusions: This newly developed immunoassay is highly sensitive and easy to
perform using a simple mix-and-measure protocol, requiring small amounts of serum/
plasma samples. This technique is considered to be useful for the identification of IgA-
deficient patients and/or blood donors distinguishing true IgA deficiency from those
with low levels of serum IgA.
P-314
DETECTION OF ANTI-PLASMA PROTEINS BY LUMINEX
SYSTEM
Miyazaki T, Sakagawa H, Matsubayashi K, Sato S, Kato T, Ikeda H
Japanese Red Cross Hokkaido Blood Center, Sapporo, Japan
Background: Anti-plasma proteins especially anti-IgA and anti-haptoglobin are
reported to cause anaphylactic transfusion reactions. Anti-IgA or anti-haptoglobin
are occasionally produced in the IgA- or haptoglobin-deficient patients who are
infused with blood products. Besides anti-HLA or anti-HNA, detection of anti-
plasma proteins is important to analyze the factors of transfusion-related adverse
reaction.
Aim: Screening of anti-plasma proteins is carried out by ELISA in our laboratory,
however, few positive sera was detected in cases of transfusion-related adverse reac-
tion. To detect anti-plasma proteins more effectively, we designed and evaluated more
sensitive and specific immunoassay using Luminex system.
Methods: Purified human plasma proteins (IgA, IgA1, IgA2, haptoglobin, a2-mac-
roglobulin, celluroplasmin, C4, C9 or albumin) were covalently coupled with dif-
ferent-colored carboxylated microspheres by standard EDC/NHS protocol,
respectively. Sample serum was incubated with the mixture of protein-coupled
microspheres and stained with PE conjugated anti-human IgG, followed by Luminex
system assay. Absorption test was performed simultaneously with sample serum
which was pre-incubated with pooled human plasma. Conventional ELISA was
performed by standard protocol with a microtiter plate coupled to each specific
plasma protein. Specific antibody was detected by HRP conjugated anti-human IgG
and TMB substrate.
Results: In sensitivity test using two fold diluted anti-IgA and anti-haptoglobin serum,
Luminex assay showed 64 times higher sensitivity than ELISA. In screening of 86 sera
derived from healthy donors, 13 sera were positive for anti-IgA, anti-IgA1 or anti-IgA2
by Luminex assay. Only 1 of the 13 positive sera was confirmed as anti-IgA2 specifici
by absorption test. Other 12 sera were regarded as nonspecific reactions since their
reactivities were not absorbed by pooled human plasma. All of 13 Luminex positive
sera were negative for anti-IgA by ELISA. Simultaneous test of Luminex and ELISA
with 39 sera derived from transfusion-related adverse reaction cases, 1 serum was
positive for anti-haptoglobin only by Luminex. This patient was confirmed as hap-
toglobin gene deletion (Hpdel/Hpdel) by PCR. No other anti-plasma proteins were
detected either by Luminex or by ELISA.
Conclusion: Screening of anti-plasma proteins using Luminex showed higher sensi-
tivity than conventional ELISA with shortened assay time up to 2 h including
absorption test. Although high sensitive immunoassay often showed nonspecific
reactions, simultaneous absorption test could improve specificity of Luminex assay.
Therefore, our Luminex assay is suitable for anti-plasma proteins detection.
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HAEMOVIGILANCE: INVESTIGATION OF ADVERSE REACTIONS
FOLLOWING BLOOD TRANSFUSION IN REGIONAL BLOOD
CENTER NORTH CENTRAL PROVINCE SRI LANKA
von Senavirathne KCD
National Blood Transfusion Service, Colombo, Sri Lanka
Background: Recipient haemovigilance consists of the detection, collection and
analysis of information regarding untoward and unexpected effects related to the
blood transfusion. All adverse reactions related to blood transfusion s are documented,
investigated and analyzed by local haemovingillance units in each blood centers and
HBBB. The results are reported to the main haemovigilance unit in National Blood
Centre (NBC) Colombo monthly. After that annual report of haemovigilance published
by NBC.
We report the summary of adverse events during the last 3 years (2008–2010) in RBC –
N.C province Sri Lanka.
Material and Methods: During 36 months, 84,815 units of red blood cells including
leucodepleted and filtered blood, 29,917 plasma units and 17,887 platelets units
including single donor aphaeresis units were given to the patients. (Total blood
transfusion units – 132,619).
Post transfusion reaction should be documented investigated and reported according to
the GMP.
Results: A total of 219 adverse reactions (0.16%) were reported as minor adverse
transfusion reactions consists of FNHTR (55%) and allergic reactions (45%). No major
reactions including ABO incompatibility and TRALI were announced. No near miss
events during 2008–2010.
Conclusion: According to the gender, 62% of female patients had reactions to blood
and blood products and 38% of men. No near miss events were reported during these
study periods due to clinical staff awareness regarding better blood transfusion prac-
tices programmes conducted by NBTS yearly.
The rate of post transfusion reactions is very low, underreporting is still probable. The
feedback of haemovigilance system is reported each year.
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ANTI-WEBB ANTIBODY CAUSING ACUTE HAEMOLYTIC
TRANSFUSION REACTION
Hong FS1, Wright T1, Brown P2
1Austin Health, Heidelberg, Vic., Australia 2Australian Red Cross Blood Service,
Melbourne, Vic., Australia
Background: Webb (Wb) antigen of the human erythroid cells is expressed on gly-
cophorin C and is part of the Gerbich (Ge) antigen family. It occurs at a low prevalence.
Antibodies against some of the Gerbich antigens, such as anti-Ge2 and anti-Ge3 are
known to cause haemolytic transfusion reactions. Anti-Wb antibody was first de-
scribed in 1963 by the Blood Transfusion Service in Brisbane, Australia, and was
thought to exhibit the characteristics of a ‘natural’ antibody rather than of immune in
nature. We report the first known case of an immediate haemolytic transfusion reaction
to an anti-Wb antibody.
Case Report: A 73 year-old woman of Greek ancestry presents with symptomatic
anaemia in the setting of progressive chronic lymphocytic leukaemia, previously
treated with fludarabine-based chemotherapy 16 months earlier. Her blood group was
Group O, Rhesus D positive, and no antibodies were detected on 3 cell screening panel
(CSL Abtectcell III). Red blood cells were crossmatched electronically and issued for
transfusion for symptomatic anaemia.
During the red cell transfusion, the patient developed an acute haemolytic transfusion
reaction with rigors, hypoxia, fever and acute renal failure. Laboratory confirmation of
haemolysis included hyperbilirubinaemia, elevated lactate dehydrogenase and sphe-
rocytosis on the blood film. The patient recovered with conservative management and
received further red cell units following crossmatching by indirect anti-globulin testing
(IAT) without incident.
The implicated red cell unit was returned to the laboratory as part of routine
investigations for blood transfusion reactions. No clerical error was identified. Repeat
grouping and manual crossmatching of pre- and post-transfusion specimens revealed a
non-compatible crossmatch by IAT and no evidence of ABO incompatibility. The
offending antibody was not able to be identified locally and the plasma was referred to
the Reference Red Cell Serology Laboratory of the Australian Red Cross Blood Service
in Melbourne, Australia.
A strongly reactive Anti-Wb was found in both pre- and post-transfusion specimens, in
the absence of other antibodies, and phenotyping of the implicated red cell unit
revealed the presence of Wb antigen. These findings were confirmed by the
International Blood Group Reference Laboratory in Bristol, United Kingdom.
Conclusion: The clinical features and laboratory findings of the transfusion reaction
are consistent with an anti-Wb antibody causing a clinically significant acute hae-
molytic transfusion reaction.
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THE SURVEY OF NON INFECTIOUS COMPLICATION OF
TRANSFUSION IN PEDIATRIC HOSPITALS AND THALASSEMIC
CENTERS IN TEHRAN
Zadsar M, Sharifi S
IBTO Research Center, Tehran, Iran
About 10% of all transfusion recipients may experience a transfusion complication
that could be acute or chronic. If the clinician has knowledge about these
complications prevention measures may be used This study evaluated the prevalence
of acute noninfectious complication in Tehran over a one year period.
In a 1 year period for each transfusion the vital signs of the recipient and every sign or
symptom of complication were recorded carefully.
The survey compiled findings on more than 152,757 transfusions in Tehran pediatric
hospitals and thalassemic centers and recorded about 217 cases of complication. One
hundred and twenty-three of them were diagnosed by the attending physician,
including hemolytic reaction in seven cases, FNHTR in 33 cases,four cases of
anaphylactic reaction,72 cases of allergic reaction and three cases of TAGVHD, and
five cases of concurrent allergic reaction and FNHTR. Three cases of TAGVHD died and
the diagnosis was confirmed by liver biopsy.
The prevalence of transfusion complication was higher in patients who received more
than one component. The most recipient diagnoses were AML, ALL and thalassemia.
After confirmation of three cases of TAGVHD the irradiation blood component center
was established in the Tehran Blood Transfusion Centre.
6.6 Haemovigilance and
Transfusion Safety
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CORRELATION OF HEAVY METALS AND THEIRS IMPACT TO
EPIDEMIOLOGICAL SURVEY IN THE MINERS BLOOD DONORS
AND OTHER HUMAN POPULATION
Velickova N, Kamceva G, Kamcev N, Panov Z
Faculty of Medical Sciences, Shtip, Macedonia
Introduction: Miners who are blood donors, and work in mines for lead-zinc ores are
constantly exposed to heavy metals (lead, zinc and cadmium) and this aspect is ex-
pected to increase or decrease many hematological parameters.
Aim of the Study: The concentration of lead, zinc and cadmium was studied in
exposed blood donors and non-exposed blood donors (control group). Knowing the
structure of various heavy metals, all of the analysis was carried out to examine
the impact of these heavy metals on the occurrence and severity of certain epi-
demiological diseases and hematological parameters on the miners who are blood
donors.
Material and Methods: In this research 120 miners were included who were blood
donors (mining for lead and zinc) from the Republic of Macedonia and a control group
of 30 participants that included blood donors not directly exposed to heavy metals,
while living in the immediate vicinity of the lead and zinc mine. In this research
biochemical analysis (inductively coupled plasma spectrometry (ICP) one of the most
sensitive analytical techniques for the determination of elements in biological materials
was applied and the basic haematological parameters were determined.
Results: The observation of increased blood lead level on blood donors in the exposed
group (mean = 0.089 mg/l) and 20% on blood donors in the control group (mean =
0066), increased blood zinc level in the exposed (mean = 1391) and in the control
group (mean = 1074), increased blood cadmium level in 62% of exposed (mean = 0007)
and in 50% of the control group (mean = 0006); If the normal BLL (blood lead level) is
0.04–0.07 mg/l, we concluded that all male blood donors in the exposed group had
above normal BLL. In the control group 20% of male blood donors had above normal
BLL; if the normal BZL (blood zinc level) is 0.1 mg/l, we concluded that all male blood
donors exposed in the control group had above normal BZL. If the normal BCL is
0.005 mg/l, we concluded that 62% of the male blood donors in the exposed group had
above normal BCL. In the control group 50% of male blood donors had above normal
BCL; The blood lead, zinc and cadmium level will rise during exposure at work. forty-
eight percent of miners (exposed group) had an exposure period of 20 years, 29%
between 10 and 20 years and the remaining 23% an exposure period under 10 years.
Results showed negative correlation between the number of red blood cells and
hemoglobin and blood levels of heavy metals; positive correlation between the number
of leukocytes and blood heavy metals levels. Epidemiological survey showed that nearly
all workers complained of headache. While 25 of 70 miners who were blood donors
(with long exposure) were found to be suffering from various diseases such as asthma,
respiratory tract, irritation and watering of eyes.
Conclusion: The research confirms that the increased content of heavy metals in blood
donors affects the concept of professional risk that involves probability that as a result
of exposure of workers to certain harmful agents in the work environment negative
effects are manifested on their health. The change of some haematological parameters
in the blood donors, results in the emergence of certain diseases with complex etio-
logiesand risks to their health.
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SETTING STANDARDS TO CLINICAL TRANSFUSION PRACTICE;
SUCCESSFUL IMPLEMENTATION OF A TRANSFUSION
MONITORING PROGRAM IN A LOW RESOURCE SETTING
Senaviratne PAUK1, Munasinghe SR2, Bandara MCPK2, Yapa DAN2,
Liyanapatabendi D2
1Base Hospital, Karavanella, Nittambuwa, Sri Lanka 2National Blood Transfusion
Service, Colombo, Sri Lanka
Introduction: Despite being an essential component of the modern medical practice
blood transfusion carries an inherent risk of serious adverse reactions. Therefore proper
monitoring of patients during transfusions to identify transfusion reactions at an early
stage plays a pivotal role in clinical transfusion. Several incidents of transfusion
reactions due to patient misidentification during year 2010 in Wathupitiwala Base
Hospital, Sri Lanka has raised concern over the necessity of an effective patient
monitoring system during transfusions.
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Aims: To evaluate and identify shortcomings in current practice of patient monitoring
and record keeping during blood transfusions, plan and implement necessary inter-
ventions to rectify these shortcomings and assess the effectiveness of interventions by
pre and post implementation audits in Wathupitiwala base hospital, Sri Lanka.
Methodology: A pre implementation audit was carried out using randomly selected
blood units and several aspects of transfusion monitoring were recorded by direct
observation in wards.
Based on these findings a printed monitoring chart was designed with structured
format including check boxes and columns to be filled with patient information, blood
component type and serial numbers, time of starting and ending the transfusion, pre
transfusion, during transfusion and post transfusion vital signs clearly defining the
intervals to be monitored. A system was implemented where this chart was sent to
wards along with every blood unit issued from the blood bank. Implementation of the
new monitoring system was followed by a post implementation audit.
Results: Fifty-seven transfusion events were audited during the pre implementation
audit and it revealed that only 47.3% (n = 27) of the total transfusions were monitored.
Monitoring was >90% in Intensive Care Units and theatres but <30% in general medical,
surgical and other wards. Even in monitored patients Recording of Vital signs prior to
starting the transfusion were done only in 22.8% (n = 13) and post transfusion values
were recorded in none of the events. Even where monitoring was done temperature as a
vital sign was monitored only in 5.2% (n = 3) of the events.
Most of the transfusions were not regularly monitored and there were lot of variation
in the frequency of monitoring (from every 5–30 min). The starting time of the blood
units were mentioned in 43.8% (n = 25) of the cases but the finishing time of the
infusion of each unit was mentioned only in 15.7% (n = 9) of the cases. Separate
monitoring charts rather than recording in the bed head tickets were used in only
29.8% (n = 17) of the events.
A total of 59 transfusion events were audited during the post implementation audit and
96.6% (n = 57) events were monitored after implementation of the new monitoring
chart. In monitored transfusions recording of patient information, blood unit
information, pre transfusion vital sign monitoring including temperature and regular
monitoring of vital signs at least during two occasions has reached 100%. Post
transfusion vital sign recording has increased to 69.4% (n = 41)
Conclusion: Successful and objective patient monitoring during transfusions can be
implemented by simple interventions and education programmes and will play an
important role in enhancing patient safety.
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HAEMOVIGILANCE IN TAIWAN
Chen W, Huang CG, Chen JW, Lin SJ, Lin KS
Taiwan Blood Services Foundation, Taipei, Taiwan
Background: Haemovigilance, in a broad scope, comprises the surveillance procedures
for adverse reactions in donors or recipients, the adverse events during the collecting,
testing, processing, storage and distribution of blood and blood components, and the
epidemiological follow up of donors for potentially infectious donations. During 2010,
Taiwan Blood Services Foundation (TBSF) distributes 4.8 million units (250 ml
equivalent) of blood and blood components and 0.18 million units of single-donor
platelets for the blood demand in Taiwan. On a voluntary basis, information related to
the blood recipients that develop adverse transfusion reactions (ATRs) are reported to
TBSF.
Aims: The aims of study are to determine the coverage and occurrence of ATRs, the
key component of haemovigilance, in Taiwan.
Methods: The information of ATRs collected during 2008–2010 were analyzed. We
determined ‘the coverage’ as the number of blood and blood components issued to the
hospitals that reported ATRs divided by total number of those issued by TBSF, and ‘the
occurrence’ as the number of blood recipients that developed ATRs per 100,000 units
of blood and blood components issued to the hospitals contributing ATRs reporting.
Since we collect both 250 and 500 ml whole blood, each 500 ml whole blood or the
blood component derived from 500 ml whole blood was considered as two units in the
analysis. The ATRs analyzed in this study were those considered as serious, including
acute hemolytic transfusion reaction, delayed hemolytic transfusion reaction, ana-
phylactic shock, dyspnea, transfusion-associated graft-versus-host disease (TA-GVHD),
transfusion-related acute lung injury (TRALI), bacterial and viral infection associated
with transfusion.
Results: Of the total bloods and blood components issued, 43% were issued to the
hospitals that contributed ATRs reporting. Between the geographic areas, the coverage
of blood and blood components being reported were 44% in Taipei, 12% in Hsinchu,
70% in Taichung, 53% in Tainan, 19% in Kaohsiung, and 60% in Hualien. The overall
occurrence of ATRs was 12 per 100,000 units of blood and blood components,
attributed in the order to dyspnea (7.7/100,000), acute hemolytic reaction (3.4/
100,000), anaphylactic shock (0.39/100,000), viral infection (0.22/100,000), TA-GVHG
(0.16/100,000), delayed hemolytic transfusion reaction (0.10/100,000), TRALI (0.09/
100,000) and bacterial infection (0.04/100,000). Further breakdown information by
components show the occurrence of ATRs per 100,000 units of blood and blood
components were 25 by whole blood, 20 by red cells, 32 by single-donor platelets, 3.9
by whole-blood platelets, and 6.1 by plasma components.
Table 1: Serious adverse events and blood products
Conclusions: In this paper the information of ATRs collected are analyzed and re-
ported. To achieve the goal for preventing recurrence of adverse events and reactions, a
comprehensible guide for the incidents to be surveyed and reported should be estab-
lished and national health authorities should contribute a role to the surveillance
procedures.
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FROZEN SYSTEM FOR ARCHIVE SPECIMENS FROM BLOOD
DONORS IN TAIWAN
Yang TT1, Huang YJ1, Yang B1, Lin KS2
1Hsinchu Blood Center, Taiwan Blood Services Foundation, Jhubei, Taiwan 2Head
Office Taiwan Blood Services Foundation, Taipei, Taiwan
Background: The retrospective investigation plays an important role in transfusion
medicine. Basing on this point of view, Taiwan Blood Services Foundation built an
automatic frozen system for archiving all specimens from blood donors in Taiwan.
These are 1.8 million specimens yearly. The system had been enabled in September
2009.
Methods: Two compressors were installed for stabilizing the frozen temperature and as
backups reciprocally. Shelves with 5616 spaces could accommodate thirteen million
and four hundred seventy thousand sample tubes. Three automatic storage/retrieval
machines are dominated by computer. For minimizing temperature difference, there is
a room of 1–5C between working area and storage and conveyor is installed to link.
This great storage has 25 sensors to measure its temperatures which were consecutively
recorded by central monitor. Moreover, an alert system is set for warning us when
temperatures are about out of limitation and saving time for us to take action. Elec-
tricity has power generator to be the backup. Functions of the system were validated in
the stability of storage temperature, the accuracy of temperature measured, tempera-
ture monitoring and alert system, the uniformity between outputs from the Blood
Donation/Distribution System (BD/DS) and inputs to Automatic Storage/Retrieval
System (AS/RS). It took 3 months to complete the validations.
Results: The storage is under )30C and the capacity was designated to store donor
specimens of 10 years. The specimens were arranged in order that one hundred
specimens were lined up in a case and six cases in a basket. The electronic data of
positions of every specimen were built by the BD/DS. The positions and the link of
specimen number, case number and basket number were filed and sent to the AS/RS
through internet. Only those basket numbers which had input to AS/RS were allowed to
be archived. Specimens were frozen before shipping and were delivered under )5C to
archive storage periodically from all blood centers.
The specimen retrieving process is as follow: the application should be approved by
medical direction first. Next is to obtain permission from Taiwan Blood Services
Foundation. The specimen is retrieved only when the administration of archive storage
received both of the application form and the permission.
Till May 2011, total of 3,187,200 tubes of specimens were archived in the storage and
they occupied 23.65% of spaces.
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Conclusions: This is the primary great automatic biological specimen storage in Tai-
wan. The manufacturer we entrusted had no such experience in building this kind of
system. It happened that conveyor didn’t work or storage/retrieval machine had trouble
in orientation. The system was getting stable after 1 year of working. The automatic
storage system has high efficiency in space and manpower utilization. The cost of land
and human affairs were cut down. Automation lessens the time spent on storing and
retrieving specimens and the opportunities of working under very low temperature
environment. Even though the maintenance fee is as high as NT$ 3.5 million per year,
automatic storage is sufficient and valuable.
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DONOR DISCLOSURE – AN INDIAN EXPERIENCE
Dontula S, Mathur A, Kamaladoss T, Jagannathan SAL
Rotary Bangalore TTK Blood Bank, Bangalore, India
Background: Rotary Bangalore TTK Blood Bank, collects 25,000–30,000 blood units
per annum from voluntary donors. Each unit is screened for HBs Antigen, anti HIV and
anti HCV using the fourth generation ELISA, and for malarial parasite & syphilis.
In India, disclosure of viral transfusion transmitted infections (TTI) to blood donor was
not permitted until December 2004. Prior to 2004, government policy stated that blood
banks discard HIV-seropositive blood without informing donors about their status in
order to maintain donor confidentiality and avoid stigmatizing those with HIV/AIDS.
The National Blood Transfusion Council now advocates the disclosure of TTI results to
blood donors based on ELISA results. NAT and other confirmatory test are not
mandatory in India.
India does not have a centralized Blood Transfusion Service. Most Blood Banks in India
are either hospital based or operate as ‘Stand Alone Blood Banks’. There is absence of
well-defined notification processes and a lack of trained counselors. This could explain
the intricacies and difficulties in maintaining uniform donor disclosure practises in
India. Hence, there is a lacuna of information regarding counseling and referral follow-
up in India.
This study describes our pioneering experiences in donor disclosure and counselling
during the period 2007–2008 and challenges associated with them in a resource-
limited environment.
Aim: To assess the success rate of donor disclosure.
Methods: All our donors are voluntary; 40% of them are repeat donors. Blood units
are screened as per our testing algorithm. The units that test repeat reactive for viral TTI
are discarded and donor is informed of his/her reactive status. These donors are re-
quested to attend confidential counselling session(s) at our blood bank.
In the counselling session, donor is informed about their TTI test result and its
significance. Information about the virus, risk factors and methods of transmission are
explained. The counselor also tries to elicit information on the donor’s sexual risk
behaviour. The donor is advised on lifestyle changes and impact on immediate family.
In case of HBV reactivity, HBV vaccine is recommended for immediate family. Finally,
the donor is encouraged to get confirmatory tests and recommended to consult a
physician or gastroenterologist.
Results: The number of units collected and tested at our blood bank in 2007 and 2008
were 21,700 and 22,479 respectively. Viral TTI reactivity in 2007 was 0.78%, 0.12%,
and 0.18% for HBs Ag, anti HIV, and anti HCV. In 2008, it was 0.73%, 0.16%, and
0.18% for HBs Ag, anti HIV, and anti HCV.
Donors who attended counseling in 2007 were 41.18%, 11.11%, & 14.63% for HBs
Antigen, anti HIV and anti HCV. In 2008, 48.17%, 16.22% and 14.63% attended
counselling for HBs Antigen, anti HIV and anti HCV.
Conclusion: Our experiences were rewarding in that it directly benefited the donor and
their families. Hurdles faced thus far in this programme were related to logistics of
donor follow-up. We endeavour to achieve a 100% donor counseling rate. This will
drastically reduce the incidence of viral TTI in the community.
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TRANSFUSION TRANSMITTED INFECTIONS FOR THE PAST
2 YEARS (2009–2010) IN JAPAN
Momose S, Taira R, Goi K, Goto N, Uchida S, Hino S, Satake M, Tadokoro K
Japanese Red Cross Society, Tokyo, Japan
Background: There are approximately 5 million blood donations and approximately 1
million blood recipients every year in Japan. Japanese Red Cross Blood Service
Headquarters has been collecting information about suspected cases of transfusion
transmitted infections (TTIs) and adverse reactions from medical institutions via
medical representatives in regional blood centers since 1993. Analysis of the recipient’s
pre- and post-transfusion samples and repository samples of the implicated donation is
performed to evaluate causal relationship between the event and transfusion. Repos-
itory samples of all the donations are stored for 11 years for the purpose of look-back
study and analysis of the suspected TTI cases.
Methods and Results: The suspected TTI cases were evaluated using individual NAT of
repository samples from the implicated donors or using blood culture of implicated
components. If the repository sample was positive for the related virus, the viral
genome sequence was compared to that from the recipient’s sample. A total of 98
suspected cases of TTI were reported in 2009 and in 2010 respectively. A detailed
breakdown of the reported cases of TTI by pathogen was 41.3% of HBV, 27.0% of HCV,
26.0% of bacteria and others (CMV, HEV, HAV, human parvovirus B19, HIV, herpes
simplex virus). In these cases, 18 cases of HBV, two cases of HCV, one case of HAV and
HEV respectively were evaluated to have a highly causal relationship with transfusion.
Also, two cases of bacterial infections were highly likely associated with the con-
taminated blood components proven by blood culture. The number of implicated donor
in 18 cases of HBV was 16 persons, so it means these two cases were come from the
same donation or donor of another two cases. The two cases of HCV were caused by
one donation as well. Of 16 implicated donations supposed to have relation with HBV,
seven cases were donated in the window period, especially of which three cases were
donated in the window period of individual NAT. The remained nine donations
including two cases of individual NAT negative seem to have been associated with the
donors with low viral load in chronic phase of infection. A detailed breakdown of
implicated donations by genotype in the 16 HBV cases was three of genotype A, three
of genotype B, and 10 of genotype C. The HAV infected case was revealed by post-
donation information, and the HEV infected case was based on HEV positive result of
quality control of the source plasma separated from the same donated blood for the
manufacturing of plasma derivatives. Two bacterial infection cases were revealed to
have a relationship with platelet concentrates contaminated with Serratia marcescens
and Streptococcus agalactiae respectively although both recipients have been recov-
ered with appropriate treatment.
Conclusions: Transfusion transmitted infections have been gradually reduced as a
result of improvement of sensitivity on NAT or serological test. In order to improve
transfusion safety further, it is highly necessary to monitor the safety of transfusion
continuously by implementing haemovigilance system, carrying out reporting systems
of adverse reactions and infectious disease and look-back study appropriately.
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THE SURVEY OF 1 YEAR PERIOD OF IRRADIATED BLOOD
COMPONENT ACTIVITY IN TEHRAN BLOOD TRANSFUSION
CENTRE (TBTC)
Zadsar M, Sadegh H, Naseranipoor M, Hajibeigi B, Mirrezaee SM
IBTO Research Center, Tehran, Iran
Objectives and Background: Pre transfusion inactivation of donor T cell by irradiation
is the method of choice for prevention of TA-GVHD complication susceptible patients.
In the present study, Tehran blood transfusion irradiation department activities were
evaluated for a year since its establishment date.
Materials and Methods: The retrospective study was run by considering 1333 requests
for irradiated blood products for 1 year period. Data including quantity and type of
irradiated products, patients’ age, irradiation indications, blood group of irradiated
products and requesting hospitals were gathered. Descriptive statistical analysis per-
formed by SPSS 18 software.
Result: Requested irradiated products in the aforementioned period of time include;
platelets (71.3%), packed RBC (28%), FFP (0.4%), paediatric bags (0.2%) and whole
blood (0.1%). Age groups of patients received irradiated products were adults
(58.4%), children (26.5%), infants (6.7%) and neonates (3.4%). In 5% of cases the
age were missed. Quantity and proportion of blood group in irradiated products
comply with general population. Indications of prescription consist of leukaemia/
lymphoma and Hodgkin (49.6%), allogeneic and autologous bone marrow trans-
plantation (17.7%), immunosuppressive therapy (9.6%), congenital immunodefi-
ciency (8.6%), premature birth (7.6%), aplastic anaemia (6.5%), relatives designated
donation (0.3%) and HLA matched plateletphaeresis (0.1%). During the period of
this study increasing trend in the quantity of requests of irradiated products and
requesting hospitals were seen.
Conclusion: Considering the important prophylactic role of blood product irradiation
on TA-GVHD, it is recommended to inform more hospitals about irradiation activities
in TBTC and more education programmes for hospitals’ staff about the proper pre-
scription of irradiated products.
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PLATELET COUNT INCREMENT AFTER TRANSFUSION OF
SINGLE DONOR APHERESIS PLATELETS IN THE HASAN
SADIKIN HOSPITAL
Puspita P1, Oehadian A2, Aprijadi H2, Wijaya I2, Irani Fianza P2, Heri Fadjari T2,
Sumantri R2, Vrielink H3, Supandiman I2
1Indonesian Red Cross, Bandung, Indonesia 2Hasan Sadikin Hospital, Bandung,
Indonesia 3Sanquin Blood Bank, Amsterdam, The Netherlands
Backround and Aim: Patients in need for Platelets,can be transfused with platelet
blood components derived from 6 to 8 whole blood donation(PRPs) or single donor
platelets product derived by apheresis (AP). The choice for the component can be made
because of economics (lower costs PRPs), and/or availability of sufficient donors. The
aim of our ongoing study was to analyze the platelets count increment in patients after
transfusion of single donor apheresis derived platelets.
Method: Apheresis platelet component were derived from 27 voluntary donors. In the
patient hematology parameters (hemoglobin, white blood cells and platelets count) be-
fore and 1 h after the platelet were examened. Data before and after platelet transfusion
were compared using Student t-test. Sixteen patients received apheresis derived platelet
components between July 2009 and July 2010. In total 27 components were transfused.
Results: Sixteen patients (five males, 11 females) with various underlying disease were
in corporate in our study. The reason for plateletpheresis transfusion was therapeutic in
15 (93%) subjects and prophylatic in 1 (7%) subject. The mean platelets increment after
plateletpheresis transfusion in our patients was 48,111 + 5812/mm3. Nine transfusion
(33.3%) had a normal platelet increment (30,000–50,000/mm3). Seven transfusion
(22.3%) had below normal response (<30,000/mm3). In 11 transfusions (40.7%) the
platelet increment were above 50,000/mm3. Four (14.8%) transfusions had platelet
refractioness (platelet increment < 11,000/mm3).
Conclusion: Mean platelets increment after 27 plateletpheresis transfusions was
48,111+5812/mm3. Good response (platelet increment > 30,000/mm3) was found in
74% (20/27) transfusions. Platelet refractioness (increment < 11,000/mm3) was found
in 14.8% (4/27). Most of of transfusions (21/27, 77.8%) are without adverse reaction.
Based on this study we conclude that in our hands apheresis derived platelets can be
safety transfused to our patients.
7. Cellular Therapies
7.1 Stem Cell and Tissue
Banking, including Cord
Blood
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AN OPTIMIZATION STUDY ON THE SEPARATION AND
CRYOPRESERVATION OF CORD BLOOD MONONUCLEAR CELLS
Liu Z
Anhui Blood Center, Hefei, China
Background: Umbilical cord blood has been widely used as a source of hematopoietic
stem cells to treat a variety of diserse. The cell dose is critical and the available number
of total nucleated cells (TNCs) plays a key role.
Aims: To optimize the procedure for separation and cryopreservation of TNCs from
umbilical cord blood.
Methods: Cord blood units were collected and processed using either a double stem
cell extraction method or a traditional method. The recovery rate of TNCs and other
relevant factors affecting cryopreservation quality were analyzed.
Results: The average number of TNCs yielded by the double extraction method and the
traditional method were (1.52 ± 0.89) · 109 and (1.11 ± 1.20) · 109 respectively. The
recovery rate of TNCs using the double extraction method was 92.12 ± 5.78% and
using the traditional method it was (86.94 ± 7.34)% (P < 0.05). The viability of TNCs,
which were cooled at either lC/min or 5C/min in a controlled-rate freezer from 4 to
)40 was (92.4 ± 2.3)% and (84.7 ± 2.4)% (P < 0.05). The recovery rates of TNCs that
were cooled at l or 5C/min in a controlled rate freezer from )40 to )90C were
(91.1 ± 1.9)% and (90.3 ± 2.8)% (P > 0.05). The cells were cooled to either )90 or
)130C using a controlled-rate freezer, then moved to liquid nitrogen, and the
recovery rates of TNCs were (91.1 ± 2.1)% and (92.3 ± 1.9%)%, respectively (P > 0.05).
Conclusions: The double extraction technique provides a high and consistent recovery
of TNCs. The optimal method to cryopreserve cord bloodmononuclear cells is to cool the
cells at 1C/min to )40C and then at 5C/min to )90C using a controlled-rate freezer.
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DIFFERENTIATION OF RAT BONE MARROW MESENCHYMAL
STEM CELLS INTO HEPATOCYTES IN VITRO AND VIVO
Feng Z, Zhao L, Jiao S, Hu B
Qingdao Blood Center, Qingdao, China
Background: Bone marrow mesenchymal stem cells (BMSCs) are highly plastic and
differentiate into various cell types, including hepatocytes. To explore the mechanisms
underlying these processes in vitro and in vivo, we focused on the initial responses of
bone marrow to hepatic injury, using a rat model.
Aims: To investigate the mechanism and regulation of differentiation from (BMSCs)
into hepatocytes and to find a new source for therapies of hepatic diseases.
Methods: We isolated BMSCs form whole bone marrow cells for subsequent differ-
entiation in the presence of HGF or beta-NGF. Cells were subjected to the examination
of hepatocyte characteristics by morphological and functional changes. Cell mor-
phology was observed and cell surface phenotypings were detected by flow cytometry.
a1-antitrypsin (AAT) expression of the hepatocyte was confirmed by immunocyto-
chemistry, and the expression of albumin was validated by real time PCR and western
blotting. The expression of high-affinity nerve growth factor receptor (TrkA) and the
activation of Erk pathway were detected by western blotting. Hepatocyte functional
activity was confirmed by uptake of indocyanine green (ICG) assay. Cultured BMSCs
were labeled with 5-bromo-2-deoxyuridine (BrdU) 24 h before injecting 2 · 106 cells
into the caudal vein of a rat model of prolonged toxic hepatic injury. Liver damage was
induced by injection of carbon tetrachloride (CCl4) labeled engraft were researched by
immunohistochemistry after transplantation 0, 1, 2, 3, 4, 5, 6 weeks. ALT, AST, AKP
were detected by ELISA.
Results: Some small round cells appeared in the presence of HGF on day 10 (beta-NGF
on day 12) and the cells increased in the course of differentiation for 21 days. Dif-
ferentiated cells expressed albumin and had the functional characteristic of liver cells,
such as uptake of ICG. BMSCs were positive for TrkA. HGF and beta-NGF significantly
upregulated the protein levels of phospho-Erk. After 1 week of transplantation labeled
engraft were detected in liver of rat model and positive labeled engraft were detected
untill 4 weeks after transplantation. ALT, AST, AKP were different with the negtive
control groups before 4 weeks after transplantation.
Conclusion: BMSCs could differentiate into hepatocytes in the differentiation media
including HGF or beta-NGF. Combination of HGF and beta-NGF significantly increased
the efficiency of hepatic differentiation. These hepatocytes were identified at the
morphology, gene and protein levels. BMSCs may be differentiated into hepatocytes by
HGF and beta-NGF. In vivo BMSCs had a notablely protective effects on the hepatocyte
injured with CCl4. It makes a potential resource for the treatment of hepatic diseases.
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GENERATION OF INDUCED PLURIPOTENT STEM (IPS) CELLS
WITH ADENOVECTORS CARRYING EMBRYONICALLY
EXPRESSED HUMAN GENES
Pourfathollah AA, Khamisipour GHR, Soleimani M
Tarbiat Modares University, Tehran, Iran
In recent years Scientists have reprogrammed the somatic cells to embryonic like cells
named Induced Pluripotent Stem (iPS) cells. Regarding to genomic insertion of lenti- or
retro-viral based vectors and subsequent adverse effects of these viruses, the current
research focused on using safer gene transfer tools. Adenoviruses are the safe tools for
gene delivery and expression in eukaryotic cells. In this study we construct
adenovectors carrying embryonically active human genes and generate these
recombinant adenoviruses aiming to produce safer transfer vectors as a nonintegrating
viruses for reprogramming. cDNAs of embryonically active human cMyc, Klf4, Oct4,
and Sox2 were amplified and then cloned individually into CMV-IRES-GFP transfer
vector. Pme1 linearized transfer vector was co-transformed with pAdenoVator E1/E3
vector into rec+ BJ5183 cells to generate recombinant adenovectors. Production of
adenoviruses was carried out by transfection of Pac1 linearized adenovectors into
293A packaging cell line. Cloning of desired genes was confirmed by PCR with specific
primers for each genes, and sequencing after co-transfection of recombinant transfer
vector and backbone adevirus plasmid, generation of recombinant adenovectors were
confirmed by duplex PCR with specific primers for kanamycin resistance gene and
adenovector plasmid. Transfection efficiency was determined by observation of GFP
expression under fluorescence microscopy. As have suggested in several studies,
adenovectors do not show insertional mutagenesis and they can produce high titer of
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virus in host cells and broad types of target cells as well as dividing and non-dividing
cells. Regarding to some limitations in using the retro- and lenti-viruses, we believe
that adenovectors carrying human genes are the best and safe choice for gene delivery
and reprogramming of somatic cells and generation of human pluripotent stem cells.
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DETECTION OF ADDITIONAL INFECTIOUS UNITS AMONG
SERONEGATIVE CORD BLOODS BY NUCLEIC ACID
AMPLIFICATION TEST
Hsu H1, Lin Y2, Chen JW1, Lin SJ1, Lin KS1
1Head Office Taiwan Blood Services Foundation, Taipei, Taiwan 2Taipei Blood Center,
Taiwan Blood Services Foundation, Taipei, Taiwan
Background: Cord blood contains a sufficient number of hematopoietic progenitor
cells allowing bone marrow restoration. To prevent the risk of viral infection from
allogeneic donors, the cord bloods and/or their maternal bloods are tested for blood
transmissible infection including HBV, HCV and HIV. Nucleic acid amplification test
(NAT) has been implemented for blood donors either on mini-pooled or individual
samples for detection of donors during window periods of serologic assays and those
with chronic occult HBV infection (OBI), i.e. the donors containing a low level of viral
DNA without detectable hepatitis B surface antigen in serum during later chronic stage.
Aims: The aim of the study is to detect infectious cord blood among those determined
as non-infectious by serologic assays.
Methods: A number of 2156 units of cord blood, that were determined as non-
infectious through detecting both cord bloods and maternal bloods for hepatitis B
surface antigen and antibodies to HCV and HIV, are stored as the buffy-coat portion
in liquid nitrogen and their plasma samples at )30C. To carry out the study,
individual plasma samples of these cord bloods were tested by Procleix Ultrio Assay
(Novartis Diagnostics), the screening NAT that detect HIV-1, HCV and HBV
simultaneously. Samples that were positive by screening NAT were further tested by
Procleix Discriminatory Assays, the assay that detect these viruses each individu-
ally.
Results: Of the cord bloods analyzed, 6 units were found positive by screening NAT.
Further discriminatory assays showed all the 6 units were negative for HBV, HCV and
HIV-1. In view of the possibility that a low level of HBV DNA approximates the
detection limit of NAT, we retested in triplicate the six samples for HBV DNA. All were
found negative by retest.
Summary/Conclusions: Of the seronegative cord bloods, 0.3% (6/2,156) were deter-
mined as positive by screening NAT, however further tests were unable to identify the
virus leading to the positive finding. Since that discriminatory assay is less sensitive
than screening assay in detecting HBV at the lower levels of 30 and 100 copies/ml (as
shown in assay manual), the reason for the non-discriminated results in this study
could be the presence of HBV at a lower concentration approximating these levels. In
view of immunosuppressive procedure to cord blood recipients, NAT should be
implemented as a supplementary to serologic assays for detection of infectious cord
blood.
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STORAGE CONDITIONS FOR TRANSPORTING UMBILICAL CORD
BLOOD TO CORD BLOOD CENTER
Garavand F1, Noormohamadi E2, Bakhshayesh F2
1Research Center, Tehran, Iran 2Tehran Medical University, Tehran, Iran
Background: Conventionally, human hematopoietic stem cells (HSCs) have been
purified on the basis of the expression of cell surface molecules such as CD34 and
CD133. Recent data has shown that ALDH is highly expressed in primitive HSCs and its
specific role in stem cell function. To assess the activity of ALDH in isolated HSCs from
cord blood we study the expression level of this enzyme in various time during cord
blood HSCs storing.
Methods: We compared the numbers of HSCs enumerated in samples processed
immediately after acquisition (n = 20) with HSCs enumerated in specimens stored for
24, 48 and 72 h in 25C, 4C and after cryopreservation of CD133+/34+ HSCs isolated
from cord blood with aldehyde dehydrogenase activity (ALDH br cells).
Results: ALDH activity was decreased during time in stored HSCs. We found signifi-
cant difference in enzyme activity between HSCs stored at RT in compare with HSCs
stored at 4C. ALDH activity did not decrease in HSCs frozen in )20.
Conclusion: We suggest to transport and store cord blood HSCs under controlled
cooling conditions.
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DECOMPRESSION OF LUMBA-SACRAL NERVE ROOT AND
STEM CELL TRANSPLANTATION FOR SPINAL CORD INJURY A
CASE REPORT
Ramanayake RDH
National Blood Center, Colombo, Sri Lanka
Background: Autologous Stem Cells from bone marrow have been shown to display
some potential for tissue reconstruction in various neurodegenerative and muscle
degenerative diseases. These cells are easily accessible frompatients and can be expanded
on a therapeutic scale. Although themechanisms are not yet fully understood, some small
open clinical trials with chronic Spinal Cord Injury (SCI) patients have demonstrated a
positive effect of Autologous Stem Cells on their use and proved to be safe.
The combination of effective mobilization protocols (Granulocyte -Colony Stimulation
Factor) and efficient use of apheresis methods have caused successful collection of
peripheral blood progenitor cells (PBPC) for transplantation. Flow cytometric
technology also can be used to assess target goal of CD34+ cell dose during harvesting
of progenitor cells. The researchers think that following the surgery, a patient is grafted
subarachnoidally, the grafted cells release a variety of axonal growth-stimulating,
neurotrophic factors, and also participate immediately in restoring affected nervous
communications.
Case Report: A 32-year-old young male who had a history of paraplegia with severe
back pain following a gun shot injury between lumbar -2 and lumbar 3 levels 2. Mean
time he had undergone two surgeries (Laminectomy with spinal fixation and removal
calcified adhesions) for on and off severe pain. As he still did not respond, he was asked
to admit for decompression and autologous stem cell transplantation by consultant
neurosurgeon at National Hospital Sri Lanka. After referring to the Departments of
Heamatology and Transfusion Medicine, he started 1 units of G-CSF(Granulocyte -
Colony Stimulation Factor) daily for 4 days and target granulocyte counts were
monitored by doing daily full blood counts and on the fifth day he underwent leuk-
opheresis for collection of Stem cells. CD34+ count in the final product was assessed by
Flow cytometry and then underwent decompression and infiltration of collected
autologous stem cells into the affected site of the spinal cord. Results:
Since third day after operation, he complained that he felt sensation and less pain and
15 days after surgery he was referred to the rehabilitation unit as he complained low
grade pain with more sensation compared with initial records.
Discussion: As this is the first case of autologous stem cell transplant for spinal cord
damage in Sri Lanka, we don’t have records to compare patient’s outcome and long
term follow up of this patient. The success rate cannot be compared with other patients
in Sri Lanka as this was the first patient however when it is compared with interna-
tional studies, it belongs to the good success. It is now known that bone marrow cells
release a variety of factors that stimulate neuronal growth from progenitor cells.
Additionally, bone marrow has been demonstrated to have the ability to directly dif-
ferentiate into neurons. Thus, the stem cell-based technology opens new feasible
opportunities for effective treatment of Spinal Cord injured patients.
7.2 Collection, Processing,
Storage and Release
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QUESTIONNAIRE SURVEY ON IN-HOUSE COLLECTION,
PROCESSING AND STORAGE OF BLOOD CELLS FOR
CELLULAR THERAPY IN JAPAN
Ikeda K1, Fujii K2, Nishimori H2, Fujii N2, Tanaka A3, Sagawa K4, Ohto H5, Takahashi K6
1Japanese Red Cross Okayama Blood Center, Okayama, Japan 2Okayama University
Hospital, Okayama, Japan 3Tokyo Medical University Hachioji Medical Center,
Hachioji, Japan 4Fukuoka Blood Center, Chikushino, Japan 5Fukushima Medical
University, Fukushima, Japan 6University of Tokyo Hospital, Tokyo, Japan
Background: More than 4000 allogeneic and autologous hematopoietic stem cell
transplantations are annually carried out in Japan. The Japan Marrow Donor Program
had confined volunteers to marrow donation since its establishment in 1991 but added
peripheral blood as an option in October 2010. Also in 2010, the Japanese Society of
Transfusion Medicine and Cell Therapy implemented Qualified Apheresis Nurse system,
and disclosed a guideline for ‘In-Hospital Blood Cell Processing’ jointly with the Japan
Society for Hematopoietic Cell Transplantation.
Aims: In order to figure out the situation and define the problems in in-house col-
lection, processing and storage of blood cells in medical facilities in Japan.
Methods: ’The Japanese Society of Transfusion Medicine and Cell Therapy annually
conducts Comprehensive Questionnaire Survey on Transfusion Medicine which
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consists of general and supplementary questions. The former questions cover
management system, laboratory tests and use of blood products, to which all hos-
pitals are expected to reply, and the latter questions include those to which only
applicable hospitals are expected to reply that include questions concerning cellular
therapy.
Results: The society requested 11,449 hospitals for replying the questionnaire and
4352 provided their information. Autologous blood stem cells, related blood stem cells,
unrelated blood stem cells, autologous bone marrow, related bone marrow, unrelated
bone marrow, and unrelated cord blood were harvested at 138, 76, 3, 9, 39, 33 and four
hospitals, respectively. Autologous blood stem cells from 1395 patients were processed,
frozen and stored at 114, 122 and 125 hospitals. As to autologous peripheral blood
cells, 56 hospitals conducted harvests at transfusion departments, 99 had standard
operating procedures, 82 recorded working processes, 96 labeled containers for defined
items, 82 identified and verified cell products according to procedures designed for
blood products, 82 carried out flow-cytometric analyses at their own facilities and 93
used dedicated clean benches for open-system processing. Pre-storage and post-stor-
age sterility tests were conducted at only 9 and 0 facilities, respectively. In aphereses,
venipuncture was performed by patient-caring physicians in 111 hospitals, and cell-
separators were operated by medical technologists or engineers in 40 or 65 hospitals,
respectively. Processing, storage management and issuance of the cells were assumed
by patient-caring physicians or medical technologists in 45 or 63, 17 or 93, and 26 or
89 hospitals.
Summary/Conclusions: This survey for 2010 revealed that process and quality control
in cell processing in hospitals require major improvement, that patient-caring
physicians still played significant roles, but at the same time, medical technologists and
engineers were taking over the physicians roles. We plan to continue this survey to
monitor the changes induced by the guideline, the Qualified Apheresis Nurse system
and introduction of unrelated peripheral blood stem cell handling.
P-334
CRYOPRESERVATION OF PERIPHERAL BLOOD HEMATOPOI-
ETIC STEM CELLS WITH LOWER DOSE OF DMSO BY ADDING
NONTOXIC NATURAL CRYOPROTECTANTS
Suh J1, Hamm JY2, Sohn YH3
1Kyungpook National University Medical Center, Daegu, South Korea 2Kyungpook
National University Hospital, Daegu, South Korea 3Joint Institute for Regenerative
Medicine, Daegu, South Korea
Background: Cryopreservation of hematopoietic stem cells has become an important
process due to the therapeutic protocol which includes peripheral blood stem cell
transplantation after chemotherapy in many hematological malignancies. The con-
ventional medium contains 10% dimethylsulfoxide (DMSO) as cryoprotectant, but it is
reported to be related with many complications.
Aims: The usefulness of trehalose, catalase and zVAD-fmk for cryopreservation were
analyzed with reduced concentration of DMSO to 5%.
Method: Peripheral blood stem cells were frozen in 10% DMSO as control and also in
5% DMSO with trehalose and catalase. After 3 weeks, the viability of each DMSO
concentration was measured using Trypan blue staining and 7-AAD analysis. The
colony forming potential was assessed using methylcellulose culture 14 days after
thawing.
Result: Cryopreserved cells in 5% DMSO with trehalose and catalase showed similar
survival with control. The viability of cells which were added with zVAD-fmk showed
better result than without it after 24 h incubation. Colony forming assay showed
similar colony formation in 5% DMSO with natural cyroprotectants.
Conclusion: Achieving better cell viability and reducing complications of high dose
DMSO cryopreserved cells are important factors in successful stem cell transplantation.
According to the results, lowering DMSO concentration to 5% in combination with
nontoxic natural cryoprotectants and using zVAD-fmk is considerable to help cell
survival. Thus we can expect better survival of hematopoietic stem cells and prevent
many potential side effects of high dose DMSO when adding natural cryprotectants in
the cryopreservation medium or adding caspase-inhibitor right after thawing.
P-335
THE SURVEY OF PLATELET PHERESIS YIELD AND FACTORS
AFFECTING IT AMONG PLATELET DONORS IN SHIRAZ BLOOD
TRANSFUSION SERVICE IN 2009–2010
Salah A1, Jalali Far MA2, Shirmohammadi Asafeh M1
1Blood Transfusion Research Center, Shiraz, Iran 2Thalasemia and Hemoglobinopathy
Research Center, Ahwaz, Iran
Millions of lives are saved each year through blood transfusions. With the
improvement of medical science and increase the life potency, the demand of blood
products increased. Due to the indication of platelet, the platelet products play vital
role in patient’s health. The single donor platelet is more effective and safer than
random platelet products. Determination of platelet apheresis yields and the factors
that affecting them help us to plan for more effective products. In this retrospective
cross sectional survey, we studied 92 platelet donors referred to Shiraz blood
transfusion service during 2009–2010 by random sampling. For all platelet donors
after physical examination and performing HIV-Ag/Ab, HBs-Ag, HCV-Ab and RPR,
we done Complete Blood count(CBC). The minimal acceptable of platelet count was
150*103. The apheresis was done by HAEMONETICS MCS+. The background
variables and other data was recorded in their special form. The data was analyzed
by using SPSS 16 (Chi-square, Independent t-test, One way ANOVA). We found that
the mean platelet apheresis yields were 4.58 in female donors and 4.17 in male. We
found significant difference between the yield (platelet counts of platelet apheresis
unites) and the pre platelet apherisis platelet counts and blood donors hematocrite (P-
value = 0 and 0.018 respectively). The difference was not significant about the
weight, sex, age blood group and hemoglobin (P-value > 0.05). According to our
findings the yield of single donor platelet apheresis is equal 8 units of random
platelet. That yield is more than some studies that mention yield equal six times of
random donor platelet. Female platelet donors and high platelet count is good donors
for apheresis. Other studies showed that just precount platelet affect the yield, but in
our study HCT affecting the yield. Because these products decrease the donor
exposure and due to high quality of these products it’s recommended for all patients
require it.
P-336
VARIOUS ALDEHYDE DEHYDROGENASE ACTIVITY IN HSCS
ISOLATED FROM UMBILICAL CORD BLOOD BEFORE & AFTER
FREEZING
Mhammadi Garavand MH1, Aghaiipoor M2, Amirizadeh N2, Hajati S2, Amani M2,
Nikougoftar M2, Bashtar M3, Rezazadeh D4
1IBTO, Tehran, Iran 2IBTO-Research Center, Tehran, Iran 3BMT Shariiati Hospital,
Tehran, Iran 4Tehran Medical University, Tehran, Iran
Introductions: Aldehyde dehydrogenase (ALDH) is highly enriched in hematopoietic
stem cells (HSCs) and is considered a selectable marker of human HSCs, although its
contribution to stem cell fate remains unknown. ALDHbr Lin population contained
committed progenitors as well as primitive repopulating cells. Recent data suggest that
the practice of using frozen allogeneic grafts is becoming increasingly common among
transplant centers. In this study, we assessed the disadvantage of HSCs freezing on
ALDH activity for evaluation freezing effect in Blood Bank.
Methods: We compared the numbers of HSCs enumerated in samples processed
immediately after acquisition (n = 10) and HSCs enumerated in specimens cultured for
7 days on MSCs feeder and cytokine cocktails. Cell harvested from these conditions
and stored in cryopreservation. After that using three identification strategies: cell
surface marker expression (CD34+/CD38)), aldehyde dehydrogenase activity (ALDH br
cells) and colony assay.
Results: HSCs assessed in these four situations correlated with HSCs enumerated be-
fore and after CD34+/CD38) cryopreservation in both expansion on MSCs and without
expansion condition. The percentage of ALDH br cells 26.8 ± 3.2 in the CD34+/CD38)
cells before freezing compared to 23.9 ± 3.0 after thawing. However after expansion
these cells on MSCs feeder the rate of ALDH br cells was decreased to 6.8 ± 1.5 for non
-storage cells and 5.3 ± 1.2 for storage cells.
Conclusion: We revealed no significant difference between level of ALDH before and
after freezing in CD34+/38) HSCs isolated from cord blood but in vitro expansion of
HSCs result in decreasing ADLH activity. Since freeze immediately after harvested
cord blood lead to remain of ALDH express level highly recommended. In feature
study to expansion of HSCs we should make a condition to prevent diminishing ALDH
activity.
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ANALYSIS OF ANTI-L- NGFR, CD133 AND CD34 EXPRESSIONS
IN BONE MARROW MONONUCLEAR CELLS BY FLOW CYTOM-
ETRY WITH THREE COLOR FLUORESCENCE LABELLING
Zhao DW1, Zhou J2, Lu FQ1
1Affiliated Zhongshan Hospital of Dalian University, Dalian, China 2The General
Hospital of Beijjing Military Area, Beijing, China
Background and Objective: Stem cells hold great promise in tissue engineering for
repairing tissues damaged by disease or wound. Mesenchymal stem cells (MSCs) are
multipotent cells able to proliferate and differentiate into multiple mesodermal tissues
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such as bone, cartilage, muscle, tendon, and fat. These MSCs can be derived from
human bone marrow (BM) and identified by their ability to form fibroblast-like colony
forming units that develop into stromal like cells when expanded in culture. These cells
are characterized by their spindle-shaped morphology, their characteristic Immuno-
phenotype [CD73(+), CD105(+), CD45()), and CD34())]. However, the identification
and purification of MSCs is hampered by the lack of suitable monoclonal antibodies
(mAb). This study was purposed to detect the expressions of low-affinity nerve growth
factor receptor (L-NGFR or CD271), CD133 and CD34, and to analyze the correlation of
CD271 with CD133, and CD133 with CD34 expressions. To define the population more
precisely, diverse surface markers have been used. We propose here to use CD271 as the
sole marker for MSCs in bone marrow.
Materials and Methods: The human bone marrow cells (BMCs) and mononucleated
cells (MNCs) were detected by flow cytomotry with CD45-PerCP, CD271-FITC, CD133-
PE and CD34-FITC labelling according to different combinations of design, cells were
located and selected repeatly by FSC, SSC and CD45 after acquirement, then the
expressions of CD271, CD133 and CD34 were detected by flow cytometry.
Results: The results showed that the expressions of CD271, CD133 and CD34 in BMCs
were 0.159%, 0.19% and 0.41% respectively, while their expressions were 0.69%,
0.44% and 1.05% respectively after isolation of MNCs. The co-expressions of CD271(+)
CD133(+) before and after isolation of MNCs were (0.021 ± 0.01)% and
(0.036 ± 0.02)% respectively. The co-expression of CD133(+) and CD34(+) before and
after isolation of MNCs were (0.19 ± 0.11)% and (0.41 ± 0.21)% respectively
(P < 0.01); mean while about 90% of cells with CD133(+) expressed CD34 and 40% of
cells with CD34(+)expressed CD133.
Conclusions: It is concluded that the established method of detection using flow
cytemetry with three color fluorescence labelling can be used to detect expression of
CD271, CD133 and CD34 in BMCs. The cells with CD271 are different from cells with
CD133 and CD34, which suggests that the CD271 may be of important role in evalu-
ating and guiding the clinical application of BM MSCs. CD271(+) MSCs may be con-
sidered alternative candidates for tissue engineering and regenerative medicine
applications.
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STUDY OF THE BONE MARROW MONONUCLEAR CELL
APHERESIS PROCEDURE AND CLINICAL APPLICATIONS
Zhao DW1, Lu FQ1, Zhou J2
1Affiliated Zhongshan Hospital of Dalian University, Dalian, China 2The General
Hospital of Beijjing Military Area, Beijing, China
Background and Objective: To study the apheresis procedure of co llecting
mononuclear cells from bone marrow for clinical treatment.
Materials and Methods: Bone marrow mononuclear cells were separated from bone
marrow using COBE Spectra apheresis system. Cell morphology, cell counts, positive
expression of CD34(+), CD133(+), and CD271(+) were detected, and the recovery rate of
nucleated cell and mononuclear cell were also calculated. And the main parameters of
the procedure with upper efficiency were set via data analysis.
Results: The efficiency of collection line with colouri-metric card of 3% was higher
than that of 5% and of 7%. The recovery rate of mononuclear cell is 75% when the
cycle times ranged from 7 to 9. The positive expression of CD34(+), CD133(+), and
CD271(+) were 1.27%, 0.49%, and 0.57%, respectively.
Conclusion: This mononuclear apheresis procedure is safety, pollution free and
efficient. The remaining part of the bone marrow could be retransfused to the
donor.
7.3 Clinical Applications
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IMMUNOSUPPRESSIVE EFFECT OF TORISEL ON HUMAN DEN-
DRITIC CELL FUNCTION: KEEP AN EYE ON DENDRITIC CELLS
WHEN TREAT CARCINOMA
Gao L1, Wang SR2
1Shanghai Blood Center, Shanghai, China 2City of Hope, Transfusion Medicine Center,
Duarte, CA, United States of America
Background: Dendritic cells (DC) are ‘professional’ antigen presenting cells (APC) of
interest both as therapeutic targets and potential cellular vaccines due to their ability to
regulate innate and adaptive immunity. However, the functional properties of human
DCs differ, depending on microenvironmental factors as well as on their stage of
maturation, especially in the patients who are treated with various drugs. Torisel is a
novel mTOR inhibitor intravenous drug for the treatment of renal cell carcinoma (RCC)
and approved by the US Food and Drug Administration (FDA) in late May 2007 and
European Medicines Agency in November 2007. Although Torisel was reported would
affect immune system and might bring patients a risk of getting an infection, it is still
rarely known that which groups in immune system are targeted by it.
Aims: On these bases, we use human DC explored the hypothesis that Torisel bing
down the immune response to infection through suppress DC, the key APC in immune
system and subsequently inhibit downstream lymphocytes.
Methods: In our work, the human monocyte-derived DC (moDC), isolated and derived
from buffy coat, were pretreated with Torisel for 1 day, with or without LPS. Lethal
concentration 50 (LC50) was analyzed through Annexin V and PI staining assay. The
treated cells were then analyzed surface mature marker CD83 and costimulatory
molecule CD80, CD86 expression by flow cytometry. Endocytic activity was analysed
through Dextron staining with FITC. T cell proliferation stimulating activity of DC was
analyzed by Cell Trace assay. The supernatants of DC culture medium were analyzed
cytokines secretion ability through cytokine array.
Results: In mixed cell culture with non-touched autologous T cells, torisel-treated DC
showed almost loss the propensity to stimulate T cell proliferation even though pre-
treated with an extra-low concentration. Later, we observed that CD83, CD80 and CD86
expression in LPS-stimulated mature DC were down-regulated by Torisel in a dose-
dependent manner. Nevertheless, Torisel also reduced Endocytic activity of immature
DC in a dose-dependent manner. Interestingly, 15 in 22 cytokines analyzed in our
study were reduced by torisel and 1 was increased both in a dose-dependent manner
when LPS present, but less was changed when LPS absent.
Summary: Accordingly, Torisel will systematically reduce the function of dendritic
cells and shows collaborate its suppress effect with the toll-like receptor pathway. Our
results give some information on the mechanisms of Torisel immune suppression and
suggest that the patients treated with Torisol should be concerned whether need supply
associated cell therapy in case.
P-340
IN VITRO EFFECT OF DIFFERENT CRYSTALLOID FLUIDS ON
ERYTHROCYTE DEFORMABILITY AND AGGREGATION
Zhou H
Institute of Transfusion Medicine, Academy of Military Medical Sciences, Beijing,
China
Background: Fluid therapy is associated with altered blood rheology. Aims This study
aimed at investigating the in vitro effect of different crystalloids including normal
saline (NS), lactated Ringer’s solution (LR) and acetated Ringer’s solution (also called
plasmalyte A, AR) on RBC deformability and aggregation.
Methods: Whole blood was obtained from the jugular veins of the rabbits. The samples
were centrifuged and the hematocrit was adjusted to 40%. The samples were diluted
with NS, LR and AR at the volume ratio of blood to crystalloid of 1:2, 1:1 and 2:1,
respectively. The blood without dilution was set as control. All samples were incubated
for 1 h at 37C. The hematocrit of all samples was again adjusted to 40% before the
measurements of erythrocyte deformability and aggregation.
Results: Erythrocyte elongation index (EI) and aggregation index (AI) in all groups were
not significantly different. When the volume ratio of blood to crystalloids was 1:2, Top
time increased significantly in the NS group compared with the LR and control groups.
The Amplitude of RBC aggregation was significantly lower in the NS, LR, AR groups
compared with control group.When the volume ratio was 1:1, Top time in all groups was
not significantly different. The Amplitude of RBC aggregation was significantly lower in
the NS and AR groups compared with the control group. When the volume ratio was 2:1,
Top time in all groups was not significantly different. The Amplitude of RBC aggregation
was significantly lower in the NS group compared with the control group.
Conclusions: Crystalloids have no effect on RBC deformability, but will affect RBC
aggregation by changing Top time and Amplitude. It is inferred that NS has the
strongest ability of decreasing RBC aggregation, followed by AR and then LR.
8. Clinical Immunogenetics
8.1 HLA in Transfusion
Medicine
P-341
GENETIC POLYMORPHISM OF THE TAROKO TRIBE, AUSTRO-
NESIAN SPEAKERS ON THE NORTHEAST COAST OF TAIWAN
Chen ZS, Trejaut JA, Chu C, Lee H, Yen JC, Loo JH, Lin M
Mackay Memorial Hospital, Dansui, Taipei, Taiwan
Background: The Taroko people, recently officially recognized as a tribe on the basis
of culture and language, live on the northeast coast of Taiwan. They are Austronesian
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speakers, and their language belongs to a distinct branch of Atayalic which is spoken in
the northern central mountain ranges by the Atayal tribe.
To this day, few genetic studies about the Aborigines of Formosa provide a clear
understanding of the origin of each tribe. Also, the relationship between the tribes and
to other neighboring populations still remains unclear.
Aims: Previous studies on the Taroko have been restricted to their language, cultural
and social activities. Here we explored a new viewpoint using genetic profiles obtained
from uni- and bi-parental descent.
Methods: The genetic affinity between the Taroko tribe and other Taiwan aboriginal
and non aboriginal groups (15 groups in all) was analyzed using mitochondrial DNA
(mtDNA), non recombining Y chromosome DNA (NRY) sequencing techniques, and
human leukocyte antigens (HLA) reverse SSO techniques.
Results: Hundred and fifty-eight mtDNA haplogroups were determined in our pooled
dataset. Six mtDNA haplogroups were seen in the Taroko (F4b, M7b3a, M7b3a1, B4a2a,
E1a and N9a10new). These six haplogroups were also seen in the Atayal, who, in
addition to language, also share with the Taroko, culture and legends. On the other
hand the Atayal tribe displayed a much greater number of haplogroups (n = 16). This
clearly indicates that the two tribes share a closed kinship and that the Taroko may be
either a subset of the Atayal tribe or a different twig of the same branch.
Our Y- chromosomal DNA analysis on 765 individuals showed 27 Y-SNP haplogroups
in the 14 populations studied. Interestingly all haplogroup except one Y haplogroup in
Toroko were O1a1* (the other one was O3a3*). Both haplogroups were also seen in the
Atayal tribe who similarly to mtDNA had more Y diversity (four different haplogroups).
Allele frequencies at the HLA-A, -B, -DR loci among 18 Taiwan groups were used to
construct a phylogenetic tree. Interestingly, we saw that the Taroko, Atayal, Bunun and
Saisiat tribes belong to a unique cluster (the northern cluster) where, again, Taroko and
Atayal showed the closest genetic relationship.
Summary: The Phylogenetic analysis showed that Taiwan groups belong to three
main separate groups: the non Aboriginal group or Han Taiwanese, the north
Aboriginal mountain tribes and the south aboriginal mountain tribes. In the northern
group, Taroko and Atayal tribes show the closest kinship (followed by Bunun, Thao,
Tsou and Saisiat).
The genetic affinity between Taroko and Atayal was the closest ever found between
any two groups in Taiwan. These results support linguistic and anthropological
findings and the Taroko appeared to be a subset of the Atayal tribes.
P-342
STRUCTURE OF Y-CHROMOSOME O1 HAPLOGROUP IN
TAIWAN AND ISLAND SOUTH EAST ASIA
Yen JC, Trejaut JA, Lin M
Mackay Memorial Hospital, New Taipei City, Taiwan
Background: Human non recombining Y chromosome (NRY) is transmitted from fa-
ther to son without recombination and the mutation rate of its Y-SNP is low. Analysis
of NRY provides useful information for population genetics and human evolution
studies. Here, we used Y-SNP (low mutation rate) and Y-STR (high mutation rate) to
investigate the paternal genetic variation between populations of Taiwan (aboriginal
and non-aboriginal), Southeast Asia (SEA) and Island South East Asia (ISEA).
Aims: As haplogroup O1 is the most commonly found in Taiwan aborigines, we
investigated the distribution, genetic structure and variation of O1 among Taiwan and
neighboring populations.
Methods: Blood or saliva samples were taken from 1593 unrelated healthy male’s
individuals from 22 populations comprised of 11 Taiwan aboriginal tribes, four Taiwan
western plain tribes, other non Taiwan aboriginal groups (Minnan and Hakka) and
neighboring groups from the Philippines, Indonesia, Thailand and Vietnam. According
to the Y chromosome evolutionary tree published in 2008 (Karafet et al.), Y-SNPs were
typed hierarchically by direct sequencing and Y-STR were defined using the AmpFlSTR
(Yfiler kit) with the ABI 310 genetic analyzer. Allele scoring was obtained using the
Genotyper software. Published data (Karafet et al. 2005, Delfin et al. 2010) were also
used for comparative analysis.
Results: While most haplogroup found in Han belonged to haplogroup O3, over 80%
of Taiwan aborigines belonged to O1. The frequency of this haplogroup decreased in
the Philippines (42%), Indonesia (26%) and SEA (5%). More refined typing of the O1
haplogroup showed that sub-haplogroup O1a1* was the major Y-lineage in these
populations (~70%). Interestingly, the highest diversity of O1a1* was found in south
Taiwan and the Philippines. This may indicate southward gene flow between the re-
gions. On the contrary, the Y-STR network of haplogroup O1 (not including O1a2)
showed two major clusters: one star shaped cluster was centered on south Taiwan and
Philippines populations with branches generally unique to Taiwan aborigines, plain
tribes or the Philippines. The other cluster was multifocal with unshared foci composed
of North Taiwan aborigines and shared foci composed of southern Taiwan aborigines,
ISEA and Taiwanese Han.
On the other hand, haplogroup O1a2 showed high diversity and frequency among
Taiwan aborigines. It decreased in ISEA (~5%), and was scarce in Han populations. STR
network analysis showed that all populations shared four major haplotypes, except
Bunun who were isolated from all others. This most likely indicated long isolation and
gene flow restricted to Taiwan aboriginal tribes. Actually, AMOVA analysis also
showed no distinct difference among aboriginal populations, strongly indicating a
common ancestry.
Summary: O1 is one of the most prevalent haplogroups in South East Asia and ISEA.
Extensive diversity was found in Taiwan and the Philippines. Here, using 7-STR net-
work in combination with literature data, we could show that the South Taiwan genetic
make- up plays a key role in the structure of other Taiwan regions and that gene flow
between regions (from Taiwan to Philippines or from mainland to ISEA) requires more
extended study to clear determine a major center of distribution.
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HLA CROSSMATCHING BY IMMUNOCOMPLEX CAPTURE
FLUORESCENCE ANALYSIS
Miyagi T, Tonami K, Ichihara T, Umezu A, Uchida M, Teraki Y, Kashiwase K, Uchikawa
M, Nakajima K
Japanese Red Cross Tokyo Blood Center, Tokyo, Japan
Background: Alloimmunization to donor class I HLA antigens is a major obstacle to
successful platelet transfusion therapy. Therefore, we perform both HLA antibody
detection and HLA crossmatching for platelet transfusion refractory (PTR) patients
before HLA compatible platelet product shipment. Anti-human globulin lymphocy-
totoxicity test (AHG-LCT) is commonly used for HLA crossmatching in Japan, but it has
drawbacks such as lower sensitivity and false positives caused by drugs, e.g. anti-
thymocyte globulin (ATG). To overcome these problems, the Japanese Red Cross
developed a new method in 2009; immunocomplex capture fluorescence analysis
(ICFA). As ICFA is based on fluorescent microbead technology (Luminex), it allows
high throughput and sensitive crossmatching. Moreover, because ICFA does not use
complement, it is not affected by ATG. We therefore shifted from AHG-LCT to ICFA in
December 2010.
Aims: To validate the reliability of ICFA as a routine crossmatch method, we analyzed
retest and positivity rates. Moreover, we attempted to identify the causes of positive tests.
Methods: Crossmatching: The ICFA kit (Wakunaga Pharmaceutical Co., Ltd.) was used
for crossmatching. White blood cells obtained by hemolysis of whole blood were
sensitized with patient sera. Sensitized cells were then lysed. The immunocomplex in
the lysate was captured by microbeads coated with HLA class I-specific monoclonal
antibody. Finally, captured HLA antibody was labeled with phycoerythrin-conjugated
secondary antibody and detected by Luminex.
Detailed Analysis: In the positive cases, donor HLA types were retyped. We usually
detect antibody specificity in patients with a phenotype panel bead kit (Wakunaga
Pharmaceutical Co., Ltd.). However, the single antigen panel bead kit (One Lambda,
Inc.) was used for detailed analysis of HLA antibody in positive cases.
Results: The retest rate was 5.0% (102 cases) among 2059 cases from December 2010
to April 2011. All of these were positive on the first test. Duplicate retesting revealed
that 48 cases were positive, and the others were negative, i.e. 54 cases gave false
positives in the first test. Donor retyping revealed that all donor HLA types were
correct. Donor-specific antibodies were newly detected by single antigen panel beads
in four cases. One patient gave two positive results because of self-reactive HLA
antibody. The remainder of positive cases have not yet been explained. The false
positive rate was 8.2% in December 2010, but decreased gradually to 0.7% in April
2011. Thus, we believe handling was likely to be a major problem at the beginning.
Summary/Conclusion: We recently applied ICFA to routine HLA crossmatching. Al-
though the retest rate was initially high, it is now <2%. Therefore, we conclude that
ICFA is useful.
P-344
ANTI-PLATELET ANTIBODY DETECTION IN PATIENTS
RECEIVING PLATELET TRANSFUSION
Mishima Y, Matsuhashi M, Tsuno NH, Takahashi K
The University of Tokyo, Tokyo, Japan
Background: In Japan, universal prestorage leukocyte-reduction was implemented to
all allogeneic blood products provided by the Japanese Red Cross Blood Center. Since
2004 the platelet concentrates transfused are supposed to contain <1 · 106 leukocytes
per bag. Patients with hematological disease usually require multiple platelet trans-
fusions, and frequently develop anti-platelet antibodies, which are responsible for
platelet transfusion refractoriness. In the present study, we aimed to investigate the
performance of anti-platelet antibody testing in our hospital, and the frequency of
antibody detection among the patients with hematological diseases receiving multiple,
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defined as twice or more, platelet transfusions, in comparison with those receiving
once or twice.
Methods: The 625 patients with hematological diseases requiring platelet transfusion
were retrospectively analyzed. They were divided into cases receiving multiple, i.e.
three or more platelet transfusions, and those receiving once or twice. The performance
of anti-platelet antibody screening and the frequency of antibody detection in each
group were analyzed.
Results: Among the 101 cases receiving 1–2 platelet transfusions, 25 (24.8%) were
tested for anti-platelet antibodies, and antibodies were detected in only two. The
antibody specificity was anti-GPIIb/IIIa in both. The remaining 76 cases (75.2%) were
not tested. On the other hand, among the 524 cases receiving multiple platelet
transfusions, 325 (62%) were tested, and antibody was detected in 60 (18.5%). The
specificities were as follows: anti-HLA in 47, anti-HLA + GPIIb/IIIa in 3, anti-
HLA + HPA-5b in 2, anti-GPIIb/IIIa in 5, anti-GPIIb/IIIa + HPA-4b in 1, anti-HPA-5b
in 1, and in one case, the specificity was undetermined. The remaining 199 (38%) were
not tested.
Conclusions: Although of the implementation of universal leukocyte reduction, the
risk of platelet transfusion refractoriness (PTR) still exists, especially in those cases
receiving multiple platelet transfusions. Whereas the risk of exposure to leukocyte
antigens is theoretically significantly reduced, patients continue being exposed to
platelet antigens. Therefore, we believe that frequent testing of anti-platelet
antibodies is very important to diagnose and take the appropriate preventive
measures to control PTR, especially in those cases receiving multiple platelet
transfusions.
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HLA ALLOIMMUNIZATION IN PATIENTS WITH END-STAGE
RENAL DISEASE IN SOUTHERN TAIWAN
Lin TM1, Hung SY1, Wang HH1, Chen YT1, Chang-Chien HH2, Hung CM2
1E-Da Hospital/I-Shou University, Kaohsiung, Taiwan 2Kaohsiung Blood Center,
Taiwan Blood Services Foundation, Kaohsiung, Taiwan
Background: Alloimmunization to human leukocyte antigens (HLA) can occur with
pregnancy and blood transfusion and have predictive value for kidney graft survival
and the occurrence of rejection episode. The prevalence and risk factors for HLA
alloimmunization in patients with end-stage renal disease (ESRD) in Taiwan are still
unknown.
Methods: A cross-sectional study of HLA alloimmunization in ESRD patients in E-DA
hospital, Kaohsiung, Taiwan. The volunteer blood donors were prospectively recruited
by Kaohsing Blood Donation Centers. Donors provided a detailed history of pregnancy
and transfusion Antibodies to class I and class II HLA were measured by an enzyme-
linked immunosorbent assay (GTI Diagnostics).
Results: A cohort of 289 ESRD patients (138 females and 151 males) were recruited
including 140 chronic hemodialysis patients, 98 chronic peritoneal dialysis patients
and 51 pre-dialysis patients. Their mean age was 58.6 ± 12.3 years. The average
dialysis duration was 3.0 ± 2.6 years. A total of 888 healthy volunteer blood donors
(688 females and 200 males) were recruited as controls. The prevalence of any HLA
antibody was significantly higher in ESRD patients (n = 67, 23.2%) and blood donors
(n = 114, 12.8%), (P < 0.001). HLA antibodies were detected in 16.3% of all female
healthy donors and in 22.4% of those with a history of previous pregnancy. The
prevalence of HLA antibodies increased in women with greater numbers of pregnancy:
2.7% (zero), 14.0% (one), 23.3% (two) and 30.0% (three or more pregnancies;
P < 0.0001). In ESRD patients, the presence of class I HLA antibody is highly correlated
to the presence of class II HLA antibody (P = 0.000). While comparing the parameters
between patients with positive and negative antibody (either to HLA class I or II), HLA
antibody-positive patients had higher numbers of pregnancies (P = 0.000), higher
numbers of blood transfusions (P = 0.005), and shorter time lag of the last transfusion
(P = 0.002), than those of HLA antibody-negative patients. In a multivariate logistic
analysis, both the pregnancy and the time lag of last transfusion had independent
associations with positive HLA alloimmunization, especially, the time lag of last
transfusion of <1 year had the highest odds ratio 10.06 (95% CI: 3.866–26.16,
P = 0.000).
Conclusions: HLA Class I and Class II antibodies are detectable at low prevalence in
male volunteer blood donors. In female, the prevalence of HLA antibodies increases
significantly with number of pregnancy. The prevalence of HLA antibodies of ESRD
patients was significantly high compared to healthy blood donors. Pregnancy and the
time lag of last transfusion remained the strongest risk factors of HLA alloimmuni-
zation in ESRD patients.
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ANALYSIS OF KILLER CELL IG-LIKE RECEPTOR (KIR) LIGAND
MATCHING IN 21 CASES OF TRANSFUSION-ASSOCIATED
GRAFT-VERSUS-HOST DISEASE (TA-GVHD) IN JAPAN
Azuma F1, Yabe T1, Kashiwase K1, Watanabe Y2, Yahagi H1, Uchida S2, Uchikawa M1,
Takanashi M1, Satake M1, Tadokoro K2, Juji T2, Nakajima K1
1Japanese Red Cross Tokyo Blood Center, Tokyo, Japan 2Central Blood Institute,
Japanese Red Cross Society, Tokyo, Japan
Background: Transfusion-associated graft-versus-host disease (TA-GVHD) is one of
the most severe and fatal complications in blood transfusion. TA-GVHD occurs when
the human leukocyte antigen (HLA) types of the recipient heterozygous, but the
donor is homozygous and one-way compatible to the recipient. As the donor T
lymphocytes cannot be rejected by the recipient’s immune system, they can then
proliferate and react with the tissues of the recipient. However, the incident fre-
quency of TA-GVHD was lower than expected, suggesting the existence of recipient
protecting system. Alloreactivity of NK cells by killer Ig-like receptor (KIR) ‘missing
self’ recognition of its HLA ligand is one of the candidate mechanisms but has not
been clarified yet.
Aims: To analyze the state of NK cell alloreactivity in TA-GVHD cases, the patient and
donor HLA KIR ligand were typed and evaluated KIR ligand matching.
Materials & Methods: Twenty-one cases of TA-GVHD in Japan between 1994 and
1999 that had been confirmed by microsatellite analysis were used for this study. TA-
GVHD patient and donor genome DNAs were amplified using a whole genome
amplification kit (illustra GenomiPhi HY kit, GE Healthcare). Genotyping of HLA-A, -B,
-C, and DRB1 loci was then performed using the PCR-rSSO-Luminex method (WAK-
Flow HLA genotyping kit, Wakunaga Pharmaceutical). KIR ligand type of KIR2DL (C1,
C2) and KIR3DL (Bw4, A3 and A11) was determined from the HLA-A, -B, and -C
genotypes.
Results: Confirmed or putative donor HLA types were all homozygous and one-way
compatible to the recipient in 21 cases. Furthermore in 17 of these recipients, a change
in HLA type after transfusion was detected, indicating proliferation of donor lym-
phocytes in the recipient’s circulation. No KIR ligand mismatch of C1/C2, Bw4, and A3,
A11 between donor and recipient was detected in any of the 21 cases.
Conclusions: The homozygocity and one-way compatibility of donor to recipient HLA
types was confirmed as a risk factor for TA-GVHD. There was no mismatch of KIR
ligand between recipients and donors, suggesting that NK cells could not function in
the removal of donor lymphocytes in these recipients who developed TA-GVHD. Still,
this is concordant with the notion that alloreactivity of NK cell is one of the mecha-
nisms for donor T lymphocyte removal. For further understanding of the role of al-
loreactivity of NK cells in TA-GVHD cases, recipient KIR genotyping and haplotype
analysis is being conducted.
8.2 Histocompatibility in
Stem Cell Transplantation
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COMPARISON OF BIALLELIC POLYMORPHISMS AND SHORT
TANDEM REPEATS FOR CHIMERISM MONITORING IN HEMA-
TOPOIETIC STEM CELL TRANSPLANTATION RELAPSE PA-
TIENTS ON DIFFERENT SAMPLES
Chen DD1, Tseng CP2, Wang WT1, Peng CT1, Sun CF1
1Chang Gung Memorial Hospital, Tao-Yuan, Taiwan 2Chang Gung University,
Taoyuan, Taiwan
Background: Chimerism kinetics permits early detection of hematopoietic stem cell
transplantation (HSCT) patients with high risks of graft-versus-host disease or those
liable to relapse. Although short tandem repeats-PCR (STR-PCR) is the gold standard
for quantitative chimerism analysis, STR-PCR has a relatively low sensitivity of 5%.
Aim: In this study, we developed a more sensitive real-time PCR method for chime-
rism analysis based on the informative biallelic polymorphisms (BP).
Methods: The informative biallelic polymorphic markers with high discrimination
power in the Taiwanese population were identified. The TaqMan probe-based real-time
BP-PCR for amplification of the informative loci was designed and the detection
sensitivity was determined. Clinical application of real-time BP-PCR in chimerism
monitoring was evaluated and was compared with the conventional STR-PCR from
four allogeneic HSCT relapsed patients. Besides, we extend our study to analyse T-cell
DNA and cell-free DNA samples collected on the new cases since 2007 and compared it
between two kinds of these samples.
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Results: Allele distribution analysis revealed that the loci of S01a, S03, S04a, S05b,
S06, S07b, S08b, S09b, S10b and S11a had a relatively high discrimination power and
were the informative BP for chimerism monitoring. Real-time BP-PCRs for these 10 BP
loci were set up with the detection sensitivity equivalent to 0.003–0.006%. Real-time
BP-PCR of the four HSCT patients revealed the presence of recipient-specific DNA at
early time point than STR-PCR for three of the patients. However, the results from T-
cell DNA and cell-free DNA samples did not show better results about early detection of
relapse.
Conclusion: We conclude that real-time BP-PCR is a sensitive and reliable method for
chimerism monitoring and is superior to the STR-PCR in identifying patients who are
at high risk for relapse after transplantation. As to the efficacy, it is the same between
whole blood, T-cell DNA and cell-free DNA.
9. Novel Development
9.1 Novel Development
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CHANGE IN THE LEVEL OF SERUM CHOLESTEROL AND URIC
ACID IN DONORS WITH ELEVATED VALUE FOLLOWING
INTRODUCTION OF THE MEASUREMENTS
Chen MH1, Chen JW2, Lin Tsai SJ2, Lin KS2
1Taipei Blood Center, TBSF, Taipei City, Taiwan 2Head Office Taiwan Blood Services
Foundation, Taipei, Taiwan
Background: The supply of blood relies on non-remunerated voluntary blood
donations. To reward blood donors, we implemented the measurements for choles-
terol and uric acid to donors every 6 months. In addition, we provide donors with
educational materials for the diet leading to elevated serum levels of cholesterol and
uric acid.
Aim: The study is to assess the implementation of cholesterol and uric acid mea-
surements in changing the serum levels of the analytes in the donors with elevated
value.
Method: A retrospective analysis has been done using data from January 2009 to
December 2010. Throughout the study, a level of cholesterol of ‡240 mg/dl and uric
acid of ‡7.3 mg/dl were considered as elevated. Blood donors in the category of
containing elevated level of the analyses and being provided with at least two sub-
sequent measurements were further analyzed for the change in their serum level of the
analytes. Data were analyzed using SigmaState version 1. For all analyses, statistical
significance was set at P < 0.05.
Results: The data indicated the serum uric acid was significantly higher in male than
in female donors (6.5 vs 4.9 mg/dl), but serum cholesterol was not (171 vs 170 mg/dl).
The serum cholesterol significantly increased with age, but serum uric acid did not. The
occurrence of hypercholesterolemia and hyperuricemia, male vs female donors, were
2.7% vs 2.8% and 27% vs 14%, respectively. Further analyses were done for the donor
groups with an elevated level of either cholesterol or uric acid, following by two
subsequent measurements. Of the donor group with an elevated cholesterol level, the
mean cholesterol levels of the three measurements in order are 260, 240, and 239 mg/
dl. Data breakdown by donor age and gender show a decreasing cholesterol level in the
subsequent measurements for each breakdown donor group. The same results were
found by analysis of donors with elevated uric acid. An overall decrease in uric acid
level was shown in the elevated donor group (8.2, 7.5, and 7.6 mg/dl) and each of the
breakdown donor group as well.
Conclusions: Provision of the measurements of cholesterol and uric acid together with
educational materials lead to a decrease in serum level of the analytes in those donors
with elevated level, probably due to changing their diet preference.
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A VALIDATED OVINE MODEL FOR BLOOD COLLECTION, PRO-
CESSING, COMPATIBILITY TESTING AND TRANSFUSION
Fung YL1, Do HL2,3, Tung JP2,3, Collier J4, Fraser JF1
1The University of Queenland & The Prince Charles Hospital, Brisbane, Qld, Australia
2Research & Development, Australian Red Cross Blood Service, Brisbane, Qld, Australia
3CCRG, The Uni of Queensland & The Prince Charles Hospital 4Emergency Department,
Princess Alexandra Hospital, Brisbane, Qld, Australia
Background: In vivo animal models of blood transfusion are useful for investigating
the mechanisms of both the positive as well as the negative clinical outcomes of
transfusion. The majority of transfusion models have been small animal models, with
their attendant and significant limitations for blood sampling volumes, the lack of
suitable blood bags and difficulties with post-transfusion haemodynamic monitoring.
To overcome these limitations, our aim was to develop a large animal ovine model of
blood collection, processing, compatibility testing and transfusion which would be
relevant to current clinical practice. The larger body mass and circulatory volume of
sheep supports multiple blood sampling, the use of human blood bags and in-line
haemodynamic monitoring using standard human hospital instrumentation. Compared
to the small animals used previously, sheep also provide the added advantage of
greater immunological and anatomical similarities with humans.
Methods & Results: Collection and processing: Whole blood (400 ml) was collected
from healthy male sheep into Leukotrap WB bags (Pall Medical, England), leucode-
pleted, and then centrifuged. As ovine red blood cells (RBC) are smaller (MCV 28–40 fL)
than human RBC, centrifugation force and time was modified (5000 g; 45 min) to
ensure clear separation between plasma and packed cells. Plasma was then removed by
manual expressor and frozen at )20C. Additive solution (SAGM: saline-adenine-
guanosine-mannitol) was added to the ovine packed red blood cell (PRBC) for storage
at 4C for up to 42 days.
Compatibility Testing and Transfusion: Using a serological ratio of one drop 10%
donor sheep RBC: two drops undiluted recipient sheep serum, the compatibility test
was performed under the following conditions, then examined and graded for visible
macroscopic RBC agglutination and any lysis.
IgM Detection: immediate centrifuge, read, then 30 min at room temperature, read for
agglutination and lysis IgG (‘complete’) antibody detection: 30 min at 37C, read for
agglutination and lysis IgG (‘incomplete’) antibody detection: 30 min at 37C, cen-
trifuge and remove supernatant, add 10% albumin, 30 min at 37C, read for aggluti-
nation and lysis.
The PRBC was considered compatible when all three assays were negative.
Two units of PRBC were transfused by a standard giving set into a male sheep.
Results: A total of 24 units of whole blood were collected from healthy male sheep
and processed into PRBC.
Seventy-seven compatibility suites were performed with sera from 24 potential male
recipient sheep. Interestingly 14 of 77 (18.18%) were found to be not compatible, of
which one incompatibilities were due to IgG, seven due to IgM and six due to both IgG
and IgM antibodies.
With compatibility confirmed, 24 units of PRBC were transfused into 12 recipient
sheep without incident.
Conclusions: Results from this ovine model of blood collection, processing, compat-
ibility testing and transfusion substantiate its usefulness and relevance. As there is
limited data on compatibility testing in animal models, the detection of incompati-
bilities in our cohort of young male sheep proves that our compatibility screening is
able to detect the presence of any alloantibodies. These results validate the application
of this ovine model for future blood transfusion modelling.
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CLINICAL OUTCOMES IN LEUKEMIC PATIENTS AFTER BLOOD
COMPONENT TRANSFUSION DURING HEMATOPOIETIC STEM
CELL TRANSPLANTATION THERAPY
Li ZJ
Xinqiao Hospital, Chongqing, China
Objective: We aimed to evaluate the clinical outcomes and any influencing factors of
the blood component transfusion in leukemic patients during hematopoietic stem cell
transplantation.
Methods: A total of 75 leukemic patients who were undergoing hematopoietic stem
cell transplantation were recruited in this study. Patients Platelet recovery rate (PPR)
and corrected platelet count increment (CCI) were calculated 24 h after platelet
transfusion. Hemoglobin (Hb) increment was also recorded 24 h after transfusion of red
blood cell suspension. We evaluated the clinical outcomes based on the improvement
in clinical symptoms in all the patients. Many factors, such as gender and blood type,
were recorded and evaluated.
Results: Gender was not correlated with clinical outcomes of platelets and red blood
cell transfusion (P > 0.05). The platelet transfusion outcomes were significantly
better in leukemic patients after hematopoietic stem cell transplantation than that in
the pre-transplant patients (61.91% vs 55.77%, P < 0.05), while the red blood cell
transfusion outcomes were better in the pre-transplant patients than that in the
post-transplant patients (71.43% vs 47.91%, P < 0.01). The blood transfusion out-
comes of the patients, whose blood type matched the type of donors, were better
than that of the patients, whose blood type didn’t match that of donors (70.00% vs
55.77% for platelet transfusion, 58.00% vs 40.00% for red blood cell transfusion,
both P < 0.05).
Conclusion: Timing of transfusion (pre-transplantation or post-transplantation) and
blood type are two major influencing factors that my affect the clinical outcomes of
blood component transfusion.
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